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Abstract
The small GTPase RHO-1 is an important regulator of neurotransmission. 
Caenorhabditis elegans nematodes expressing activated RHO-1 (G14V) in 
their cholinergic motor neurons (nRHO-1*) become hypersensitive to the 
acetylcholinesterase inhibitor aldicarb, demonstrating increased acetylcholine 
release, and acquire a highly loopy, uncoordinated locomotion.  
RHO-1 inhibits diacylglycerol kinase (DGK-1), and so increases the availability 
of diacylglycerol (DAG), a key second messenger for release at the presynaptic 
membrane.  Inhibiting RHO-1 in a dgk-1 mutant causes a decrease in neurotransmitter 
release, demonstrating the presence of additional targets downstream of RHO-1.
During a forward genetic screen for suppressors of the loopy locomotion of nRHO-
1* animals we obtained a mutant, nz94, which carried an additional ‘fainter’ 
phenotype, helping us identify it as an allele of unc-80, a large, conserved protein, 
important in the localization of NCA-1 and NCA-2, C. elegans homologues of the 
novel mammalian ion channel NALCN.  
RHO-1*;unc-80 double mutants are non-loopy, but still hypersensitive to aldicarb, 
indicating that the loopy locomotion and high levels of neurotransmitter release 
can be uncoupled. unc-80 mutants do not suppress non-neuronal phenotypes 
associated with heat-shock expression of RHO-1*, such as tail swelling and sterility. 
Expressing an unc-80 transgene under a cholinergic promoter is sufficient to rescue 
the suppression of loopy locomotion seen in the nRHO-1*;unc-80 double mutants, 
indicating that unc-80 acts presynaptically in the same cells as nRHO-1* for the 
generation of this loopy locomotion.  
Work from other labs shows that unc-80 mutants suppress gain-of-function PPK-
1 (PI4P5K) phenotypes, most likely through changes in the localisation of the ion 
channels.    
Our current model involves RHO-1 binding to and activating PPK-1, increasing 
levels of PIP2 and hyperactivating the NCA-1/NCA-2 channels.  We suspect this ion 
channel complex may regulate the release of neuropeptides involved in locomotive 
behaviour. 
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1 - INTRODUCTION
1.1 - Neurobiology - a perspective
One of the essential properties of all living organisms is the ability to sense and respond 
to their environments.  Multicellular organisms have the task of coordinating inputs from 
many different cell types and from the environment and producing a suitable, organism-
wide response to changing conditions.  Coordination between cells that does not require 
a fast output is conducted through paracrine signalling, but this is limited by the rate of 
diffusion and the strength of the diffused signal.  More distant signalling makes use of 
blood or lymph for endocrine signalling, but this is still limited by the speed of transport in 
a liquid medium.  For fast responses, multicellular organisms make use of a specialised 
branch of endocrine signalling - the nervous system.  The individual cells of the nervous 
system - neurons - have adapted basic principles found in all cells - electrochemical 
potential, excitibility, cell-cell contacts, signalling pathways - for reception, transmission 
and processing of data over distance.  From a mouse searching for food in a maze to 
a man listening his iPod, the nervous system has developed from humble beginnings 
to manage highly complex behaviours.  The power of the nervous system arises from 
coupling a common unit - the neuron - into vast networks, with billions of neurons in the 
human brain each potentially contacting and communicating with thousands of others.  
1.1.1 - C. elegans as a model organism for the study of 
neuroscience
In the 19th century, a debate raged between George Cuvier (1769-1832) and Geoffroy 
Saint-Hilaire (1772-1844), prominent scientists of the day, as to the nature of the 
relationship between living things (Striedter 2007).  Cuvier proposed that animals be 
divided into four distinct groups, which shared no common ancestory; any similarities 
arose as a product of body parts having a similar function.  Geoffroy maintained that all 
animals descended from a common ancestor, and that there was a common structural 
blueprint linking all animals together, modified between organisms on the basis of function, 
but constrained by a common unity of composition.  One of Geoffroy’s theories was that 
the dorsal side of vertebrates, where the central nervous system is located, is analogous 
to the ventral side of invertebrates, which contains the nerve cord (Hirth 2007).
While many of Geoffroy’s predictions and similarities were shown to be superficial, 
Charles Darwin’s (1809-1882) theories on the basis of common descent and evolution 
by natural selection provided a framework for the re-examination of these models.  In 
our modern era of molecular analysis, we can see that homologous proteins, such as the 
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Notch family, control the patterning of the nervous system from the fruit fly to the mouse 
(Lardelli, Williams et al. 1995), and increasingly we see molecular homologies in function 
between the nervous systems of disparate organisms, for instance in the components of 
neurotransmitter release (Sudhof, Baumert et al. 1989), neuropeptide signalling (Nassel 
2002) or the action of G-protein coupled receptors (GPCRs) (Fredriksson and Schioth 
2005).
This perspective gives a rationale for the use of model organisms to study biology.  Our 
brains are composed of cells not dissimilar to those found in apes or rodents, squid or sea 
slugs, flies or worms.  These organisms offer huge practical and technical advantages in 
terms of scientific investigation compared with working directly in humans.   Much work 
can be accomplished in simpler, smaller, faster-growing organisms than ourselves, and 
then scaled up for application to human health. 
This model for conducting scientific research was used by Sydney Brenner (1927-) when 
he decided to work on a simple organism, one which he believed was so tractable that 
its entire nervous system and behaviour could be completely understood.  Working in the 
late 1960s, Brenner wrote to Max Perutz, then head of the Medical Research Council, 
that ‘it is now widely realized that nearly all the ‘classical’ problems of molecular biology 
have either been solved or will be solved in the next decade’ (Brenner 1988) - referring 
to the understanding of the encoding of genetic information in DNA and the unravelling 
of the genetic code which was underway at the time.  Instead Brenner proposed that to 
solve the next level of problems in biology - issues of why animals behave as they do 
- it would be necessary to study a single animal, ‘to tame a small metazoan organism 
to study development directly’ and for this he proposed to study a nematode worm. 
The fruit fly Drosophila had already been established as a model, but was deemed 
too complicated for the purpose (Brenner 1988).  In his proposal to the MRC, Brenner 
wrote that ‘we think we have a good candidate in the form of a small nematode worm, 
Caenorhabditis briggsiae...To start with we propose to identify every cell in the worm and 
trace lineages. We shall also investigate the constancy of development and study its 
genetic control by looking for mutants’ (Brenner 1988).  Interestingly, Brenner changed 
his mind and decided to concentrate on the related nematode Caenorhabditis elegans, a 
decision that proved of great significance decades later, as C. briggsiae has proven less 
tractable to RNA interference (Winston, Sutherlin et al. 2007), a key technique in the field 
of nematode biology.  
Even in that initial proposal to the MRC Brenner identified some key factors which make 
nematode worms a favourable organism for biological manipulation.  C. elegans is small, 
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a fully-grown adult is approximately 1mm in length, and passes through its lifecycle in 
approximately 3 days.  These properties allow large numbers of animals to be grown in 
the laboratory.  It had earlier been recognised that nematodes of this genus appeared 
to have an invariant cell number, and that this might make them useful for genetic study 
(Dougherty and Calhoun 1948).  
C. elegans is a self-fertilising hermaphrodite, producing sperm and eggs separately. This 
aspect of the biology of the worm is highly useful to us in the laboratory, as an isogenic 
population can be maintained simply by picking a single individual to a fresh plate of 
bacteria and allowing it to self-fertilise.  A single hermaphrodite may lay up to 300 eggs 
allowing rapid population expansion.  
C. elegans does produce a low, spontaneous proportion of males, with a rather elegant 
developmental switch occurring in animals which carry only one copy of the sex 
chromosome, leading to the development of male characteristics (Hodgkin, Horvitz et al. 
1979; Hodgkin 1983).  Males exhibit a number of behaviours distinct from hermaphrodites, 
including a vulva detection pattern of movement when they encounter another worm or 
obstacle, and a mate-searching behaviour.  Most of this behaviour is governed by an 
additional 205 male-specific somatic cells, including 89 neurons and 41 muscle cells. 
As well as assaying for male-specific behaviours, males are useful in experimentation 
because they allow for genetic crosses to be made allowing the generation of double 
mutants, backcrossing mutated animals and conducting epistasis and complementation 
experiments.  
One of the key criticisms of Brenner’s approach was that the worm appeared to be so 
simple that no useful mutants would be identified, although a mutant of C. briggsae 
had been identified and published much earlier (Nigon and Dougherty 1950).  Brenner 
therefore spent the majority of his first years working with C. elegans screening for 
mutants generated by exposure to ethyl methanesulfonate (EMS), which he published in 
a ground-breaking paper in 1974 (Brenner 1974).  
Brenner was able to identify a wide range of mutant phenotypes in the worm, relating 
to development and behaviour, and perform genetic mapping to place these mutants 
into complementation groups.  These mutants are classified using a three letter code 
to represent the phenotype (Brenner 1974).  For instance, mutants which are longer 
than wild-type are designated lon (for long), while mutants whose movement is different 
from wild-type are given the code unc (uncoordinated).  Similarly mutants were identified 
which were egg-laying defective (egl), lethal (let) and dumpy (dpy), amongst others. 
Subsequent cloning and identification of the genetic mutations responsible for these 
25
phenotypes has identified key genes required for nervous system development or 
function, growth, behavioural responses, cell division and cell signalling - all essential 
processes common across species.  This method of naming mutants has been translated 
into a structure for naming genes and proteins in C. elegans (Horvitz, Brenner et al. 
1979).  Gene names are three or four letters long, and written in lower case italics, for 
instance unc-64 encodes the C. elegans homologue of the vertebrate syntaxin gene. 
The protein encoded by the gene is written in capitals, i.e. UNC-64 denotes the syntaxin 
protein.  
These early screens demonstrated that C. elegans could be used to identify mutants 
defective in aspects of nervous system function, the very processes Brenner was 
originally interested in.  For instance, UNC-5 and UNC-6 and UNC-40 are involved in axon 
guidance (Hedgecock, Culotti et al. 1990) and were identified in the original EMS screen 
(Brenner 1974) which also uncovered UNC-29, UNC-38 and UNC-63, subsequently 
shown to encode the nicotinic acetylcholine receptor (Lewis, Wu et al. 1980).  
Much subsequent work has determined the structure of the C. elegans nervous system 
including synaptic connections (White 1986), the processes of synaptic vesicle fusion 
and neurotransmitter release, and the behaviours which result from a the workings of the 
nervous system. I will briefly review the use of C. elegans as a model organism, followed 
by an examination of the workings of its nervous system, and finally discuss a number of 
ways in which regulation of the nervous system controls a variety of complex behaviours. 
1.1.2 - The small size and fast life cycle of C. elegans lends 
itself to biological analysis
An adult C. elegans worm is approximately 1mm in length, and 25μm in diameter  (Figure 
1-1), meaning that thousands of individuals can be grown on a single 55mm plate. C. 
elegans passes through four larval stages, named L1, L2, L3 and L4, before a final 
moulting to produce the mature adult.  Under conditions of stress the animals can enter 
an alternative developmental stage known as dauer (Cassada and Russell 1975), which 
is highly resistant to dessication. At an average of 1000 animals per plate, a C. elegans 
laboratory can easily contain well over a million individuals at any one time.  This is 
several orders of magnitude greater than for any other multicellular model system, and 
adds to the power of investigation in the worm. 
The growth of C. elegans can be continued in liquid culture (Lewis 1995).  Flasks 
containing basic nutrients allow the worms to grow in aerated liquid, and this is especially 
useful for cultivating even greater quantities of worms for biochemical analysis, for 
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instance, although the animals appear starved and their behaviour may not be equivalent 
to animals grown on solid plates.  
The small size of C. elegans also lends itself to investigation using microfluidic devices 
(Chung, Crane et al. 2008).  This rapidly growing field involves manipulating the worm 
using tiny quantities of liquid contained within channels created typically in PDMS.  Worms 
tend to move in a 2-dimensional plane of liquid on the surface of an agar plate, and seem 
to suffer no ill effects when moving in a similar plane of liquid under microfluidic conditions. 
They can be manipulated and handled using liquid flow, offering the opportunity for mass 
handling of individual animals in an automated or semi-automated fashion.  This has 
been applied to high-throughput genetic screening (Crane, Chung et al. 2009), and on-
chip laser microsurgery (Chung and Lu 2009). 
Other devices challenge the worms to move through ‘artificial soil’ (Lockery, Lawton et 
al. 2008), or to navigate mazes (Qin and Wheeler 2007).  Interacting with the worm on 
its own scale opens up many new possibilities for experiments.  
Pharynx
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Dorsal Nerve Cord
Nerve Ring
Rectum
Intestine
Anterior Posterior
Dorsal
Ventral
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Right
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Length: approximately 1.3mm (adult hermaphrodite)
Gonad Arm
Figure 1-1 Schematic of a nematode worm
C. elegans is a self-fertilising hermaphrodite which grows to a length of approximately 1.3 mm as 
an adult.  Food is ingested through the pharynx, a large muscular organ which grinds up bacteria, 
passing it through to the intestine for digestion.  Dorsal and ventral nerve cords contain neurons 
which synapse onto the body wall muscles for the production of locomotion, while the nerve ring 
in the head is the site of synapses between neurons responsible for controlling behaviour.
27
1.1.3 -  C. elegans is transparent, allowing detailed visual 
characterisation
The importance of C. elegans being transparent can hardly be overstated.  Cells within the 
organism can be observed directly, including neurons.  Transparency allows a number of 
phenotypic observations to be made with the aid of nothing more than a standard bench 
microscope.  For instance, the pharangyl muscle contains a grinding component which 
breaks up bacteria for easier digestion in the intestine.  This grinder pumps with a regular 
rhythm and is clearly visible in the head of the worm (Raizen, Lee et al. 1995); measuring 
the rate of grinding gives an indication of the satiety state of the organism, as well as 
being a useful diagnostic tool for certain mutants (Brundage, Avery et al. 1996).  Similarly, 
the defecation cycle, in which the intestine contracts and expels waste can be clearly 
observed within the live worm (Avery 1997).  This cycle operates on a regular timescale 
of around 55 seconds in a wild-type animal and is governed by known pathways, again 
making it an excellent diagnostic of pathways regulating rhythmic behaviours.  
The transparency of the worm also allowed observation of the cell lineage to be conducted 
in live animals (Sulston and Horvitz 1977; Horvitz and Sulston 1980), and other features, 
such as the number of eggs contained within the organism can clearly be counted.
The transparency of the worm has become vital over the last 20 years since the 
development of green fluorescent protein and its derivatives (Chalfie, Tu et al. 1994). 
These proteins have transformed biology, and are ubiquitous in C. elegans experiments.
The list of experiments using this technology is too great to cover, but some of the 
aspects of cell and particularly neurobiology which have been investigated include: 
using tagged proteins or promoter-GFP constructs to assess the expression patterns 
of neurobiological proteins (McKay, Johnsen et al. 2003); tagged neuropeptides acting 
as reporters of secretion (Sieburth, Madison et al. 2007); tagged UNC-13 acting as 
a reporter of DAG levels at the presynaptic membrane (Nurrish, Ségalat et al. 1999); 
reconstitution of GFP across synapses to define partner cells (Feinberg, Vanhoven et al. 
2008); and live reporting of the activity of neurons by using the calcium-sensitive GFP 
reporter cameleon (Suzuki, Kerr et al. 2003).
1.1.4 - Transformation of C. elegans allows the generation 
of genetically modified organisms
The introduction of exogenous genetic material into C. elegans is made possible by the 
way the worm processes DNA and by the presence of a syncitia of nuclei in the gonad. 
Direct injection of DNA into the gonad (Figure 1-1) allows, at low frequency, incorporation 
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of that DNA into the developing egg.  In some cases this DNA is maintained as a large 
extrachromosomoal complex, and this can even be heritable, allowing the production of 
stable, transformed lines (Mello and Fire 1995).  
These constructs can be integrated into the genome by the introduction of double stranded 
breaks by UV irradiation, after which (also at low frequency) the extrachromosomal arrays 
can be incorporated into the DNA of the animal.  If this occurs in cells of the germline it 
is possible to create integrated lines (Mello, 1995).
Alternative methods for the introduction of exogenous genetic material include the use 
of the gene gun and, more recently, targetted introduction of DNA at specific sites in the 
genome using the Mos transposase (Frokjaer-Jensen, Davis et al. 2008).  
1.1.5 - The genome of C. elegans has been fully sequenced
Ever since those original screens for mutants conducted by Sydney Brenner, the aim has 
been to achieve an understanding of the biology of C. elegans by using genetic methods. 
The initial approach of mutational screening combined with forward genetics and mapping 
is still in use today, while additional tools provide even greater advantages.  The most 
significant of these is the complete genome sequence of C. elegans, obtained in 1998 
(Consortium 1998).  This information is accessible online, and has been used to search 
for orhtologues of genes in other species, as well as providing detailed information for 
producing gene models and rescuing constructs, and for quickly analysing sequencing 
data of mutant animals.  This genome has been joined by sequences for four other 
Caenorhabditis species: C. briggsae (Gupta and Sternberg 2003),  C. remanei, C. 
brenneri and C. japonica; as well as data for a number of other nematode species, all of 
which can be accessed online at Wormbase.org (Harris, Antoshechkin et al. 2010).
This data has been combined with the latest high-throughput sequencing machines to 
achieve high-resolution sequencing of individual genomes (Sarin, Prabhu et al. 2008; 
Shen, Sarin et al. 2008).  While the original genome sequence was achieved through 
sequencing of thousands of large, overlapping DNA pieces, further sequence of mutant 
genomes can be achieved by mapping short reads back onto the original sequence and 
observing discrepancies. 
The usefulness of the whole genome sequence is complemented by two techniques for 
reverse genetic analysis of C. elegans.  Gene knockouts are currently obtained through 
random mutagenesis using mutagens such as UV irradiation or trimethylpsoralen (TMP) 
which are able to induce large deletions in the genome, and then sequencing is used 
to look for deletions in particular genes of interest (Jansen, Hazendonk et al. 1997; Liu, 
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Spoerke et al. 1999; Edgley, D’Souza et al. 2002).  Large libraries containing around a 
million mutants can be screened for deletions in genes of interest, or individual labs can 
make use of the services of two gene knockout consortia at http://celeganskoconsortium.
omrf.org or http://shigen.lab.nig.ac.jp/c.elegans/index.jsp rather than producing libraries 
of their own.
The alternative method for gene knockout is the use of RNA interference (Fire, Xu et 
al. 1998; Tabara, Grishok et al. 1998; Timmons, Court et al. 2001).  It has been used 
to screen large libraries containing dsRNA against the majority of genes in the genome 
(Fraser, Kamath et al. 2000; Kamath, Fraser et al. 2003), and more recently to screen for 
mutants in the nervous system (Sieburth, Ch’ng et al. 2005).  
1.2 - The nervous system of C. elegans
The basic unit of the nervous system is the neuron, which consists of a cell body, 
containing the nucleus, a long projection called an axon, and dendrites, which receive 
information from signalling cells (Figure 1-2).  Neurons can have multiple projections for 
both axons and dendrites, and each dendrite can receive multiple signals, allowing a 
single cell to complex with potentially thousands of others.  In large animals, axons can 
span an incredible range of distances, from less than 1mm to over a metre in length.  The 
transmission of information along a single neuron, and communication between neurons, 
requires a large number of specific protein components and specialised membrane 
domains.  
It had been shown by Luigi Galvani (1737-98) as long ago as the 18th century that there 
was a connection between living tissue and electricity, and early models of neuronal 
function saw them as wires connecting an electrical circuit.  Ramón y Cajal (1852-
1934) was the first to identify that, at the point of contact between cells in the nervous 
system, there was no direct contact, but instead there existed a gap between the cells 
- the synapse.  This was a blow to the prevailing electrical theories of brain activity, as 
electrical circuits by their very nature do not contain gaps.  It was left to Otto Loewi (1873-
1961) to discover that neurons communicate with one another through the release of 
chemicals we now know as neurotransmitters.  These chemicals are released from the 
presynaptic cell and bind to receptors on the post-synaptic cell. Synapses are defined 
by the presence of vesicles, which store neurotransmitter.  The postsynaptic side is 
defined by the presence of the postsynaptic density, which includes the receptors which 
recognise neurotransmitter released by the presynaptic cell.  
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Neurons do utilise electrical signalling to transmit information along their length, and this 
electrical signal is converted to a chemical signal at the synapse.  The transmission of a 
signal along the axon of a neuron requires manipulation of the electrochemical potential 
of the cell.  
The interior of a typical mammalian neuron is negatively charged compared with the 
extracellular medium, at approximately -70mV (Alberts, 2008) (although this varies 
significantly between cell types).  The sodium potassium ATPase uses the energy 
from ATP hydrolysis to export three sodium ions out of the neuron while moving two 
potassium ions into the cell.  This helps maintain the interior of the cell as negatively 
charged compared with the outside, and ensures a higher external concentration of 
sodium (Alberts, 2008). 
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Figure 1-2 Schematic of a neuron
Neurons are cells specially adapted for the reception, processing and transmission of information. 
In a typical neuron, inputs are received at the dendrites, processed and transmitted along the 
axon to the pre-synaptic terminus, from where neurotransmitter can be released to signal to 
further cells.  
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Excitatory neurotransmitters activate receptors which can act as ion channels at 
postsynaptic sites.  Upon reception of these neurotransmitters, these channels are 
opened, allowing an influx of positively charged ions, mainly sodium and calcium.  This 
causes a local depolarisation of the membrane which triggers the opening of voltage-
gated sodium channels.  A rapid influx of sodium ions occurs, further depolarising the 
membrane.  This depolarisation of a small patch of membrane is sufficient to activate 
voltage-gated sodium channels in neighbouring membrane regions and a wave of 
depolarisation spreads along the membrane of the cell. The depolarisation is terminated 
by the inactivation of the voltage-gated sodium channels, preventing the influx of further 
sodium ions, and by the opening of voltage-gated potassium channels, which allow the 
rapid efflux of stored potassium, rebalancing the membrane potential (Alberts, 2008).  
This process generates an action potential, an ‘all-or-nothing’ response with a 
stereotypical waveform which is independent of the amplitude and waveform of 
the initial depolarisation (Figure 1-3).  The rate of stimulation, and hence the rate of 
propagation of action potentials, is a key mechanism by which information is transmitted 
in neural networks.  For instance, fast trains of action potentials in a presynaptic cell are 
associated with the establishment of long term potentiation (LTP) in the postsynaptic 
cells, particularly in the hippocampus, a region associated with learning and memory. 
Following the induction of LTP, a subsequent single action potential in the presynaptic cell 
is more likely to induce firing in the postsynaptic cell (Bliss and Gardner-Medwin 1973). 
Alternatively, low frequency trains of presynaptic firing can induce long term depression 
(LTD), where the postsynaptic cell becomes more resistant to subsequent activation.  
In C. elegans, there is an ongoing debate about the nature of neurotransmission.  While 
the C. elegans genome encodes a large and varied population of potassium channels 
and voltage-gated calcium channels, no voltage gated sodium channels have so far 
been uncovered.  It is likely that the small size of neurons in C. elegans, along with their 
high resistance, allows propagation of membrane depolarisation without the requirement 
for voltage-gated sodium channels, in a graded response (Goodman, Hall et al. 1998) 
(Figure 1-3).  The waveform and amplitude of graded potentials is directly coupled to that 
of the stimulus received by the cell.  In addition, the novel ion channels NCA-1 and NCA-
2, which are related to voltage-gated sodium channels but not voltage regulated, are 
thought to allow a leak of sodium ion into neurons which helps bring the resting potential 
closer to that required for excitation (Yeh, Ng et al, 2008).  
There have been reports of action potentials in some C. elegans neurons (Mellem, Brockie 
et al. 2008), although these may more accurately be described as plateau potentials, in 
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which neurons have two equally stable membrane potentials, (in this case at -70mV 
and -35mV), between which they can switch in response to depolarisation (Lockery and 
Goodman 2009).  
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Figure 1-3 Action potentials and graded potentials
Action potentials are self-terminating, all-or-nothing potentials with a stereotyped waveform.  So 
long as the initial depolarisation is above a pre-determined threshold, the response curve in the 
stimulated neuron is identical regardless of the strength of the stimulus (middle panel).  This kind 
of response has not been observed in C. elegans neurons, although some have been reported to 
have bistable waveforms (Mellem, Brockie et al 2008).  A more typical profile of the response of a 
C. elegans neuron is a graded response (bottom panel), where the waveform of the response is 
directly linked to the strength of the depolarising current.  Adapted from Alberts 2008.  
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How these types of potential encode information is less well understood than for action 
potentials, but their presence in a wide variety of cell types hints at a complex ‘code’ of 
neuronal activity  (Lockery and Goodman 2009).
Propagation of an action or graded potential to the synapse activates voltage-gated 
calcium channels and an influx of calcium ions, triggering exocytosis of synaptic vesicles 
and the release of neurotransmitter, which can signal to additional neurons.  In this way, 
cells can form complex process networks of activation and inhibition, as well as rapidly 
communicating information over great distances.  As predicted by Donald Hebb (Hebb 
1949), neurons which are in proximity to each other in networks become ‘wired together’ 
by repeated stimulation, as demonstrated by phenomena such as LTP.  Neurons in these 
networks have an intrinsic plasticity, allowing them to respond to these changes over 
time, which likely underpins learning and memory. One of the challenges of neuroscience 
is to find ways to investigate the function of neuronal networks in culture systems and in 
whole organisms. 
1.2.1 - Reconstruction of the nervous system of C. elegans
C. elegans has an invariant somatic cell lineage, as demonstrated by John Sulston who 
showed by careful analysis of the worm using DIC microscopy that essentially every cell 
division occurs in the same order in every individual (Sulston, Schierenberg et al. 1983). 
This provides a highly useful tool for probing a wide range of biological questions.  It 
allows a researcher to identify cells by their appearance and type, and using modern 
laser technology, to specifically ablate and kill specific cells during experiments (Sulston 
and Horvitz 1977; Sulston and White 1980; Kimble 1981).  This form of development 
reduces the variation between individuals; in all other model organisms even genetically 
identical animals have differences in the number of neurons in their nervous system. 
John White performed serial section electron microscopy reconstructions of the worm 
nervous system (White 1986).  This identified 302 neurons in the adult hermaphrodite, 
which can be classified into 118 groups defined by their structure.  The neurons in C. 
elegans generally have a simple structure, with few branches, and form approximately 
5000 chemical synapses, 2000 neuromuscular junctions and 600 electrical synapses, or 
gap junctions in the adult hermaphrodite.  Definition of synapses is by proximity, as the 
post-synaptic side of worm synapses generally lack the post-synaptic density seen in 
other organisms.  While individual synapses may form differently from animal to animal, 
the overall structure of the nervous system is consistent.  
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More recent work suggests that the arrangement of the nervous system follows an 
optimised pattern, reducing the energetic costs of wiring the neurons together, while 
maintaining functionality (Chen, Hall et al. 2006).
1.2.2 - Chemical synapses in C. elegans contain two classes 
of vesicle
Chemical synapses define the connection between neurons, while neuromuscular 
junctions (NMJ) are the interface between a muscle cell and a neuron.  These tend 
to operate in a one-to-one fashion, with each muscle cell receiving input from just 
one neuron.  As the contraction of striated muscle is important for quick responses in 
organisms, the rate of action at the NMJ is required to be extremely fast.  The distance 
between cell and muscle is between 20-30nm, meaning a diffusion time of around 100μs. 
The C. elegans neuromuscular junction is a key target of the research in this thesis. 
Neuromuscular junctions, like other synapses in C. elegans, are en passant, i.e. the 
axon runs parallel to the body wall muscles from which projections emerge to synapse 
onto the neuron (White 1986).  Unlike NMJs in mammalian systems, which demonstrate 
‘all-or-nothing’ action potentials, control of the C. elegans NMJ occurs through a graded 
response, more like that found in sensory neurons or in the mammalian central nervous 
system (Liu, Hollopeter et al. 2009).  
Both neuromuscular junctions and chemical synapses are defined by the presence of 
vesicles, containing neurotransmitter ready for release and signalling to the postsynaptic 
cell.  Two types of vesicle are observed in electron micrograph images of C. elegans 
synapses (Figure 1-4).  
1.2.3 - Small synaptic vesicles 
The first are small, clear vesicles of between 35–45 nm in diameter (Takamori, Holt et al. 
2006), and many of these are packaged with small molecule neurotransmitters (Figure 
1-4).  These vesicles bear resemblance to those found in endocrine cells, although unlike 
in endocrine cells the vesicles are produced in the Golgi and mature as they travel to the 
synapse.  Once in place and fully matured the vesicle can be emptied, recycled, refilled 
and readied for release again (Sudhof 2004).  This is a highly specialised and efficient 
version of the endo- and exocytosis cycles seen in trafficking in many other cell types, 
specially adapted for neuronal signalling.  It allows neuronal signalling to be sustained 
for long periods of time, long after an initial pool of filled vesicles produced in a more 
conventional fashion would have been depleted.  
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Vesicles were first isolated from cells using sucrose gradients to separate out structures 
based on their density, followed by filtering with controlled pore glass beads to separate 
out structures based on size.  This allowed pure preparation of synaptic vesicles leading 
to analysis of their composition and the raising of antibodies against protein targets.  It 
was found that many of these antibodies cross reacted with proteins from other species. 
Figure 1-4 Synapses contain synaptic vesicles and dense core 
vesicles
Shown is a cross section through the ventral nerve cord of C. elegans, bisecting three neurons 
- VA, VB and VD.  Shown below is a schematic illustrating some of the components observed in 
the electron micrograph - including small synaptic vesicles (blue circles) and larger, dense core 
vesicles (red circles).  The blue arrow indicates a docked small synaptic vesicle, while the red 
arrow points to a docked dense core vesicle.  
Taken from Hammarlund, Watanabe et al. 2008. Scale bar indicates 200 nm.  
B
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This demonstrated the conservation of structures between organisms, reinforcing 
the utility of genetic model organisms in neurobiology, such as that of mammalian 
synaptobrevin, which was found to be orthologous to the vesicle-associated membrane 
protein (VAMP) isolated from the electric organ of the Torpedo fish, and subsequently 
identified in fruit flies (Trimble, Cowan et al. 1988). 
Recent mass spectrometry analysis of purified vesicles demonstrates that they contain 
a vast array of proteins, many present in multiple copies.  Including the clathrin coat, 
involved in recycling, synaptic vesicles have been isolated containing over 400 distinct 
proteins, while a single vesicle may contain over 200 proteins in its vesicle membrane 
(Takamori, Holt et al. 2006).  Many of these are involved in the trafficking of the vesicle, 
filling with neurotransmitter, or are other components of the presynaptic membrane, such 
as ion channels, which may be transitory ‘visitors’ to the synaptic vesicles themselves, 
incidentally incorporated into the vesicle membrane following endocytosis.  The protein 
to lipid ratio is so high that each protein may be surrounded by only a few lipid molecules, 
or proteins may cluster into protein-rich domains on the vesicle membrane (Takamori, 
Holt et al. 2006).  
1.2.4 - Dense core vesicles
The second class of vesicles observed are larger, dense-core vesicles (LDCV) range 
from 40–53nm, and as their name suggests appear electron-dense in EM micrographs 
(Figure 1-4). Unlike small synaptic vesicles, they do not cluster at defined pre-synaptic 
release sites, and do not recycle at the synapse.  They contain larger neurotransmitter 
molecules, neuropeptides, synthesised in the endoplasmic reticulum, and catecholamine 
neurotransmitters such as dopamine and serotonin. Neuropeptides are large signalling 
molecules and can diffuse over long distances, ultimately binding to target receptors on 
neuronal and non-neuronal cells (Nassel 2002, Li 2008). 
1.2.5 - Electrical synapses in C. elegans
A third class of synapse is present in the nervous system of C. elegans, which lacks 
these neurotransmitter filled vesicles.  These are GAP junctions, and they comprise 
direct electrical linkages between cells.  They allow the passage of small molecules, 
generally estimated at less than 1 kD in size (Flagg-Newton, Simpson et al. 1979) and 
1.5nm in radius (Lo and Gilula 1979)  although this varies depending on the composition 
of the channel and the charge on the molecules.
Molecules such as inorganic ions, cyclic AMP and inositol 1,4,5 trisphosphate (IP3) have 
been shown to move through these channels (Kumar and Gilula 1996) directly coupling 
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the electrical potentials of linked cells.  There are an estimated 600 gap junctions in the 
C. elegans nervous system (White 1986) comprising some 10% of connections in the 
nervous system, although their biological significance is not well understood.  
GAP junctions in mammalian systems are composed of hemichannels formed of 6 
subunits of connexin proteins, while innexins, a related protein family, are the structural 
components of GAP junctions in invertebrates (Phelan, Bacon et al. 1998; Phelan 
and Starich 2001).  unc-7 and unc-9 encode innexins in C. elegans; they, along with 
unc-1, which encodes a stomatin which regulates GAP junction activity (Chen, Liu et 
al. 2007), have been implicated in the action of volatile anaesthetic compounds on the 
worm (Morgan, Sedensky et al. 1990), which cause a number of phenotypes including 
immobility.  Mutations in unc-1, unc-7 and unc-9 cause uncoordinated phenotypes, 
indicating that GAP junctions are important for locomotion in C. elegans (Chen, Liu et al. 
2007; Starich, Xu et al. 2009).  
1.2.6 - Neurotransmitters in C. elegans  
While direct electrical couplings between cells exist in the form of GAP junctions, the 
classical synapse has been the focus of most neuroscience work.  Neurotransmitters 
released from either small synaptic vesicles or dense core vesicles bridge the physical gap 
between neurons, converting an electrical signal into a chemical signal.  Neurotransmitters 
can be classified by their effects on a target cell, being either excitatory and depolarising 
the target, or inhibitory and hyperpolarising the target.  Some, such as acetylcholine, can 
be excitatory or inhibitory, depending on the receptors activated.  In chemical terms, we 
can distinguish between small molecule neurotransmitters, which includes amino acids 
such as glutamate, modified amino acids such as dopamine, or larger peptides which 
typically interact with G-protein coupled receptors, although all three neurotransmitter 
classes can interact with GPCRs.  Each class has its own mechanisms of production; for 
instance neuropeptides can be regulated at the transcriptional and translational levels, 
while the use of amino acids for neurotransmission is linked their roles in metabolism.  
1.2.6.1 - Acetylcholine
Acetylcholine is the major excitatory neurotransmitter at the human and worm 
neuromuscular junction, acting through the nicotinic acetylcholine receptor to stimulate 
muscle contraction (Rand 2007).  Acetylcholine is synthesised from acetyl-CoA and 
choline by choline acetyltransferase, encoded by cha-1 (Rand and Russell 1985, Figure 
1-5), which generates a protein similar to that found in Drosophia and mice (Rand 
and Russell 1985).  It is subsequently loaded into synaptic vesicles by the vesicular 
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acetylcholine transporter, encoded by unc-17 (Alfonso, Grundahl et al. 1993, Figure 
1-5).  Once released into the synapse, acetylcholine is broken down by acetylcholine 
esterases which help terminate signalling.  Four genes encode acetylcholine esterases 
in C. elegans - ace-1, ace-2, ace-3 and ace-4 (Combes, Fedon et al. 2000)- and a triple 
mutant ace-1;ace-2;ace-3 is embryonic lethal (Johnson, Rand et al. 1988) although this 
mutant may actually also contain a mutation in the ace-4 locus, making it a quadruple 
mutant (Combes, Fedon et al. 2000).  ace-2 is the dominant neuronal acetylcholine 
esterase, while ace-1 is expressed mainly in muscle cells (Combes, Fedon et al. 2003). 
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Figure 1-5 Acetylcholine signalling at the C. elegans NMJ
Acetycholine was the first chemical established as a neurotransmitter.  It is the major excitatory 
neurotransmitter at the C. elegans NMJ, where it is released from small synaptic vesicles to 
stimulate receptors on the body wall muscles. In this figure, the levamisole-sensitive receptor 
is depicted.  Acetylcholine esterases break down acetylcholine, terminating signalling, while the 
choline transporter, choline acetyltransferase and vesicular acetylcholine transporter combine to 
produce new acetylcholine molecules for loading into synaptic vesicles.  Acetylcholine signaling 
can be peturbed by a number of a pharmacological agents, including aldicarb and trichlorfon, 
which inhibit acetylcholine esterases, and levamisole and nicotine which directly stimulate 
different populations of acetylcholine receptors.  These drugs can be used to dissect pre- and 
post-synaptic changes in acetylcholine signalling.  Adapted from Rand 2007.  
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While screening for neurobiological mutants, Brenner used lannate, an inhibitor 
of acetylcholine esterases, along with tetramisole (also known as levamisole), an 
acetylcholine agonist to identify mutants (Brenner 1974, Figure 1-5).  Excess exposure 
to either chemical overstimulates acetylcholine signalling, hypercontracting the body 
wall muscles, and this leads to paralysis and eventually death of the animals through 
suppression of pumping of the pharynx.  Trichlorfon has also been used as an 
acetylcholinesterase inhibitor, but aldicarb is the more commonly used drug to inhibit the 
breakdown of acetylcholine (Figure 1-5).  
While having similar effects on the treated worms, levamisole and aldicarb have rather 
different mechanisms of action which are useful for identifying different kinds of mutants. 
Together, levamisole and aldicarb can be used to dissect mutants which otherwise have 
a similar phenotype, and provide a way of probing whether mutations act pre- or post-
synaptically.  
Aldicarb treatment enhances endogenous signalling, and screens have been conducted 
for mutants which are resistant to aldicarb (ric).  This screening can identify mutants 
in which the either the reception of the acetylcholine signal has been lost, or where 
the production or release of acetylcholine is inhibited (Nguyen, Alfonso et al. 1995). 
ric screens use either a chronic form of acetlycholine treatment, where growth and 
development occur at concentrations of aldicarb which would inhibit growth in wild-type 
animals (Nguyen, Alfonso et al. 1995); an alternative is to use an acute assay, with high 
concentrations of aldicarb for short (typically 1-2 hour) exposure times (Lackner, Nurrish 
et al. 1999; Nurrish, Ségalat et al. 1999).  The response of animals to aldicarb correlates 
with the level of acetylcholine release at the neuromuscular junction (Nurrish, Ségalat et 
al. 1999), allowing classfication of acetylcholine signalling in mutant animals.  
ric screens identified general components of the release machinery, such as 
synaptotagmin (snt-1) (Nguyen, Alfonso et al. 1995) and synaptobrevin (snb-1) (Nonet, 
Saifee et al. 1998), the production of acetylcholine (cha-1) and its transort into vesicles 
(unc-17) (Nguyen, Alfonso et al. 1995), along with many other previously unclassified 
mutations, including mutations in G-protein coupled receptors (Miller, Alfonso et al. 
1996).  Many proteins involved in acetylcholine signalling have also been identified 
through screening for mutants in acetylcholine-regulated behaviours, such as egg-laying 
(egl-30) and locomotion (unc-13).  
More recent forward genetic screens for ric mutants have been used to identify 
components of neurotransmitter release and signalling in the C. elegans nervous 
system (Sieburth, Ch’ng et al. 2005).  These screens are still identifying new mutants 
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which suggests that these screens are not saturated, despite many repeated rounds of 
screening.  
Treatment with levamisole has led to the identification of levamisole insensitive (lev) 
mutants; these represent mutations in the reception and processing of acetylcholine 
signalling.  For instance, the first levamisole insensitive mutant, lev-1, has been shown to 
encode a component of the acetylcholine receptor in the body wall muscles of C. elegans 
(Fleming, Squire et al. 1997).  The nicotinic acetylcholine receptors are pentameric, ligand-
gated ion channels (Unwin 2005), and one of the two nicotinic acetylcholine receptors 
in the body wall muscles is sensitive to levamisole and a number of its constitutent parts 
were identified through levamisole screening (Lewis, Wu et al. 1980).  The receptor is 
composed of five subunits - UNC-29, UNC-38 and UNC-63, along with the non-essential 
LEV-1 and LEV-8 subunits (Fleming, Squire et al. 1997; Richmond and Jorgensen 
1999; Culetto, Baylis et al. 2004).  The levamisole-insensitive receptor includes ACR-
16, thought to form a homo-pentameric receptor, but other components of the structure 
are unknown (Touroutine, Fox et al. 2005); loss of both classes of receptor ablates 
acetylcholine signalling at the neuromuscular junction (Touroutine, Fox et al. 2005). 
A great variety of other genes encode protein associated with nicotinic acetylcholine 
receptors in C. elegans (Gottschalk, Almedom et al. 2005), which act in the trafficking 
and stability, or modulation of the activity of the levamisole receptor, both in the muscles 
and when expressed in neurons.  
Acetylcholine also signals through two other classes of receptor, although their functional 
significance is less well understood.  G-protein coupled receptors, similar to the muscarinic 
acetylcholine receptor found in vertebrates, are encoded by gar-1 (Park, Lee et al. 2000), 
gar-2 (Lee, Park et al. 2000, Dittman and Kaplan 2008) and gar-3 (Park, Kim et al. 2003), 
all of which undergo alternative splicing, creating a great diversity of protein products.  C. 
elegans also posesses a novel class of acetylcholine-gated chloride channels (Putrenko, 
Zakikhani et al. 2005); these do not have a mammalian homologue.  
1.2.6.2 - Monoamines
Four monoamine neurotransmitters are present in C. elegans: serotonin and octopamine 
(Horvitz, Chalfie et al. 1982), dopamine (Sulston, Dew et al. 1975) and tyromine (Alkema, 
Hunter-Ensor et al. 2005); octopamine and tyromine are nematode-specific, while the 
others are found in mammalian systems.
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These neurotransmitters act through a large number of receptors, identified by homology 
to mammalian receptors or through screens for mutants (Schafer, du Bois et al. 1996, 
Chase 2007).  
Mutants display a wide range of phenotypes, ranging from egg-laying defects, 
misregulation of locomotion responses such as slowing in presence of food, changes in 
pumping, and modulation of learning and memory-associated behaviours, which will be 
explored later in the introduction.  
1.2.6.3 - Glutamate
C. elegans also makes use of glutamate, which in mammalian systems carries much of 
the fast synaptic transmission between cells (Brockie 2006).  In C. elegans, ten ionotropic 
glutamate receptors subunits have been identified (Brockie and Maricq 2003).  C. elegans 
has both N-methyl-D-aspartate (NMDA) and non-NMDA receptors, which are similar to 
the AMPA receptors found in mammalian systems.  These allow for exitatory signalling, 
while a third class of glutamate receptors, which allow the influx of chloride ions and 
are sensitive to the drug invermectin, mediate inhibitory signalling (Yates, Portillo et al. 
2003).  
1.2.6.4 - GABA
GABA is the major inhibitory neurotransmitter in C. elegans, and is used to control 
relaxation of body wall muscles during locomotion.  While one side of the body is 
stimulated to contract by the action of acetylcholine, the opposite side relaxes due to 
the action of GABA on GABA A receptors, which encode GABA-gated chloride channels 
(Schofield, Darlison et al. 1987).  A second class of GABA receptor, GABA B receptors, 
are 7-pass transmembrane proteins, which act through trimeric G-proteins to either 
activate potassium channels or inhibit voltage-gated calcium channels; both lead to an 
inhibition of the target neuron.  Loss of GABA signalling has less impact on locomotion 
than loss acetylcholine signalling, with the main locomotive phenotype in GABA mutants 
being defects in switching to backwards locomotion, as the animals exhibit a ‘shrinker’ 
phenotype (McIntire , Jorgensen et al, 1993).  
Interestingly, during defecation, GABA also controls an excitatory transmission event 
(Jorgensen 2005; Brockie 2006), highly unusual for an adult organism, although an 
important part of GABA signalling during mammalian development (Ben-Ari 2002). 
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1.2.6.5 - Neuropeptides
Neuropeptides are formed from large precursor molecules, processed into smaller 
signalling molecules by a variety of enzymes, including EGL-3 (Kass, Jacob et al. 2001) 
which is expressed throughout the nervous system.  The egl-3 mutants display defects 
in locomotion, egg-laying and mechanosensation.  After processing, the basic residues 
at which cleavage occurs are removed from the peptide sequences by the activity of 
carboxypeptidase E, encoded by egl-21.  Loss of egl-21 causes severe phenotypes in 
egg laying, locomotion, mechanosensation, and defecation (Jacob and Kaplan 2003). 
As assayed by mass spectrometry, both egl-3 and egl-21 mutants have lost the majority 
of processed neuropeptides (Husson, Clynen et al. 2006; Husson, Janssen et al. 2007). 
Neuropeptides are packaged into large dense core vesicles (DCVs), and some elements 
in the release of small synaptic vesicles and dense core vesicle are the same, including 
a possible requirement for UNC-13 in DCV exocytosis (Richmond, Davis et al. 1999; 
Sieburth, Madison et al. 2007), although this is debated (Hammarlund, Watanabe et al. 
2008).  
There is a requirement for calcium-dependent activator protein (CAPS) for release 
of DCV.  UNC-31, the C. elegans CAPS homologue, is required for the release of 
neuropeptides (Speese, Petrie et al. 2007; Zhou, Dong et al. 2007), and requires PKC-1 
activity (Sieburth, Madison et al. 2007).  unc-31 mutants are lethargic, but display either 
some (Miller, Alfonso et al. 1996) or no resistance to aldicarb (Charlie, Schade et al. 
2006), and has little or no role in the release of neurotransmitter from small synaptic 
vesicles (Speese, Petrie et al. 2007).  There are situations in which the requirement for 
unc-31 can be bypassed, such as by increasing the activity of PKA (Zhou, Dong et al. 
2007).
pkc-1 mutants are also resistant to aldicarb, but do not demonstrate any defects in release 
of acetylcholine from small synaptic vesicles as measured using electrophysiology 
(Sieburth, Madison et al. 2007).  They are, however, defective in dense core vesicle 
exocytosis as measured by the release of a fluorescently-tagged NLP-21::YFP fusion 
protein (Sieburth, Madison et al. 2007).  
These results indicate that the release of neuropeptides can be used by the worm’s nervous 
system to alter locomotion rates without directly altering the release of neurotransmitter. 
Neuropeptides act both by direct signalling to the receiving cell (Nassel 2009), and as 
neurohormones, affecting many different aspects of behaviour, including foraging, egg-
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laying, locomotion, as well as modulating the effects of other neurotransmitters (Li 2008, 
Nassel 2009).
1.3 - Analysis of behaviours in C. elegans
A major advantage of studying neurobiology in a whole organism is that the effects of 
changes in the nervous system can be observed by looking for changes in the behaviour 
of the animal.  The neurotransmitters listed above have a wide variety of effects on 
the behaviour of C. elegans, and a number of techniques have been developed to 
qualitatively and quantitatively analyse behaviour in C. elegans.  
Of particular interest to the focus of this thesis is the locomotive behaviour of the worm. 
Wild-type animals have a smooth sinusoidal locomotion, travelling predominantly in 
a forward direction when well fed.  Individual animals have stereotyped responses to 
touch, lack of food, or encountering noxious stimuli, for example; deviations from these 
can be observed, and mutants identified.
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Figure 1-6 Locomotion is mediated by alternate contraction and 
relaxation of the body wall muscles
Locomotion in C. elegans occurs as a result of contraction of the body wall muscles on one side of 
the body, due to the release of acetylcholine (ACh), and the relaxation of muscles on the alternate 
side of the body, due to the release of GABA.  The cell bodies of the motor neurons are all found 
in the ventral side.  Some theories predict the existence of stretch receptors (light blue arrows) 
which coordinate contraction of the body wall muscles along the anterior/posterior axis.  (Adapted 
from Seifert, Schmidt et al. 2006).  
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Measuring the number of body bends within a defined period of time, the change in the 
rate of locomotion between travelling on food or off food or total distance travelled in a 
given time provide metrics of behaviour (Hart 2005).  More detailed analysis includes 
the use of automated tracking devices, where worms are tracked for extended periods 
of time and algorithms used to extract data relating to their behaviour (Feng, Cronin et 
al. 2004).  Several packages have been developed for this purpose which either analyse 
individual animals in great detail (Cronin, Feng et al. 2006; Hoshi and Shingai 2006), 
providing data on the waveforms they produce and the amount of movement of the head 
relative to the body for instance, while others track multiple worms at low resolution 
(Ramot, Johnson et al. 2008) to obtain population-level information about the behaviour 
of animals in response to various stimuli.  These approaches offer the possibility of 
standardising behavioural analysis between labs, and of revealing subtle differences 
and similarities between phenotypes, allowing greater degrees of classification.  
1.3.1 - Locomotion is a complex, regulated behaviour
C. elegans is limited to movement in the dorsal-ventral axis.  On an agar plate, the 
animal effectively lies on its side, with the dorsal-ventral axis perpendicular to the plane 
of the plate (Figure 1-1).  Contractions of the 95 body wall muscles allow the production 
of sinusoidal waves to pass through the body of the animal, propelling the worm forwards 
(Seifert, Schmidt et al. 2006).  
These body wall muscles are innervated by motor neurons which have their cell bodies 
in the ventral nerve cord, but which can synapse onto either the dorsal or ventral muscles 
(Figure 1-6).  Three classes of motor neuron coordinate locomotion - class A and B are 
cholinergic neurons, releasing acetylcholine to stimulate contraction enabling backwards 
and forwards locomotion respectively, while class D motor neurons release GABA onto 
the muscles, allowing them to relax (Schuske, Beg et al. 2004).  Alternating patterns of 
contraction and relaxation on opposite sides of the animal set up the typical sinusoidal 
waveform.  Interestingly, animals completely lacking the neurotransmitter GABA are still 
capable of generating forwards and backwards locomotion; however they do exhibit 
more subtle locomotion defects including the ‘shrinker’ phenotype, where animals which 
are touched shorten, as all muscles improperly contract (Schuske, Beg et al. 2004).
Movement of the head of the animal is more complex and can occur in the left-right axis 
as well, enabling the head to move with a much greater degree of freedom compared to 
the rest of the body.  This may be important for foraging behaviours, allowing the animal 
to chemotax to distant food sources or avoid noxious substances (Hart 2005).    
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Locomotion is not limited to movement in the plane of the plate.  Animals are capable 
of climbing behaviours, evidenced by animals ‘escaping’ from the surface of agar plates 
onto the plastic sides or lids of their dishes, or climbing chunks of agar deposited on the 
surface.  C. elegans also presents an interesting although poorly understood behaviour, 
known as nictation, where animals climb the stalks of some types of fungi, and project 
their heads upwards (Schuske, Beg et al. 2004).  The reason for this behaviour is not 
known, nor is it clear that it has any physiological significance, but it is interesting to note 
that the environment in which we maintain C. elegans as a laboratory model is distinct 
from that which it would encounter in the wild, where the worm must navigate a three-
dimensional landscape of solid and semi-solid particles and liquids.  
The rate of locomotion is dependent on many factors, one of which is the presence 
of food.  Well-fed and starved animals move at the same rate in the absence of food. 
When they encounter food, however, they exhibit different responses.  Well-fed animals 
encountering food reduce their rate of locomotion, and this is known as the ‘basal slowing 
response’ (Sawin, Ranganathan et al. 2000).  This is a mechanosensory response to 
the physical contact with bacteria and can be replicated by an encounter with small 
beads which have no nutritional value (Sawin, Ranganathan et al. 2000).  This response 
requires dopamine signalling and can be mimiked by exposure to exogenous dopamine 
(Sawin, Ranganathan et al. 2000).  
Starved animals further reduce their rate of locomotion upon encountering food, in an 
‘enhanced slowing response’ (Sawin, Ranganathan et al. 2000).  This is evidence that the 
animals are able to recall the history of their nutritional status, and use this to modulate 
their behaviour.  This enhanced slowing requires serotonin signalling, as mutants which 
are defective in serotonin biosynthesis, such as cat-4, are unable to perform the enhanced 
slowing response (Sawin, Ranganathan et al. 2000).  This demonstrates a great degree 
of behavioural plasticity for an organism with such a simple nervous system, and this 
plasticity is a key feature of other aspects of behaviour as described below.  
1.3.2 - Swimming: a distinct form of locomotion, or a 
modified form of crawling? 
C. elegans is also capable of swimming behaviour, also refered to as thrashing.  In liquid, 
worms initiates a series of fast body bends, which occur with a frequency of between 50 
and 200 per minute, depending on the age of the animal, taking on a characteristic ‘C’ 
shape, as opposed to the ‘S’ shape observed when crawling on a plate, leading to some 
to label this as a distinct form of locomotion.  Swimming behaviour has been shown to be 
directional, allowing the worm to respond to and possibly navigate towards food sources 
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in a liquid environment (Pierce-Shimomura, Chen et al. 2008), a situation that the animal 
is highly likely to encounter in its native environment (Kiontke 2006).  
It is a topic of debate whether swimming behaviour is generated by a distinct motor 
program, or whether swimming and crawling represent the same behaviour in different 
mediums (Pierce-Shimomura, Chen et al. 2008; Berri, Boyle et al. 2009).  Screens for 
mutants incapable of swimming behaviour but capable of crawling locomotion have 
identified distinct a distinct set of genes - unc-80 and unc-79 - as more important for 
swimming than crawling (Pierce-Shimomura, Chen et al. 2008), although these mutants 
still present a crawling phenotype known as fainting (Pierce-Shimomura, Chen et al. 
2008, and see discussion as the end of Chapter 5 for more information).  
Other researchers have demonstrated a consistent, gradual change in locomotion when 
moving between media of different viscosities (Berri, Boyle et al. 2009).  This research 
argues that if the worms are moving through or over a solid or semi-solid medium, the 
amplitude of body bends decreases and the frequency increases (as viewed across a 
single worm from head to tail).  In liquid, the resistance offered by the medium is greatly 
decreased, and the frequency decreases while the amplitude increases, giving rise to 
the ‘C’ shape, an exagerrated form of the ‘S’ shape composed of a single body bend. 
This simpler model suggests that there is a single movement pattern in the worm, and 
that differences in swimming and crawling are generated by external physical properties 
but from a single internal pattern (Berri, Boyle et al. 2009).
This integrated model invokes the presence of stretch receptors along the length of the 
body of the worm which are able to sense curvature and influence the propogation of a 
wave along the body.  It has been proposed that the long extensions of the cholinergic 
motor neurons act to detect flex in the animal through putatitive stretch receptors (White 
1986).  This input from the body of the worm itself is referred to as proprioception. 
While these stretch receptors have not been biologically identified, they are predicted 
to exist in the majority of computer models of locomotion so far developed (reviewed 
in Boyle, 2010).  A number of mechanosensory components which have an impact on 
body posture and locomotion have been identified.  TRP-4, part of the transient receptor 
potential channel superfamily, is able to respond to mechanical stresses, and the trp-4 
mutant animals have exagerated body bends with a greater amplitude than wild-type (Li 
et al., 2006).  Rescue experiments demonstrate that is required in the single, long DVA 
neuron which runs the length of the worm’s body, and acts as a stretch receptor (Li et al., 
2006).  Mutants in unc-8, part of DEG/ENaC channel family (which have been identified 
as mechanosensory components in other systems), also have a locomotive phenotype 
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of reduced amplitude and wavelength (Tavernarakis, Shreffler et al., 1997).  Based on 
its expression pattern and genetic interaction with mec-6, UNC-8 is predicted to act as a 
stretch receptor component in C. elegans (Tavernarakis, Shreffler et al., 1997). 
C. elegans possess a number of mechanosensory neurons which respond to external 
touch, important for responses when encountering food (Sawin, Ranganathan et al. 
2000), as described above.  A touch to the head or tail elicits a movement away from 
the touch.  Animals can distinguish between light and harsh touch, and will also change 
direction in response to a tap on the plate on which they live (Chalfie and Sulston 1981) 
which produces reversals (Rose and Rankin 2001).  This factor can cause problems in 
the quantification locomotive of behaviours if the plates are not handled gently, although 
it has also been used to address questions of habituation to touch (Rose and Rankin 
2001).  Habituation requires the activity of dopamine through the DOP-1 receptor; dop-
1 mutants habituate at a much higher rate than wild-type animals (Sanyal, Wintle et al. 
2004).
Touch-insensitive mutants have been isolated, and the circuits for anterior and posterior 
touch sensitivity have been determined (Chalfie, Sulston et al. 1985) to produce a complex 
model for the integration of touch responses (Ernstrom and Chalfie 2002).  Experiments 
using genetically encoded calcium sensors have shown that components MEC-4 (a 
sodium channel) and its associated protein MEC-2 are required within a touch sensitive 
neuron for the processing of mechanical sensation, but the search for the component(s) 
which directly senses mechanical force continues (Bounoutas and Chalfie 2007). 
1.3.3 - Chemotaxis
C. elegans is able to detect a wide variety of chemical signatures, relating either to food 
or noxious substances, and a number of assays exist to quantify this behaviour (Ward 
1973), which allowed the identification of mutants defective in chemotactic behaviour 
(Lewis and Hodgkin 1977) and the unravelling of the structures and genetic pathways 
involved. The mechanisms governing chemosensory behaviour are complex, with cycles 
of turning behaviour known as pirouettes (Pierce-Shimomura, Morse et al. 1999) allowing 
animals to change their direction and search along chemotactic gradients.  
Worms respond to a variety of stimuli, including high concentrations of salt (Culotti and 
Russell 1978), and can chemotax to a variety of water-soluble chemicals, including 
nucleotides and amino acids (Ward 1973), as well as volatile organic compounds 
(Bargmann, Hartwieg et al. 1993).  Individual neurons be assayed using microfluidic 
chips to expose worms to specific compounds while observing the neuronal activity using 
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fluorescent reporters of neuronal activity (Chronis, Zimmer et al. 2007).  Worms can also 
adapt their responses based on their environment.  32 neurons in the head of the worm 
are exposed to the external environment through openings in the cuticle, while in males 
phasmids in the tail are also contain exposed nerve endings.  Laser ablation experiments 
identified a number of these as responsive to specific volatile organic compounds, such 
as benzaldehyde (Bargmann, Hartwieg et al. 1993).  Brief exposure to any of these 
compounds is attractive, but longer exposures of up to two hours allow the worms to 
adapt to the presence of the attractant (Colbert and Bargmann 1995), demonstrating the 
plasticity of this sensory system, and adaptation-specific mutants have been identified 
(Colbert and Bargmann 1995).   
This response to chemosensory stimuli is modulated by the presence of food; 
benzaldehyde, for example, is treated as a indicator of the presence of food, making 
chemotaxis to this chemical worthwhile.  If worms are conditioned by exposure to 
benzaldehyde in the absence of food, the chemical no longer acts as an attractant 
(Nuttley, Atkinson-Leadbeater et al. 2002).  This effect is mimiked by the presence of 
serotonin, which acts as a signal for the presence of food, and mutants in serotonin 
signalling are unable to suppress adaptation to benzaldehyde in the presence of food 
(Nuttley, Atkinson-Leadbeater et al. 2002).  This adaptation is also sensitive to the 
presence of high densities of C. elegans population, regulated through sensation of 
a secreted neuropeptide (Yamada, Hirotsu et al. 2010); together these variations of 
response indicate something of the sensitivity and processing power produced by such 
a small nervous system.  
1.3.4 - Oxygen, light and temperature sensitivity 
Soil temperature can vary by tens of degrees during the course of a day (Kiontke 2006), 
and temperature changes can have a large effect on growth rate (Byerly, Cassada 
et al. 1976) and lifespan (Lakowski and Hekimi 1996).  C. elegans will avoid noxious 
temperatures outside of a range of 12oC to 25oC.  This behaviour is dependent on 
a number of sensory neurons in the head of the worm; when ablated, the worm no 
longer tracks temperature (Mori and Ohshima 1995).  When grown at temperatures 
between 16 and 25 degrees in the presence of food, C. elegans is able to migrate to 
its growth temperature when offered a range of temperatures as an adult (Hedgecock 
and Russell 1975) and track along this gradient (isothermal tracking).  The presence 
of food is important; animals grown at a set temperature in the absence of food will not 
perform isothermal tracking.  This behaviour is remarkably precise, allowing the animals 
to navigate in a range of ±0.2oC outside of their growth temperature (Hedgecock and 
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Russell 1975).  When transferred to a temperature range in the absence of food, this 
tracking behaviour is maintained for several hours, after which a searching behaviour 
is intiated to look for new sources of food (Mori 1999).  This again demonstrates the 
plasticity of behaviour in C. elegans - the ability to learn and follow a pattern of behaviour 
is overruled once that pattern is no longer productive.  
C. elegans is sensitive to the concentration of oxygen in the atmosphere, preferring 
a range between 5-12%, which is thought to be part of a strategy to detect anaerobic 
environments, such as those generated by the digestion of rotting plant matter by bacteria 
(de Bono and Bargmann 1998; Gray, Karow et al. 2004),.  This aerotaxis behaviour can 
also be modulated by experience and the presence of food, thought to be integrated by 
the neuropeptide npr-1 (Cheung, Cohen et al. 2005), a homologue of neuropeptide Y (de 
Bono and Bargmann 1998).  
C. elegans also responds to light in the blue part of the spectrum; animals exposed to 
short wavelength light move away from the point of exposure (Ward, Liu et al. 2008). 
Ablation of seven ciliated neurons in the head abolished this response, which requires 
cyclic guanosine monophosphate (cGMP)-sensitive cyclic nucleotide–gated (CNG) 
channels - specifically tax-2, which was identified as a chemotaxis mutant (Ward, Liu 
et al. 2008).  This phototaxis response may help animals avoid exposure to damaging 
levels of light, or help them navigate in the complex three-dimensional environment of 
the soil.  
1.3.5 - Feeding is a regulated behaviour
Two other behaviours are of importance for the experiments conducted in this thesis. 
The uptake of food and the removal of food waste are both regulated behaviours which 
can be directly observed in living worms, and provide a measure of the nutritonal status 
of the animal, as well as providing indicators for the activity of a number of important 
genetic pathways.  C. elegans feeds upon bacteria which it finds through a variety of 
sensing behaviours.  
When it locates bacteria, they are drawn into the pharynx of the worm, where strong 
pharyngeal muscles and an organ known as the grinder combine to physically disrupt 
the integrity of the bacterial cells, making them easier to digest in the intestine (Avery and 
Horvitz 1987; Avery and Horvitz 1989).  
Bacteria are drawn into the pharynx through the corpus, the most anterior region of the 
pharynx, which contracts, along with the isthmus, the central portion of the pharynx, 
opening the lumen and allowing bacterial entry.  Bacteria which have already been 
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subject to grinding are expelled into the intestine by contraction of the terminal bulb.  This 
cycle of contraction is complemented by isthmus peristalsis, where bacteria previously 
drawn into the pharynx are transferred to the grinder, and processed. 
This feeding behaviour, which is important for the survival of the worm, also provides 
a useful tool for studying neuronal networks.  20 neurons innervate the pharyngeal 
muscles, and these neurons function separately from the rest of the C. elegans nervous 
system (Avery and Horvitz 1989; Avery 1993).  Inhibition of feeding by paralysis of the 
pharangyel muscles provides a measure of acetylcholine release.
1.3.6 - Defecation follows a rhythmic motor pattern
Defecation in an adult hermaphrodite C. elegans occurs approximately once every 50 
seconds when well fed (Avery 1997).  The defecation motor programme (DMP) can be 
divided into three phases: posterior body contraction (pBoc), anterior body contraction 
(aBoc) and enteric muscle contraction (Emc) causing expulsion (Exp).  The initial 
contraction of the posterior dorsal and ventral body wall muscles drives the contents 
of the intestine forwards (pBoc). This is followed by contraction of the anterior dorsal 
and ventral body wall muscles and movement of the pharynx backwards into the gut 
(aBoc). This pressurises the intestine, so upon contraction of the enteric muscles, which 
is regulated by GABA (acting in an excitatory fashion (Thomas 1990)), the anus opens 
and the gut contents are expelled (Exp).  Other neurotransmitters, including serotonin, 
are involved in regulating this cycle (Segalat, Elkes et al. 1995).  
The length of the cycle is determined by cyclical fluctuations in the release of calcium 
in the posterior intestine, and this in turn is determined by the activity of the inositol 
trisphophate (IP3) receptor (Dal Santo, Logan et al. 1999), which when reduced 
lengthens the cycle, and when overexpressed decreases the cycle length.  As such this 
has provided a model for studying the effects of drugs which disrupt the activity of the IP3 
cycle (Tokuoka, Saiardi et al. 2008).  Cycle times are also affected by a large number of 
genes expressed in the intestine (Branicky and Hekimi 2006).
1.4 - The regulation of neurotransmitter release
The behaviours and analysis described above demonstrate the importance of tight 
control of neurotransmitter release in C. elegans.  Locomotion is vital to the survival of 
worms, allowing them to avoid noxious substances and temperatures, navigate to food 
and to find a mate, while the strength of these responses can all be varied to account for 
the nutritonal status of the animal.  These aspects of behaviour are dependent on the 
correct regulation and release of neurotransmitters such as dopamine, serotonin and 
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acetylcholine, and therefore the control of release must be properly managed.  In the 
next section, I will examine the process by which neurotransmitter is released, and some 
of the ways in which that release can be regulated at the molecular level.  
1.4.1 - The synaptic vesicle cycle
Release of neurotransmitter is stimulated by the depolarisation of the presynaptic 
membrane, activating voltage-gated calcium channels and allowing the entry of calcium 
ions.  This initiates is a specialised form of exocytosis, a conserved mechanism for 
releasing the contents of vesicles, adapted and refined in neurons for rapid signalling. 
Exocytosis is confined to a distinct region of the synapse, known as the active zone, 
which is defined by its specific lipid and protein content.  The active zone aligns with the 
post-synaptic density of the receiving cell such that neurotransmitter is released directly 
towards the post-synaptic target site, reducing diffusion time.  This spatial regulation of 
release also helps confine neurotransmitter to the synapse, reducing off-target effects.
The machinery underpinning this release has been the subject of intense investigation 
for over thirty years.  Early in vitro studies determined that fusion was an active process, 
requiring ATP and cytosol, and could be inhibited by the sulfydryl reagent N-ethylmalemide 
(NEM) (Rothman 1994).  This lead to a hunt for the NEM-sensitive factor (NSF), which was 
identified as an ATPase (Block, Glick et al. 1988), followed by biochemical identification 
of three interactors of NSF, known as α/β and γ-SNAP (for soluble NSF attachment 
protein), the components in cytosol necessary for fusion.  These SNAPs were able 
to interact with three previously identified neuronal proteins - syntaxin-1, VAMP2 (for 
vesicle associated membrane protein, also known as synaptobrevin) and SNAP-25 (for 
synaptosome-associated protein of 25kD) - and these proteins were named SNAREs 
(SNAP Receptors) (Sollner, Whiteheart et al. 1993).  Using non-hydrolysable analogues 
of ATP to inhibit NSF and dissasembly of the protein complex, it was found that these 
three proteins formed a highly stable structure.  They now form the basis for growing 
families of SNARE proteins, which have been shown to mediate membrane fusion events 
in all cell types.  
1.4.2 - Fusion and the SNARE Proteins
SNAREs contain a domain of around 60 amino acids capable of forming helical bundles 
when brought together in close proximity.  Four helices are required for the formation 
of this SNARE complex.  In neurotransmission the pre-synaptic membrane-associated 
SNAP-25 donates two helices along with one from syntaxin, an integral membrane 
protein.  The fourth helix is provided by synaptobrevin, which is part of the vesicle 
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membrane.  The formation of the complex appears to occur in a stepwise fashion (Figure 
1-7).  Syntaxin contains an inhibitory domain which binds to its own SNARE helix and 
prevents formation of the SNARE complex - this is known as the closed conformation of 
syntaxin (Figure 1-7).  Once syntaxin is in the open conformation, it is compenent to bind 
to SNAP-25, and this intermediate complex is able to then bind to synaptobrevin on the 
vesicle membrane.  This forms the trans SNARE complex; once the two membranes have 
fused, the complex is referred to as the cis SNARE complex, with all of the components 
in the same membrane (for review see Palfreyman 2008).  
This interaction appears to provide some level of specificity, as only specific combinations 
of vesicle- and presynaptic membrane-associated SNAREs are able to form SNARE 
complexes.  For instance, vesicles containing synaptobrevin are not competent to fuse 
with one another or with membrane regions other than the active zone (Sudhof 2004).
Cell membranes are composed of lipid bilayers with a hydrophobic interior.  Although 
the exact membrane conformation produced during fusion is unknown, this hydrophobic 
surface must interact with the charged surface of the membrane during fusion.  It is 
thought that the formation of this highly stable SNARE complex generates the energy 
required to overcome the energetically unfavourable process of membrane fusion 
(Sudhof 2004).  One early hypothesis is that SNARE proteins constitute the minimal 
protein machinery required for fusion of membranes, as evidenced by their ability to 
induce fusion between vesicles in vitro (Weber, Zemelman et al. 1998).  Mouse knock-
outs of synaptobrevin (Schoch, Deak et al. 2001) show significantly decreased regulated 
exocytosis (down by a factor of 100), although they retain some membrane fusion events, 
with spontaneous release downregulated by a factor of 10; this is most likely due to the 
activity of homologous proteins.  Over 20 different SNARE proteins have been isolated 
in preparations of synaptic vesicles, although there is a potential that some of these 
represent contamination from other trafficking vesicles (Takamori, Holt et al. 2006).  
In C. elegans there is an absolute requirement for SNARE proteins.  unc-64, snb-1, ric-
4, which encode syntaxin, synaptobrevin and SNAP-25 orthologues in C. elegans, are 
required for viability; mutations which disrupt their function cause early embryonic lethality 
(Nonet, Saifee et al. 1998; Saifee, Wei et al. 1998).  Analysis of these dying animals 
demonstrated that they were still capable of some degree of movement, indicating that 
there are likely to be other SNARE proteins in addition to these classically recognised 
ones active in the worm nervous system; this movement could also be due to the effect 
of maternally-contributed mRNAs.  
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Additionally, a role has been proposed for the vesicular ATPase in membrane fusion in 
C. elegans (Liegeois, Benedetto et al. 2006).  While the V-ATPase is more commonly 
associated with establishing a proton gradient which is required to load vesicles with 
neurotransmitter (Futai, Oka et al. 2000), the role in membrane fusion can be separated 
from this function (Liegeois, Benedetto et al. 2006), although the importance of this result 
has been long debated.  A recent report demonstrates that the V-ATPase is able to bind 
directly to synaptobrevin (Di Giovanni, Boudkkazi et al. 2010) and that this interaction 
is mediated by calcium ions and the protein calmodulin.  Injection of an interfering 
peptide into presynaptic cells in tissue culture was able to ihibit neurotransmitter release, 
demonstrating that this interaction is important for neurotransmitter release (Di Giovanni, 
Boudkkazi et al. 2010).  
Figure 1-7 SNARE complex formation
Syntaxin is an integral membrane protein containing a SNARE helix (red) and three additional 
helices (Habc, brown).  Syntaxin exists in two conformations - a closed conformation where 
the Habc helices block access to the SNARE helix - and an open conformation.  In the open 
conformation, syntaxin is able to bind to SNAP-25 (green) and ultimately form a tight SNARE 
complex with SNAP-25 and synaptobrevin (purple), a SNARE protein found on vesicle 
membranes.  Adapted from Toonen and Verhage, 2003.  
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1.4.3 - Docking and Priming
Before the formation of a SNARE complex can occur, vesicles must be brought into 
contact with the presynaptic membrane in a process referred to as docking, and prepared 
for release by entering a primed state by the formation of the SNARE complex.  The 
status of individual vesicles as either docked or primed is infered through morphological, 
biochemical and electrophysiological criteria (see references in Palfreyman 2008), 
although the boundaries between these classes are becoming more blurred.  
Ca2+
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Clatrhin-mediated
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Filling
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Figure 1-8 The synaptic vesicle cycle
Synaptic vesicles are produced in the Golgi and trafficked to the synapse.  They are filled 
with neurotransmitter and stored in the synapse ready for release.  They undergo a series of 
steps - docking, priming and fusion - mediated by a large number of synaptic proteins, allowing 
release of neurotransmitter into the synaptic cleft to activate receptors on the post-synaptic cell. 
The vesicles are recovered from the pre-synaptic membrane by a process of clathrin-mediated 
endocytosis, recycled back into the synapse and refilled, ready for further rounds of regulated 
exocytosis.  Adapted from Sudhof 2004.  
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For instance, docking is normally considered to occur before priming (Broadie, 
Prokop et al. 1995), but more recent studies suggest that the primed vesicles (defined 
electrophysologically) may correspond to the class of vesicles considered to be docked in 
EM micrographs, based on their location and distance from the membrane (Hammarlund, 
Watanabe et al. 2008).  Recent studies utilising high pressure freezing have identified 
reductions in docked vescile number in unc-13 and unc-64 mutant animals.   
UNC-13 is a cytoplasmic syntaxin binding protein (Betz, Ashery et al. 1998) originally 
identified in early screens for C. elegans mutants, where unc-13 reduction-of-function 
mutants were observed to be paralysed and almost completely incapable of movement 
(Brenner 1974).  Complete loss of function of UNC-13 is lethal.  
unc-13 mutants are highly resistant to aldicarb, but sensitive to levamisole, the classic 
phenotype of a presynaptic mutant with reduced neurotransmitter release. unc-13 is 
required for synaptic vesicle release in C. elegans (Richmond, Davis et al. 1999).  Roles 
for UNC-13 in both docking and priming have been suggested, and the separation of 
these roles is controversial, but UNC-13 appears to promote neurotransmitter release, at 
least in part, by binding to and altering the conformation of syntaxin, and by recognising 
specific membrane domains.  
UNC-13 proteins contain C1 and C2 domains, originally identified as domains of protein 
kinase C (Nishizuka 1988).  C1 domains bind to diacylglycerol (DAG), a lipid second 
messenger found in the presynaptic membrane (Ono, Fujii et al. 1989).  Regulation of 
the composition of the presynaptic membrane is important for the recruitment of UNC-
13 (Lackner, Nurrish et al. 1999; Nurrish, Ségalat et al. 1999). DAG defines distinct 
docking sites for UNC-13, which in turn is responsible for binding syntaxin and promoting 
SNARE complex formation.  UNC-13 also contains a C2 domain; some C2 domains are 
sensitive to phospholipids and able to bind Ca2+ ions, while others may act as protein-
protein interaction domains (Cho and Stahelin 2006).  The C2 domain of both UNC-13 
and munc13 are required for UNC-13 and munc13 to bind to syntaxin (Madison, Nurrish 
et al. 2005; Stevens, Wu et al. 2005).
UNC-13 binds to the N-terminus of syntaxin, and may promote the open form of syntaxin 
(Brose, Rosenmund et al. 2000; Madison, Nurrish et al. 2005).  UNC-13 is proposed to 
flip syntaxin from its closed to open state, promoting the incorporation of syntaxin into the 
SNARE complex (Richmond, Weimer et al. 2001).  Expression of a constiutively open 
form of syntaxin in an unc-13 mutant is able to bypass the need for UNC-13 in priming of 
synaptic vesicles (Richmond, Weimer et al. 2001), although some have argued that the 
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loss of tomosyn is also required to completely bypass the need for UNC-13 (McEwen, 
Madison et al. 2006).  
Tomosyn is another protein which interacts with the core release machinery during 
priming, and acts in an inhibitory fashion with respect to neurotransmitter release with 
a negative effect on priming.  Tomosyn contains a SNARE domain homologous to that 
of synaptobrevin, and forms an inhibitory complex with syntaxin (Fujita, Shirataki et al. 
1998; Yokoyama, Shirataki et al. 1999; Hatsuzawa, Lang et al. 2003).  The single C. 
elegans homologue, TOM-1, is an inhibitor of both synaptic vesicle release and dense 
core vesicle release (Gracheva, Burdina et al. 2006; Gracheva, Burdina et al. 2007; 
Gracheva, Burdina et al. 2007).  
Another protein thought to play a role in docking is rab3 (rab-3) a small GTPase associated 
with synaptic vesicles, mutants of which exhibit subtle defects in neurotransmission and 
locomotion (Nonet, Staunton et al. 1997; Mahoney, Liu et al. 2006).  Rabs are commonly 
found on vesicles in non-neuronal cells and act to provide specificity during trafficking. 
They require a receptor on the target membrane, and one candidate in C. elegans is Rim 
(unc-10) an interactor of rab-3, mutants of which have an aldicarb defect (Nonet, Staunton 
et al. 1997).  unc-10 mutants also display a reduction in the number of docked vesicles 
at synapses (Weimer, Gracheva et al. 2006) and further work has demonstrated that 
UNC-10 and RAB-3 directly interact to recruit synaptic vesicles to the correct location in 
the presynaptic membrane in preparation for release (Gracheva, Hadwiger et al. 2008).
Munc18 (unc-18) a syntaxin-interacting protein, is also believed to play a role in docking 
- 80% of neurotransmission is abolished in the unc-18 mutant, and the number of docked 
vesicles is dramatically reduced (Weimer, Richmond et al. 2003).  The mammalian 
homologue - Munc-18 - is important for synaptic function, Munc-18 mice exhibit severe 
synaptic defects, with a complete loss in synaptic activity and the death of neurons, 
while the initial wiring of the nervous system is unaffected, suggesting an adult role for 
Munc-18 (Verhage, Maia et al. 2000).  While Munc-18 and UNC-18 both bind to the 
SNARE protein syntaxin in vitro (Toonen and Verhage 2003), analysis of C. elegans unc-
18 mutant animals has revealed no difference in the localisation of UNC-64 (syntaxin) 
and the open form of syntaxin does not rescue mutants in unc-18 (Weimer, Richmond et 
al. 2003).  The precise role of munc-18 remains under investigation.   
1.4.4 - Calcium sensing and release - a role for synaptotagmin
Primed vesicles represent an intermediate in exocytosis which is calcium-ion sensitive. 
Neurotransmitter release is temporally controlled by the influx of calcium ions via voltage-
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gated calcium channels.  Following the influx of calcium, neurotransmitter release can 
occur on the order of 100μs (Heidelberger, Heinemann et al. 1994), the fastest rate 
of exocytosis yet measured, because the exocytosis machinery is effectively frozen 
half-way through the process.  One of the proteins thought to regulate this release is 
synaptotagmin, an integral membrane protein of the synaptic vesicle which can bind 
calcium.  Encoded by snt-1 in the worm, mutants are uncoordinated and have impaired 
synaptic transmission (Nonet, Grundahl et al. 1993).   Synaptotagmin is thought to be a 
key sensor of calcium-regulated release (Fernandez-Chacon, Konigstorfer et al. 2001), 
although its precise mechanism of action is still under investigation (Koh and Bellen 
2003), and it may in have other roles in the synaptic vesicle cycle which complicate this 
picture (Jorgensen, Hartwieg et al. 1995).  
This regulation by calcium release is imperfect however, as neurons are capable of 
spontaneous release, which can be measured electrophysiologically and is observed 
as spontaneous mini-post-synaptic currents.  Therefore every neuron is said to have a 
certain release probability, which is considerably enhanced by the influx of calcium ions. 
Neurons are considered to be ‘reliably unreliable’ in their release frequency (Goda and 
Sudhof 1997) and this characteristic provides an opportunity for regulation and either 
enhancement or depression of release.  
1.4.5 - Models of release dynamics
The standard model of vesicle fusion is complete fusion of the vesicle with the presynaptic 
membrane, with in which the curvature of the vesicle is completely lost.  A fresh vesicle is 
then reformed away from the active zone and membrane removed to prevent growth of the 
presynaptic membrane.  This process utilises the clathrin-mediated endocytosis pathway 
(Heuser and Reese 1973; De Camilli and Takei 1996), and involves the reformation 
of vesicles through the action of dynamin, which scissions the budding vesicle from 
the presynaptic membrane (Sweitzer and Hinshaw, 1998).  This endocytosis event is 
accompanied by refilling of the vesicle with neurotransmitter ready for additional rounds 
of release (Sudhof 2004).  
1.4.6 - Vesicle endocytosis - a role for membrane lipid 
regulation
A number of key players in vesicle recycling have been identified, and play clear roles 
in behavioural responses in C. elegans.  One of these is synaptotagmin, which binds to 
AP-2, the clathrin adaptor protein, suggesting a role in endocytosis (Fukuda, Moreira et 
al. 1995; Haucke and De Camilli 1999).  EM imaging of C. elegans reveals that vesicles 
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are depleted in a snt-1 mutant (Jorgensen, Hartwieg et al. 1995), although this evidence 
for a role in endocytosis does not rule out a role in calcium-mediated exocytosis.  
Synaptojanin and endophilin, encoded in worms by unc-57 and unc-26 respectively, 
also play roles in vesicle recycling.  Endophilin is a BAR-domain containing protein, and 
may aid the reformation of vesicles by causing bending of the membrane, but it also 
associates with synaptojanin via an SH3 domain, and may be responsible for its correct 
localisation in the presynaptic membrane (Schuske, Richmond et al. 2003).  These two 
roles - in membrane bending and scaffolding - have been separated in a recent set of 
experiments in C. elegans (Bai, Hu et al. 2010).  These demonstrate that mutations in the 
BAR domain of endophilin disrupt endocytosis, while mutation of the scaffolding regions 
do not (Bai, Hu et al. 2010), suggesting that the dominant role for endophilin is inducing 
membrane curvature.  Interestingly, endophilin appears to cycle between the plasma 
membrane and synaptic vesicles, leading to a model where exchange of endophilin may 
help couple exocytosis and endocytosis (Bai, Hu et al. 2010).  
Synaptojanin encodes a polyphosphoinositide phosphatase which is responsible for the 
removal of PIP2 from the presynaptic membrane, and synaptojanin mutant mice have 
defects in the uncoating of synaptic vesicles (Cremona, Di Paolo et al. 1999), as do 
unc-57 and unc-26 mutants in C. elegans (Schuske, Richmond et al. 2003).  Evidence 
from C. elegans mutants also points to a role in vesicle recycling for these proteins; unc-
26 and unc-57 mutants are uncoordinated, and have a reduction in synaptic vesicles 
as observed by EM.  The double mutant is no more severely affected than the single 
mutants (Schuske, Richmond et al. 2003) suggesting that they act in the same pathway 
for recycling. 
The small GTPase dynamin is responsible for the fission step of endocytosis, where 
clathrin-coated pits separate from the plasma membrane allowing the reformation of 
vesicles (Sweitzer and Hinshaw 1998); in C. elegans, temperature-sensitive dyn-1 
mutants are highly uncoordinated at the non-permissive temperature (Clark, Shurland et 
al. 1997).  The activity of dynamin is closely regulated.  Mutations in two proteins known 
to interact with dynamin cause defects in synaptic transmission and more specifically a 
reduction in the number of synaptic vesicles, EHS-1 (Eps15) and UNC-57 (endophilin) 
(Salcini et al., 2001; Schuske et al., 2003), although the recent report on the nature of 
the endophilin scaffolding role reduces the significance of this interaction (Bai, Hu et al. 
2010).  
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1.4.7 - Exocytosis of dense core vesicles
Neuropeptides are packaged into large dense core vesicles (DCVs), and some 
elements in the exocytosis of small synaptic vesicles and dense core vesicle are the 
same, particularly a requirement for SNARE proteins in membrane fusion (Hammarlund, 
Watanabe et al. 2008).  The requirement for other proteins important in synaptic 
vesicle docking and priming, such as UNC-13 is more controversial, with some papers 
demonstrating a requirement for UNC-13 in DCV exocytosis (Richmond, Davis et al. 
1999; Sieburth, Madison et al. 2007), while others detect no role for UNC-13 in DCV 
exocytosis (Hammarlund, Watanabe et al. 2008).  
The protein CAPS - calcium-dependent activator protein (UNC-31 in C. elegans) - is 
structurally related to UNC-13, containing an UNC-13 homology domain, a PH domain, 
PI binding domain and a C2 phosphoinositide and calcium-binding motif. In C. elegans 
unc-31 mutants are defective in DCV release (Speese, Petrie et al. 2007; Zhou, Dong 
et al. 2007) and there is an almost complete absence of docked DCVs (Hammarlund, 
Watanabe et al. 2008).   This suggest that UNC-31 may play a complementary role with 
respect to dense core vesicle exocytosis to UNC-13 in small synaptic vesicle exocytosis. 
unc-31 mutants are lethargic, but display either some (Miller, Alfonso et al. 1996) or 
no resistance to aldicarb (Charlie, Schade et al. 2006), suggesting that UNC-31 plays 
little or no role in the release of neurotransmitter from small synaptic vesicles (Speese, 
Petrie et al. 2007). There are situations in which the requirement for unc-31 can be 
bypassed, such as by increasing the activity of PKA (Zhou, Dong et al. 2007) although 
the mechanism of action in this case is unknown.  
Treatment with phorbol esters, an analogue of the membrane-bound second messenger 
diacylglycerol (DAG), increases the size of the readily releasable pool of both DCVs 
and synaptic vesicles in tissue culture preparations (Malenka, Madison et al. 1986), 
consistent with a role for proteins which bind to DAG.  UNC-13 and PKC-1 both contain 
C1 domains which are able to bind DAG and phorbol esters, and in mammalian systems 
both MUNC-13 and PKC are required for synaptic vesicle and DCV exocytosis.  In C. 
elegans however, PKC-1 appears to play a more dedicated role in DCV release, as pkc-
1 mutants do not display a reduction in synaptic vesicle exocytosis (Sieburth, Madison 
et al. 2007), although they do demonstrate a reduction in DCV release.  Evidence from 
mammalian systems suggests that PKC may act to regulate DCV release through 
phosphorylation of SNAP-25, part of the SNARE complex (Nagy, Matti et al. 2002) or 
through phosphorylation of munc-18 (Barclay, Craig et al. 2003).  
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Unlike synaptic vesicles which continually recycle at the synapse, undergoing rounds of 
refilling and release, the dense core vesicle pool is restocked directly by vesicles budding 
from the Golgi, although a single DCV may undergo several repeated exocytosis events 
- each of which sees the release of only a portion of its contents (Perrais, Kleppe et al. 
2004). 
1.5 - The genetic pathways regulating neurotransmitter 
release in C. elegans
The synaptic vesicle cycle is a specially adapted form of exocytosis allowing regulated 
release of neurotransmitter.  The amount of neurotransmitter released at any one time 
from any particular neuron can be modulated by a large number of factors, and it is these 
which help an organism like C. elegans which has only 302 neurons to produce and 
modulate the a wide range of behaviours described earlier.  A large number of experiments 
have defined an extensive genetic pathway, ranging from reception of neurotransmitter 
at the post-synaptic membrane through to the release of acetylcholine onto the body wall 
muscles to initiate locomotive responses, and this pathway can be modulated to allow for 
changes in regulated release over time. 
1.5.1 - G-protein coupled receptors are targets for 
neuromodulators in C. elegans
There are two main classes of receptor that are sensitive to neurotransmitters.  The first 
class is ionotropic receptors, such as the nicotinic acetylcholine receptor which tend 
to be associated with rapid signalling.   They can also induce long-lasting effects on 
the behaviour of neurons as well, a good example being the calcium-permeable NMDA 
receptor, which is associated with formation of LTP (Collingridge 2003).  
The other major class of neurotransmitter receptor are the seven-transmembrane helix 
family of G-protein coupled receptors (GPCRs).  These receptors are associated with 
more subtle modulation of the activity of neurons, acting over longer time periods than 
the fast action of ligand-gated ion channels (Nassel 2009).  Neuromodulators such as 
serotonin and dopamine, and larger molecules such as neuropeptides, interact with 
these receptors, which tend to have a higher affinity for their neurotransmitter substrate 
than ionotropic receptors, allowing them to function at lower concentration of signalling 
molecules and at longer distances from the site of neurotransmitter release (Nassel 
2009).  
GPCRs in turn interact with heterotrimeric G-proteins, and it is these second messengers 
which transduce the signals through the cell.  G-proteins consist of alpha, beta and 
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gamma subunits, and are regulated through the exchange of GDP for GTP on the alpha 
subunit.  In their inactive state, the alpha subunit associates with GDP, which allows 
binding to the beta/gamma subunit and to the GPCR.  Upon activation of the GPCR by 
ligand binding, the receptor acts as a guanine nucleotide exchange factor (GEF), and 
acts to substitute the GDP bound to the alpha subunit for GTP.  This activates the alpha 
subunit, causing dissociation from the beta/gamma subunit, and binding to downstream 
effectors can occur.  
In C. elegans there are 21 Gα subunits, 2 Gβ subunits and 2 Gγ subunits, expressed 
in many neurons and muscle cells, with 14 of the Gα subunits expressed specifically in 
chemosensory neurons in the head of the animal (Jansen, Thijssen et al. 1999).  The Gβ 
and Gγ subunits bear strong homology to their mammalian counterparts, and have roles 
in development and locomotion, and in regulating the activity of Gα subunits, as well as 
some instances of direct modulation of ionotropic receptors.  The main focus of interest 
however is on the Gα subunits themselves.  The roles of a number of Gα subunits in 
the regulation of neuronal activity have been defined through experiments in C. elegans, 
demonstrating how they allow neurons to become responsive to neuromodulatory 
signals, effecting long-lasting changes in the release potential of the cell.  
1.5.2 - G-alpha  subunits regulate behaviour in C. elegans 
There are worm homologues of all the mammalian classes of Gα proteins.  The 
mammalian Gα subunits are divided into four classes: Gαs, Gαi/o, Gαq and Gα12.  All 
four classes are represented in C. elegans (Jansen, Thijssen et al. 1999), and all have 
been demonstrated to have an impact on behaviour.  
1.5.2.1 - GOA-1
The Gαo homologue GOA-1 was the first G-protein subunit demonstrated to have an 
effect on behaviour (Mendel, Korswagen et al. 1995; Segalat, Elkes et al. 1995).  GOA-1 
encodes the only clear C. elegans homologue of the Gαi/o family, and is 80% identical 
to the mammalian Gαo (Lochrie, Mendel et al. 1991), although it also bears a similar 
amount of identiy to Gαi.  It was demonstrated that C. elegans mutants lacking GOA-1 
activity were viable and hyperactive, with exaggerated body bends, increased rates of 
locomotion and increased egg-laying, accompanied by reductions in pharyngeal pumping. 
This led to the hypothesis that GOA-1 natively acts to regulate these behaviours.  
goa-1 mutants are resistant to the effects of serotonin (Segalat, Elkes et al. 1995), a 
neuromodulator which causes animals to reduce their rate of locomotion, increase 
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pharyngeal pumping and increase egg-laying, and are hypersensitive to the effects 
of aldicarb (Nurrish, Ségalat et al. 1999) demonstrating an increase in acetylcholine 
release.  Loss of GOA-1 in the cholinergic neurons, by expression of pertussis toxin 
(which specifically inhibits GOA-1) caused the same decreases in acetylcholine release 
(Nurrish, Ségalat et al. 1999), while expressing constitutively active GOA-1 in cholinergic 
neurons decreased acetylcholine release and rates of locomotion (Nurrish, Ségalat et 
al. 1999).
GOA-1 acts to reduce the amount of diacylglycerol at sites of neurotransmitter release 
in the presynaptic membrane (Nurrish, Ségalat et al. 1999, Figure 1-9).  As described in 
the section detailing the synaptic vesicle cycle, DAG is an important second messenger 
involved in neurotransmitter release.  It is through regulation of DAG levels, and through 
changes in the binding of UNC-13 and PKC-1 that GOA-1 is able to affect neurotransmitter 
release.  Mutation of goa-1 causes an increase in recruitment of UNC-13 and PKC-1 to 
release sites in a DAG-dependent manner (Nurrish, Ségalat et al. 1999), whereas the 
endogenous activity of GOA-1 is to reduce UNC-13 recruitment.  However, the exact 
mechanism of the modulation of DAG levels by GOA-1 remains to be established.    
1.5.2.2 - EGL-30
The Gαq homologue EGL-30 is also able to regulate a diverse set of phenotypes in 
C. elegans.  Complete loss of function is thought to be lethal (Brundage, Avery et al. 
1996), while less severe mutations reduce locomotion, pharyngeal pumping, egg-laying 
(Brundage, Avery et al. 1996), and are resistant to the effects of aldicarb (Miller, Alfonso 
et al. 1996; Miller, Emerson et al. 1999).  
Expressing activated EGL-30 in the cholinergic neurons increases locomotion rates and 
acetylcholine release, the opposite effect of increasing GOA-1 activity (Brundage, Avery 
et al. 1996; Lackner, Nurrish et al. 1999).  
The mechanism of EGL-30 action was initially inferred from comparisons with the 
mammalian homologue Gαq.  Gαq activates phospholipase C, an enzyme which converts 
phosphatidylinositol-(4,5)-bisphosphate (PIP2) into DAG and inositol trisphosphate 
(IP3).  EGL-30 has been shown to activate the C. elegans PLC homologue EGL-8 in 
transfected cells (Brundage, Avery et al. 1996), and mutations in egl-8 mimic those of 
EGL-30.  egl-8 mutants are lethargic, have reduced egg-laying and are resistant to the 
effects of aldicarb (Lackner, Nurrish et al. 1999), and are able to suppress some (but 
not all) of the aldicarb sensitivity of animals expressing egl-30 gain-of-function alleles 
from a heat-shock transgene (Lackner, Nurrish et al. 1999), demonstrating that egl-8 
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Figure 1-9 Multiple G-proteins regulate neurotransmitter release
A network of G-proteins act to increase or decrease neurotransmitter release in the C. elegans 
nervous system.  Proteins depicted in blue act to reduce release, while those depicted in red 
increase neurotransmitter release.  Signalling from three G-protein alpha subunits - GOA-1, 
EGL-30 and GPA-12 - converges on RHO-1, a membrane-bound small GTPase, which inhibits 
the activity of DGK-1, increasing levels of the membrane-bound second messenger in the 
presynaptic membrane.  DAG regulates the release of both small molecule neurotransmitters 
and neuropeptide.   
The production of DAG is also regulated by EGL-30 increasing the activity of EGL-8, the 
phospholipase C homologue which produces DAG from PIP2.  Evidence discussed in the text 
indicates that additional pathways act downstream of RHO-1 to regulate neurotransmitter release. 
Adapted from Perez-Mansilla and Nurrish 2009.
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works downstream of egl-30.  Mutations in egl-8 and egl-30 are rescued for acetylcholine 
release by exposure to the DAG analogue PMA, a phorbol ester (Malenka, Madison et al. 
1986), suggesting that these proteins lie upstream of the pathway regulated by DAG and 
UNC-13.  Expression of EGL-8 in motor neurons fully rescues both locomotion and the 
response to aldicarb, suggesting that for locomotory behaviour and acetylcholine release 
EGL-8 is only required in these cells.  However, while egl-30 null mutants are lethal, egl-
8 mutants are merely lethargic, suggesting additional roles for egl-30.  Similarly, egl-8 
mutations only partially suppress the increased neurotransmitter release phenotype of 
egl-30 (gain-of-function) mutants, indicating that there are additional pathways regulated 
by EGL-30 (Lackner, Nurrish et al. 1999).  
While the classical Gαq pathway stimulates the production of DAG, leading to an increase 
in neurotransmitter release, EGL-30 also inhibits a pathway which leads to the removal 
of DAG from the membrane.  As will be discussed below, screens for suppression of 
activated EGL-30 (Williams, Lutz et al. 2007) and subsequent research demonstrated 
that EGL-30 inhibits a diacylglycerol kinase, DGK-1, whose action converts DAG to 
phosphatidic acid.  
The EGL-30 pathway is activated by arecoline, a pharamacological agent which activates 
the G-protein coupled muscarinic acetylcholine receptor (Lackner, Nurrish et al. 1999), 
although this activation may be indirect (Dittman and Kaplan 2008).  
1.5.2.3 - EGL-30 and GOA-1 antagonistically regulate 
neuronal activity
These two G-proteins, EGL-30 and GOA-1, function antagonistically in the neuron to 
regulate the overall activity and amount of release of neurotransmitter, and the majority 
of this regulation is DAG-dependent, putting the membrane bound second messenger 
as a key player in the regulation of neurotransmitter release.  The goa-1;egl-30 double 
mutant is lethargic, and animals overexpressing gain-of-function GOA-1 are suppressed 
by mutations in egl-30, indicating that egl-30 acts either downstream of or in parallel to 
goa-1 (Hajdu-Cronin, Chen et al. 1999; Miller, Emerson et al. 1999).  
GOA-1 and EGL-30 also antagonistically regulate expression of TPH-1, a key enzyme 
involved in serotonin biosynthesis (Tanis, Moresco et al. 2008) suggesting that this 
antagonistic pairing is utilised in multiple situations.  
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1.5.2.4 - Regulation linking GOA-1 and EGL-30
GOA-1 and EGL-30 are both regulated by RGS (regulator of G-proteins) proteins (Watson, 
Linder et al. 1996).  RGS proteins negatively regulate the activity of heterotrimeric G 
proteins by functioning as GTPase activating proteins (GAPs) catalysing the intrinsic 
hydrolysis of Gα-GTP to Gα-GDP.
GOA-1 is negatively regulated by EGL-10 (Koelle and Horvitz 1996), and egl-10 mutations 
decrease locomotion and acetylcholine release due to an increase in GOA-1 activity, 
while EGL-30 is negatively regulated by EAT-16 (Hajdu-Cronin, Chen et al. 1999), and 
eat-16 mutants have increased rates of locomotion due to an increase in EGL-30 activity 
(see Figure 1-9).  
The activity of these two RGS proteins is dependent upon the protein GPB-2, a Gβ5 
homologue of heterotrimeric G-proteins (van der Linden, Simmer, et al, 2001).  Both 
EGL-10 and EAT-16 contain a G-gamma like (GGL) domain, and this domain interacts 
with GPB-2 (van der Linden, Simmer, et al, 2001).  A null mutation of gpb-2 increases 
locomotion, while point mutants of gpb-2 can either increase or decrease acetylcholine 
release, presumably by differentially activating either EGL-10 or EAT-16, and hence 
inhibiting either GOA-1 or EGL-30 (Chase, Patikoglou et al, 2001; van der Linden, 
Simmer et al, 2001).  This protein therefore marks a point of cross-talk between these 
two antagonistic signalling pathways.  
1.5.2.5 - GSA-1 regulates behaviour in C. elegans
Gαs heterotrimeric G-protein subunits commonly activate adenyl cyclase, producing 
the second messenger cyclic AMP (cAMP).  In C. elegans, activation of GSA-1, the 
homologue of Gαs, causes hyperactive locomotion, and this effect is completely blocked 
by loss of ACY-1, the C. elegans adenyl cyclase (Schade, Reynolds et al. 2005), while 
mutations in gsa-1 cause lethargy which is rescued by expression in the motor neurons 
(Reynolds, Schade et al. 2005).  By homology to Drosophila, activation of this pathway 
is thought to lead to recruitment of UNC-13 in a DAG-independent fashion (Aravamudan 
and Broadie 2003; Speese, Trotta et al. 2003).  
Activation of ACY-1 causes hyperactive locomotion which is blocked by mutations in egl-
30, while paralysis in an acy-1 mutant is partially rescued by activation of EGL-30 or by 
phorbol esters (Reynolds, Schade et al. 2005) indicating a link between these pathways, 
although how these pathways integrate to control locomotion is unclear.  As measured 
by the chronic aldicarb assay there is little change in aldicarb release in acy-1 mutants, 
despite their almost complete paralysis (Reynolds, Schade et al. 2005).  However, the 
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gsa-1 (gf) mutants are hypersensitive to aldicarb in a chronic assay (Schade, Reynolds et 
al. 2005) suggesting a role in synaptic vesicle exocytosis.  This appears to be mediated 
by ric-8, an orthologue of the mammalian protein synembryn, which acts as a receptor-
independent GEF to stimulate signalling by the alpha subunit of G-proteins (Tall et al, 
2003).  RIC-8 stimulates signalling by both EGL-30 and GSA-1 (Reynolds, Schade et al. 
2005), and the ric-8 mutants are highly resistant to aldicarb; the ric-8;gsa-1 (gf) mutants 
are restored to a wild-type level of acetylcholine release (Schade, Reynolds et al. 2005) 
Interestingly, the activation of PKAc, known as KIN-1 in C. elegans, is able to bypass 
the requirement for UNC-31 (CAPS) in dense core vesicle exocytosis (Zhou, Dong et al. 
2007).  This is consistent with the phenotype of unc-31 mutants, which are highly lethargic 
on food but move much faster when starved (Speese, Petrie et al. 2007), suggesting the 
activation during starvation of an additional pathway independent of unc-31 which acts 
to increase locomotion.  
1.5.3 - DGK-1
Diacylglycerol is a key point of cross-talk between GOA-1 and EGL-30.  A screen for 
animals which were resistant to the effects of serotonin, which normally causes animals to 
reduce their body bend rate and increase egg-laying, identified mutants in a diacylglycerol 
kinase, dgk-1 (Nurrish, Ségalat et al. 1999).  In an alternative experiment, dgk-1 was 
identified as a mutation which caused animals to become hyperactive in their locomotion 
(Miller, Emerson et al. 1999).  Also called sag-1, dgk-1 mutants were also identified as 
suppressors of activated GOA-1 (Hajdu-Cronin, Chen et al. 1999), demonstrating that 
they act downstream of or in parallel  to GOA-1 in the response to serotonin.  As yet the 
relevant GOA-1 effector for control of DAG levels and locomotion is unknown.  
The DGK-1 enzyme phosphorylates DAG to phosphatidic acid, removing the binding site 
for UNC-13 and PKC-1, involved in the release of neurotransmitter from both synaptic 
vesicles and DCVs.  dgk-1 mutants are not lethal, demonstrating that this function is not 
part of the core release machinery.  They do however demonstrate hypersensitivity to 
aldicarb, resistance to serotonin and have a loopy locomotion (Nurrish, Ségalat et al. 
1999), and are predicted to have increased levels of DAG and lowered levels of PA.  
Expression of DGK-1 in the motor neurons of dgk-1 mutant was sufficient to restore 
the response to aldicarb (Nurrish, Ségalat et al. 1999), demonstrating that, along 
with GOA-1, EGL-30 and EGL-8, DGK-1 acts in the motor neurons to alter levels of 
acetylcholine release.
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egl-30;dgk-1 and egl-8;dgk-1 double mutants have virtually wild-type levels of 
neurotransmitter release, suggesting that these lie in parallel pathways acting to either 
increase or decrease the levels of DAG, in turn increasing or decreasing the release of 
neurotransmitter (Miller, Emerson et al. 1999), and that there is a basal level of DAG 
production in these mutants.  
1.5.4 - RHO GEFs regulate behaviour
Examination of unc-73RhoGEF mutants (Steven, Zhang et al. 2005) gave an indication 
of the mechanism linking EGL-30 to changes in DGK-1 activity.  UNC-73 contains 
both Rac and Rho GEF domains, and mutations in the Rac GEF domain causes axon 
guidance defects (Steven, Kubiseski et al. 1998).  However, mutations affecting only 
the Rho GEF domain were isolated, and caused reduction in locomotion and egg laying 
(Steven, Zhang et al. 2005), similar to severe mutations in EGL-30 although with only a 
small effect on acetylcholine release.  Nonetheless this demonstrated a role for a Rho 
GEF and hence for Rho in neurotransmitter release.    Loss of unc-73RhoGEF activity 
causes a severe decrease in locomotive activity, although it has little effect on the level of 
acetylcholine release.  The likely target of UNC-73RhoGEF is the small GTPase RHO-1, 
and this suggests that presynaptic RHO-1 is able to regulate locomotion via changes in 
acetylcholine release and by some additional mechanism.  
Loss of the Rho-specific GEF domain in UNC-73 suppresses the activity of EGL-30, the 
Gαq which also regulates the activity of EGL-8, the phospholipase C (Williams, Lutz et al. 
2007).  Loss of both EGL-8 and UNC-73 RhoGEF activity phenocopies egl-30 mutants, 
suggesting that these two proteins represent the effectors of EGL-30 in the cholinergic 
neurons of C. elegans (Williams, Lutz et al. 2007), and in vitro studies suggest a close 
physical interaction between EGL-30 and UNC-73.  The model predicts that UNC-73, as 
activated by EGL-30 is upstream of a target which is able to inhibit DGK-1 and increasing 
levels of DAG at the presynaptic membrane.  
In mammalian studies, RhoA, the mammalian orthologue of RHO-1, is also regulated 
p115RhoGEF, which in turn is activated by a fourth class G-protein subunits, Gα12/13. 
The C. elegans homologue of Gα12/13 is GPA-12, and RNAi of this gene in an RNAi-
sensitised strain (rrp-3) has been shown to affect locomotion (Yau, Yokoyama et al. 
2003), although the deletion mutant has no effect on locomotion (Hiley, McMullan et 
al. 2006).  The p115RhoGEF homologue, RHGF-1, which is activated by GPA-12, has 
in turn been demonstrated to activate RHO-1, increase UNC-13 levels at release sites, 
and hence stimulate neurotransmitter release (Hiley, McMullan et al. 2006).  Using the 
mutant form of UNC-13 (H173K), which is unable to bind to DAG, completely blocks 
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the effects of activated RHGF-1 in increasing neurotransmitter release.  This suggests 
that GPA-12 and RHGF-1 act to stimulate the DAG/UNC-13 dependent pathway.  pkc-1 
mutations have no effect on the action of GPA-12 and RHGF-1, suggesting the presence 
of two pools of DAG, one of which acts through UNC-13 and the other through PKC-1. 
Interestingly, rhgf-1 and gpa-12 mutants have little effect on neurotransmitter release 
or locomotion (Hiley, McMullan et al. 2006) suggesting that under basal laboratory 
conditions this pathway is not active.  
These two RhoGEFs activate RHO-1 but with different effects.  RHO-1 activated by 
RHGF-1 stimulates neurotransmitter release and changes in locomotion solely through 
the DAG/UNC-13 dependent pathway, but loss of RHGF-1 has little effect on acetylcholine 
release.  Stimulation of RHO-1 activity by UNC-73 increases the rate of locomotion but 
has little effect on neurotransmitter release.  This suggests that either these two proteins 
act redundantly, or that there are additional RhoGEFs which act in the nervous system 
of C. elegans.  
1.5.5 - RHO-1
The mechanism of the link between EGL-30, UNC-73, RHGF-1 and DGK-1 lies in the 
activity of the small GTPase RhoA, known as RHO-1 in C. elegans.  By homology to 
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Figure 1-10 RHO-1 is a membrane-bound GTPase
RHO-1 is the C. elegans orthologue of RhoA, a small, membrane bound GTPase.  It cycles 
between an inactive GDP-bound state and an active GTP-bound state due to the action of Rho 
GEFs (guanine nucleotide exchange factors) , which exchange GDP for GTP, and Rho GAPs 
(GTPase activating proteins), which stimulate the intrinsic GTPase activity of Rho, converting 
GTP back to GDP.  RhoA is sequestered from the membrane by Rho GDI proteins.  Adapted 
from Etienne-Manneville and Hall 2002.  
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mammalian systems, diacylglycerol kinases can be regulated by Rho family GTPases 
(van Blitterswijk and Houssa 2000).  DGKθ, the closest homologue of DGK-1, is regulated 
by RhoA (Houssa, de Widt et al. 1999).  RHO-1 is the single C. elegans orthologue of 
RhoA, and it was therefore an attractive candidate for the regulation of neurotransmitter 
release.  
RHO-1 is a membrane-associated GTPase; it can bind guanine triphosphate (GTP) or 
guanine diphosphate (GDP), and is has innate enzymatic activity capable of converting 
bound GTP into GDP (Jaffe and Hall 2005).  The exchange of one nucleotide for another 
induces conformational changes in the structure of RHO-1.  In its GTP-bound state 
RHO-1 is considered to be active; switching to GDP inactivates the protein.  The rate of 
this activity is enhanced by additional proteins known as GTPase Activating Proteins, 
or GAPs.  The dissociation of GDP for GTP is enhanced by another set of associated 
proteins known as Guanine nucleotide Exchange Factors, or GEFs.  Therefore the 
endogenous activity of RHO-1 can be further enhanced by association with these other 
molecules (Jaffe and Hall 2005).  GAPs, despite their name, act to reduce the signalling 
activity of RHO-1, while GEFs, by allowing RHO-1 to enter its active state, enhance 
signalling through the GTPase.  
RHO-1 is prenylated at its C-terminus; this allows it to interact with the cell membrane 
and is required for function.  Another set of associated proteins, the Guanine nucleotide 
Dissociation Inhibitors (GDIs) extract RHO-1 from the membrane and sequester the 
inactive GDP-bound form (Jaffe and Hall 2005). 
RhoA has been implicated in a vast range of biological processes, including development, 
immunity, cell shape changes and movement (Etienne-Manneville and Hall 2002, Jaffe 
and Hall 2005, Lundquist 2006).  The first clues to the function of Rho came from 
observations that constitutively active Rho was able to induce the formation of stress 
fibres and lamellipodia in transfected fibroblasts (Ridley and Hall 1992), and much of 
the activity of Rho family GTPases is connected to (but not limited to) changes in cell 
shape and the reorganisation of cytoskeletal proteins.  The roles of Rho GTPases can be 
broadly divided into three categories: morphology, movement and behaviour, regulating 
processes as diverse as wound closure, growth cone guidance and phagocytosis 
(Etienne-Manneville and Hall 2002).
In C. elegans, Rho GTPases play a number of very important roles. In the first cell division 
in the developing zygote, CDC-42, in complex with the polarity protein PAR-6 and the 
atypical protein kinase PKC-3 are required to establish polarity in the zygote (Gotta, 
Abraham et al. 2001).  Experiments with the RHO-1 target Rho kinase (ROCK) and the 
70
RhoGAP RGA-2 have demonstrated that a balance of RHO-1 signalling is important for 
morphogenesis during C. elegans development (Diogon, Wissler et al. 2007).
Later in development, Rho GTPases are important for elongation of the developing 
embryo which occurs as a result of contraction of actin rings, mediated by LET-502, 
which encodes the worm ortholgoue of Rho Kinase, and MEL-11, a myosin phosphatase 
Increasing locomotion rate
Increasing acetylcholine release
Figure 1-11 RHO-1 increases neurotransmitter release in C. 
elegans
Expression of constitutively active RHO-1, a small GTPase, under the unc-17 promoter (N:RHO-
1(G14V)) causes an increase in rate of paralysis on 1mM aldicarb, indicating that RHO-1 
increases acetylcholine release.  These animals also become highly loopy and uncoordinated. 
Alternatively, inhibiting endogenous RHO-1 with C3 transferase, a RhoA specific toxin expressed 
under the unc-17 promoter (N:C3T), reduces neurotransmitter release and causes lethargic 
locomotion with reduced depth of body bends.  From McMullan, Hiley et al. 2006
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(Wissmann, Ingles et al. 1997, Wissmann, Ingles et al. 1999).  RHO-1 also plays a role 
in the migration of hypodermal cells in C. elegans (Spencer, Orita et al. 2001), and in 
neuronal development; a dominant negative RHO-1 increases neurite outgrowth (Zallen, 
Peckol et al. 2000).  
In other model systems, Rho GTPases regulate nervous system development (Govek, 
Newey et al. 2005) and act in synaptic transmission and there is a strong link between 
mutations affecting Rho GTPases and mental retardation (Govek, Newey et al. 2005). 
Rac and Cdc42 regulate synaptic strength in Aplysia (Humeau, Popoff et al. 2002, Udo, 
Jin et al. 2005), while inhibition of RhoB blocks stimulated release of neurotransmitter 
from PC12 cells (Ishida, Zhang et al. 2004).  In mice, stimulation of Rho GTPase activity 
by cytotoxic necrotizing factor 1 (CNF1), a toxin from Escherichia coli, increased the 
ability in tasks assessing learning and memory, most likely due to alterations in synaptic 
connections (Diana, Valentini et al. 2007).  Other roles for Rho in synaptic activity include 
the phosphorylation of syntaxin by the Rho effector ROCK (Sakisaka, Baba et al. 2004), 
loss of which impairs learning and memory in mice (Dash, Orsi et al. 2004).   
A RHO-1 deletion mutant is lethal (R. McMullan, personal communication), and so the 
first evidence that RHO-1 plays a direct role in neurotransmitter release came with 
experiments on the protein UNC-73 as discussed above.  Roles for Rho family GTPases 
in regulating behaviour had been demonstrated through mutations of the RhoGEF 
vav-1, which produces defects in pharangyl pumping, ovulation and defecation (Norman, 
Fazzio et al. 2005), and more recent evidence suggests that RHO-1 is the target of 
VAV-1 for regulating these behaviours (McMullan and Nurrish, 2011).  
The Nurrish lab also become interested in RHO-1, because the mammalian homolgoue 
had been demonstrated to bind to DGKθ (Houssa, de Widt et al. 1999), the orthologue 
of DGK-1 and this binding has been demonstrated to be conserved between the 
C. elegans homologues (McMullan, Hiley et al. 2006).  In mammalian cells, this interaction 
decreases the activity of DGK-1, preventing the removal of DAG from the membrane and 
hence increasing neurotransmitter release.
Expression of activated RHO-1 in motor neurons is sufficient to increase acetylcholine 
release, and leads to exaggerated body bends similar to those seen in a dgk-1 mutant 
animal (McMullan, Hiley et al. 2006, Figure 1-11). Inhibition of endogenous RHO-1 by the 
expression of the RHO-1 specific inhibitor C3 transferase (Aktories and Hall 1989) from 
either a heatshock of motor-neuron specific promoter causes a decrease in the level of 
acetylcholine release (McMullan, Hiley et al. 2006), demonstrating a role for RHO-1 in 
the motor neurons (Figure 1-11).  
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While RHO-1 has been shown to have effects during development, these effects 
on locomotion occur post-developmentally, as demonstrated by the activation of 
RHO-1 from a heatshock promoter in fully developed adults.  This leads to an increase in 
sensitivity to acetylcholine esterase aldicarb, demonstrating an increase in acetylcholine 
release (McMullan, Hiley et al. 2006), and an increase in the levels of DAG at existing 
synapses, as measured by the accumulation of fluorescently tagged UNC-13 (McMullan, 
Hiley et al. 2006, Figure 1-12). 
This recruitment of UNC-13 suggests that RHO-1 acts by inhibiting DGK-1, increasing 
levels of DAG, and hence increasing recruitment of UNC-13 to release sites (Figure 
1-12).  However, use of a mutant form of UNC-13, which contains the H173K mutation 
and is unable to bind to DAG (Lackner, Nurrish et al. 1999), is insufficient to completely 
block the effects of constitutively active RHO-1 on locomotion and sensitivity to aldicarb 
Figure 1-12 RHO-1 recruits UNC-13 to prexisting synapses
Activation of a heatshock RHO-1 transgene in adult animals causes an accumulation of YFP-
tagged UNC-13 at synapses in C. elegans.  RHO-1 inhibits DGK-1, causing an accumulation of 
DAG, a target for UNC-13 binding.  From McMullan, Hiley et al. 2006 
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(McMullan, Hiley et al. 2006), while RHO-1 still demonstrates some ability to increase 
neurotransmitter release in an unc-13(H172K);pkc-1 double mutant (R. McMullan, 
personal communication). 
A mutant form of activated RHO-1 carrying the F25N mutation demonstrates reduced 
binding to DGK-1 (McMullan, Hiley et al. 2006), and is unable to stimulate neurotransmitter 
release as effectively as RHO-1 which is wild-type at this position (McMullan, Hiley et al. 
2006).  This mutation was isolated by Alan Hall in early experiments with RhoA, improves 
the expression of RhoA in tissue culture experiments, and is generally regarded as having 
Figure 1-13 RHO-1 acts through DGK-1-dependent and DGK-1-
independent pathways 
Inhibition of endogenous RHO-1 activity by C3 transferase decreases neurotransmitter release 
as measured by rate of paralysis on 1mM aldicarb.  A dgk-1 mutant has increased levels of 
neurotransmitter release and is hypersensitive to aldicarb.  If DGK-1 were the only target of 
RHO-1 in the nervous system, inhibiting RHO-1 activity by expressing C3 in a dgk-1 mutant 
background should have no effect on neurotransmitter release.  However, there is a reduction in 
neurotransmitter release in the neuro:C3T;dgk-1 double mutant animals, suggesting that there 
are additional targets of RHO-1 in the C. elegans nervous system.   It should be noted that dgk-
1 significantly suppress the effects of C3T, demonstrating that it is a major effector of RHO- in 
motor neurons.  From McMullan, Hiley et al. 2006
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little effect on the activity of the GTPase on changes in actin remodelling (McMullan and 
Nurrish 2007).
Further, inhibition of RHO-1 by C3 transferase in a dgk-1 null mutant background 
decreases neurotransmitter release (McMullan, Hiley et al. 2006), indicating that RHO-
1 has targets other than DGK-1 (Figure 1-13).  If DGK-1 were the only downstream 
effector of RHO-1, then changes in RHO-1 activity in a dgk-1 null mutant should have no 
impact on acetylcholine release.  However, as can be seen in Figure 1-13, inhibition of 
endogenous RHO-1 by C3 transferase still leads to a decrease in acetylcholine release. 
Together these pieces of evidence - DAG effector mutants which do not completely block 
the activity of RHO-1, the F25N mutation which is able to stimulate neurotransmitter 
release, and the action of C3 transferase in a dgk-1 mutant - suggest the presence of 
a DAG-independent, DGK-1-independent pathway by which RHO-1 is able to stimulate 
neurotransmitter release.  However, activated RHO-1 combined with a dgk-1 mutant 
background does not demonstrate any additional increase in neurotransmitter release 
compared with a dgk-1 mutant alone.  This is surprising because the activated RHO-1 
would be expected to activate the dgk-1 independent pathway in this genetic background. 
However, it is possible that the body bend rates in a dgk-1 animal, used as a measure of 
the activity of the motor neurons, represent a maximum rate which cannot be increased 
even by activation of the dgk-1 independent pathway.  
1.6 - Aims of this thesis
The regulation of RHO-1 in its role in neurotransmitter release has been well 
characterised (Steven, Zhang et al. 2005; Hiley, McMullan et al. 2006; McMullan, Hiley 
et al. 2006; Williams, Lutz et al. 2007), although additional RhoGEFs most likely remain 
to be uncovered (McMullan and Nurrish 2007).  It is known that RHO-1 acts to regulate 
DAG levels by inhibiting DGK-1, but number of experiments, including use of the RHO-1 
specific inhibitor in a dgk-1 mutant background, reveal the presence of additional RHO-
1 targets, demonstrating that RHO-1 acts through both a DAG/UNC-13 dependent and 
independent pathway (McMullan, Hiley et al. 2006).  It is the nature of this independent 
pathway or pathways which is under investigation here. 
I have set out to characterise these through the use of a genetic screen for suppressors 
of activated RHO-1, as described in Chapter 3, where a number of potential targets 
are identified and characterised.  One particularly interesting mutant was identified as 
an allele of the large, conserved gene unc-80, and characterisation of this mutant is 
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examined in more detail in Chapter 4, while the unc-80 functionally related genes unc-
79, nca-1 and nca-2, and their effects on RHO-1 activity, are examined in Chapter 5.
Also of interest is the regulation of the core release machinery, including tomosyn (tom-
1) and syntaxin (unc-64), and work in collaboration with the Fujita laboratory to examine 
the roles of these proteins in C. elegans, and characterisation of a novel phosphorylation 
site, is described in Chapter 6.  
Finally, Chapter 7 documents my attempt to produce a new tool for the regulation of 
protein activity in C. elegans, utilising tamoxifen to regulate fusion proteins.   
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2 - MATERIALS AND METHODS
2.2 - Worm Maintenance
Worms were grown following conditions described in Brenner 1974.  Worms are 
maintained on 55mm petri dishes containing 13ml worm agar, otherwise referred to as 
normal growth media (NGM).  Plates were seeded with E. coli strain OP50, which is 
resistant to streptomycin, as food for the worms.  To maintain stocks, small chunks of 
agar containing worms are removed from a plate using a spatula flamed in ethanol, 
and the chuck transferred to a fresh plate with food.  Best practice is to prevent stocks 
becoming starved; should starvation occur worm strains are grown for a week in the 
presence of food before being used for any physiological assays, although starved 
males can be successfully used for crosses.  Individual worms are picked using a flamed 
platinum wire.  
Worms are grown at 20oC in a temperature-controlled room.  To maintain strains for long 
periods of time without being starved, 3 or 4 L4 animals are transferred to a fresh plate 
with food, and the plate placed at 15oC to decrease the growth rate.  
2.3 - Freezing and defrosting worm stocks
2.3.2 - Freezing
10 plates of the strain to be frozen were grown to starvation on 55mm petri dishes.  The 
starved animals were washed in 15ml of M9 buffer and left on ice for 15 minutes.  The 
worms settled to the bottom of the M9 buffer, and the volume was reduced by pipetting 
to 2ml.  2ml of molten freezing solution and agar was added and the resulting mixture 
divided into two 2ml aliquots and transferred to 2ml cryovial tubes (Corning).  These 
were then placed in a polystyrene box and stored at –80oC.  One vial was subsequently 
transferred the liquid nitrogen store.  
2.3.3 - Defrosting
When defrosting animals cryovial tubes were maintained on dry ice at all times when 
outside the freezer or liquid nitrogen.  A small amount of agar from the tube was scraped 
onto a fresh seeded plate using a flamed spatula before returning the cryovial.  The 
plates were examined for live worms 1 hour after defrosting, and for up to three days 
subsequently.  Live worms were transferred to fresh plates using a platinum wire.  
In many instances defrosting caused fungal contamination, in which case the animals 
were bleached once sufficient stocks had been obtained (see 2.4).  
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Where the original cryovial was completely emptied of agar, animals were grown for re-
freezing (see 2.2.1).  
2.4 - Crossing worm strains
For standard crosses, 55mm petri dishes containing worm agar were seeded with 50μl 
of OP50, forming a small lawn (cross plate).  Five larval stage 4 (L4) hermaphrodites of 
the first strain were transferred onto the lawn of the cross plate.  Males from the second 
strain were picked to a fresh seeded plate and allowed to crawl free of any eggs or 
hermaphrodites before at least 10 males were transferred to the cross plate.  In instances 
where mating efficiency was low, up to 50 males were transferred to the cross plate.  The 
cross plate was placed at 15oC for between 1 and 3 days. The hermaphrodites were 
then singled to individual plates and the progeny examined after 3 days.  
2.5 - Bleaching
2.5.2 - Removing contamination
To remove contamination, household bleach (5% solution of sodium hypochlorite) was 
mixed with 5M NaOH in a 1:1 ratio, and a drop (200μl) pippetted onto a fresh plate, 
away from the lawn of OP50 bacteria.  Adult hermaphrodites were picked into the 
bleach:NaOH drop, and were killed and dissolved, while their eggs were unharmed. 
Plates were left overnight, and the lawn examined for live worms the following day; these 
worms were transferred to a fresh plate.  Sometimes this procedure was repeated for 
stubborn contamination.  
2.5.3 - Producing a synchronous culture
5 plates of mixed-stage worms were washed in 15ml of M9 buffer.  Worms were spun 
at 1500rpm, pelletting them.  The volume was reduced by pipetting, and the pellet was 
resuspended in 2ml M9, to which was added 2ml household bleach and 1ml 5M NaOH. 
The worms were placed on a shaker for 15 minutes, before being washed three more 
times in M9, before being resuspended in 2ml fresh M9.  They were then pipetted to 5 
fresh plates using a glass dropping pipette.  The process left eggs intact which hatched 
into a synchronous culture.  
2.6 - Microinjection
Plasmid DNA was injected into the gonad of young adult worms (best results were usually 
obtained by picking L4 hermaphrodities the day before injection), along with a suitable 
marker as described in the text, to identify the transgenic animals. 
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The markers used were TTX-3::GFP, which is expressed in the cell bodies and axonal 
processes of bilaterally symmetric head neurons AIY left and right (a gift from Oliver 
Hobert); UNC-122::GFP, which is expressed in the coelomocytes (a gift from Piali 
Sengupta) p.acr-2::GFP, which is expressed in ventral cord motor neurons VA, DA, 
VB, DB, DA, IL1, RMD, and PVQ (the promoter for acr-2 was a gift from Yishi Jin), 
and p.unc-17::GFP.  The total DNA concentration in the injection mix was made up to 
150ng/µl using pBluescript (Stratagene) in TE buffer.  Pads for injecting the worms were 
made from 2% agarose on 22mm X 50mm cover slips (Chance Propper Ltd).  A small 
drop of halothane oil (Sigma) was placed on the pad and the worm transferred to the oil. 
The animal was then gently stuck to the agarose pad using a platinum wire pick.  If the 
animal failed to stick, it was transferred to a fresh drop of oil with the aim of removing 
excess bacteria adhering to the cuticle. 
A Leica DM IRB microscope and Intracel picospritzer III injector were used to perform the 
injections with 0.5mm diameter injection needles (Harvard apparatus), 
Once injected the worms were carefully removed from the pad by the addition of a small 
volume of M9 buffer that released the worm. The animal was then transferred with a 
platinum wire to a seeded agar plate, each injected animal to an individual plate.  
The F1 generation from injected adults was screened for the transgenic marker and any 
positive animals singled to fresh plates. The progeny of these transgenic animals were 
then screened for the transgenic marker and those that contained it were considered a 
line of transgenic animals.  
2.7 - Extraction of DNA from worms
2.7.2 - For PCR and standard sequencing
10 starved plates of worms were washed in 15ml ice-cold EN solution in a 15ml tube 
and spun down for 1 minute at 1000rpm at 4oC, then resuspended in 2ml clean ice-cold 
EN solution and left to settle on ice for 10 minutes. 2.5ml cold sucrose solution (68% 
sucrose) was added and the tube vortexed.  3ml EN solution was then carefully layered 
on top of the sucrose solution. The tube was spun at 2500rpm for 10 minutes to allow all 
the unwanted material to pellet at the bottom. The worms banded in a thin layer and were 
transferred to a new tube with a glass pipette. They were washed twice with EN solution 
to remove any remaining sucrose. The worms were suspended in a small volume of EN 
solution and transferred to a 1.5ml Eppendorf tube. 
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500μl lysis buffer, 5μl of β-mercaptoethanol and 5μl of proteinase K (20mg/ml) were 
added and the tubes incubated at 65C with mixing every 15 minutes for the first 90 minutes 
followed by incubation overnight. The next morning a further 5μl β-mercaptoethanol and 
5µl proteinase K was added and the tube incubated at 65C for a further 4 hours.  DNA 
was then extracted using an ethanol precipitation by adding 1/10 volume 2.5M NaAc, 
2ml 100% EtOH centrifuging for 30 minutes at 1300rpm. The pellet was washed with 
70% EtOH and resuspended in 50μl TE buffer. The concentration was assayed using the 
NanoDrop spectrophotometer (Thermo Scientific).  
2.7.3 - For Whole Genome Sequencing
To obtain large quantities of genomic DNA at higher purity, we made use of a modified 
version of the Quiagen Blood and Tissue Kit protocol.  10 plates of mixed-population 
worms were washed in 15ml PBS, centrifuged at 1000rpm for 1 minute, and the volume 
reduced to 2ml.  This was repeated 3 times to remove unwanted material, such as 
bacteria.  Following the final spin, the final 2ml was divided between between 3 1.5ml 
tubes (Eppendorf.)  These were then placed on ice, and sonicated for bursts of 1-2 
seconds, until the solution had a consistent thickness.  The tubes were returned to ice, 
and the sonicator washed with distilled water each time.  Added 20μl proteinase K (20mg/
ml)  and 200μl buffer AL to each tube, and tubes were incubated at 56oC with mixing 
every 15 minutes for the first 90 minutes followed by incubation overnight.
200μl 100% EtOH was added, the tube vortexed and the contents of each tube transfered 
to a DNEasy mini column (Qiagen), and the standard Qiagen washing protocols followed, 
before elution in 200μl of Quiagen buffer AE.  The final concentration was assayed using 
the NanoDrop spectrophotometer (Thermo Scientific).  
2.8 - Heatshock Treatment
To activate genes controlled by the heatshock response, larval stage 4 (L4) hermaphrodites 
were picked the day before the assay.  To induce heatshock, the animals were placed at 
33oC for one hour, followed 30 minutes at 20oC, and this was repeated.  Where animals 
were then assessed for their response to pharmacological agents they were directly 
transferred to drug plates as described below.   
2.9 - Aldicarb assays 
2.9.2 - Acute Assay
Small (35mm) drug plates were filled with 5ml worm agar (see page 94) containing 1mM 
aldicarb (Greyhound Chromatography and Allied Chemicals Ltd) made using 100mM 
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aldicarb stock solution dissolved in 70% ethanol.  They were seeded with 50μl OP50 
and left to dry overnight with lids on.  40 larval stage 4 (L4) worms were picked onto 
clean seeded plates and left overnight at 20oC.  The plates were blinded and the details 
recorded for future analysis.  
The following day 25-30 adult animals were transferred to the small drug plates containing 
aldicarb and observed every 10 minutes for 100 minutes to record the number of worms 
that had paralysed. 
Paralysis was defined as a worm that could not move any body wall muscles upon 
stimulation with a platinum wire. Worms which were paralysed were removed from the 
plate.  A graph was drawn showing the percentage of paralysed animals against time. 
To determine whether the effects of aldicarb were reversible, worms counted as 
paralysed were picked to plates without aldicarb and left to recover for two hours before 
their locomotion was observed by eye.  
2.9.3 - Chronic Assay
Small (35mm) drug plates were filled with 5ml worm agar containing 0.2mM aldicarb. 
These were seeeded with 200μl OP50 and left to dry overnight with the lids on.  The 
following day, 5 larval stage 4 (L4) hermaphrodites for each strain to be assayed were 
picked directly onto these plates, and left to grow and lay eggs for 5 days.  At the end of 
this time the plates were examined by eye for the number of progeny and their stage of 
growth compared with wild-type animals grown under the same conditions.  
2.10 - Levamisole assays 
Small (35mm) drug plates were filled with 5ml worm agar containing 100μM levamisole 
(Sigma) made using a 100mM stock solution dissolved in S. Basal.  They were seeded 
with 50μl OP50 and left to dry overnight with lids on.  40 larval stage 4 (L4) worms were 
picked onto clean seeded plates and left overnight at 20oC.  The plates were blinded and 
the details recorded for future analysis.  
The following day 25-30 adult animals were transferred to the small drug plates containing 
aldicarb and observed every 10 minutes for 100 minutes to record the number of worms 
that had paralysed. 
Paralysis was defined as a worm that could not move any body wall muscles upon 
stimulation with a platinum wire.  Worms counted as paralysed were removed from the 
drug plates.  A graph was drawn showing the percentage of paralysed animals against 
time. 
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2.11 - Phorbol ester treatment 
Small (35mm) drug plates were made, in which 2μg/ml phorbol-12-myristate-13-acetate 
(PMA) dissolved in DMSO and 1mM aldicarb were added to the worm agar.  Control 
plates were also made which contained 1mM aldicarb and DMSO.  These plates were 
not seeded.
Plates were left overnight to dry at 20oC. 40 larval stage 4 (L4) worms were picked onto 
clean seeded plates and left overnight at 20oC.  The plates were blinded and the details 
recorded for future analysis.  The following day 25-30 adult animals were transferred to 
either a plate containing 
2μg/ml PMA alone or a DMSO control plate and left for 2 hours at 20oC to pre-treat. 
Animals from the PMA plate were transferred to the plate containing 2μg/ml PMA 
and 1mM aldicarb and the control animals were transferred to the 1mM aldicarb plate 
containing DMSO.  The aldicarb assay was undertaken as described above. 
Where the assay was designed to investigate the effects of PMA alone, the protocol 
above was used without the inclusion of aldicarb.  
2.12 - Serotonin treatment
Small (35mm) drug plates were made, in which serotonin creatine sulphate (3.8mg/ml) 
(Sigma) were added to the worm agar.  Control plates were also made which contained 
1mM aldicarb and DMSO.  These plates were not seeded.
2.13 - Dispersal Assay
Large (100mm) worm plates were filled with NGM worm agar, and OP50 bacteria was 
seeded around the very edge of the plate.  The plates were left to dry overnight with the 
lids on.  
The following day, mixed populations of the animals be assayed were washed from their 
plates with 15ml M9 and spun at 1000rpm for 1 minute to pellet the worms.  Excess M9 
was removed by gentle suction and the volume brought up to 15ml with fresh M9.  This 
was repeated three times to remove OP50 from the worms.  
All excess M9 was removed following the final spin, and the washed worms were 
transferred to the centre of the 100mm plates.  A timer was started once the M9 droplet 
had evaporated, and the number of adult animals on and off food was recorded at 
intervals of 30, 60, 90 and 120 minutes. 
2.14 - Defecation assays 
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L4 worms were picked the night before assaying. The resulting adults were transferred 
onto clean seeded plates and left for 5 minutes to recover. An individual animal was 
then observed for between 5 and 10 minutes and the time recorded every time the pBoc 
and Exp phase of the defecation cycle (Avery 1997) were observed using the Ethotimer 
software (J. Thomas, University of Washington). If an animal moved off the bacterial food 
in this time, the assay was terminated at that point.  The average intervals between pBoc 
and Exp steps was calculated.  
2.15 - Swimming Assays
2.15.2 - Average thrashing assay
Animals were picked the day before the experiment as larval stage 4 (L4) and left to grow 
overnight on fresh plates.  The following day each animal to be assayed was placed into 
a drop of M9 buffer pipeted onto a 22mm X 50mm cover slip, using a flamed platinum 
wire, and left to recover for three minutes.  The number of body bends was then assayed 
for a period of two minutes for each animal.  
2.15.3 - Intial thrashing assay
Larval stage 4 animals were used for this assay.  Each animal to be assayed was 
transferred directly into a drop of M9 buffer pipeted onto a 22mm X 50mm cover slip, and 
the number of body bends in the first five seconds following immersion were counted.  If 
the animal performed 2 or more body bends it was recorded as ‘thrashing’; if it failed to 
perform 2 body bends it was recorded as ‘not thrashing’.  15 to 20 animals were used for 
each assay, and the percentage thrashing was recorded. 
2.16 - Worm length assay
Worms were staged by picking larval stage 4 (L4) animals one day before the experiment. 
Images were taken using a Hammamatsu camera attached to a Leica dissecting scope at 
consistent magnification, and recorded using the MicroManager add-on to ImageJ (NIH). 
Worm length was determined in ImageJ by drawing a series of straight lines from the 
visible tip of the head to the visible tip of the tail, not including the long whip-like structure 
present in hermaphrodites, and then repeating this measurement, starting at the tip of 
the tail to the tip of the head.  An average was taken of these two measurements.  At 
least 20 animals were measured per experiment.  
Width was measured at the widest point across the mid-section of the worm including the 
vulva, but this measurement was not used in the analysis.
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2.17 - Parallel worm tracking
We made use of software developed by Daniel Ramot of the Goodman lab (Ramot, 
Johnson et al. 2008) to measure the speed of multiple animals and assess the effects of 
serotonin and PMA.  Larval stage 4 animals were picked the day prior to the experiment, 
and small (35mm) plates were prepared with small (50μl) OP50 lawns in the centre. 
The plates must be very clear for optimum image processing; any plates containing dark 
deposits of cholesterol or clumped bacterial lawns were not used.  
Animals were transferred to the plates at a point away from the OP50 lawn, and allowed 
to recover for 5 minutes.  Videos were taken using a Hammamatsu camera attached to 
a Leica dissecting scope and captured using the MicroManager add-on to ImageJ (NIH). 
2.18 - Bacterial protocols
2.18.2 - Transformation of chemically competent cells
A 50 μl aliquot of the chemically competent E. coli DH10β was defrosted on ice. 450μl 
of ice-cold 100mM CaCl2 was added and the solution divided into 5 100μl aliquots. 
Approximately 10μl of a 20μl ligation mix (see below), or 10ng of plasmid, were added 
and the mixture placed on ice for 5 minutes. The bacteria were heatshocked for 2 minutes 
at 37oC and briefly returned to ice. 200 μl LB broth was added and the bacteria grown for 
1 hour at 37oC. The bacteria were then plated onto an LB agar plate with the appropriate 
selection antibiotic (ampicillin at 100μg/ml, kanamycin at 25μg/ml or tetracycline at 
50μg/ml) and incubated overnight at 37oC.  
2.18.3 - Isolation of plasmid DNA from bacteria 
Individual bacterial colonies were picked using a sterile inoculation loop and used to 
inoculate LB broth cultures grown at 37oC overnight with the appropriate selection 
antibiotic. For small scale isolation 2ml cultures were grown and the bacteria harvested 
by centrifugation at 1300rpm for 2 minutes. The bacteria were resuspended in 50 μl of 
Solution I, to which 150μl of Solution II (TENS buffer) was added, followed by 100μl of 
Solution III (3M sodium acetate, pH5.2). The DNA was precipitated, washed and purified 
using 96% EtOH and resuspended in 50 μl TE buffer with RNAse. Large-scale DNA 
preparations were performed using 200ml bacterial cultures and the QIAgen midi filter 
kit. The DNA was resuspended in TE buffer. The concentration of DNA was determined 
using the NanoDrop spectrophotometer (Thermo Scientific).
2.18.4 - Restriction digestion and ligation of DNA
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5μg DNA was digested with 10 units of restriction enzyme (New England Biolabs or 
Promega) at 37oC for 2 hours unless otherwise stated.  Digests were run on 1% agarose 
gel made with 1x TBE buffer containing 75μl ethidium bromide per 100ml of agarose gel 
to visualise the DNA.  The DNA band was cut from the gel, cleaned using QIAquick gel 
extraction kit (QIAgen) and resuspended in 50μl TE buffer.  Ligations were performed 
using T4 Quick Ligase (New England Biolabs) as per manufacturer’s instructions. 
5μg of purified digested vector DNA, 5μg of purified digested insert DNA, ligase buffer 
and 2,000 units of T4 Quick Ligase were incubated at RT for 15 minutes and then placed 
on ice ready for transformation. 
2.19 - Polymerase Chain Reaction (PCR)  
2.19.2 - Standard PCR - e.g. for sequencing unc-80 genomic 
regions
10pmol of each primer, 0.2mM dNTP mix, 2.5 units Taq polymerase and 1mM MgCl2 
were used unless otherwise stated.  Sigma Taq Polymerase was used in all PCR 
reactions where the product was used diagnostically or for sequencing.  The same PCR 
programme was used for all reactions with changes in the annealing temperature and 
extension time for different primer sets. 
1) 95oC 3 minutes 
1) 95oC 45 seconds 
1) Annealing temperature (from 55-65oC, depending on program)  40 seconds 
1) 72oC extension time 
1) Back to step 2, repeat 35 times 
1) 72oC 10 minutes (final extension)
1) 4oC   hold 
The extension time was calculated as 1 minute per 1kb of DNA being amplified rounded 
up to nearest 30 seconds.  The annealing temperature was determined by trial and error 
beginning at 60oC - increasing due to non-specific amplification and decreasing due to 
no amplification until the correct temperature for specific amplification was found. 
2.19.3 - PCR for cloning using Phusion
10pmol each primer, 0.2mM dNTP mix, 1x Phusion HE buffer, containing 1mM MgCl2 
(Buffer GC was used on some more difficult genomic templates), 1 unit Phusion Hot 
Start DNA polymerase and 1mM MgCl2 were used unless otherwise stated.  Phusion 
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polymerase (New England Biolabs) was used for all cloning as it has a significantly lower 
error rate than standard Taq polymerase.   The same PCR programme was used for all 
reactions with changes in the annealing temperature and extension time for different 
primer sets. 
1) 98oC 30 seconds 
2) 98oC 10 seconds 
3)  Annealing temperature (from 55-65oC, depending on program)  30 seconds 
4) 72oC extension time (30 seconds per kb)
5) Back to step 2, repeat 30-35 times 
6) 72oC 10 minutes (final extension)
7)  4oC   hold
2.19.4 - Site-directed mutagensis using Quikchange
Site-directed mutations were introduced into plasmids using the Quikchange II protocol 
from Agilent Technologies.  10pmol each primer, 0.2mM dNTP mix, 1x reaction buffer, 
containing 1mM MgCl2, 2.5 units Pfu Ultra High Fidelity DNA polymerase were used in a 
PCR reaction along with 50 ng of the plasmid template to be mutated.  
1) 95oC 30 seconds 
2) 95oC 10 seconds 
3)  55oC  1 minute 
4) 68oC extension time (1 minute per kb of plasmid)
5) Back to step 2, repeat 18 times 
7) 4oC   hold
Following the PCR reaction, 10 units of DpnI restriction enzyme were added to the 
reaction mix, mixed thoroughly, and incubated at 37oC for 1 hour to digest the template 
DNA.  1 μl of the digestion mix was used to transform XL1 Blue supercompentent cells 
using a heat pulse: 45 seconds at 42°C and then place the reactions on ice for 2 minutes. 
Cells were grown in 0.5 ml of L Broth for one hour at 37oC, and the entire mix was spread 
onto a plate containing an appropriate selection marker.  
2.20 - Sequencing of DNA
2.20.2 - Short read sequencing
200ng of purified DNA in water was dried down. This was sent to MWG Biotech with 10ng 
of the desired primer for sequencing. Value read sequencing was used.  The sequence, 
clipped by MWG for sequence purity, was blasted against the known sequence using 
NCBI Blast to identify any base pair changes.  
2.20.3 - Whole Genome Sequencing (WGS)
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Whole Genome Sequencing was performed by GeneService.  We purified DNA using 
the method above (2.6.2), and sent DNA from four mutants for sequencing.  QT317 was 
generated by UV/TMP mutagenesis and contains allele nz90 which confers resistance 
to aldicarb, and was identified by Emma Hiley, a previous PhD student in our lab (Hiley, 
2006).  We also sequenced three suppressors of the loopy locomotion of nRHO-
1* - QT677 (nz99), QT788 (nz97) and QT834 (nz110) which were generated by EMS 
mutagenesis (see Chapter 3).  
2.21 - Analysis of Whole Genome Sequencing Data
2.21.2 - Analysis of Geneservice Data
The data obtained from Geneservice included an Excel spreadsheet containing a list 
of all the single nucleotide polymorphisms (SNPs) predicted from analysis of the short 
reads by the program MAQ (Mapping and Assembly with Quality) (Li, Ruan et al, 2008). 
This did not contain biologically relevant information, i.e. whether the mutations affected 
protein-coding regions and were non-silent mutations.
To filter mutations which are likely to be background mutations in some or all of the 
strains, the first step was to assign a unique code to each mutation.  This was done using 
Excel, with the formula
=C2&”_”&D2&”_”&F2
where C2 is the chromosome name, D2 is the position of the mutation, and F2 is the 
mutant base.  We made the assumption that if all three factors are identical between two 
or more strains then the mutation can be counted as a background mutation.  Anything 
common between QT317 and any other mutant is almost certainly a background mutation, 
as this strain was created several years before the others, does not contain the nRHO-1* 
transgene and was not EMS mutagenised, unlike QT677, QT788 and QT834.  Anything 
common between the other mutants is also likely to be a background mutation, but there 
is a small possibility that it could represent a real, common base change that may have 
a suppressive effect.  
To compare these codes between different mutants requires a further Excel formula:
=MATCH(G2,QT317_Mutations,0)
where G2 is the unique code generated for a particular mutation, QT317_Mutations is 
an array containing all the unique codes for strain QT317, and 0 specifies that only exact 
matches be returned as positive hits.  This formula can be added to each row for each 
mutation in each mutant, to produce columns listing whether a mutation is present in any 
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of the other mutants being screened.  The formula will return #N/A if no match is found; 
otherwise it will return a number referring to the row on which a match has been found.
This result can be used to filter for only those mutations which have no match in any of 
the other strains sequenced.  
Once filtered, the position of the point mutations (Chromosome number and base on 
the chromosome) can be run through the UCSC Genome Browser (http://genome.ucsc.
ed) and this will only return an output if the position corresponds to part of an annotated 
region - i.e. an exon, intron or 5’/3’ UTR of a gene.  This can be used to filter the list of 
mutations to only those which affect protein-coding regions, for example. 
The output for each gene from the UCSC Genome browser also contains a list of intron/
exon boundaries relative to the start codon of the gene.  Deducting the genomic position 
of the start codon from the mutated base position and comparing it to this list allows us 
to identify whether a mutation affects an exon or an intron, and to filter only for exonic 
mutations.
For each mutation affecting an exon, we downloaded the cDNA sequence and used 
custom Excel formulas to extract the relevant codon.  We then substituted the mutated 
base into the appropriate position in the codon (1,2 or 3), translated this mutated codon, 
and compared it to the wild-type codon to determine whether the mutation caused a 
silent or non-silent change in the protein sequence.  
This analysis was performed for data from QT834, and a number of problems prevented 
it being rolled out to the other mutants.  Firstly, the extraction of data from the UCSC 
Genome Browser was often incomplete (we believe this is because the browser does not 
have access to the most up-to-date genome annotations for the C. elegans genome) and 
therefore we miss a number of potential mutations at the start of the analysis.  Secondly, 
due to a bug in the formulas used the predictions were often inaccurate when compared 
with the data on Wormbase, especially for genes transcribed from the minus strand of 
DNA.  Finally, we uncovered a systematic error in the Geneservice data which meant 
that the position of the mutated base was shifted by one base compared with the wild-
type genome.  Thus a different program was used for analysis.  
2.21.3 - Analysis using MAQGene
From GeneService we obtained both the raw data (36bp, 55bp and 76bp paired-end 
reads) and the results of running that data through MAQ.  We had doubts about the 
reliability of this bioinformatic data, and re-analysed the raw data ourselves. 
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With the help of Janos Kriston-Vizi of the Kettler lab at the MRC LMCB, we installed 
MAQGene, developed in the Hobert lab (Bigelow, Doitsidou et al. 2009).  MAQGene 
allows a user to run the program MAQ without accessing the Linux command line.  Within 
MAQGene, the MAQ-specific commands are entered into a user-friendly webpage-
format, MAQGene generates all MAQ-specific files, and produces a list of SNPs, similar 
to that obtained from Geneservice.  
Additionally, MAQGene then interrogates these SNPs using its own specific parameters, 
and then maps those that pass these thresholds onto an annotated database of the 
worm genome.  This database can be updated to hold the most up-to-date release of the 
C. elegans genome.
We ran MAQGene using the default settings detailed from the Hobert lab in their 
publications using their latest paramater for filtering hits - fraction of wild-type reads - at 
0.86 (Bigelow, Doitsidou et al. 2009; Sarin, Bertrand et al. 2010).  
The setting “ Maximum sum of error qualities” is used to assess the likelihood that a 
particular mismatch is due to sequencing error.  Each sequenced base is given a quality 
score based, and the authors of MAQGene recommend a setting of 100 for 36bp reads. 
However, our data set incudes 36, 55 and 76bp reads; longer reads could be allowed to 
accumulate more errors than shorter ones and still be valid.  However, we are unable to 
specific settings for individual read lengths, and therefore left this setting at 100.  This 
means that some longer reads have been discounted.  We have yet to determine a way 
to run the data sets individually and then successfully recompile them for analysis.  
2.21.4 - Filtering MAQGene output for background mutations
The final output from MAQGene is a list of SNPs and small deletions referred to as indels, 
detailing both their position in the genome, any genes which are affected by the predicted 
changes, and the nature of those changes – for instance, introducing premature STOP 
codons, or creating read-through mutations.  We filtered for mutations using the same 
Excel formulas developed to filter the Genservice data (section 2.19.1).  
2.21.5 - Matching mutations to gene names
The output from MaqGene references each mutation to the gene it hits/nearest exon etc, 
and outputs the orf details – i.e. the designation refers to the particular position on the 
cosmid on which that gene is found.
To make the data set more user-friendly, we wanted to translate these into the more 
common Sanger Gene names, and to add links out to WormBase.
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To do this we input the list of open reading frames into the UCSC Genome Browser. 
MAQGene outputs a column called ‘parent features’ which contains the names of all the 
ORFs which are affected by a specific mutation.  Excel’s ‘Text-to-Columns’ feature was 
used to separate these into individual columns, and the data from the first column as be 
entered into the UCSC Genome Browser, in the ‘Identifiers’ box of the OrfToGene table, 
with the species set to Nematode and the C. elegans database chosen.  
 [For some reason, not all of the identifiers are matched in the Table Browser, so for Q317 
Run I we get an error message like this:
Note: 35 of the 871 given identifiers (e.g. C04B4.1.1) have no match in table orfToGene, 
field name. Try the “describe table schema” button for more information about the table 
and field.
I think this is because the Table Browser doesn’t have access to the most recent 
annotations of the genome; the majority are found however.  Missing names can be found 
manually by searching Wormbase which has the most up-to-date genome annotations.]
The output from UCSC Genome Browser is sorted alphabetically, so to match them to 
their gene of origin we can use another Excel formula:
=VLOOKUP(V2,QT317_ID,2,FALSE)
where V2 refers to the particular mutation which we wish to match to a gene name, 
QT317_ID is the range containing the gene names; the number 2 tells the formula to 
look in the second column after finding a match in the first, and FALSE tells Excel to only 
look up exact matches.
To generate a hyperlink to the Wormbase reference for the gene of interest, the following 
two formulas were used.  In the first cell (X2) we entered:
=”http://www.wormbase.org/db/gene/
gene?name=”&V2&”;class=Gene”
where V2 contains the specific ORF details, and the surrounding details create the correct 
format for a link to Wormbase.  Then in the adjacent cell, Y2, we entered: SJN466v
=Hyperlink(X2,U2)
where X2 is the link generated above and U2 is the Sanger gene name determined 
earlier.  This creates an efficient way to link between the sequencing data and the gene 
details.
2.21.5.2 - Finding regions of high mutational frequency
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During outcrossing, the region around the causative mutation is likely to contain a higher 
frequency of mutations than the rest of the genome due to unlinked mutations being 
lost during recombination.  To search for regions with high levels of mutation we filtered 
the sequencing data for mutations which occur in 100% of the reads, contain only the 
classical G/C to A/T mutation which results from EMS, and had a quality score above 
20.  We then produced a histogram of this data to identify regions of high mutational 
frequency.
2.22 - Making UNC-80 rescuing constructs
The most complete cDNA of unc-80 is on plasmid yk1260h6, which we obtained as a gift 
from Yuji Kohara.  However, sequencing of this plasmid revealed that the 3’ end of the 
cDNA is not consistent with the published sequence of unc-80 cDNA.  
We therefore decided to produce an unc-80 minigene, constructed partly from the wild-
type 5’ end of the cDNA and partly from genomic DNA.
Primers UNC-80.63 and UNC-80.64 were used to clone the whole yk1260h6 by PCR. 
UNC-80.63 introduces a KpnI site 5’ of the start condon and a NotI site just 3’ of the start 
codon (which can be used to introduce protein tags such as GFP), while UNC-80.64 
introduces a SacI site 3’ of the STOP codon.  The product was digested with KpnI and 
SacI and subcloned into a Bluescript vector cut with SacI and KpnI (plasmid SJN455).  
The KpnI/SacI fragment was digested from SJN455 and subcloned into plasmid psc#205, 
which contains the acr-2 promoter, cut with KpnI and SacI, and named SJN463.  The 
unc-80 cDNA contains an internal BlpI site, before which the sequence is wild-type.  
The genomic sequence of unc-80 from this BlpI site to the STOP codon was amplified 
from a cyk-2 genomic DNA template as a substitute for the mutated cDNA sequence. 
Primers UNC-80.53 and UNC-80.64 were used, which cover the internal BlpI site, and 
introduce a SacI site 3’ of the STOP codon.  
SJN463 was digested with BlpI and SacI to excise the mutated cDNA sequence, while 
the genomic DNA PCR product was digested with BlpI and SacI, and ligated into the cut 
SJN463 vector.  This new plasmid is acr-2-driven UNC-80 minigene, and was named 
SJN467.  The unc-80 minigene in this plasmid was sequenced and found to be wild-type. 
SJN467 was digested with NotI (which cleaves just after the start codon) and with SpeI 
and ligated into vector QT#220 cut with NotI and SpeI, which excises p.unc-17-driven 
RHO-1 from this vector.  This ligated product, named SJN469, unc-80 expression from 
the same vector as the nRHO-1* transgene used in this thesis. 
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The KpnI-SacI fragment of SJN467, containing the unc-80 minigene, was inserted into 
QT#42 cut with KpnI-SacI to produce a heat-shock driven unc-80 minigene, expressed 
from the same vector backbone as the heat-shock driven RHO-1* used in this thesis. 
This new plasmid was named SJN470.  
The KpnI-SacI fragment of SJN467, containing the unc-80 minigene, was inserted into 
QT#237 cut with KpnI-SacI to produce a synaptobrevin-driven unc-80 minigene, and this 
new plasmid was named SJN471.  
Plasmids SJN467, SJN469, SJN470 and SJN471 were modified to produce GFP fusion 
proteins by digesting the plasmid backbones with NotI and inserting the NotI fragment 
of KP#295, which contains the Fire GFP  sequence with introns.  These plasmids where 
named SJN483, SJN477, SJN479 and SJN481 respectively.
Plasmids SJN467, SJN469, SJN470 and SJN471 were modified to produce mCherry 
fusion proteins by digesting the plasmid backbones with NotI and inserting the NotI 
fragment of SJN445, which contains the mcherry cDNA sequence..  These plasmids 
where named SJN483, SJN478, SJN480 and SJN482 respectively.
2.23 - Making a constitutively active PKC-3 construct
We obtained three pkc-3 cDNAs as gifts from Yuji Kohara - YK1447b7, YK284f7, 
YK526h11 – and grew these according to standard methods.  These plasmids were 
miniprepped as detailed above, and used as a template for a PCR reaction to amplify 
the full-length cDNA of PKC-3.  Primers PKC-3.1 and PKC-3.2 were used to amplify the 
coding region, and introduced unique NcoI and SacI sites at the 5’ and 3’ ends of the 
cDNA for further subcloning.  PKC-3.1 also introduces a unique NotI site at the 5’ end, 
just after the start codon, which can be used for the introduction of protein tags such as 
GFP.  
PCR from YK526h11 produced a band of the predicted size (1800bp) for full-length pkc-
3 cDNA.  When this was digested with NheI as a diagnostic test for pkc-3 this digestion 
produced two bands of approximately 1200bp and 700bp, as predicted.  
The pkc-3 cDNA fragment was subcloned into plasmid pSC#205, which contains the acr-
2 promoter, which drives expression in the cholinergic neurons of C. elegans and some 
interneurons (Jospin, Qi et al, 2009).  Diagnostic digests with NotI and SacI suggested 
that this cloning had been successfully accomplished, and the plasmid, APP001 was 
sent for sequencing, using primers PKC-3.3, PKC-3.4, PKC-3.5 and PKC-3.6.   
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To generate a constiutively active PKC-3 protein we used site-directed mutagenesis, 
following the QuikChange protocol, to modify APP001.  Primers PKC-3.7 and PKC-3.8 
were used to change an alanine at position 116 in the protein to glutamate, with a base 
change in the cDNA from GCT to GAG.  These primers also introduce a silent mutation 
which produces a unique SacII site, which is diagnostic for successful site-directed 
mutagenesis.  Digests of the plasmid indicated that this mutation had been successfully 
introduced.  This plasmid was named APP002. 
However, when the sequencing reactions returned, we noticed that the YK526h11 
cDNA from whcih we had obtained cDNA of PKC-3 was not wild-type at the 5’ end.  We 
sequenced the other cDNA clones we had obtained, and established that YK447b7(b) 
had a wild-type coding sequence over these regions.   We were able to make use of 
the the novel SacII restriction site which we introduced as a marker for the QuikChange 
reaction to allow swapping of 5’ end of our mutant cDNA for the wildtype version found in 
the YK447b7(b).  We therefore used PCR to amplify the relevant section of YK447b7(b) 
using primers PKC-3.7 and PKC-3.2, digested this product and the APP002 plasmid 
using SacII and SacI, and ligated these products to make a fresh constitutively active 
PKC-3 plasmid.  This construct was named APP003.  
2.24 - Making constitutively active and dominant negative 
CDC-42 constructs
Oligos CDC-42.1 and CDC-42.2 were used to PCR the CDC-42 cDNA from plasmid 
yk1443h08 (a gift from Yuji Kohara) which contains full-length CDC-42 cDNA.  The 
PCR product was digested with NheI and SacI and subcloned into vector pPD49_73 
(containing the heat-shock promter) which had also been cut with NheI and SacI. 
This was sequenced and shown to contain no mutations, and the plasmid was named 
SJN379.   The PCR product was also subcloned into vector pSC#205 (containing the 
acr-2 promoter) which had been cut with NheI and SacI. This was also sequenced with 
primers CDC-42.1 and CDC-42.2 and shown to contain no mutations, and the new 
plasmid was named SJN381.
To produce a constiutively active version of CDC-42, we performed site-directed 
mutagenesis using the Quickchange protocol and primers CDC-42.3 and CDC-42.4 
primers, which introduce the mutation G12V, and also create a silent SfcI site as a 
marker of successful site-directed mutagenesis. These primers were used to modify 
plamsids SJN379 and SJN381 to produce constitutively-active CDC-42 driven by the 
acr-2 promoter (APP004) and from the heatshock promoter (APP006).  These plasmids 
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were sequenced with primers CDC-42.1 and CDC-42.2 and found to contain the G12V 
mutation and the SfcI site.
To produce a dominant negative version of CDC-42, we performed site-directed 
mutagenesis using the Quickchange protocol and primers CDC-42.5 and CDC-42.6, 
which introduce the mutation T17N and also create a silent AccI site as a marker of 
successful site-directed mutagenesis. These primers were used to modify plasmid 
SJN379 to produce dominant negative CDC-42 driven by the heatshock promoter 
(APP005).  This plasmid was sequenced with primers CDC-42.1 and CDC-42.2 and 
found to contain the T17N mutation and the AccI site, as well as an additional silent 
mutation in the coding sequence. 
2.25 - Solutions and buffers
2.25.5.2 - Worm NGM agar 
20.8g/litre agar 
2.34g/litre Bacto-peptone 
50mM NaCl 
Autoclave then add: 
0.25M potassium phosphate 
1mM MgSO4 
1mM CaCl2 
5μg/ml cholesterol 
200μg/ml streptomycin 
10μg/ml nystatin 
2.25.5.3 - M9 buffer 
0.02M KH2PO4 
0.04M Na2HPO4 
0.09M NaCl 
0.01M MgSO4 
2.25.2 - Worm freezing agar 
0.1M NaCl 
0.05M KH2PO4 
300g/litre glycerol 
0.05M NaOH 
Autoclave then add: 
3mM MgSO4 
4g/litre Bacto-agar 
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T.E. Buffer 
10mM Tris/Cl 
1mM EDTA 
2.25.3 - EN solution 
10mM EDTA 
100mM NaCl 
Worm lysis buffer 
130mM Tris pH8.5 
1% SDS 
50mM EDTA 
0.1M NaCl  
2.25.4 - S. basal 
0.1M NaCl 
0.05M potassium phosphate (pH6) 
5mg/litre cholesterol 
2.25.5 - Single worm PCR lysis buffer: 
10mM Tris pH8.0 
50mM KCl 
2.5mM MgCl2 
0.45% Igepal 
0.45% Tween 20 
0.01% gelatin 
(Stored at 4oC) 
2.25.6 - TBE (Tris-Borate EDTA) buffer 
0.089M Tris Base 
0.089M Boric acid 
2mM EDTA 
2.25.7 - Transformation buffer 1 (TFB1) 
30mM KOAc 
100mM RbCl 
10mM CaCl2 
50mM MnCl2 
2.25.8 - Transformation buffer 2 (TFB2) 
10mM MOPS 
75mM CaCl2 
10mM RbCl 
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15% v/v glycerol 
2.25.9 - L broth 
1% Bacto-tryptone  
0.5% Bacto-yeast extract  
10mM NaCl 
(Stored at 4oC) 
2.25.10 - LB agar 
1% Bacto-tryptone 
0.5% Bacto-yeast extract 
10mM NaCl 
1.5% Bacto-agar 
(Stored at 4oC) 
2.25.11 - TENS buffer 
1mM Tris/Cl pH7.5  
1mM EDTA pH8  
0.1N NaOH  
0.5% SDS 
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Strain Geneotype Made By
CB1068 unc-79(e1068)III. CGC
CB1069 unc-80(e1069)V. CGC
CB4856
C. elegans wild type, 
CB subclone of HA-8 
(Tc1 pattern IX).
CGC (20/3/01)
N2 wildtype (08/04/2009) CGC
NM979
unc-64(js115)/bli-
5(e518) III.
CGC
QT47 nzIs1 *4 I nuz
QT309 nzIs29 *2
QT622
nzEx304 
[rjm050;KP307]
Rachel
QT623
nzEx305 
[rjm050;KP307]
Rachel
QT631 nzIs1;nzIs29 Rachel
QT670 nzIs1;nzIs29;nz92 Rachel
QT671 nzIs1;nzIs29;nz93 Rachel
QT672 nzIs1;nzIs29;nz94 Rachel
QT673 nzIs1;nzIs29;nz95 Rachel
QT674 nzIs1;nzIs29;nz96 Rachel
QT675 nzIs1;nzIs29;nz97 Rachel
QT676 nzIs1;nzIs29;nz98 Rachel
QT677 nzIs1;nzIs29;nz99 Rachel
QT678 nzIs1;nzIs29;nz100 Rachel
QT679 nzIs1;nzIs29;nz101 Rachel
QT680 nzIs1;nzIs29;nz102 Rachel
QT683 nzIs1;nzIs29;nz104 Andrew
QT684 nzIs1;nzIs29;nz105 Andrew
QT685 nzIs1;nzIs29;nz106 Andrew
QT686 nzIs1;nzIs29;nz107 Andrew
QT687 nzIs1;nzIs29;nz108 Andrew
Notes and Comments
Unc-fainter. Stops. Stiff anterior.
Unc-stiff anterior.
Isolated from a pineapple field in Hawaii in 1972 by L. 
Hollen.Wild type. Low copy Tc1; pattern IX.
C. elegans wild type, DR subclone of CB original (Tc1 
pattern I).
Heterozygotes are WT and segregate WT, Bli and L1 
arrestedparalyzed animals (js115 homozygotes). Well 
balanced.
nzIs1 [QT#42(h.s. rho-1 (G14V)); ttx-3::gfp]
Expresses G14V, F25N RHO-1 from the heatshock 
promoter.  line 11.3
Expresses G14V, F25N RHO-1 from the heatshock 
promoter.  line 11.6
line 7.1.3
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
QT688 nzIs1;nzIs29;nz109 Andrew
QT700 nzIs1;nzIs29;nz110 Andrew
QT701 nzIs1;nzIs29;nz111 Andrew
QT738 nzIs1;nz94 Rachel
QT739 nzIs1;nz98 Rachel
QT748 nz94;nzIs29 Rachel
QT749 nz97;nzIs29 Rachel
QT750 nz98;nzIs29 Rachel
QT759 z94;nzIs29*2 Rachel
QT760 nz97;nzIs29*2 Rachel
QT761 nz98;nzIs29*2 Rachel
QT775 nz98;nzIs29 Rachel
QT782 z94;nzIs29 Rachel
QT788 nz97;nzIs29 Rachel
QT804 nz110; nzis29 1* Andrew
QT812 nz108; nzis29 1*
QT813 nz108; nzis29 1*
QT816 nz110;nzis29 2* Andrew
QT821 nz107; nzis29 1* Andrew
QT822 nz107; nzis29 1* Andrew
QT823 nz105; nzi29 1* Andrew
QT824 nca-2(gk5); nzis29 Andrew
QT825 nca-1(gk9); nzis29 Andrew
QT826
unc-
64(js115);nzEx454[SJN
367;cc:gfp]
Andrew
QT827
unc-
64(js115);nzEx454[SJN
368;ttx-3:gfp]
Andrew
QT828
unc-
64(js115);nzEx454[SJN
368;ttx-3:gfp]
Andrew
QT829 nz94; nzIs33 Rachel
QT830 nz94 Rachel
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
QT094 and QT672
QT094 and QT676
nz94 rho-1 suppressor backcrossed 1 time.  nzIs1 has been 
lost.  QT733 crossed with QT672
nz97 rho-1 suppressor backcrossed 1 time.  nzIs1 has been 
lost.  QT733 crossed with QT675
nz98 rho-1 suppressor backcrossed 1 time.  nzIs1 has been 
lost
QT748 backcross
QT749 backcross
QT750 backcross
rho-1 suppressor nz98 backcrosses three times through 
nzIs29
rho-1 suppressor nz94 backcrossed three times through 
nzIs29
rho-1 suppressor nz97 backcrosses three time through 
nzIs29
This strain is him.  nz110 1x backcross.  QT700 crossed with 
QT733.
nz108 1x backcross.  QT687 crossed with QT733
This strain is nz108 1x backcross.  Produces males.  QT687 
crossed with QT733.
This strain is 2x backcrossed nz110.  QT804 crossed with 
QT733
1x backcrossed.  QT686 crossed with QT733. Non-loopy.
1x backcrossed.  Produces males.  QT686 crossed with 
QT733.  Non-loopy.
1x backcrossed.  QT684 crossed with QT733
non-loopy; nca-2 mutation appears to suppress nRho-1*.  
VC9 crossed with QT733
non-loopy; nca-1 mutation appears to suppress nRho-1*.  
QT816 crossed with QT733.  3x backcrossed
Same as QT930; use strain QT930 instead for consistency.  
NM979 injection.  CC::GFP marker
One of several successfully rescued animals from the 
nm979 injections with this construct. This came from 
injection gamma-1.
One of several successfully rescued animals from the 
nm979 injections with this construct. This came from 
injection 53.1.1.
Suppressor of p.unc-17::rho-1* loopy locomotion
Suppressor of p.unc-17::rho-1* loopy locomotion
Table 2.1 List of strains used or referenced in this thesis
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QT688 nzIs1;nzIs29;nz109 Andrew
QT700 nzIs1;nzIs29;nz110 Andrew
QT701 nzIs1;nzIs29;nz111 Andrew
QT738 nzIs1;nz94 Rachel
QT739 nzIs1;nz98 Rachel
QT748 nz94;nzIs29 Rachel
QT749 nz97;nzIs29 Rachel
QT750 nz98;nzIs29 Rachel
QT759 z94;nzIs29*2 Rachel
QT760 nz97;nzIs29*2 Rachel
QT761 nz98;nzIs29*2 Rachel
QT775 nz98;nzIs29 Rachel
QT782 z94;nzIs29 Rachel
QT788 nz97;nzIs29 Rachel
QT804 nz110; nzis29 1* Andrew
QT812 nz108; nzis29 1*
QT813 nz108; nzis29 1*
QT816 nz110;nzis29 2* Andrew
QT821 nz107; nzis29 1* Andrew
QT822 nz107; nzis29 1* Andrew
QT823 nz105; nzi29 1* Andrew
QT824 nca-2(gk5); nzis29 Andrew
QT825 nca-1(gk9); nzis29 Andrew
QT826
unc-
64(js115);nzEx454[SJN
367;cc:gfp]
Andrew
QT827
unc-
64(js115);nzEx454[SJN
368;ttx-3:gfp]
Andrew
QT828
unc-
64(js115);nzEx454[SJN
368;ttx-3:gfp]
Andrew
QT829 nz94; nzIs33 Rachel
QT830 nz94 Rachel
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
Isolated as non-loopy suppressor of nzIs29 and nzIs1 
following EMS mutagenesis of QT631
QT094 and QT672
QT094 and QT676
nz94 rho-1 suppressor backcrossed 1 time.  nzIs1 has been 
lost.  QT733 crossed with QT672
nz97 rho-1 suppressor backcrossed 1 time.  nzIs1 has been 
lost.  QT733 crossed with QT675
nz98 rho-1 suppressor backcrossed 1 time.  nzIs1 has been 
lost
QT748 backcross
QT749 backcross
QT750 backcross
rho-1 suppressor nz98 backcrosses three times through 
nzIs29
rho-1 suppressor nz94 backcrossed three times through 
nzIs29
rho-1 suppressor nz97 backcrosses three time through 
nzIs29
This strain is him.  nz110 1x backcross.  QT700 crossed with 
QT733.
nz108 1x backcross.  QT687 crossed with QT733
This strain is nz108 1x backcross.  Produces males.  QT687 
crossed with QT733.
This strain is 2x backcrossed nz110.  QT804 crossed with 
QT733
1x backcrossed.  QT686 crossed with QT733. Non-loopy.
1x backcrossed.  Produces males.  QT686 crossed with 
QT733.  Non-loopy.
1x backcrossed.  QT684 crossed with QT733
non-loopy; nca-2 mutation appears to suppress nRho-1*.  
VC9 crossed with QT733
non-loopy; nca-1 mutation appears to suppress nRho-1*.  
QT816 crossed with QT733.  3x backcrossed
Same as QT930; use strain QT930 instead for consistency.  
NM979 injection.  CC::GFP marker
One of several successfully rescued animals from the 
nm979 injections with this construct. This came from 
injection gamma-1.
One of several successfully rescued animals from the 
nm979 injections with this construct. This came from 
injection 53.1.1.
Suppressor of p.unc-17::rho-1* loopy locomotion
Suppressor of p.unc-17::rho-1* loopy locomotion
QT831 nz94; him-5 Rachel
QT832 nz98 Rachel
QT834 nz110; nzis29 Andrew
QT834 nz110; nzis29 Andrew
QT835 nz108; nzis29 2* Andrew
QT838
unc-
64(js115);nzEx454[SJN
368;ttx-3:gfp]
Andrew
QT838
unc-
64(js115);nzEx454[SJN
368;ttx-3:gfp]
Andrew
QT839
unc-
64(js115);nzEx454[SJN
368;ttx-3:gfp]
Andrew
QT840 unc-79(e1068); nzis29 Andrew
QT841 unc-80(e1069);nzis29 Andrew
QT842 nca-2(vc9);nzis29 Andrew
QT854
nzEx401 
[rjm039;QT238]
Rachel
QT869
nzIs29;nz92*1 
[labelled 689]
Rachel
QT902 nz101;nzIs29*2 Rachel
QT930
unc-64(js115);nzEx465 
[SJN367;cc:gfp]
Andrew
QT931
unc-64(js115);nzEx466 
[SJN368;ttx-3:gfp]
Andrew
QT931
unc-64(js115);nzEx466 
[SJN368;ttx-3:gfp]
Andrew
QT931
unc-64(js115);nzEx466 
[SJN368;ttx-3:gfp]
Andrew
QT947
nzEx474[SJN447;KP#3
07] (18.3)
Andrew
QT948
nzEx475[SJN447;KP#3
07] (8.2.9)
Andrew
QT949
nzEx476[SJN447;KP#3
07] (12.1)
Andrew
QT950
nzEx477[SJn368;ttx-3]; 
tom-1 (ok285) (2.6.5)
Andrew
Suppressor of p.unc-17::rho-1* loopy locomotion
Suppressor of p.unc-17::rho-1* loopy locomotion
non-loopy
Non-loopy.  3x backcrossed
2x backcrossed.  QT813 crossed with QT309.  Non-loopy
One of several successfully rescued animals from the 
nm979 injections with this construct. This came from 
injection 7.6.
One of several successfully rescued animals from the 
nm979 injections with this construct. This came from 
injection 7.6.
One of several successfully rescued animals from the 
nm979 injections with this construct. This came from 
injection 7.13.
Non-loopy, unc-79 appears to suppress nRho-1*.  CB1069 
and QT733
Non-loopy.  CB1069 crossed with QT733
VC9 crossed with QT733
n:F25N G14V RHO-1
NB this tube is mislabelled as QT689
nz101 was backcrossed through nzIs29 twice and non-
loopy animals were isolated
Non-blister, which suggests construct rescues unc-64 
lethality. From injection h.1.d.
Animals are non-blister, suggesting that the construct 
rescues the unc-64 lethality.
Animals are non-blister, suggesting that the construct 
rescues the unc-64 lethality.
Animals are non-blister, suggesting that the construct 
rescues the unc-64 lethality.
This is the mouse modified estrogen receptor bound to C3 
toxin. This strain is designed to only have activated C3 in 
the presence of tamoxifen. N2 Injection
This is the mouse modified estrogen receptor bound to C3 
toxin. This strain is designed to only have activated C3 in 
the presence of tamoxifen.  N2 injection
This is the mouse modified estrogen receptor bound to C3 
toxin. This strain is designed to only have activated C3 in 
the presence of tamoxifen.  N2 injection
Looking for changes in the locomotion/acetylcholine 
release of tom-1 mutants in the presence of the 
phosphomimetic form of syntaxin. No changes yet 
detected; animals are NOT paralysed - unlike unc-64 
animals rescued with this plasmid (i.e does not appear to 
be dominant.)  Injection into tom-1 (ok285)
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QT831 nz94; him-5 Rachel
QT832 nz98 Rachel
QT834 nz110; nzis29 Andrew
QT834 nz110; nzis29 Andrew
QT835 nz108; nzis29 2* Andrew
QT838
unc-
64(js115);nzEx454[SJN
368;ttx-3:gfp]
Andrew
QT838
unc-
64(js115);nzEx454[SJN
368;ttx-3:gfp]
Andrew
QT839
unc-
64(js115);nzEx454[SJN
368;ttx-3:gfp]
Andrew
QT840 unc-79(e1068); nzis29 Andrew
QT841 unc-80(e1069);nzis29 Andrew
QT842 nca-2(vc9);nzis29 Andrew
QT854
nzEx401 
[rjm039;QT238]
Rachel
QT869
nzIs29;nz92*1 
[labelled 689]
Rachel
QT902 nz101;nzIs29*2 Rachel
QT930
unc-64(js115);nzEx465 
[SJN367;cc:gfp]
Andrew
QT931
unc-64(js115);nzEx466 
[SJN368;ttx-3:gfp]
Andrew
QT931
unc-64(js115);nzEx466 
[SJN368;ttx-3:gfp]
Andrew
QT931
unc-64(js115);nzEx466 
[SJN368;ttx-3:gfp]
Andrew
QT947
nzEx474[SJN447;KP#3
07] (18.3)
Andrew
QT948
nzEx475[SJN447;KP#3
07] (8.2.9)
Andrew
QT949
nzEx476[SJN447;KP#3
07] (12.1)
Andrew
QT950
nzEx477[SJn368;ttx-3]; 
tom-1 (ok285) (2.6.5)
Andrew
Suppressor of p.unc-17::rho-1* loopy locomotion
Suppressor of p.unc-17::rho-1* loopy locomotion
non-loopy
Non-loopy.  3x backcrossed
2x backcrossed.  QT813 crossed with QT309.  Non-loopy
One of several successfully rescued animals from the 
nm979 injections with this construct. This came from 
injection 7.6.
One of several successfully rescued animals from the 
nm979 injections with this construct. This came from 
injection 7.6.
One of several successfully rescued animals from the 
nm979 injections with this construct. This came from 
injection 7.13.
Non-loopy, unc-79 appears to suppress nRho-1*.  CB1069 
and QT733
Non-loopy.  CB1069 crossed with QT733
VC9 crossed with QT733
n:F25N G14V RHO-1
NB this tube is mislabelled as QT689
nz101 was backcrossed through nzIs29 twice and non-
loopy animals were isolated
Non-blister, which suggests construct rescues unc-64 
lethality. From injection h.1.d.
Animals are non-blister, suggesting that the construct 
rescues the unc-64 lethality.
Animals are non-blister, suggesting that the construct 
rescues the unc-64 lethality.
Animals are non-blister, suggesting that the construct 
rescues the unc-64 lethality.
This is the mouse modified estrogen receptor bound to C3 
toxin. This strain is designed to only have activated C3 in 
the presence of tamoxifen. N2 Injection
This is the mouse modified estrogen receptor bound to C3 
toxin. This strain is designed to only have activated C3 in 
the presence of tamoxifen.  N2 injection
This is the mouse modified estrogen receptor bound to C3 
toxin. This strain is designed to only have activated C3 in 
the presence of tamoxifen.  N2 injection
Looking for changes in the locomotion/acetylcholine 
release of tom-1 mutants in the presence of the 
phosphomimetic form of syntaxin. No changes yet 
detected; animals are NOT paralysed - unlike unc-64 
animals rescued with this plasmid (i.e does not appear to 
be dominant.)  Injection into tom-1 (ok285)
QT951
nzEx478[SJn368;ttx-3]; 
tom-1 (ok285) (1.69)
Andrew
QT952 nzEx479[SJN368;ttx-3] Andrew
QT953
nzEx480[APP4;QT#23
8]
Andrew
QT954
nzEx481[App6;QT#23
8]
Andrew
QT955 nzEx[SJN376;QT#238] Andrew
QT958 unc-77(e625)IV, nz112 CGC
QT1081
zEx534[SJN477;ttx-
3];nzIs29;unc-
80(e1069)
Andrew
QT1082
nzEx535[SJN477;ttx-
3];nzIs29;unc-
80(e1069)
Andrew
QT1083
nzEx536[SJN478;ttx-
3;KP#307];nzIs29;unc-
80(e1069)
Andrew
QT1084
nzEx537[SJN478;ttx-
3;KP#307];nzIs29;unc-
80(e1069)
Andrew
QT1085
nzEx538[SJN481;ttx-
3];nzIs29;unc-
80(e1069)
Andrew
QT1086
nzEx539[SJN481;ttx-
3];nzIs29;unc-
80(e1069)
Andrew
Looking for changes in the locomotion/acetylcholine 
release of tom-1 mutants in the presence of the 
phosphomimetic form of syntaxin. No changes yet 
detected; animals are NOT paralysed - unlike unc-64 
animals rescued with this plasmid (i.e does not appear to 
be dominant.)
Looking for effect of syntaxin phosphomimetic form in a 
wild-type background.
p.acr-2::cdc-42* (G12V) injected into wild-type animals.
hs-cdc-42*(G12V) injected into N2 animals.
hs-cdc-42 (WT) injected into N2 animals.
This strain supposed to be loopy - however, was seen to 
have more of a 'fainter' phenotype after thawing (like unc-
80). Crossing with him-5 produced loopy animals in the F1 
generation, which suggests the presence of a suppressor 
(which we are calling nz112, isolated presumably by 
accident in the lab). 
Strain expresses GFP-tagged UNC-80 from a minigene 
construct under control of the unc-17 promoter.  
Rescues the loopy locomotion of nzIs29 animals that had 
been suppressed by loss-of-function of unc-80.  Injection 
into QT841
Strain expresses GFP-tagged UNC-80 from a minigene 
construct under control of the unc-17 promoter.  
Rescues the loopy locomotion of nzIs29 animals that had 
been suppressed by loss-of-function of unc-80.  Injection 
into QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the unc-17
promoter.  Rescues the loopy locomotion of nzIs29 
animals that had been suppressed by loss-of-function of 
unc-80.  Injection into QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the unc-17
promoter.  Rescues the loopy locomotion of nzIs29 
animals that had been suppressed by loss-of-function of 
unc-80.  Injection into QT841
Strain expresses GFP-tagged UNC-80 from a minigene 
construct under control of the snb-1 promoter.  Rescues 
the loopy locomotion of nzIs29 animals that had been 
suppressed by loss-of-function of unc-80.  Injection into 
QT841
Strain expresses GFP-tagged UNC-80 from a minigene 
construct under control of the snb-1 promoter.  Rescues 
the loopy locomotion of nzIs29 animals that had been 
suppressed by loss-of-function of unc-80.  Injection into 
QT841
99
QT951
nzEx478[SJn368;ttx-3]; 
tom-1 (ok285) (1.69)
Andrew
QT952 nzEx479[SJN368;ttx-3] Andrew
QT953
nzEx480[APP4;QT#23
8]
Andrew
QT954
nzEx481[App6;QT#23
8]
Andrew
QT955 nzEx[SJN376;QT#238] Andrew
QT958 unc-77(e625)IV, nz112 CGC
QT1081
zEx534[SJN477;ttx-
3];nzIs29;unc-
80(e1069)
Andrew
QT1082
nzEx535[SJN477;ttx-
3];nzIs29;unc-
80(e1069)
Andrew
QT1083
nzEx536[SJN478;ttx-
3;KP#307];nzIs29;unc-
80(e1069)
Andrew
QT1084
nzEx537[SJN478;ttx-
3;KP#307];nzIs29;unc-
80(e1069)
Andrew
QT1085
nzEx538[SJN481;ttx-
3];nzIs29;unc-
80(e1069)
Andrew
QT1086
nzEx539[SJN481;ttx-
3];nzIs29;unc-
80(e1069)
Andrew
Looking for changes in the locomotion/acetylcholine 
release of tom-1 mutants in the presence of the 
phosphomimetic form of syntaxin. No changes yet 
detected; animals are NOT paralysed - unlike unc-64 
animals rescued with this plasmid (i.e does not appear to 
be dominant.)
Looking for effect of syntaxin phosphomimetic form in a 
wild-type background.
p.acr-2::cdc-42* (G12V) injected into wild-type animals.
hs-cdc-42*(G12V) injected into N2 animals.
hs-cdc-42 (WT) injected into N2 animals.
This strain supposed to be loopy - however, was seen to 
have more of a 'fainter' phenotype after thawing (like unc-
80). Crossing with him-5 produced loopy animals in the F1 
generation, which suggests the presence of a suppressor 
(which we are calling nz112, isolated presumably by 
accident in the lab). 
Strain expresses GFP-tagged UNC-80 from a minigene 
construct under control of the unc-17 promoter.  
Rescues the loopy locomotion of nzIs29 animals that had 
been suppressed by loss-of-function of unc-80.  Injection 
into QT841
Strain expresses GFP-tagged UNC-80 from a minigene 
construct under control of the unc-17 promoter.  
Rescues the loopy locomotion of nzIs29 animals that had 
been suppressed by loss-of-function of unc-80.  Injection 
into QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the unc-17
promoter.  Rescues the loopy locomotion of nzIs29 
animals that had been suppressed by loss-of-function of 
unc-80.  Injection into QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the unc-17
promoter.  Rescues the loopy locomotion of nzIs29 
animals that had been suppressed by loss-of-function of 
unc-80.  Injection into QT841
Strain expresses GFP-tagged UNC-80 from a minigene 
construct under control of the snb-1 promoter.  Rescues 
the loopy locomotion of nzIs29 animals that had been 
suppressed by loss-of-function of unc-80.  Injection into 
QT841
Strain expresses GFP-tagged UNC-80 from a minigene 
construct under control of the snb-1 promoter.  Rescues 
the loopy locomotion of nzIs29 animals that had been 
suppressed by loss-of-function of unc-80.  Injection into 
QT841
QT1087
nzEx540[SJN481;ttx-
3];nzIs29;unc-
80(e1069)
Andrew
QT1088
nzEx540[SJN482;ttx-
3;KP#307];nzIs29;unc-
80(e1069)
Andrew
QT1089
nzEx542[SJN482;ttx-
3;KP#307];nzIs29;unc-
80(e1069)
Andrew
QT1090
nzEx543[SJN482;ttx-
3;KP#307];nzIs29;unc-
80(e1069)
Andrew
QT1091
nzEx536[SJN478;ttx-
3;KP#307];unc-
80(e1069)
Andrew
QT1092
nzEx542[SJN482;ttx-
3;KP#307];unc-
80(e1069)
Andrew
VC12 nca-1(gk9) IV CGC
VC9 a-2(gk5) III. CGC
ZM2389
unc-
80(e1272);hpEx630 
(pJH983; 984; 916 
(punc-80;UNC-
80::RFP); odr-1::GFP)
Mei Zhen
Strain expresses GFP-tagged UNC-80 from a minigene 
construct under control of the snb-1 promoter.  Rescues 
the loopy locomotion of nzIs29 animals that had been 
suppressed by loss-of-function of unc-80.  Injection into 
QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the snb-1 promoter.  
Rescues the loopy locomotion of nzIs29 animals that had 
been suppressed by loss-of-function of unc-80.  Injection 
into QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the snb-1 promoter.  
Rescues the loopy locomotion of nzIs29 animals that had 
been suppressed by loss-of-function of unc-80.  Injection 
into QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the snb-1 promoter.  
Rescues the loopy locomotion of nzIs29 animals that had 
been suppressed by loss-of-function of unc-80.  Injection 
into QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the unc-17 
promoter.  Rescues the loopy locomotion of nzIs29 
animals that had been suppressed by loss-of-function of 
unc-80.  Injection into QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the snb-1 promoter.  
Rescues the loopy locomotion of nzIs29 animals that had 
been suppressed by loss-of-function of unc-80.  Injection 
into QT841
C11D2.6. Superficially wild type. This strain was provided 
by the C. elegans Reverse Genetics Core Facility at UBC, 
which is part of the International C. elegans Gene 
Knockout Consortium, which should be acknowledged in 
any publications resulting from its use. URLs: URL: 
aceserver.biotech.ubc.ca/cgi-bin/stable/strain.pl?cl 
ass=Strain;name=VC12, URL: 
www.celeganskoconsortium.omrf.org/
C27F2.2. Superficially wild type. This strain was provided 
by the C. elegans Reverse Genetics Core Facility at UBC, 
which is part of the International C. elegans Gene 
Knockout Consortium, which should be acknowledged in 
any publications resulting from its use. URLs: URL: 
aceserver.biotech.ubc.ca/cgi-bin/stable/strain.pl?cl 
ass=Strain;name=VC9, URL: 
www.celeganskoconsortium.omrf.org/
unc-80(e1272);hpEx630 (pJH983; 984; 916 (punc-80;UNC-
80::RFP) with odr-1::GFP)
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QT1087
nzEx540[SJN481;ttx-
3];nzIs29;unc-
80(e1069)
Andrew
QT1088
nzEx540[SJN482;ttx-
3;KP#307];nzIs29;unc-
80(e1069)
Andrew
QT1089
nzEx542[SJN482;ttx-
3;KP#307];nzIs29;unc-
80(e1069)
Andrew
QT1090
nzEx543[SJN482;ttx-
3;KP#307];nzIs29;unc-
80(e1069)
Andrew
QT1091
nzEx536[SJN478;ttx-
3;KP#307];unc-
80(e1069)
Andrew
QT1092
nzEx542[SJN482;ttx-
3;KP#307];unc-
80(e1069)
Andrew
VC12 nca-1(gk9) IV CGC
VC9 a-2(gk5) III. CGC
ZM2389
unc-
80(e1272);hpEx630 
(pJH983; 984; 916 
(punc-80;UNC-
80::RFP); odr-1::GFP)
Mei Zhen
ZM2390
unc-
80(e1272);hpIs98[odr-
1::GFP; punc80;UNC-
80::RFP]
Mei Zhen
Strain expresses GFP-tagged UNC-80 from a minigene 
construct under control of the snb-1 promoter.  Rescues 
the loopy locomotion of nzIs29 animals that had been 
suppressed by loss-of-function of unc-80.  Injection into 
QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the snb-1 promoter.  
Rescues the loopy locomotion of nzIs29 animals that had 
been suppressed by loss-of-function of unc-80.  Injection 
into QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the snb-1 promoter.  
Rescues the loopy locomotion of nzIs29 animals that had 
been suppressed by loss-of-function of unc-80.  Injection 
into QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the snb-1 promoter.  
Rescues the loopy locomotion of nzIs29 animals that had 
been suppressed by loss-of-function of unc-80.  Injection 
into QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the unc-17 
promoter.  Rescues the loopy locomotion of nzIs29 
animals that had been suppressed by loss-of-function of 
unc-80.  Injection into QT841
Strain expresses mCherry-tagged UNC-80 from a 
minigene construct under control of the snb-1 promoter.  
Rescues the loopy locomotion of nzIs29 animals that had 
been suppressed by loss-of-function of unc-80.  Injection 
into QT841
C11D2.6. Superficially wild type. This strain was provided 
by the C. elegans Reverse Genetics Core Facility at UBC, 
which is part of the International C. elegans Gene 
Knockout Consortium, which should be acknowledged in 
any publications resulting from its use. URLs: URL: 
aceserver.biotech.ubc.ca/cgi-bin/stable/strain.pl?cl 
ass=Strain;name=VC12, URL: 
www.celeganskoconsortium.omrf.org/
C27F2.2. Superficially wild type. This strain was provided 
by the C. elegans Reverse Genetics Core Facility at UBC, 
which is part of the International C. elegans Gene 
Knockout Consortium, which should be acknowledged in 
any publications resulting from its use. URLs: URL: 
aceserver.biotech.ubc.ca/cgi-bin/stable/strain.pl?cl 
ass=Strain;name=VC9, URL: 
www.celeganskoconsortium.omrf.org/
unc-80(e1272);hpEx630 (pJH983; 984; 916 (punc-80;UNC-
80::RFP) with odr-1::GFP)
Integrated version of unc-80(e1272);hpEx630 (pJH983; 
984; 916 (punc-80;UNC-80::RFP) with odr-1::GFP)
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Plasmid 
Name
Made By
Lab Book 
Reference
Plasmid 
Details
APP001 Andrew Andrew 2:42
p.acr-2::PKC-3 
(contains 
mutations, not WT)
APP002 Andrew Andrew 2:57
p.acr-2::PKC-3* 
(contains 
mutations)
APP003 Andrew Andrew 2:93 p.acr-2::PKC-3*
APP004 Andrew Andrew 2:116
p.acr-2::cdc-42* 
(G12V)
APP005 Andrew Andrew 2:116
p.acr-2::cdc-42 DN 
(T17N)
APP006 Andrew hs-cdc-42
APP007 Andrew hs-nca-1
Notes and Comments
Selection 
Marker
Cloned pkc-3 sequence from the 
YK526h11b cDNA with PKC-3.1 (NcoI 
consensus at ATG) and PKC-3.2 (SacI after 
stop codon.)  Digested and ligated into 
pacr-2 (with same restriction sites.)  
Sequenced maxipreps 1#10 and 5#11.  
Contains non-silent mutations in the 
region 5’ to the site which is to be 
mutated by QuikChange.
amp
Performed QuikChange on APP003 (midi 
preps 1#10 and 5#11) using PKC-3.7 an d 
PKC-3.8 primers.  This introduced a SacII 
site along with changing an alanine at 
position 116 to glutamate to make 
activated PKC-3.  However, this plasmid 
also contains mutations in the 5’ region 
(carried over from APP001).  Do not use 
this plasmid - use APP003 instead.
amp
To repair the mutations in the 5’ region of 
APP002, I did a PCR on plasmid YK1447b7 
(which was sequenced as WT PKC-3 
cDNA) using PKC-3.1 and PKC-3.8.  This 
fragment has a NcoI site at the 5’ and 
SacII site at the 3’ end, and can be 
exchanged for the equivalent region of 
APP002 to repair the mutations.
amp
Performed QuikChange of SJN381 using 
cdc-42.3 and cdc-42.4 primers. This 
introduced the G12V activating mutation, 
and a SfcI site (silent base changes).  
Sequenced maxipreps n*1 and n*3.  n*1 
has the correct introduced base changes 
(and also a silent mutation in the coding 
sequence).
amp
Performed QuikChange of SJN381 using 
cdc-42.5 and cdc-42.6 primers. This 
introduced the T17N dominant negative 
mutation, and an SfcI site (silent base 
change). DN3 has the correct introduced 
base changes (and also a silent mutation 
in the coding sequence).
amp
The coding region of cdc-42 digested 
from SJN381 and placed under control of 
the heatshock promoter
AMP
An attempt to make a rescuing version of 
nca-1.  PCR from the longest available 
cDNA; but subsequent sequencing 
detected numerous rearrangements and 
mutations; this construct should not be 
used.
AMP
KP#305 nuz hypers6.52 p.acr-2::ptx
KP#307 nuz hypers6.56 p.acr-2::gfp
KP#315 Mark ML3-42 p acr-2::egl-30(gf).
KP#505 nuz hypers8.5
pBS unc-64 full 
length rescuing 
construct
QT#238 nuz nuz10.123 p.unc-17::gfp
rjm039 Rachel book8
punc-17: rho-1 
G14V F25N 
SJN367 nuz nuz11.132
unc-64 T252A 
genomic
oligos ptx5’ and ptx3’b were used to PCR 
up ptx from p519 0012 and this was 
digested with BspHI and cloned into 
pSC#205 cut with NcoI and RV. The Nco 
and BspHI sites are destroyed. The idea is 
that the PCR creates flush ends with can 
be cloned into the RV site. NB this will 
generate an RI site and a run of 5 G’s 
immediately 3’ of the STOP codon.
pPD95_75 was cut with RI and filled in, it 
was then cut with KpnI. The resulting KpnI-
RI(fillin) frament was ligated into pSC#205 
cut with KpnI and RV.
amp
insert can be cut out w/ Nhe/Kpn. Amp
This contains 5kb of the unc-64 promoter, 
the 6.5kb coding region (with all 3 splice 
variants), and 450bp of 3’UTR past the B 
splice form (including the polyA site as 
determined by my recovery of cDNAs).  
The PstI-NheI fragment of KP#501, and the 
NheI-XhoI fragment of KP#502 were 
subcloned into pBS Not BamHI cut with 
PstI-XhoI.
The BamHI-SpeI fragment of KP#307 
containing the Fire GFP sequence was 
inserted into QT#220 cut with BamHI-SpeI.
amp
This corrects sjn327.  The 160bp SphI/BspEI 
fragment of sjn327 and the 175bp 
BamHI/SphI fragment of QT220 were 
inserted into QT220 cut with BamHI/BspEI. 
This should remove the mutations at 
position7 and in the Cterminus but should 
keep the G14V and F25N mutations. 
Correct plasmids were checked using 
BamHI and the HpaI unique site added 
with the mutation
amp
This generates a syntaxin mutant based 
on Yasu Fujita's work.  The mutation also 
creates a BglI site.  The mutation also 
creates a BglI site.  Oligo pairs unc-
64.4/unc-64.53 and unc-64.54/unc-64.52 
were used on KP#505 in a PCR reaction. 
The products were cut with NheI/BglI and 
BglI/NsiI respectively and subcloned into 
KP#505 cut with NheI and NsiI in a 3 way 
ligation.
amp
Table 2.2 List of plasmids used or referenced in this thesis
102
KP#305 nuz hypers6.52 p.acr-2::ptx
KP#307 nuz hypers6.56 p.acr-2::gfp
KP#315 Mark ML3-42 p acr-2::egl-30(gf).
KP#505 nuz hypers8.5
pBS unc-64 full 
length rescuing 
construct
QT#238 nuz nuz10.123 p.unc-17::gfp
rjm039 Rachel book8
punc-17: rho-1 
G14V F25N 
SJN367 nuz nuz11.132
unc-64 T252A 
genomic
oligos ptx5’ and ptx3’b were used to PCR 
up ptx from p519 0012 and this was 
digested with BspHI and cloned into 
pSC#205 cut with NcoI and RV. The Nco 
and BspHI sites are destroyed. The idea is 
that the PCR creates flush ends with can 
be cloned into the RV site. NB this will 
generate an RI site and a run of 5 G’s 
immediately 3’ of the STOP codon.
pPD95_75 was cut with RI and filled in, it 
was then cut with KpnI. The resulting KpnI-
RI(fillin) frament was ligated into pSC#205 
cut with KpnI and RV.
amp
insert can be cut out w/ Nhe/Kpn. Amp
This contains 5kb of the unc-64 promoter, 
the 6.5kb coding region (with all 3 splice 
variants), and 450bp of 3’UTR past the B 
splice form (including the polyA site as 
determined by my recovery of cDNAs).  
The PstI-NheI fragment of KP#501, and the 
NheI-XhoI fragment of KP#502 were 
subcloned into pBS Not BamHI cut with 
PstI-XhoI.
The BamHI-SpeI fragment of KP#307 
containing the Fire GFP sequence was 
inserted into QT#220 cut with BamHI-SpeI.
amp
This corrects sjn327.  The 160bp SphI/BspEI 
fragment of sjn327 and the 175bp 
BamHI/SphI fragment of QT220 were 
inserted into QT220 cut with BamHI/BspEI. 
This should remove the mutations at 
position7 and in the Cterminus but should 
keep the G14V and F25N mutations. 
Correct plasmids were checked using 
BamHI and the HpaI unique site added 
with the mutation
amp
This generates a syntaxin mutant based 
on Yasu Fujita's work.  The mutation also 
creates a BglI site.  The mutation also 
creates a BglI site.  Oligo pairs unc-
64.4/unc-64.53 and unc-64.54/unc-64.52 
were used on KP#505 in a PCR reaction. 
The products were cut with NheI/BglI and 
BglI/NsiI respectively and subcloned into 
KP#505 cut with NheI and NsiI in a 3 way 
ligation.
amp
SJN368 nuz nuz11.132
unc-64 T252E 
genomic
SJN381 nuz nuz11.137 p.acr-2 cdc-42
SJN447 nuz 12.127 p.acr-2::TMX C3T
SJN466 nuz 12.151
h.s. unc-80 
minigene
SJN467 nuz 12.151
p.acr-2 unc-80 
minigene
SJN469 nuz 13.5
p.unc-17::unc-80 
minigene
SJN470 nuz 13.5
p.hs::unc-80 
minigene
SJN471 nuz 13.5
p.snb-1::unc-80 
minigene
SJN477 nuz 13.21
p.unc-17::GFP::unc-
80 minigene
This generates a syntaxin mutant based 
on Yasu Fujita's work.  The mutation also 
creates a BtgI site.  Oligo pairs unc-
64.4/unc-64.55 and unc-64.56/unc-64.52 
were used on KP#505 in a PCR reaction. 
The products were cut with NheI/BtgI and 
BtgI/NsiI respectively and subcloned into 
KP#505 cut with NheI and NsiI in a 3 way 
ligation.
amp
for expression in the cholinergic 
motorneuons.  Oligos cdc-42.1 and cdc-
42.2 were used to PCR up the cdc-42 
cdna from yk1443h08. The PCR product 
was digested with NheI and SacI and 
subcloned into pSC#205 cut with NheI 
and SacI.  
amp
This is tamoxifen sensitive oestrogen 
receptor fused N terminal to C3 
transferase.
amp
This is unc-80 cdna (from yk1260h6 which 
lacks one predicted exon) up until the BlpI 
site after which it is genomic unc-80. The 
ATG is preceeded by a KpnI site and there 
is a NotI site immediately 3’ to the ATG. 
There is a SacI site about 50bp 3’ of the 
STOP codon.  Oligos unc-80.53/64 were 
used on cyk-2 genomic DNA. The PCR 
product was digested with BlpI and SacI 
and subcloned into SJN462 cut with BlpI 
and SacI. 
amp
This is unc-80 cdna (from yk1260h6 which 
lacks one predicted exon) up until the BlpI 
site after which it is genomic unc-80. The 
ATG is preceeded by a KpnI site and there 
is a NotI site immediately 3’ to the ATG. 
There is a SacI site about 50bp 3’ of the 
STOP codon.  Oligos unc-80.53/64 were 
used on cyk-2 genomic DNA. The PCR 
product was digested with BlpI and SacI 
and subcloned into SJN463 cut with BlpI 
and SacI. 
amp
The NotI-SpeI fragment of SJN467 was 
inserted into QT#220 cut with NotI-SpeI
amp
The KpnI-SacI fragment of SJN467 was 
inserted into QT#42 cut with KpnI-SacI
amp
The KpnI-SacI fragment of SJN467 was 
inserted into QT#237 cut with KpnI-SacI
amp
The NotI fragment of KP#295, 
containingthe Fire GFP with introns, was 
inserted into SJN469 cut with NotI.  
Miniprep 12 was maxiprepped
amp
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SJN368 nuz nuz11.132
unc-64 T252E 
genomic
SJN381 nuz nuz11.137 p.acr-2 cdc-42
SJN447 nuz 12.127 p.acr-2::TMX C3T
SJN466 nuz 12.151
h.s. unc-80 
minigene
SJN467 nuz 12.151
p.acr-2 unc-80 
minigene
SJN469 nuz 13.5
p.unc-17::unc-80 
minigene
SJN470 nuz 13.5
p.hs::unc-80 
minigene
SJN471 nuz 13.5
p.snb-1::unc-80 
minigene
SJN477 nuz 13.21
p.unc-17::GFP::unc-
80 minigene
This generates a syntaxin mutant based 
on Yasu Fujita's work.  The mutation also 
creates a BtgI site.  Oligo pairs unc-
64.4/unc-64.55 and unc-64.56/unc-64.52 
were used on KP#505 in a PCR reaction. 
The products were cut with NheI/BtgI and 
BtgI/NsiI respectively and subcloned into 
KP#505 cut with NheI and NsiI in a 3 way 
ligation.
amp
for expression in the cholinergic 
motorneuons.  Oligos cdc-42.1 and cdc-
42.2 were used to PCR up the cdc-42 
cdna from yk1443h08. The PCR product 
was digested with NheI and SacI and 
subcloned into pSC#205 cut with NheI 
and SacI.  
amp
This is tamoxifen sensitive oestrogen 
receptor fused N terminal to C3 
transferase.
amp
This is unc-80 cdna (from yk1260h6 which 
lacks one predicted exon) up until the BlpI 
site after which it is genomic unc-80. The 
ATG is preceeded by a KpnI site and there 
is a NotI site immediately 3’ to the ATG. 
There is a SacI site about 50bp 3’ of the 
STOP codon.  Oligos unc-80.53/64 were 
used on cyk-2 genomic DNA. The PCR 
product was digested with BlpI and SacI 
and subcloned into SJN462 cut with BlpI 
and SacI. 
amp
This is unc-80 cdna (from yk1260h6 which 
lacks one predicted exon) up until the BlpI 
site after which it is genomic unc-80. The 
ATG is preceeded by a KpnI site and there 
is a NotI site immediately 3’ to the ATG. 
There is a SacI site about 50bp 3’ of the 
STOP codon.  Oligos unc-80.53/64 were 
used on cyk-2 genomic DNA. The PCR 
product was digested with BlpI and SacI 
and subcloned into SJN463 cut with BlpI 
and SacI. 
amp
The NotI-SpeI fragment of SJN467 was 
inserted into QT#220 cut with NotI-SpeI
amp
The KpnI-SacI fragment of SJN467 was 
inserted into QT#42 cut with KpnI-SacI
amp
The KpnI-SacI fragment of SJN467 was 
inserted into QT#237 cut with KpnI-SacI
amp
The NotI fragment of KP#295, 
containingthe Fire GFP with introns, was 
inserted into SJN469 cut with NotI.  
Miniprep 12 was maxiprepped
amp
SJN478 nuz 13.21
p.unc-
17::mcherry::unc-
80 minigene
SJN479 nuz 13.21
hs::GFP::unc-80 
minigene
SJN480 nuz 13.21
hs::mcherry::unc-
80 minigene
SJN481 nuz 13.21
p.snb-1::GFP::unc-
80 minigene
SJN482 nuz 13.21
p.snb-
1::mcherry::unc-80 
minigene
SJN483 nuz 13.21
p.acr-2::GFP::unc-
80 minigene
SJN484 nuz 13.21
p.acr-
2::mcherry::unc-80 
minigene
SJN492 nuz 13.26 hs::MUNC80 full
SJN493 nuz 13.28 p.unc-17::ptx
SJN495 nuz 13.3 p.unc-17::MUNC80
ttx-3gfp
TTX-3 gfp in 
ppD95.75 from 
Oliver Hobert
The NotI fragment of SJN#445, containing 
mcherry, was inserted into SJN469 cut with 
NotI.  Miniprep 15 was maxiprepped
amp
The NotI fragment of KP#295, 
containingthe Fire GFP with introns, was 
inserted into SJN470 cut with NotI.
amp
The NotI fragment of SJN#445, containing 
mcherry, was inserted into SJN470 cut with 
NotI.
amp
The NotI fragment of KP#295, 
containingthe Fire GFP with introns, was 
inserted into SJN471 cut with NotI.
amp
The NotI fragment of SJN#445, containing 
mcherry, was inserted into SJN471cut with 
NotI.
amp
The NotI fragment of KP#295, 
containingthe Fire GFP with introns, was 
inserted into SJN467 cut with NotI.  
Miniprep 84 was maxiprepped
amp
The NotI fragment of SJN#445, containing 
mcherry, was inserted into SJN467 cut with 
NotI.  Miniprep 87 was maxiprepped
amp
this expresses mammalian MUNC80 from 
the heatshock promoter.  The NheI-Spe 
fragment from SJN492 was inserted into 
SJN493 cut with NheI-SpeI.
amp
This expresses pertussis toxin from the unc-
17 promoter. This will selectively inhibit goa-
1 (G alpha o) in cholinergic neurons.  The 
NheI-Spe fragment from SJN492 was 
inserted into SJN493 cut with NheI-SpeI.
This expresses the mammalian munc80 
cdna in cholinergic cells from the unc-17 
promoter.  The NheI-Spe fragment from 
SJN492 was inserted into SJN493 cut with 
NheI-SpeI.
NB there are 2 XhoI sites in this construct. amp
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gatatccgcatattgagagctttag unc-80.1
gcagtgttttatcctgaggctc unc-80.2
agcatgtgaagtggtctgttg unc-80.3
cgtggttcaaaagatgcaatcg unc-80.4
ccgggtgctcaatcccaaaag unc-80.5
cagaatgcagtcctaatatgccga unc-80.6
cattgactagaagaatcttcatcgtg unc-80.7
catgtggatacgttgtagcattag unc-80.8
gcgttgaacaattatagtgtgcggc unc-80.9
gaggaaatgcagtacaaataac unc-80.10
ggctcatttacagtcgttaggccacta unc-80.11
gtagaggtcgaaaaatgcgacattgcttcg unc-80.12
cctattttgcaaggtttctttcagcatg unc-80.13
caattcatcgcattcgatctcgtgggtgc unc-80.14
gcaccgatactatgcaccgatatgacac unc-80.15
cagcaagcttaatacgacattttgtcg unc-80.16
cggcgtcacgcataccacatgtatccg unc-80.17
gccagaagtagagtctagaccgtgtac unc-80.18
ggcgttatcaatatgttggctattatc unc-80.19
ccgttgcagaatggcctctgtcggtgac unc-80.20
ctctgacaacgactttcattagaggg unc-80.21
gtgtgatcacttaacatcaaac unc-80.22
ggattaagctacatgttcagcgcc unc-80.23
gagatacattttctgtgataatc unc-80.24
gggatattgcaacctcaagtgg unc-80.25
gctgcgccgctctcacatgaagg unc-80.26
aatgaacatgtagattgaatatg unc-80.27
ggcactcatgaataggtggaaatg unc-80.28
aatccccactggcgctactac unc-80.29
gggtccgcctggcatcacgtgg unc-80.30
attttgacaacatgtggataatg unc-80.31
ttacacaaaactcatgaaacag unc-80.32
cacgcatacgttgaacaattggtgac unc-80.33
cctgttgtccttagatgcaattg unc-80.34
gtttcacgtaaagctgagaaacc unc-80.35
gttgtggtcaagcatacaacgc unc-80.36
ggcctgtggatgaatgttcagc unc-80.37
ggactgtatttcaaggatc unc-80.38
cctctacttcagcagcttccc unc-80.39
gacccgccgactacaaatgaagacg unc-80.40
gtgaacgcttgttcgtcgat unc-80.41
ggtcaaatgctaccaggaacttc unc-80.42
gacgtgctagcaatttcagatcg unc-80.43
gcgaaagttagaagaggagaag unc-80.44
ggatgccctcatggatgcaacg unc-80.45
ccatacacttaaacgacaaagag unc-80.46
gaggagcttagcctcaaggagg unc-80.47
gggggcggccgcttagaccaattgatgttgttct
gttatttg
unc-80.48
ggagaacgaaaattatctgtc unc-80.49
This is to pcr unc-80 in 3 fragments from genomic DNA in order to rescue unc-
80 It primes on the top strand  See Jospin et. al.
This is to pcr unc-80 in 3 fragments from genomic DNA in order to rescue unc-
80 It primes on the bottom strand  See Jospin et. al.  THIS IS THE TOP 
STRAND!!! WILL NOT WORK WITH UNC-80.1
This is to pcr unc-80 in 3 fragments from genomic DNA in order to rescue unc-
80 It primes on the top strand  See Jospin et. al.
This is to pcr unc-80 in 3 fragments from genomic DNA in order to rescue unc-
80 It primes on the bottom strand  See Jospin et. al.  THIS IS THE TOP 
STRAND!!! WILL NOT WORK WITH UNC-80.3
This is to pcr unc-80 in 3 fragments from genomic DNA in order to rescue unc-
80 It primes on the top strand  See Jospin et. al.
This is to pcr unc-80 in 3 fragments from genomic DNA in order to rescue unc-
80 It primes on the bottom strand  See Jospin et. al.  THIS IS THE TOP 
STRAND!!! WILL NOT WORK WITH UNC-80.5
This is to sequence unc-80. Primes on top strand 5’ of exon 1
This is to sequence unc-80 it primes on the bottom strand 3’ of exon 5
This is to sequence unc-80 it primes on the top strand 5’ of exon 6
This is to sequence unc-80 it primes on the bottom strand 3’ of exon 6
This is to sequence unc-80 it primes on the top strand 5’ of exon 7
This is to sequence unc-80 it primes on the bottom strand 3’ of exon 13
This is to sequence unc-80 it primes on the top strand 5’ of exon 14
This is to sequence unc-80 it primes on the bottom strand 3’ of exon 18
This is to sequence unc-80 it primes on the top strand 5’ of exon 19
this is to sequence unc-80 it primes on the top strand 5’ of exon 23
This is to sequence unc-80 it primes on the bottom strand 3’ of exon 23
This is to sequence unc-80 it primes on the bottom strand 3’ of exon 27
This is to sequence unc-80 it primes on the top strand 5’ of exon 28
This is to sequence unc-80 it primes on the bottom strand it primes on the 
bottom strand 3’ of exon 32
This is to sequence unc-80 it primes on the top strand 5’ of exon 33
This is to sequence unc-80 it primes on the bottom strand 3’ of the last exon
This is to sequence unc-80 it primes on the bottom strand 3’ of exon 1
This is to sequence unc-80 it primes on the top strand 5’ of exon 2
this is to sequence unc-80 it primes on the top strand 5’ of exon 4
this is to sequence unc-80 it primes on the top strand 5’ of exon 6
this is to sequence unc-80 it primes on the top strand 5’ of exon 7
this is to sequence unc-80 it primes on the top strand 5’ of exon 9
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 3
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 14
this is to sequence unc-80 it primes on the top strand 5’ of exon 15
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 18
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 19
this is to sequence unc-80 it primes on the top strand 5’ of exon 20
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 23
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 25
this is to sequence unc-80 it primes on the top strand 5’ of exon 26
this is to sequence unc-80 it primes on the top strand 5’ of exon 28
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 30 
this is to sequence unc-80 it primes on the top strand 5’ of exon 31
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 34
this is to sequence unc-80 it primes on the top strand in exon 35
this is to sequence unc-80 it primes on the top strand 5’ of exon 37
This is to pcr up the cDNA of unc-80 it primes on the top strand in exon 6
This is to pcr up the cDNA of unc-80 it primes on the top strand in exon 11
This is to pcr up the cDNA of unc-80 it primes on the top strand between exons 
16 and 17
This is to pcr up the cDNA of unc-80 it primes on the top strand in exon 23
This is to amplify unc-80 cDNAs. This primes on the predicted STOP codon, 
which is also present in the Kohara clone, on the bottom strand. It has a NotI 
site 3’ of the STOP codon.  NB as an alternative unc-80.65 has a SacI instead of 
NotI
To sequence the cDNA of unc-80 (based on the predicted sequence from 
wormbase.)  Primes at around 1750 in the predicted cDNA on the bottom 
strand.
Table 2.3 List of primers used or referenced in this thesis
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gggatattgcaacctcaagtgg unc-80.25
gctgcgccgctctcacatgaagg unc-80.26
aatgaacatgtagattgaatatg unc-80.27
ggcactcatgaataggtggaaatg unc-80.28
aatccccactggcgctactac unc-80.29
gggtccgcctggcatcacgtgg unc-80.30
attttgacaacatgtggataatg unc-80.31
ttacacaaaactcatgaaacag unc-80.32
cacgcatacgttgaacaattggtgac unc-80.33
cctgttgtccttagatgcaattg unc-80.34
gtttcacgtaaagctgagaaacc unc-80.35
gttgtggtcaagcatacaacgc unc-80.36
ggcctgtggatgaatgttcagc unc-80.37
ggactgtatttcaaggatc unc-80.38
cctctacttcagcagcttccc unc-80.39
gacccgccgactacaaatgaagacg unc-80.40
gtgaacgcttgttcgtcgat unc-80.41
ggtcaaatgctaccaggaacttc unc-80.42
gacgtgctagcaatttcagatcg unc-80.43
gcgaaagttagaagaggagaag unc-80.44
ggatgccctcatggatgcaacg unc-80.45
ccatacacttaaacgacaaagag unc-80.46
gaggagcttagcctcaaggagg unc-80.47
gggggcggccgcttagaccaattgatgttgttct
gttatttg
unc-80.48
ggagaacgaaaattatctgtc unc-80.49
this is to sequence unc-80 it primes on the top strand 5’ of exon 4
this is to sequence unc-80 it primes on the top strand 5’ of exon 6
this is to sequence unc-80 it primes on the top strand 5’ of exon 7
this is to sequence unc-80 it primes on the top strand 5’ of exon 9
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 3
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 14
this is to sequence unc-80 it primes on the top strand 5’ of exon 15
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 18
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 19
this is to sequence unc-80 it primes on the top strand 5’ of exon 20
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 23
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 25
this is to sequence unc-80 it primes on the top strand 5’ of exon 26
this is to sequence unc-80 it primes on the top strand 5’ of exon 28
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 30 
this is to sequence unc-80 it primes on the top strand 5’ of exon 31
this is to sequence unc-80 it primes on the bottom strand 3’ of exon 34
this is to sequence unc-80 it primes on the top strand in exon 35
this is to sequence unc-80 it primes on the top strand 5’ of exon 37
This is to pcr up the cDNA of unc-80 it primes on the top strand in exon 6
This is to pcr up the cDNA of unc-80 it primes on the top strand in exon 11
This is to pcr up the cDNA of unc-80 it primes on the top strand between exons 
16 and 17
This is to pcr up the cDNA of unc-80 it primes on the top strand in exon 23
This is to amplify unc-80 cDNAs. This primes on the predicted STOP codon, 
which is also present in the Kohara clone, on the bottom strand. It has a NotI 
site 3’ of the STOP codon.  NB as an alternative unc-80.65 has a SacI instead of 
NotI
To sequence the cDNA of unc-80 (based on the predicted sequence from 
wormbase.)  Primes at around 1750 in the predicted cDNA on the bottom 
strand.
ctagaccttatcatttgaaag unc-80.50
aaggcaaactgccctaaggcttgc unc-80.51
gcatttctactggaaactgcca unc-80.52
ccaattggtacattccccaatct unc-80.53
GGAAACTGCCAGACCGGGAACGTT unc-80.54
GCTGCTATCATGCACCTTAAAT unc-80.55
CCTGGTCCAAAGTACATTCCAA unc-80.56
CGAACATGTCGGACATCATCTT unc-80.57
CCTACATGATGAATTCACTCAT unc-80.58
CGTTCTTTTTATCCTCAATTGA unc-80.59
gactgaaaatatatgagaaatgt unc-80.60
GAGCTCctGGTACCtcTTAGGCGGCCG
Cgaccaattgatgttgttctgt
unc-80.61
ggggggggtaccgtccgaaaattataaagaat
gc
unc-80.62
For RTPCR of unc-80, to check whether the nz94 mutation is a null (nonsense-
mediated decay because of premature stop codon) or a forms a truncated 
mRNA.  Primes on the bottom strand between two exons in the predicted 
cDNA (start at 7680) with about 60 bases of intron inbetween (should not prime 
on genomic sequence.)    Forward primer for unc-80.51
For RTPCR of unc-80, to check whether the nz94 mutation is a null (nonsense-
mediated decay because of premature stop codon) or a forms a truncated 
mRNA.  Primes on the top strand between two exons in the predicted cDNA 
(start at 8385) with about 50 bases of intron inbetween (should not prime on 
genomic sequence.)    Reverse primer for unc-80.50
To sequence the cDNA of unc-80 (based on the predicted sequence from 
wormbase.)  Primes at around 3300 in the predicted cDNA on the top strand.
To sequence the cDNA of unc-80 (based on the predicted sequence from 
wormbase.)  Primes at around 5100 in the predicted cDNA on the top strand.
Cloning central portion of unc-80 cDNA, between two XhoI sites.  This primes 
on the top strand, and is the outside primer for the first nested pcr.
Cloning central portion of unc-80 cDNA, between two XhoI sites.  This primes 
on the top strand, and is the inside primer for the second nested pcr.
Cloning central portion of unc-80 cDNA, between two XhoI sites.  This primes 
on the bottom strand, and is the outside primer for the first nested pcr.
Cloning central portion of unc-80 cDNA, between two XhoI sites.  This primes 
on the bottom strand, and is the inside primer for the second nested pcr.
Cloning the 3’ end of unc-80 cDNA.  Primer primes just before the 2nd XhoI site 
in the unc-80 cDNA.  This primer primes on the top strand, and is the inside 
primer for the 2nd nested pcr.  
Cloning the 3’ end of unc-80 cDNA.  Primer primes just before the 2nd XhoI site 
in the unc-80 cDNA.  This primer primes on the bottom strand, and is the 
outside primer for the 1st nested pcr.  
Cloning the 3’ end of unc-80 cDNA.  Primer primes just after the stop 
codon.  This primer primes on the top strand, and is the inside primer for the 
2nd nested pcr.  (use after PolyT Not I).  
To clone the 3’ end of unc-80 cDNA.  Primer primes over the stop codon (TAA) 
with 21 bases 5’ of the stop codon.    A Not I site is introduced 5’ of the stop 
codon for adding in GFP/other tags.    The primer contains a Kpn I and Sac I 
site for sub-cloning into pcDNA 3.1 (for mammalian expression) and into 
hs/unc-17 vectors.  BUT the SacI site is right at the end of the oligo and may not 
This primes over and 5’ of the UNC-80 ATG on the top strand. It has a KpnI site 
at the 5’ end. This is used to clone the 5’ and of the unc-80 cdna which does 
not introduce a notI site.
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ctagaccttatcatttgaaag unc-80.50
aaggcaaactgccctaaggcttgc unc-80.51
gcatttctactggaaactgcca unc-80.52
ccaattggtacattccccaatct unc-80.53
GGAAACTGCCAGACCGGGAACGTT unc-80.54
GCTGCTATCATGCACCTTAAAT unc-80.55
CCTGGTCCAAAGTACATTCCAA unc-80.56
CGAACATGTCGGACATCATCTT unc-80.57
CCTACATGATGAATTCACTCAT unc-80.58
CGTTCTTTTTATCCTCAATTGA unc-80.59
gactgaaaatatatgagaaatgt unc-80.60
GAGCTCctGGTACCtcTTAGGCGGCCG
Cgaccaattgatgttgttctgt
unc-80.61
ggggggggtaccgtccgaaaattataaagaat
gc
unc-80.62
For RTPCR of unc-80, to check whether the nz94 mutation is a null (nonsense-
mediated decay because of premature stop codon) or a forms a truncated 
mRNA.  Primes on the bottom strand between two exons in the predicted 
cDNA (start at 7680) with about 60 bases of intron inbetween (should not prime 
on genomic sequence.)    Forward primer for unc-80.51
For RTPCR of unc-80, to check whether the nz94 mutation is a null (nonsense-
mediated decay because of premature stop codon) or a forms a truncated 
mRNA.  Primes on the top strand between two exons in the predicted cDNA 
(start at 8385) with about 50 bases of intron inbetween (should not prime on 
genomic sequence.)    Reverse primer for unc-80.50
To sequence the cDNA of unc-80 (based on the predicted sequence from 
wormbase.)  Primes at around 3300 in the predicted cDNA on the top strand.
To sequence the cDNA of unc-80 (based on the predicted sequence from 
wormbase.)  Primes at around 5100 in the predicted cDNA on the top strand.
Cloning central portion of unc-80 cDNA, between two XhoI sites.  This primes 
on the top strand, and is the outside primer for the first nested pcr.
Cloning central portion of unc-80 cDNA, between two XhoI sites.  This primes 
on the top strand, and is the inside primer for the second nested pcr.
Cloning central portion of unc-80 cDNA, between two XhoI sites.  This primes 
on the bottom strand, and is the outside primer for the first nested pcr.
Cloning central portion of unc-80 cDNA, between two XhoI sites.  This primes 
on the bottom strand, and is the inside primer for the second nested pcr.
Cloning the 3’ end of unc-80 cDNA.  Primer primes just before the 2nd XhoI site 
in the unc-80 cDNA.  This primer primes on the top strand, and is the inside 
primer for the 2nd nested pcr.  
Cloning the 3’ end of unc-80 cDNA.  Primer primes just before the 2nd XhoI site 
in the unc-80 cDNA.  This primer primes on the bottom strand, and is the 
outside primer for the 1st nested pcr.  
Cloning the 3’ end of unc-80 cDNA.  Primer primes just after the stop 
codon.  This primer primes on the top strand, and is the inside primer for the 
2nd nested pcr.  (use after PolyT Not I).  
To clone the 3’ end of unc-80 cDNA.  Primer primes over the stop codon (TAA) 
with 21 bases 5’ of the stop codon.    A Not I site is introduced 5’ of the stop 
codon for adding in GFP/other tags.    The primer contains a Kpn I and Sac I 
site for sub-cloning into pcDNA 3.1 (for mammalian expression) and into 
hs/unc-17 vectors.  BUT the SacI site is right at the end of the oligo and may not 
This primes over and 5’ of the UNC-80 ATG on the top strand. It has a KpnI site 
at the 5’ end. This is used to clone the 5’ and of the unc-80 cdna which does 
not introduce a notI site.
gggggggtaccaaagaatggcggccgcgcat
gttcgatacttacagcacg
unc-80.63
gggggggagctcaaatagaacagaaaatgac
tagaaatgg
unc-80.64
gggggagctcaaaattaggcggccgcgacca
attgatgttgttctg
unc-80.65
gagcctcaggataaaacactgc UNC-80.66
cgattgcatcttttgaaccacg UNC-80.67
tcggcatattaggactgcattctg UNC-80.68
ggggggGCTAGCggATGGTGAAGAGGA
AGAGCTCCGAGGAGCAG
munc-80.1
cccccgatatccccCTAAACGTGGGACTC
ATCTAGTGCTGAG
munc-80.2
ggg ggg GCT AGC ggA TGG TGA AGA 
GGA AGA GCT CCG AGG GCC
munc-80.3
gggggggcggccgcGAATTTCTCGAGAAG
AATTCAGAAGACCCCGGG
munc-80.4
gggggctagcaaaattataaagaATGGTGAA
GAGGAAGAGCTCCGAGGGC 
munc-80.5
ATGCCGCGGCCGCCGTCCTGCTCCTG
GCCCTCGGAGCTCTTCCTCTTCAC
munc-80.6
CCCCCCCgcggccgcAGTAAAGGAGAA
GAACTTTTCACTG
munc-80.7
This is to subclone the unc-80 cdna. The primes on the top strand over the ATG 
and inserts an in frame NotI site immediately 3’ of the ATG. It also adds a KpnI 
site 5’ to the ATG.
The is to PCR the 3’ end of the unc-80 cdna. This primes on the bottom strand 
approx. 60bp 3’ of the STOP codon. This introduces a SacI site at the 3’ end.
This is to PCR up the 3’ end of the unc-80 cDNA. This primes on the bottom 
strand over the STOP codon and introduces a NotI site immediately before the 
STOP codon, followed by the STOP codon, some cDNA sequence and then a 
SacI site.
Replaces UNC-80.2 as a the correct bottom strand primer to go with UNC-80.1 
for PCR of 1st large genomic region of unc-80 (See Jospin et. al.)
Replaces UNC-80.4 as a the correct bottom strand primer to go with UNC-80.3 
for PCR of 2nd large genomic region of unc-80 (See Jospin et al.)
Replaces UNC-80.6 as a the correct bottom strand primer to go with UNC-80.5 
for PCR of 3rd large genomic region of unc-80 (See Jospin et al.)
To clone the cDNA of mouse unc-80 from pcDNA3.1 vector.  Primes on the top 
strand, over the start codon [ATG], and introduces a unique NheI site just 5’ of 
the start codon, for cloning into the heat shock vector. Use in conjunction with 
munc-80.2 to clone whole of munc-80 cDNA.  CONTAINS AN ERROR - THERE IS 
A GAP COMPARED TO WT cDNA - use munc-80.3 instead
To clone the cDNA of mouse unc-80 from pcDNA3.1 vector.  Primes on the 
bottom strand, over the stop codon [TAG], and introduces a unique EcoRV site 
just 3’ of the start codon, for cloning into the heat shock vector.  Use in 
conjunction with munc-80.1 to clone whole of munc-80 cDNA.
To clone the cDNA of mouse unc-80 from pcDNA3.1 vector.  Primes on the top 
strand, over the start codon [ATG], and introduces a unique NheI site just 5’ of 
the start codon, for cloning into the heat shock vector.  Use in conjunction with 
munc-80.2 to clone whole of munc-80 cDNA.  Replaces munc-80.1 which 
contains a gap in compared to the WT munc-80 sequence.
This primes on the top strand over the unique XhoI site and has a NotI site 5’ to 
the XhoI site. This allows PCRs of the 5’ end (Nhe-Not) and 3’ end (XhoI-RV) to 
be joined together. Then the central NotI-XhoI fragment can be subcloned in 
without PCR.
This is the top strand and is designed to be annealed with munc-80.6, filled in, 
cut with NheI and NotI, to synthesize the very 5’ end of munc-80
This is the top strand and is designed to be annealed with munc-80.5, filled in, 
cut with NheI and NotI, to synthesize the very 5’ end of munc-80
To PCR gfp from ppd95.75 and insert into the NotI site present in the munc-80 
cDNA.  Primes on the top strand, just after the ATG of gfp, and introduces a 
NotI site.
GGGGGGgcggccgcGTTTGTATAGTTCAT
CCATGCCATGT
munc-80.8
ggggGCTAGCggATGtcggaacgaaaaaa
gagtctg
nca-1.1
ggggAGATCTggCTAatcaacaagggaattc
cacca
nca-1.2
gagaatggactatcattgtgttca nca-1.3
gttgaatgtatcatcaagattct nca-1.4
ccaatgccaaaagttcgaggaag nca-1.5
gcaatggccactgttacaattgt nca-1.6
gtgattcgagatattttatgga nca-1.7
cgatcattcttcattatcactgct nca-1.8
ggacatccggttattcattcatca nca-1.9
ggg gGG ATC Cgg CTA atc aac aag 
gga att cca cca 
nca-1.10
cctgttcgttgTcgtaattctAgataacttggaaat
ggacgaa
nca-1.11
ttcgtccatttccaagttatcTagaattacgAcaa
cgaacagg
nca-1.12
cattgctgtGatcactgaaacatttgctgaaattc
Aagtccagttcag
nca-1.13
To PCR gfp from ppd95.75 and insert into the NotI site present in the munc-80 
cDNA.  Primes on the bottom strand, just before the stop codon of gfp, and 
introduces a NotI site.
to PCR nca-1 cDNA from Kohara clone and subclone into various vectors.  
Primes over the start codon on the bottom strand, and introduces an NheI site 
5’ of the start condon.  
To PCR up cDNA of nca-1 from Kohara clone and subclone into various 
vectors.  Primes over the stop codon (TAG) on the top strand and introduces a 
BglII site just 3’ of the stop codon.
To sequence nca-1 cDNA (primes around 700 bases in, on the bottom strand).
To sequence nca-1 cDNA (primes around 1400 bases in, on the bottom 
strand).
To sequence nca-1 cDNA (primes around 2100 bases in, on the bottom 
strand).
To sequence nca-1 cDNA (primes around 2800 bases in, on the bottom 
strand).
To sequence nca-1 cDNA (primes around 3500 bases in, on the bottom 
strand).
To sequence nca-1 cDNA (primes around 4200 bases in, on the bottom 
strand).
To sequence nca-1 cDNA (primes around 5000 bases in, on the bottom 
strand).
To PCR up cDNA of nca-1 from Kohara clone and subclone into pcDNA3.1.  
Primes over the stop codon (TAG) on the top strand and introduces a BamHI 
site just 3’ of the stop codon.
To introduce the e625 mutation into the nca-1 cDNA.  Change is A717V (GCC -
-> GTC) at position 2150 in the C11D2.6c transcript.    Primes on the bottom 
strand.    Also introduces a unique XbaI site for testing the Quikchange 
efficacy.  
To introduce the e625 mutation into the nca-1 cDNA.  Change is A717V (GCC -
-> GTC) at position 2150 in the C11D2.6c transcript.    Primes on the top strand.  
  Also introduces a unique XbaI site for testing the Quikchange efficacy.  
To introduce the hp102 mutation into nca-1 cDNA.  Change is R403Q (CGA --> 
CAA) at position 1208 in the C11D2.6c transcript.    Primes on the bottom 
strand.    Also introduces a fourth BclI site into the cDNA for testing the 
Quikchange efficacy.  
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GGGGGGgcggccgcGTTTGTATAGTTCAT
CCATGCCATGT
munc-80.8
ggggGCTAGCggATGtcggaacgaaaaaa
gagtctg
nca-1.1
ggggAGATCTggCTAatcaacaagggaattc
cacca
nca-1.2
gagaatggactatcattgtgttca nca-1.3
gttgaatgtatcatcaagattct nca-1.4
ccaatgccaaaagttcgaggaag nca-1.5
gcaatggccactgttacaattgt nca-1.6
gtgattcgagatattttatgga nca-1.7
cgatcattcttcattatcactgct nca-1.8
ggacatccggttattcattcatca nca-1.9
ggg gGG ATC Cgg CTA atc aac aag 
gga att cca cca 
nca-1.10
cctgttcgttgTcgtaattctAgataacttggaaat
ggacgaa
nca-1.11
ttcgtccatttccaagttatcTagaattacgAcaa
cgaacagg
nca-1.12
cattgctgtGatcactgaaacatttgctgaaattc
Aagtccagttcag
nca-1.13
To PCR gfp from ppd95.75 and insert into the NotI site present in the munc-80 
cDNA.  Primes on the bottom strand, just before the stop codon of gfp, and 
introduces a NotI site.
to PCR nca-1 cDNA from Kohara clone and subclone into various vectors.  
Primes over the start codon on the bottom strand, and introduces an NheI site 
5’ of the start condon.  
To PCR up cDNA of nca-1 from Kohara clone and subclone into various 
vectors.  Primes over the stop codon (TAG) on the top strand and introduces a 
BglII site just 3’ of the stop codon.
To sequence nca-1 cDNA (primes around 700 bases in, on the bottom strand).
To sequence nca-1 cDNA (primes around 1400 bases in, on the bottom 
strand).
To sequence nca-1 cDNA (primes around 2100 bases in, on the bottom 
strand).
To sequence nca-1 cDNA (primes around 2800 bases in, on the bottom 
strand).
To sequence nca-1 cDNA (primes around 3500 bases in, on the bottom 
strand).
To sequence nca-1 cDNA (primes around 4200 bases in, on the bottom 
strand).
To sequence nca-1 cDNA (primes around 5000 bases in, on the bottom 
strand).
To PCR up cDNA of nca-1 from Kohara clone and subclone into pcDNA3.1.  
Primes over the stop codon (TAG) on the top strand and introduces a BamHI 
site just 3’ of the stop codon.
To introduce the e625 mutation into the nca-1 cDNA.  Change is A717V (GCC -
-> GTC) at position 2150 in the C11D2.6c transcript.    Primes on the bottom 
strand.    Also introduces a unique XbaI site for testing the Quikchange 
efficacy.  
To introduce the e625 mutation into the nca-1 cDNA.  Change is A717V (GCC -
-> GTC) at position 2150 in the C11D2.6c transcript.    Primes on the top strand.  
  Also introduces a unique XbaI site for testing the Quikchange efficacy.  
To introduce the hp102 mutation into nca-1 cDNA.  Change is R403Q (CGA --> 
CAA) at position 1208 in the C11D2.6c transcript.    Primes on the bottom 
strand.    Also introduces a fourth BclI site into the cDNA for testing the 
Quikchange efficacy.  
ctgaactggactTgaatttcagcaaatgtttcagt
gatCacagcaatg
nca-1.14
cccccccagctgttaaaaaatgaaCTAatcaa
caagggaattccacc
nca-1.15
ccccagctgtaaaaaatgaaCTAggcggccg
catcaacaagggaattcc
nca-1.16
gtttcaaatcataacacaagaaggatgg nca-1.17
gtggttgaagttttgagagcaactgacg nca-1.18
gatggtatgcgacaaaatagagagcc nca-1.19
gatggtatgcgacaaaatagagagcc nca-1.20
acctccaattccttctggagc nca-1.21
tccttctggttcaacttctcc nca-1.22
gtcactgatctgcaaatatcc nca-1.23
tgttaaaagagctgttcctcg nca-1.24
gtgtttgctaactgccattcc nca-1.25
cgtcactcttgaataaattggctttcggtgc nca-1.26
To introduce the hp102 mutation into nca-1 cDNA.  Change is R403Q (CGA --> 
CAA) at position 1208 in the C11D2.6c transcript.    Primes on the top strand.  
  Also introduces a fourth BclI site into the cDNA for testing the Quikchange 
efficacy.  
To PCR up cDNA of nca-1 from Kohara clone and subclone into worm 
expression vectors. This primes on the bottom strand over the STOP codon and 
adds a PvuII site 3’ to the STOP codon. This produces a blunt end that can be 
ligated to an RV site.
To PCR up cDNA of nca-1 from Kohara clone and subclone into worm 
expression vectors. This primes on the bottom strand over the STOP codon and 
adds a NotI site immediately 5’ to the STOP codon and a PvuII site 3’ to the 
STOP codon. This produces a blunt end that can be ligated to an RV site.
This is to PCR up nca-1 cdna (this is the outer nested 5’ primer) and parts of the 
genomic nca-1 sequence. This is the top strand and primes approx. 60bp 5’ of 
the unique KpnI site.
This is to PCR up nca-1 cdna (this is the inner nested 5’ primer) and parts of the 
genomic nca-1 sequence. This is the top strand and primes 7 bp 5’ of the 
unique KpnI site.
This is to PCR up nca-1 cdna (this is the inner nested 3’ primer). This is the 
bottom strand and primes 6 bp 3’ of the unique KpnI site.
This is to PCR up nca-1 cdna (this is the outer nested 3’ primer) and parts of the 
genomic nca-1 sequence. This is the bottom strand and primes 90 bp 3’ of the 
unique SacIII site.
This is to sequence the nca-1 cdna. This is the bottom strand and primes over 
residues APEGIGG
This is to sequence the nca-1 cdna. This is the bottom strand and primes over 
residues GEVEPEG
This is to sequence the nca-1 cdna. This is the bottom strand and primes over 
residues GYLQISD
This is to sequence the nca-1 cdna. This is the bottom strand and primes over 
residues RGTALLT
This is to sequence the nca-1 cdna. This is the bottom strand and primes over 
residues GMAVSKH
This is to replace the cdna between the KpnI and RV sites with genomic DNA, 
via two parts. A KpnI-Xba 5’ part and a XbaI-RV 3’ part. This is the top strand 
and primes within a non coding region approx 70bp 5’ of the XbaI site. This will 
PCR the Xba-RV section.
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ctgaactggactTgaatttcagcaaatgtttcagt
gatCacagcaatg
nca-1.14
cccccccagctgttaaaaaatgaaCTAatcaa
caagggaattccacc
nca-1.15
ccccagctgtaaaaaatgaaCTAggcggccg
catcaacaagggaattcc
nca-1.16
gtttcaaatcataacacaagaaggatgg nca-1.17
gtggttgaagttttgagagcaactgacg nca-1.18
gatggtatgcgacaaaatagagagcc nca-1.19
gatggtatgcgacaaaatagagagcc nca-1.20
acctccaattccttctggagc nca-1.21
tccttctggttcaacttctcc nca-1.22
gtcactgatctgcaaatatcc nca-1.23
tgttaaaagagctgttcctcg nca-1.24
gtgtttgctaactgccattcc nca-1.25
cgtcactcttgaataaattggctttcggtgc nca-1.26
To introduce the hp102 mutation into nca-1 cDNA.  Change is R403Q (CGA --> 
CAA) at position 1208 in the C11D2.6c transcript.    Primes on the top strand.  
  Also introduces a fourth BclI site into the cDNA for testing the Quikchange 
efficacy.  
To PCR up cDNA of nca-1 from Kohara clone and subclone into worm 
expression vectors. This primes on the bottom strand over the STOP codon and 
adds a PvuII site 3’ to the STOP codon. This produces a blunt end that can be 
ligated to an RV site.
To PCR up cDNA of nca-1 from Kohara clone and subclone into worm 
expression vectors. This primes on the bottom strand over the STOP codon and 
adds a NotI site immediately 5’ to the STOP codon and a PvuII site 3’ to the 
STOP codon. This produces a blunt end that can be ligated to an RV site.
This is to PCR up nca-1 cdna (this is the outer nested 5’ primer) and parts of the 
genomic nca-1 sequence. This is the top strand and primes approx. 60bp 5’ of 
the unique KpnI site.
This is to PCR up nca-1 cdna (this is the inner nested 5’ primer) and parts of the 
genomic nca-1 sequence. This is the top strand and primes 7 bp 5’ of the 
unique KpnI site.
This is to PCR up nca-1 cdna (this is the inner nested 3’ primer). This is the 
bottom strand and primes 6 bp 3’ of the unique KpnI site.
This is to PCR up nca-1 cdna (this is the outer nested 3’ primer) and parts of the 
genomic nca-1 sequence. This is the bottom strand and primes 90 bp 3’ of the 
unique SacIII site.
This is to sequence the nca-1 cdna. This is the bottom strand and primes over 
residues APEGIGG
This is to sequence the nca-1 cdna. This is the bottom strand and primes over 
residues GEVEPEG
This is to sequence the nca-1 cdna. This is the bottom strand and primes over 
residues GYLQISD
This is to sequence the nca-1 cdna. This is the bottom strand and primes over 
residues RGTALLT
This is to sequence the nca-1 cdna. This is the bottom strand and primes over 
residues GMAVSKH
This is to replace the cdna between the KpnI and RV sites with genomic DNA, 
via two parts. A KpnI-Xba 5’ part and a XbaI-RV 3’ part. This is the top strand 
and primes within a non coding region approx 70bp 5’ of the XbaI site. This will 
PCR the Xba-RV section.
caaaattcccgtagttgagaagctcggcc nca-1.27
acgacgagatatccaaatgtataagtgaatttctt
caactcc
nca-1.28
gcagaaatcCAGgtacagtttcaacaaatgtg
gggatcCagaagcagc
NALCN-1.1
gctgcttctGgatccccacatttgttgaaactgta
cCTGgatttctgc
NALCN-1.2
cctcctgagtttgtttgttgTGgttattCtAgacaac
ttagaacttg
NALCN-1.3
caagttctaagttgtcTaGaataacCAcaacaa
acaaactcaggagg
NALCN-1.4
GGGGGGtctagaGGGGGGatgCTCAAA
AGAAAGCAGAGTTCCAGG
NALCN-1.5
TGGCAGTGAACACCACCAAGCTTCC NALCN-1.6
ACTTCCAGGTTCTTCGGGTAGTCC NALCN-1.7
TCTGAAGATGCCGTTACAGTCTTCC NALCN-1.8
AGTTGTTCGAGAACTTTTCAGTGG NALCN-1.9
ggggggGAGCTCggggggCTAGATATCTA
GGAGGTCATCTCC
NALCN-1.10
This is to replace the cdna between the KpnI and RV sites with genomic DNA, 
via two parts. A KpnI-Xba 5’ part and a XbaI-RV 3’ part. This is the bottom 
strand and primes within the cdna approx 100bp 3’ of the XbaI site. This will 
PCR the Kpn-Xba section.
This is to replace the cdna between the KpnI and RV sites with genomic DNA, 
via two parts. A KpnI-Xba 5’ part and a XbaI-RV 3’ part. This is the bottom 
strand and primes over the RV site within the cdna.
To introduce the hp102-type mutation into the human NALCN cDNA.  Changes 
R329Q (AGA --> CAG) at position 1174 in the VGCNL1-001 transcript.  Primes 
on the bottom strand.  Also introduces a unique BamHI site 3’ of the mutation 
to check QuikChange efficacy.
To introduce the hp102-type mutation into the human NALCN cDNA.  Changes 
R329Q (AGA --> CAG) at position 1174 in the VGCNL1-001 transcript.  Primes 
on the top strand.  Also introduces a unique BamHI site 3’ of the mutation to 
check QuikChange efficacy.
To introduce the e625-type mutation into the human NALCN cDNA.  Changes 
A596V (GCT --> GTG) at position 1975 in the VGCNL1-001 transcript.  Primes on 
the bottom strand.  Also introduces a unique XbaI site 3’ of the mutation to 
check QuikChange efficacy.
To introduce the e625-type mutation into the human NALCN cDNA.  Changes 
A596V (GCT --> GTG) at position 1975 in the VGCNL1-001 transcript.  Primes on 
the top strand.  Also introduces a unique XbaI site 3’ of the mutation to check 
QuikChange efficacy.
To clone the 5’ end of rat NALCN cDNA.  Adds a unique XbaI site to the 5’ 
end, which will allow cloning into the MCS of psc#205.  Use in conjunction with 
NALCN-1.6 to clone FRAGMENT 1 of NALCN.
To clone the 3’ end of FRAGMENT 1 of NALCN.    5’ of this site is a XmaI site, 
which conmbined with the XbaI site in NALCN-1.5 allows cloning of this 
fragment into psc#205.  
Clone the 5’ end of FRAGMENT 2 of rat NALCN cDNA.   Use with NALCN-1.8.  3’ 
of this oligo is a unique XmaI site in the cDNA, which allows this fragment to be 
combined with FRAGMENT 1, and also allows cloning into psc#205.  
Clones the 3’ end of FRAGMENT 2 of rat NALCN cDNA.  Use with NALCN-1.7 to 
clone this fragment.  5’ of this oligo is a unique NheI site which can be used for 
joining this fragment onto FRAGMENT 3, and for cloning into psc#205.
Clones the 5’ end of FRAGMENT 3 of rat NALCN cDNA.    Use with NALCN-1.10 
to clone the rest of this fragment.  3’ of this site is a unique NheI site in the 
cDNA, which can be used for cloning into psc#205 and for combining with 
FRAGMENT 2.  
Clones the 3’ end of rat NALCN cDNA, including the stop codon.  Introduces a 
unique SacI site for cloning into psc#205.  Also is the 3’ end of FRAGMENT 3 of 
the cDNA.  Use with NALCN-1.9 to obtain this fragment.
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caaaattcccgtagttgagaagctcggcc nca-1.27
acgacgagatatccaaatgtataagtgaatttctt
caactcc
nca-1.28
gcagaaatcCAGgtacagtttcaacaaatgtg
gggatcCagaagcagc
NALCN-1.1
gctgcttctGgatccccacatttgttgaaactgta
cCTGgatttctgc
NALCN-1.2
cctcctgagtttgtttgttgTGgttattCtAgacaac
ttagaacttg
NALCN-1.3
caagttctaagttgtcTaGaataacCAcaacaa
acaaactcaggagg
NALCN-1.4
GGGGGGtctagaGGGGGGatgCTCAAA
AGAAAGCAGAGTTCCAGG
NALCN-1.5
TGGCAGTGAACACCACCAAGCTTCC NALCN-1.6
ACTTCCAGGTTCTTCGGGTAGTCC NALCN-1.7
TCTGAAGATGCCGTTACAGTCTTCC NALCN-1.8
AGTTGTTCGAGAACTTTTCAGTGG NALCN-1.9
ggggggGAGCTCggggggCTAGATATCTA
GGAGGTCATCTCC
NALCN-1.10
This is to replace the cdna between the KpnI and RV sites with genomic DNA, 
via two parts. A KpnI-Xba 5’ part and a XbaI-RV 3’ part. This is the bottom 
strand and primes within the cdna approx 100bp 3’ of the XbaI site. This will 
PCR the Kpn-Xba section.
This is to replace the cdna between the KpnI and RV sites with genomic DNA, 
via two parts. A KpnI-Xba 5’ part and a XbaI-RV 3’ part. This is the bottom 
strand and primes over the RV site within the cdna.
To introduce the hp102-type mutation into the human NALCN cDNA.  Changes 
R329Q (AGA --> CAG) at position 1174 in the VGCNL1-001 transcript.  Primes 
on the bottom strand.  Also introduces a unique BamHI site 3’ of the mutation 
to check QuikChange efficacy.
To introduce the hp102-type mutation into the human NALCN cDNA.  Changes 
R329Q (AGA --> CAG) at position 1174 in the VGCNL1-001 transcript.  Primes 
on the top strand.  Also introduces a unique BamHI site 3’ of the mutation to 
check QuikChange efficacy.
To introduce the e625-type mutation into the human NALCN cDNA.  Changes 
A596V (GCT --> GTG) at position 1975 in the VGCNL1-001 transcript.  Primes on 
the bottom strand.  Also introduces a unique XbaI site 3’ of the mutation to 
check QuikChange efficacy.
To introduce the e625-type mutation into the human NALCN cDNA.  Changes 
A596V (GCT --> GTG) at position 1975 in the VGCNL1-001 transcript.  Primes on 
the top strand.  Also introduces a unique XbaI site 3’ of the mutation to check 
QuikChange efficacy.
To clone the 5’ end of rat NALCN cDNA.  Adds a unique XbaI site to the 5’ 
end, which will allow cloning into the MCS of psc#205.  Use in conjunction with 
NALCN-1.6 to clone FRAGMENT 1 of NALCN.
To clone the 3’ end of FRAGMENT 1 of NALCN.    5’ of this site is a XmaI site, 
which conmbined with the XbaI site in NALCN-1.5 allows cloning of this 
fragment into psc#205.  
Clone the 5’ end of FRAGMENT 2 of rat NALCN cDNA.   Use with NALCN-1.8.  3’ 
of this oligo is a unique XmaI site in the cDNA, which allows this fragment to be 
combined with FRAGMENT 1, and also allows cloning into psc#205.  
Clones the 3’ end of FRAGMENT 2 of rat NALCN cDNA.  Use with NALCN-1.7 to 
clone this fragment.  5’ of this oligo is a unique NheI site which can be used for 
joining this fragment onto FRAGMENT 3, and for cloning into psc#205.
Clones the 5’ end of FRAGMENT 3 of rat NALCN cDNA.    Use with NALCN-1.10 
to clone the rest of this fragment.  3’ of this site is a unique NheI site in the 
cDNA, which can be used for cloning into psc#205 and for combining with 
FRAGMENT 2.  
Clones the 3’ end of rat NALCN cDNA, including the stop codon.  Introduces a 
unique SacI site for cloning into psc#205.  Also is the 3’ end of FRAGMENT 3 of 
the cDNA.  Use with NALCN-1.9 to obtain this fragment.
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ggggggccatggcggccgcctcgtctccgaca
tcattagaggagg
pkc-3.1
ggggggagctcgggggaatcagactgaatctt
cccgac
pkc-3.2
gctatgaatggaaatgggtcg pkc-3.3
cacaacttttgcataagatccacg pkc-3.4
aatgttctgattgacgctgaagg pkc-3.5
tggtgcaatataattgggtgttcc pkc-3.6
gacaaaactgtatatcgccgcggtgagcgacg
atggaagaaaatttatc
pkc-3.7
gataaattttcttccatcgtcgctcaccgcggcga
tatacagttttgtc
pkc-3.8
ggggggctagccatgcagacgatcaagtgcgt
cg
cdc-42.1
ggggggagctcctagagaatattgcacttcttc cdc-42.2
cgtcgttggagatgTCgctgtAggtaaaacttgt
ctcc
cdc-42.3
ggagacaagttttaccTacagcGAcatctcca
acgacg
cdc-42.4
ggagctgtcggtaaaaAttgtctActgatcagct
atacc
cdc-42.5
ggtatagctgatcagTagacaaTttttaccgaca
gctcc
cdc-42.6
GGGGGGGCGGCCGCCCGAAATGAA
ATGGGTGCTTCAGG
tam-1.1
GGGGGGGGCGGCGCCGATCGTGTTG
GGGAAGCCCTCTGC
tam-1.2
CCCCCCGGCGGCCGCGCCGATCGTG
TTGGGGAAGCCCTCTGC
tam-1.3
This is to subclone the pkc-3 cDNA into various vectors. This primes on the top 
strand over the ATG. The start ATG is in an NcoI consensus and a NotI site is 
inserted in frame immediately 3’ to the ATG.
This is to subclone the pkc-3 cDNA into various vectors. This primes on the 
bottom strand over the STOP codon. 3’ of the STOP is a SacI site.
To sequence pkc-3 cDNA and other versions of this gene.  Primes on the top 
strand, just 3’ of the Nhe I site.  
To sequence pkc-3 cDNA and other versions of this gene.  Primes on the 
bottom strand, in between the Nhe I and Eco RV sites.  
To sequence pkc-3 cDNA and other versions of this gene.  Primes on the top 
strand.
To sequence pkc-3 cDNA and other versions of this gene.  Primes on the 
bottom strand.
To modify the sequence of the pkc-3 cDNA to create a constitutively active 
form.  Primes on the top strand.  Changes an alanine at position 116 to 
glutamate, with base change GCT to GAG.    Introduces a unique sac II site 
into the sequence.     Sequence changed from: gta tat cga aga ggt gct  to: 
gta tat cgG CGC ggt gAG
To modify the sequence of the pkc-3 cDNA to create a constitutively active 
form.  Primes on the bottom strand.  Changes an alanine at position 116 to 
glutamate, with base change GCT to GAG.    Introduces a unique sac II site 
into the sequence.     
This is to PCR and subclone the cdc-42 cdna into various expression vectors. 
This primes on the top strand over the ATG and introduces an NheI site.
This is to PCR and subclone the cdc-42 cdna into various expression vectors. 
This primes on the bottom strand over the STOP codon and introduces a SacI 
site.
This is to create cdc-42(G12V) using quikchange. Also creates an SfcI site. This 
primes on the top strand.
This is to create cdc-42(G12V) using quikchange. Also creates an SfcI site. This 
primes on the bottom strand.
This is to create cdc-42(T17N) using quikchange. Also creates an AccI site. This 
primes on the top strand.
This is to create cdc-42(T17N) using quikchange. Also creates an AccI site. This 
primes on the bottom strand.
To clone the mouse Estrogen receptor binding domain which is responsive to 
tamoxifen.  Introduces a NotI site 5’ of the start of the coding sequence.   
Primes on the top strand (forward primer).  No start codon, designed to be 
dropped into plasmids with a NotI site 3’ to the start codon, and 5’ to the 
coding sequence of the gene to be regulated by tamoxifen.  
To clone the mouse Estrogen receptor binding domain which is responsive to 
tamoxifen.  Primes on the bottom strand.  (reverse primer)  DOES NOT CONTAIN 
A NOT-I SITE -- DO  NOT USE THIS PRIMER TO CLONE INTO A NOT-1 SITE!!
To clone the mouse Estrogen receptor binding domain which is responsive to 
tamoxifen.  Primes on the bottom strand.  (reverse primer)  Added correct NotI 
site, compared to Tam-1.3.  USE THIS INSTEAD OF Tam-1.3!!  No stop codon, 
designed to be dropped into plasmids with a NotI site 3’ to the start codon, 
and 5’ to the coding sequence of the gene to be regulated by tamoxifen.   
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3 - SUPPRESSOR SCREENING IDENTIFIES 
NOVEL TARGETS OF RHO-1
3.1 - Introduction
Previous work in the lab demonstrated that the small GTPase RHO-1 is able to increase 
neurotransmitter release in the developed C. elegans nervous system by increasing 
levels of diacylglycerol (DAG), a key second messenger (McMullan, Hiley et al. 2006). 
RHO-1 inhibits DGK-1, a diacylglycerol kinase, which normally acts to remove of DAG 
from presynaptic membrane (Nurrish, Ségalat et al. 1999).  DAG is a ligand for a number 
of proteins involved in synaptic vesicle and dense core vesicle release, including UNC-
13 and PKC-1 (Betz, Ashery et al. 1998; Lackner, Nurrish et al. 1999; Nurrish, Ségalat 
et al. 1999), and is a positive regulator of neurotransmitter release (Lou, Korogod et al. 
2008).  
Animals carrying an integrated construct containing constitutively-active RHO-1 (G14V) 
expressed in the cholinergic neurons using the unc-17 promoter (Alfonso, Grundahl et 
al. 1993; Sieburth, Ch’ng et al. 2005; McMullan, Hiley et al. 2006) are henceforth referred 
to as nRHO-1*.  These animals are hypersensitive to the acetylcholinesterase inhibitor 
aldicarb which inhibits the breakdown of acetylcholine and potentiates signalling (Nguyen, 
Alfonso et al. 1995).  This hypersensitivity indicates increased levels of acetylcholine 
release (Nurrish, Segalat et al. 1999).  These nRHO-1* animals also have a highly 
characteristic loopy locomotion (Movie 3-2) compared to wild-type animals (Figure 3-1, 
and see Movie 3-1 for wild-type locomotion).  This loopy locomotion may be linked to the 
increase in acetylcholine release (McMullan, Hiley et al. 2006).  
The proteins acting upstream to control the activity of RHO-1 have been well characterised, 
and a complex network of guanine nucleotide exchange factors (GEFs), G-proteins, 
G-protein coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs) has been 
determined (see Figure 1-9) (Steven, Zhang et al. 2005; Hiley, McMullan et al. 2006; 
McMullan, Hiley et al. 2006; Williams, Lutz et al. 2007).  
Several experiments suggest that much more remains to be discovered with respect 
to the pathways downstream of the RHO-1 GTPase itself.  In a dgk-1 mutant animal 
(in which neurotransmitter release is increased in line with an increase in DAG levels), 
inhibiting RHO-1 with the specific inhibitor C3 transferase (Aktories and Hall 1989) 
causes a reduction in neurotransmitter release (McMullan, Hiley et al. 2006).  If DGK-1 
were the only target of RHO-1 within the nervous system, inhibiting RHO-1 in this mutant 
background should have no effect on acetylcholine release.  Additionally, a mutation in 
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B
p.unc-17 RHO-1 (G14V)
C
Figure 3-1  nRHO-1* animals are highly loopy compared with 
wild-type
A) Wild-type C. elegans have a smooth, sinusoidal body posture as they move across the surface 
of an agar plate.  
B) In contrast, animals overexpressing an activated form of RHO-1, the C. elegans homologue 
of the human small GTPase RhoA, have a highly uncoordinated and loopy locomotion.  These 
animals were staged and are imaged at the same magnification as the wild-type animals in (A), 
indicating that the transgene reduces the size of animals compared with wild-type.  
C) The structure of the nRHO-1* transgene.  Driven by the unc-17 promoter, this transgene 
expresses in the cholinergic neurons (highlighted in red in the animal outline) and this expression 
is sufficient to drive highly loopy locomotion.  
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RHO-1 - F25N - specifically reduces binding to DGK-1 (McMullan, Hiley et al. 2006). 
This mutant form of RHO-1 is still able to drive an increase in acetylcholine release 
(although to a lesser degree than the non-mutant), and generate loopy behaviour.  These 
results strongly suggests the presence of alternative targets of RHO-1 within the nervous 
system other than DGK-1.
Although over 40 proteins are known to be Rho effectors, they do not all share a 
common Rho interaction domain (Etienne-Manneville and Hall 2002), which makes it 
difficult to identify novel targets of Rho.  In an attempt to discover some of these potential 
downstream targets we undertook a genetic suppressor screen using our nRHO-1* 
mutants. Genetic screens in C. elegans have proven a powerful technique for identifying 
neurobiological mutants (Brenner 1974; Nguyen, Alfonso et al. 1995; Miller, Alfonso et 
al. 1996), and suppressor screens have identified genes which interact with a variety of 
proteins.  For instance, suppressors of activated Ras were identified as components of 
the MAPK pathway (Lackner, Kornfeld et al. 1994) and identification of axon guidance 
proteins were uncovered while screening for suppression of guidance defects caused by 
overexpression of UNC-5 (Colavita and Culotti 1998).  
We decided to screen for suppressors of loopy locomotion, as opposed to changes in 
aldicarb response, for two main reasons.  Firstly, there have been exhaustive screens 
for aldicarb resistant mutants (ric) (Nguyen, Alfonso et al. 1995; Miller, Alfonso et al. 
1996), and we believed we would identify a large number of mutations which suppressed 
aldicarb sensitivity indirectly of RHO-1 signalling.   Secondly, the loopy phenotype can 
be observed using a standard dissecting microscope, allowing us to screen mutants 
at a faster rate than a pharmacological assay; aldicarb phenotypes can be tested in a 
secondary screen following the initial rapid visual screen.  
3.2 - Strain QT631, which carries two integrated RHO-1 
transgenes, was selected for the screen
We decided to screen for suppressors of our stably integrated nRHO-1* transgene, 
nzIs29.  This was integrated into transformed animals by Dr Rachel McMullan, and is 
carried in strain QT309, which was two-times backcrossed through wild-type to remove 
background mutations generated by integration.  The integration maps to Chromosome 
II (R. McMullan, personal communication).  nzIs29 consists of the nRHO-1* plasmid 
QT#42, which expresses the G14V activated form of RHO-1 under a fragment of the unc-
17 promoter that has been shown not to cause any developmental defects (McMullan, 
Hiley et al. 2006), along with an unc-122::gfp marker, which produces fluorescence in 
the ceolomocytes. 
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To ensure that any mutations generated by EMS were real suppressors of RHO-1, and 
not simply the result of silencing the transgene, we crossed strain QT309 with QT47, 
which contains a second, stably-integrated RHO-1* transgene, nzIs1, which expresses 
the G14V form of RHO-1 from the heatshock promoter (hsRHO-1*) from vector pPD79.48, 
part of the Fire Lab Vector Kit.  This integration maps to Chromosome I (S. Nurrish, 
personal communication.)  Observations with this integrated transgene have previously 
been published (Hiley, McMullan et al. 2006; McMullan, Hiley et al. 2006).  Heatshock 
RHO-1* activation has non-neuronal phenotypes, such as tail swelling and death (R. 
McMullan and S. Nurrish, in press), so we could not use the heatshock construct for our 
primary screen.  We did however use this transgene to conduct secondary screening of 
mutant animals.
3.2.1 - A ‘False Positive’ screen Identified a false positive 
rate of 5%
To judge the level of confidence in our ability to distinguish genuinely suppressed animals 
from mutated animals behaving in a less loopy fashion, we conducted a small false 
positive screen.  Here we took 5 plates of mixed population QT631 and subjected them 
to the same treatment regime as for EMS mutagenesis, with the exception of addition of 
the mutagen (Figure 3-2).  These worms were subjected to pelleting by centrifugation, 
agitation in M9 solution for 4 hours at 20oC, and pippetting onto fresh NGM plates.
After one hour of recovery time, 44 L4s were picked to a fresh plate and left to grow to 
adulthood overnight.  The following day, adult animals were picked to fresh plates (5 
animals per plate, labelled A to I) and left for a total of 5 hours to lay eggs.  After the 5 
hours, the adults were removed and the eggs left to grow for two days, after which two 
plates were placed at 15oC, to mimic the effects of searching for temperature sensitive 
mutations.  
After a total of 5 days growth, the plates were screened to look for any animals that 
looked non-loopy (i.e. had more wild-type locomotion than our QT631 starting strain).
From a total of 214 F1 animals, 14 F2s were picked which looked to be moving better 
than the starting QT631 strain.  These were singled to individual plates.  Examination 
of the F3 generation of these potentially suppressed animals demonstrated that their 
progeny were not suppressed.  This experiment estimated a false positive rate of 
approximately 5%, but strongly suggested that these were due to behavioural variations 
and not spontaneous mutations or silencing of the transgene.  
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1) Washed 25 plates of 
mixed population QT631
3) Washed animals
returned to plates
4) 250 L4 larvae picked 
to fresh plates;
5 animals per plate
5) Removed animals 
following egg-laying;
eggs allowed 
to develop
2) Nematodes exposed 
to EMS in solution
6) Screen for 
non-loopy F1 
animals, 
none found
7) F1 animals removed 
following egg-laying, 
965 F1 animals in total
8) Screened for 
non-loopy
F2 animals
9) Singled non-loopy animals 
to look at F3 generation;
835 non-loopy animals identified
Figure 3-2  Scheme of EMS mutagenesis and screening
A mixed population of QT631 animals was exposed to 50mM EMS following washing (Steps 1-3), 
and 250 larval stage 4 (L4) animals were placed on fresh plates (4).  These were allowed to lay 
eggs before being removed, and the progeny were screened for non-loopy behaviour (5 & 6). 
These animals were in turn singled, and their progeny screened (7 - 9).  
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3.3 - EMS Mutagenesis of QT631 generated 835 suspected 
suppressor mutants (in collaboration with Dr Rachel 
McMullan)
We conducted the primary screening in two parts, a small pilot screen and a larger 
screen, and I will consider the results from these two parts as a whole.   
A total of 25 plates of mixed population QT631 animals were washed in M9 to remove 
excess OP50 bacteria, and then exposed to 50mM EMS for 4 hours in a solution of M9. 
The EMS solution was removed and disposed of, while the worms were again washed 
in M9, suspended in a small volume of M9, and pipetted onto a fresh plate (Figure 3-2). 
Approximately 250 L4 larvae were then picked onto a total of 5 fresh plates and left to 
grow overnight.  The L4 larvae stage contains a large number of meiotic nuclei, and it is 
into these which we are attempting to introduce the mutations.  This way, by exposing a 
relatively small number of L4 animals to EMS we can screen a large number of progeny. 
Mutagenesis of L3 animals would increase the likelihood of ‘jackpot mutations’ whereby 
all progeny would carry the same mutation, while mutagenesis of adult animals is likely 
to produce chimeric mutants or non-heriditable mutations. 
The following day groups of 5 adult animals were picked onto fresh plates, labelled 1 to 
24 and A to AB.  These animals were left to lay eggs over a period of approximately 7 
hours, due to the slow egg-laying rate of this strain.  The P0 adults were then removed 
and the eggs left to hatch (Figure 3-2). 
In total, across all the plates, we captured 965 F1 animals.  As mutations could be 
introduced either in the developing egg or sperm of the L4 animals exposed to EMS, 
this allowed us to screening double the number of genomes to the number of animals 
exposed, i.e. we screened 1930 haploid genomes in total.  
Once the F1 animals had laid eggs, the F1 adults were removed to allow the eggs to hatch. 
While counting and removing these F1 animals, we screened them to look for non-loopy 
animals.  Any mutations at this stage might represent dominant mutations; however, 
we found no non-loopy animals in the first generation after screening, suggesting no 
dominant mutations were isolated.
The eggs from the F1 generation were left to grow at 15oC to reduce the chances of 
leaky hs::RHO-1* expression (McMullan, Hiley et al. 2006; Diogon, Wissler et al. 2007). 
We know that RHO-1 plays significant roles in development (Govek, Newey et al. 2005), 
and that complete loss-of-function mutations in effectors of RHO-1 are likely to cause 
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lethality.   We therefore grew the animals at 15oC as a potential permissive temperature, 
with the aim of capturing any temperature-sensitive mutations that may give partial loss-
of-function at low temperature.  
3.3.1 - Further generational analysis revealed 116 strong 
suppressor candidates
Each plate of F2 animals was examined at least once following growth at 15oC and 
once after subsequent growth at 25oC before the food supply was exhausted to test 
for temperature sensitive mutations.  During growth at 15oC we picked a total of 606 
animals whose locomotion could be considered to be more like wild-type than the QT631 
starting strain; many of these came from the same original plate and may contain the 
same suppressor mutation.  When grown at 25oC we found a further 229 animals whose 
locomotion looked more wild-type than the starting strain. 
Unclassified
Odd
Uncertain
Loopy at 25C
Loopy at 15C
Slow Growing
Sterile or Dead
Lethargic
Less Loopy
Non-loopy
Figure 3-3 - Categories of Suppressor Mutants
After the initial screening round, we identified 835 mutants with a locomotion which was described 
as more like wild-type than our starting strain.  Of these, the majority were either too slow growing, 
sterile or died before we could classify them further.  Around one third of the mutants classified 
produced progeny which were also suppressed (i.e. non-loopy or less loopy), and could be 
analysed further. 
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These ‘non-loopy’ F2 were singled to their own individual plates and allowed to lay eggs. 
We then examined the F3 generation to see if the suppressive phenotype was maintained. 
Examining the progeny of a single animal gave us a clearer indication of phenotype.  We 
assigned each plate to a category based on the overall phenotype displayed.  
• Non-loopy – animals look essentially the same as wild-type
• Less loopy – animals have a higher numbers of body bends than wild-type, or assume 
a coiled posture, but to a lesser degree than the starting strain
• Lethargic – animals move slowly, rate of body bends reduced
• Loopy (at either 15oC or 25oC) – in the first round of screening we picked any animals 
that appeared to move better than the starting strain.  However, when looking at a clonal 
population of these worms it was often clear that the mutations had not caused the 
animals to become non-loopy.  These animals represent false positives obtained from 
the screen
• Sterile/dead/eggs only – plates which produced no live progeny, so were eliminated 
from the screen
• Unclassified - plates which produced no live progeny and on which the original mutant 
had died or crawled off the plate  
• Slow growing – the starting strain QT631 is itself a slow growing strain, and a number 
of mutants appear to have acquired mutations that enhance this slow growth, making 
them unsuitable for further study.  In hindsight, these animals should have been retained 
and frozen for future study, as their growth rate is incidental to the locomotion phenotype
During this round of categorisation, we also made a note of those mutants that appeared, 
by visual inspection, to be the most suppressed.  
These results are summarised in the pie chart in Figure 3-3.  A high proportion of the 
animals became sterile or died.  68.7% of the suppressors picked in the first round of 
screening were eliminated from the screen following inspection of the F3 generation, 
either because the animals were obviously loopy, or because the F2 animal were now 
homozygous for a mutation causing death, sterility or very slow growth. 
This left us with 260 mutants whose locomotion was more like wild-type than the starting 
strain - classed as ‘Non-loopy’, ‘Less Loopy’ and ‘Lethargic’ (see Figure 3-3).  Of these, 
144 were in the  ‘Less Loopy’ category.  We decided to eliminate these from the screen, 
as the difference between their locomotion and that of the starting strain was insufficiently 
strong to enable successful backcrossing or mapping.
This left us with 116 mutants with a locomotion substantially different to the starting 
strain, from a starting total of 1930, of 6% of our starting total.  We therefore undertook 
a round of secondary screening to find the best candidates to from this set of mutants.  
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X
F3 Suppressed Worm
Grow at 15oC
Grow at 20oC
Apply Heat-Shock
Non-neuronal phenotypes
1) Test for maintenance of non-loopy 
phenotype at 15oC
2) Test for maintenance of non-loopy 
phenotype, and observe growth rate at 20oC
3) Activate hsRHO-1* and look for 
non-loopy animals; test suppression
 of two separate transgenes
4) Examine additional hsRHO-1*
phenotypes, such as rate
of pumping, sterilty
and the dar phenotype
Non-sterile, non-dar animals which 
have WT pumping rates
may indicate inactivation 
of both transgenes
Sterile
Slow pumping
Swollen tail
Removed from 
screen
Removed from 
screen
Removed from 
screen
Figure 3-4 - Secondary Screening
Animals which appeared non-loopy after the initial round of screening were subjected to a 
number of further tests   
First, we tested for maintenance of the non-loopy phenotype at both 15 and 20oC (1 & 2). 
Next, we looked for maintenance of the non-loopy locomotion after activation of the heatshock 
RHO-1* transgene (3).  Finally, the animals were classified based on their additional hsRHO-1* 
phenotypes, such as sterility or tail swelling (4).    
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3.4 - Secondary Screening of Mutants (in collaboration 
with Dr Rachel McMullan)
3.4.1 - Screening for maintenance of the locomotion 
phenotype at room temperature eliminated 15 poorly 
suppressed mutants
From the animals that passed the first round of screening, we created an Excel spreadsheet 
to track all further experiments (Appendix 1).   The first round of the secondary screening 
was to confirm the locomotion phenotypes already observed at 15oC and when grown 
at 20oC (Figure 3-4).  To make comparisons between strains easier, we used a series of 
fixed categories to describe locomotion:
• Not Loopy (Suppressed)
• Less Loopy than QT631 (Partially Suppressed)
• Loopy (Not Suppressed) 
• Lethargic (Partially Suppressed, locomotion different from wild-type)
• Lethargic, not loopy (Suppressed, locomotion different from wild-type)
• Lethargic, loopy (Not suppressed, slow moving)
15 mutants were relabelled as ‘Loopy’ following further examination.  These animals 
appeared to have suppressed locomotion for one or two generations, with this effect 
reducing over time.  It is not clear whether these animals represented very subtle 
suppressor mutations, epigenetic reduction in the activity of the transgenes, or are simply 
false positives, but they were discounted from the remainder of the screen.  
Several mutants, as well as being non-loopy, also appeared to move slower than our 
wild-type animals, and were labelled as lethargic.  While we were initially looking for 
suppressors that would return locomotion to wild-type levels, we were also interested 
in this lethargic phenotype, as although the rate of locomotion is reduced, the animals 
move with a wild-type body posture.  
3.5 - Screening for maintenance of the locomotion 
phenotype after heatshock identified 15 potential cases 
of inactive nRHO-1* transgenes
One possible reason why we might see suppression of the nRHO-1 phenotype would be 
if we have isolated mutants in which the transgene is silenced.  Transgenes are highly 
repetitive arrays, and so are subject to silencing by endogenous mechanisms (Mello and 
Fire 1995; Kelly, Xu et al. 1997).  It is possible that some of our suppressors represent 
natural silencing of the transgene, or are mutations that enhance silencing.  A number of 
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mutants in the RNAi pathway, such as rde-1, have been shown to increase the levels of 
silencing of transgenes (Tabara, Sarkissian et al. 1999).
The integrated nRHO-1* transgene contains an unc-122::GFP marker, which expresses 
in the coelomocytes and appears as six green dots along the body of the worm (McMullan, 
Hiley et al. 2006).  Throughout the course of the experiments, we checked under UV light 
to see if this was still being expressed as an indication of the status of the transgene, and 
a few mutants were identified that no longer expressed this marker (e.g. mutants B.20 & 
D.07).   These were discarded from the rest of the screen (see Appendix 1).  
However, it is possible that even though this component of the transgene is being 
expressed, expression of RHO-1 (G14V) from the unc-17 promoter may be down-
regulated.  Therefore, we tested all of our mutant animals by activating the second, 
hsRHO-1* transgene, which is integrated at a separate location in the genome, co-
expresses ttx-3::GFP as a marker, and causes wild type animals to become loopy.  It is 
less likely that both integrated transgenes are silenced, so any animals which continue 
to be non-loopy after activation of the heatshock gene are likely to represent genuine 
RHO-1 suppressors.
To test this, we grew two plates of mixed populations of each suppressor, and heatshocked 
one plate using our standard protocol, activating the hsRHO-1* transgene which is 
independently capable of generating loopy locomotion. We recorded the locomotion 
phenotype of these animals compared to the unheatshocked animals (Figure 3-4).   15 
of the mutants tested became loopy after heatshock, suggesting that the reason for 
suppression in these animals is due to reduced expression of RHO-1 (G14V) from the 
unc-17 promoter.  For examples of the appearance of mutants following heatshock, see 
Figure 3-13.
This experiment also controls for an additional class of mutants which we predict would 
appear non-loopy.  Mutations which affect expression from the unc-17 promoter would 
reduce expression of nRHO-1*, making the animals appear non-loopy.  However, these 
mutations would not affect expression from the heatshock promoter.  In addition, animals 
with total reduction of unc-17 (and cha-1, which shares the same promoter) would likely 
be paralysed or even dead, so we would either not see these animals in our screen, or 
would have discarded them due to their paralysed phenotype.  
3.6 - Screening additional RHO-1 phenotypes
Although it is unlikely that a mutation would affect both transgenes, it is not impossible. 
While continued expression of both GFP reporters suggests that both transgenes 
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are operational, we also examined the functional consequences of activating 
heatshock RHO-1.  
We took advantage of our hsRHO-1* transgene and the additional RHO-1 non-neuronal 
effects that occur on heatshock.  These include changes in pumping and defecation 
rates, sterility and eventual death of the heatshocked animal, and the development of 
the dar (deformed anal region) phenotype (R. McMullan and S. Nurrish, in press).  The 
dar and sterility phenotypes are thought to have a non-neuronal origin.  We screened our 
suppressors to identify those which still displayed some or all of these additional RHO-1 
phenotypes.  These mutants likely represent:
• Mutants in which both transgenes are efficiently expressed
• True suppressors of loopy locomotion
• Neuronal-specific suppressors of RHO-1 activity
3.6.1 - 45 mutants screened suppress the sterility phenotype 
of heatshock RHO-1*
We picked 2 sets of 5 L4s of each suppressor strain onto two fresh plates, and heatshocked 
one plate using our standard protocol.  Both plates were then stored at 15oC for five 
days, after which we compared the heatshocked plate to the control plate and examined 
the number of progeny.  Again, we used a limited number of categories to allow easier 
comparison between strains. These were:
• Not Sterile, looks wild-type (Suppressed)
• Sterile, no eggs or larvae (Not suppressed)
• Eggs only, no larvae (Partially suppressed)
• Slow growth – some larvae, but growing slowly (Partially suppressed)
45 mutant strains were listed as “Not Sterile” in this test, suggesting that they are 
either silenced for both nRHO-1* and hsRHO-1* transgenes, or that these are general 
suppressors of RHO-1 function throughout the animal.  As this category may contain 
genuine RHO-1 suppressors, we did not automatically eliminate animals which were 
not sterile, but used the information as part of our assessment of the best mutants to 
continue studying.  It is also possible that locomotion and sterility defects are suppressed 
by independent mutations in some of these strains.  
3.6.2 - 40 mutants suppress the pharyngeal pumping 
phenotype of hsRHO-1* 
The pharyngeal muscles pump rhythmically to cause entry of bacteria into the grinder the 
worm.  This pumping is severely reduced after heatshock RHO-1 activation, probably due 
123
to hypercontraction of the pharangyl muscle (R. McMullan, personal communication). 
We assayed the rate of pumping of our mutants after heatshock.  Again, we used a 
simple set of categories to classify the mutants based on a 2 minute inspection of the 
pumping rate of at least 5 animals following heatshock:
• Like wild-type (completely suppressed)
• Like QT631 with heatshock (not suppressed)
• Slower than QT631 with heatshock (not suppressed)
• Faster than QT631 with heatshock (partially suppressed)
40 mutants displayed a pumping phenotype that was faster than QT631 following 
heatshock – i.e. where the hsRHO-1* effect is suppressed.  This did not lead to elimination 
from the screen, but those with unsuppressed pumping were of more interest to us, as 
they likely represented locomotion-specific suppressors.  
3.6.3 - Protruding vulva and deformed anal region: 
additional heatshock RHO-1 effects
Heat-shock activated RHO-1 induces a swelling around the vulval, known as the 
protruding vulval phenotype (pvul), and a swelling around the tail region (dar phenotype) 
(McMullan and Nurrish, in press).  While we were observing the other phenotypes, we 
also recorded any instances of these two phenotypes (Appendix 1).  While this was not 
conducted in a systematic way, but it does give additional insight into the activity of the 
hsRHO-1 transgene in individual suppressor mutants.  
3.6.4 - Growth at 20oC of suppressor mutants
We also made note of other distinguishing characteristics of the mutants.  Rate of growth 
at 20oC was noted, as measured by the ability of a singled animal to starve a standard 
plate in six days.  This was considered as a factor in choosing mutants to continue 
investigating, from the practical viewpoint that slow-growing strains are more difficult to 
work with.
3.6.5 - Suppressor mutants can be grouped into 3 categories
Based on all the information we had gathered from the screen, we selected 20 mutants 
for continuing study.  The primary factor for this selection was the degree of suppression 
of the loopy phenotype at 20oC as our original objective was to identify suppressors of 
this phenotype.  While cataloguing our mutants we used the designations ‘Not Loopy’ 
and ‘Less loopy (than QT631)’ for ease of classification, a number of animals clearly had 
a phenotype that was more easily distinguished from the starting strain, marked with an 
asterisk (Appendix 1, Column 2).  In addition, we favoured those mutants which had the 
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least suppression of the sterility and pumping defects associated with heatshock RHO-
1* activation.  The 20 selected mutant animals can be arranged into three groups (Table 
3-1)  These classifications were performed prior to backcrossing and it is possible that 
additional mutations act in these strains to modify the supression of various nRHO-1* 
and hsRHO-1* phenotypes.
Group 1: Non-loopy at 20oC, and non-loopy and sterile after heatshock
These are the suppressors that best match our original target phenotypes. Five mutants 
meet these criteria - nz94, nz97, nz98, nz99, and nz104, although nz94 and nz98 
are additionally categorised as lethargic.  These animals fully suppress the neuronal 
phenotype of RHO-1 in generating loopy locomotion, but fail to suppress the sterility 
phenotype upon heatshock.  These animals also show little suppression of the reduction 
in pumping of the pharyngeal muscles after heatshock. 
Group 2: Non-loopy at 20oC but more loopy than wild-type after heatshock; sterile 
following heatshock
These animals demonstrate less effective suppression of the loopy phenotype following 
heatshock, suggesting that they are slightly weaker alleles compared to Group 1, that 
hsRHO-1* had additional effects on locomotion or because of modifying mutations in 
the background.  Group 2 animals become sterile after heatshock, suggesting that the 
hsRHO-1* transgene is still active.  Three suppressors make up this category, nz100, 
nz105 and nz110.  
Group 3: Non-loopy at 20oC, non-loopy following heatshock; non-sterile after 
heatshock
This group composes 10 mutants.  They may represent more general RHO-1 suppressors, 
as the sterility effects of heatshock RHO-1 are suppressed.  Not all non-neuronal 
phenotypes are suppressed in these mutants, however, as we still see a reduction in 
pumping following heatshock, and also the emergence of dar and pvul swellings in 
some of these mutants.  The suppression of sterility of the heatshock transgene is of 
interest and may be pursued in future investigations.  Group 3 mutants are most likely to 
represent loss of activity of both transgenes.  
3.7 - Suppressor mutants display a range of aldicarb 
phenotypes 
The suppressor mutants we chose for further study were all selected primarily on their 
ability to restore wild-type locomotion in the presence of nRHO-1*.  We also know that 
125
 allele  Mutant
 Movement 
at 20oC
Movement 
after heatshock
 Sterility after 
heatshock
 Pumping 
after 
heatshock
Group 1
nz99 7.12 Not loopy Not loopy Sterile
Faster than 
QT631 w/ hs
nz97 1.03 Not loopy Not loopy Sterile
Like QT631 
w/ hs
nz104 A.01 Not loopy
Lethargic, not 
loopy
Sterile
Faster than 
QT631 w/ hs
nz94 4.13
Lethargic, 
not loopy
Not loopy Sterile
Like QT631 
w/ hs
nz98 4.36
Lethargic, 
not loopy
Lethargic, not 
loopy
Sterile
Faster than 
QT631 w/ hs
Group 2
nz100 13.05 Not loopy Less loopy Sterile
Like QT631 
w/ hs
nz105 A.17 Not loopy Less loopy Sterile
Faster than 
QT631 w/ hs
nz110 A.20 Not loopy Less loopy Sterile
Faster than 
QT631 w/ hs
Group 3
nz92 1.05 Not loopy Not loopy Not sterile
Faster than 
QT631 w/ hs
nz93 2.09 Not loopy Not loopy Not sterile Like N2
nz95 15.02 Not loopy Not loopy Not sterile
Faster than 
QT631 w/ hs
nz96 2.29 Not loopy Not loopy Not sterile
Faster than 
QT631 w/ hs
nz101 13.15 Not loopy Not loopy Not sterile
Like QT631 
w/ hs
nz102 18.06 Not loopy Not loopy Not sterile
Like QT631 
w/ hs
nz103 8.07 Not loopy Not loopy Not sterile
Faster than 
QT631 w/ hs
nz106 D.07 Not loopy Less loopy Not sterile
Like QT631 
w/ hs
nz107 L.09 Not loopy Not loopy Not sterile Like N2
nz108 L.10 Less loopy Not loopy Not sterile Like N2
nz109 L.15 Not loopy Not loopy Not sterile
Faster than 
QT631 w/ hs
nz111 D.03 Less loopy Less loopy Not sterile
Slower than 
QT631 w/ hs
Table 3-1 Mutants isolated from the screen cluster into three 
groups
We selected the 20 mutants displaying the most suppressed locomotion, and satisfying the 
criteria of observing some degree of activity of the hsRHO-1* transgene.  They can be classified 
into three groups based on the strength of suppression of the two RHO-1* transgenes.  
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nRHO-1* is able to increase sensitivity to aldicarb, and therefore we wanted to see 
whether these suppressors of locomotion also suppressed the aldicarb phenotype.  Our 
typical aldicarb assay lasts 100 minutes.  25-30 animals were placed on a 35mm plate 
containing 1mM aldicarb, in the presence of food, with each animal assayed every 10 
minutes.  To more rapidly assess the phenotype of all our mutants we instead looked at 
two time points for paralysis.  We chose 50 and 80 minute time points, as these show a 
distinct difference between wild type and QT631.  At 50 minutes around 20% of wild-type 
animals are paralysed (Figure 3-5, blue line) compared to over 60% of QT631 animals 
(Figure 3-5, red line).  Looking at 80 minutes gives information about whether any of the 
suppressors are resistant to aldicarb compared to N2, as at this time point 70% of wild 
type animals are paralysed (Figure 3-5, blue line). 
We observed a range of aldicarb phenotypes (Figure 3-5) across the mutants tested. 
The majority of mutants are as or more sensitive to aldicarb than the starting strain, 
suggesting that mutations in these strains only affect the locomotion phenotype of RHO-
1, and do not suppress the acetylcholine release phenotype.  This is evidence that 
these two phenotypes, which often appear together, for example in goa-1 and dgk-1 
mutants (Lackner, Nurrish et al. 1999; Nurrish, Ségalat et al. 1999) , can be successfully 
separated.
Other mutants, such as nz101 (Group 3), nz105 (Group 1) and nz111 (Group 3) display 
aldicarb profiles more similar to wild-type, suggesting that these mutant suppress 
both the acetylcholine release phenotype and the locomotion phenotype of nRHO-1*. 
Additionally, this could be evidence that these suppressors have lost activity in both 
transgenes.  
It could be that we have introduced some mutations that are affecting aldicarb resistance 
in parallel to the nRHO-1* transgene effects, but we cannot distinguish between these 
possibilities at this stage. 
3.8 - Detailed analysis of individual suppressor mutants
Following isolation of twenty strongest RHO-1 suppressor mutants from the screen, we 
decided to examine the behaviours of individual mutants in more detail.  Our original aim 
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was to backcross all the mutants, analyse their responses to aldicarb and levamisole as 
markers of activity of the nervous system, and perform mapping experiments on the best 
candidates to isolate the suppressor mutations.  
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Figure 3-5 - Aldicarb phenotypes of suppressor mutants
Mutants were tested for rate of paralysis on 1mM aldicarb at 2 time points, 50 and 80 minutes. 
For comparrision, the red line indicates % of nRHO-1* animals paralysed, while the dark blue 
line indicates % wild-type animals paralysed at each time point.  Mutant nz110 was not included 
in this experiment (see Figure 3-9 for aldicarb curves of this mutant).  Error bars indicate S.E.M. 
of at least two trials.  
Orange bars - Group 1 Mutants, green bars - Group 2 Mutants, light blue bars - Group 3 
Mutants (see Table 3-1).    
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During the course of this process we became particularly interested in the suppressor 
mutant nz94.  Initially classified as lethargic, this mutant actually has a rare ‘fainting’ 
phenotype, which allowed us to identify it as an allele of the novel gene unc-80.  Following 
this discovery, the focus of experimention was concentrated on analysis of this mutant, 
as detailed in Chapters 4 and 5.  Therefore a number of the mutants from this screen 
remain to be characterised in detail, but those which have been analysed are described 
here.  
3.8.1 - Aldicarb profile of nz105 
The suppressor mutant nz105 completely suppresses the locomotion phenotype of 
nRHO-1* and partially suppresses the loopy locomotion induced by hsRHO-1*, and was 
placed in Group 2 (Table 3-1).  The one-times backcrossed strain, QT823 (nz105 1*) is 
shown here (Figure 3-6, see also Movie 3-3).  Tracks left in the OP50 lawn indicate wild-
type movement and body bends.  
However, despite completely suppressing the locomotion phenotype of nRHO-1*, this 
mutation only partially suppresses the aldicarb phenotype associated with the nRHO-
1* transgene (Figure 3-7).  Both the strains assayed, the orginal mutant isolated from 
the screen and the one-times backcrossed mutant, appear hypersensitive to aldicarb 
compared with wild-type.  Their aldicarb curves are only partially shifted to the right 
Figure 3-6 - nz105 suppresses the loopy locomotion phenotype 
of nRHO-1*
nRHO-1* animals are highly loopy, but animals carrying the nz105 mutation suppress this 
phenotype.  QT823 (nRHO-1*;nz105 1*) animals, shown here, are one-times backcrossed, and 
have a wild-type body posture and leave tracks similar to those of wild-type animals.
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compared with nRHO-1* animals alone, demonstrating that they still have high levels of 
neurotransmitter release.  
This indicates that the nRHO-1* transgene remains active in these animals, and is able to 
drive high levels of acetylcholine release independently of generating loopy locomotion, 
although it is possible that upon further backcrossing the sensivity to aldicarb will change. 
3.8.2 - Aldicarb profile of nz110
As already mentioned, it is possible that the suppressor mutation in nz110 is the same 
as that seen in nz105, as they were obtained from the same plate of P0 animals.  The 
three times backcrossed strain appears wild-type in its locomotion (Figure 3-8, see also 
Movie 3-4).  
The aldicarb curve for the one-times backcrossed nz110 strain appears intermediate 
between wild-type and QT631, as it did for nz105, suggesting some degree of suppression 
of the neurotransmitter release phenotype of nRHO-1* (Figure 3-9).  A second round 
Figure 3-7 - Aldicarb profile of mutants carrying the nz105 
suppressor
Animals were exposed to 1mM aldicarb and the number of paralysed animals assayed every 
10 minutes.  Both lines assayed, QT684 (nz105, orange line, n=4) and QT823 (nz105 1*, green 
line, n=6) only partially suppress the aldicarb hypersensitivity of nRHO-1*.  Error bars indicate 
SEM.
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of backcrossing, following the suppression of the loopy phenotype, moves the aldicarb 
curve to the right, while a third round of backcrossing shifts the curve to the left.  These 
changes could indicate the presence of some modifying loci causing slight variations in 
the sensitivity to aldicarb in the genetic background of this mutant and potentially (by 
extension) in animals carrying the nz105 suppressor.  
3.9 - Aldicarb profile of nz107 and nz108 
nz107 and nz108 were obtained from the same original plate, and so may contain the 
same suppressor mutation.  Both belong to Group 3 of the mutants obtained from the 
screen; they strongly suppress the loopy locomotion phenotype of both transgenes, and 
are also capable of some suppression of the sterility and pumping phenotypes.  This 
might indicate a reduction in the action of the transgenes, but both mutants exhibit tail 
swelling following heatshock, demonstrating some action of hsRHO-1*.  
In the initial round of aldicarb analysis, the aldicarb profile of both nz107 and nz108 
looked intermediate between that of wild-type and the starting strain (Figure 3-5), so 
nz107 may be a more general RHO-1 suppressor.
In the more detailed neurotransmitter release analysis using the standard aldicarb assay, 
we see that both unbackcrossed and one-times backcrossed mutants carrying nz107 
Figure 3-8 - nz110 suppresses the loopy locomotion phenotype 
of nRHO-1*
Animals carrying the nz110 mutation suppress the loopy locomotion generated by the nRHO-1* 
transgnee.   QT834   (nRHO-1*;nz110 3*) animals, shown here, are three-times backcrossed, 
have a wild-type body posture and leave tracks similar to those of wild-type animals.
131
have an aldicarb phenotype intermediate between that of wild-type and the starting 
strain (Figure 3-10).  This, along with the presence of the cc::gfp marker of the nRHO-
1* transgene, suggests that the transgene is still functional, and that nz107 is able to 
partially suppress the increase in neurotransmitter release caused by nRHO-1*.
Suppressor nz108 demonstrates an aldicarb profile highly similar to that of the starting 
strain (Figure 3-11).  This indicates that while this mutant can suppress the locomotion 
phenotype of the nRHO-1* trasgene it has little effect on the release of acetylcholine.
3.9.1 - Additional RHO-1 suppressor mutant aldicarb profiles
A number of other suppressors have been assessed using the more detailed 100 minute 
aldicarb assay.  Although this data is for a single repeat of unbackcrossed animals, the 
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Figure 3-9 Aldicarb profile of mutants carrying the nz110 
suppressor
Animals were exposed to 1mM aldicarb and the number of paralysed animals assayed every 
10 minutes.  All the lines assayed, QT804 (nz110 1*, orange line, n=3), QT816 (nz110 2*, green 
line, n=5) and QT834 (nz110 3*, light blue line, n=4) are hypersensitive to aldicarb compared 
with wild-type, and only slightly suppress the aldicarb sensitivity of nRHO-1*.  Error bars indicate 
SEM.
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sensitivity to aldicarb seems to follow the same trend as the initial assessment for each 
mutant (Figure 3-5). 
nz92 and nz95 are hypersensitive to aldicarb and show no suppression compared to 
nRHO-1* animals, while nz97 and nz99 mutants are partially suppressed (Figure 3-12) 
nz101 appears almost wild-type in its response to aldicarb (Figure 3-12).  
While all these experiments require additional repeats, and a number of mutants remain 
to be assayed in detail, the data so far suggests that the majority of mutations show a far 
stronger suppression of the nRHO-1* locomotion phenotype than the aldicarb phenotype. 
3.9.1.1 - Chronic aldicarb assay of mutants
To further assess the aldicarb phenotype of these mutants, a chronic aldicarb assay was 
performed (Miller, Alfonso et al. 1996)(Miller, Emerson et al. 1999).  Here, instead of 
acutely treating the worms on plates containing 1mM aldicarb for a period of 100 minutes 
and observing the time of paralysis, 5 L4 worms were placed onto plates containing 
0.2mM aldicarb or ethanol control and left to grow for 6 days.  Wild type animals are able 
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Figure 3-10 Aldicarb profile of mutants carrying the nz107 
suppressor
Animals were exposed to 1mM aldicarb and the number of paralysed animals assayed every 10 
minutes.  Both the lines assayed, QT686 (nz107, orange line, n=3), QT821 (nz107* 1*, green 
line, n=6) exhibit an aldicarb phenotype intermediate between wild-type and nRHO-1* animals. 
Error bars indicate SEM.
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to grow on this concentration of aldicarb, although more slowly than in the absence of the 
drug, while nRHO-1* animals have severely inhibited growth (Table 3-2). 
When tested using this chronic assay, the suppressor mutants all tend to look more like 
the nRHO-1* starting strain, growing poorly in the presence of 0.2mM aldicarb (although 
even in the absence of aldicarb some mutants grew poorly).  This demonstrates that while 
they are suppressed for the loopy locomotion generated by the nRHO-1* transgene, they 
are still releasing more acetylcholine than wild-type animals.  
nz105 alone of those mutants tested is able to grow in the presence of 0.2mM aldicarb, 
looking more like wild-type worms, which is consistent with the initial aldicarb tests for 
nz105 which showed some suppression of the aldicarb sensitivity of the starting strain 
(Figure 3-7).
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Figure 3-11 Aldicarb profile of mutants carrying the nz108 
suppressor
Animals were exposed to 1mM aldicarb and the number of paralysed animals assayed every 10 
minutes.  All the lines assayed, QT687 (nz108, orange line, n=3), QT812 (nz108* 1*, green line, 
n=2) QT835 (nz108 2*, light blue line, n=5) exhibit an aldicarb phenotype very similar to that of 
the starting strain.  Error bars indicate SEM.
134
0% 
20% 
40% 
60% 
80% 
100% 
0 10 20 30 40 50 60 70 80 90 100 
Wild-type
nRHO-1*
nz92;
nRHO-1*
nz97;
nRHO-1*
nz95;
nRHO-1*
%
 p
a
ra
ly
sd
 o
n
 1
m
M
 A
ld
ic
a
rb
Time (minutes)
nz101;nRHO-1*
nz99;nRHO-1*
Figure 3-12 Aldicarb profiles of additional unbackcrossed 
mutants
Animals were exposed to 1mM aldicarb and the number of paralysed animals assayed every 10 
minutes.  All lines except for nRHO-1* and WT are for a single trial.  Error bars indicate SEM.
3.9.2 -  nz106 suppresses the dar phenotype induced by 
hsRHO-1*
RHO-1 Activation of the heatshock RHO-1* transgene causes an additional phenotype 
to develop in the tail of the worm.   This is the deformed anal region (dar) phenotype, 
commonly associated with infection by bacteria (Hodgkin, Kuwabara et al. 2000). 
Wild-type worms become dar in the presence of pathogen, first identified in strains 
contaminated with the nematode-specific pathogen M. nematophilum, while hsRHO-1* 
animals become dar even in the absence of pathogen.  
We were interested to see whether any of our suppressors had an altered tail swelling 
response, so we examined a number of the unbackcrossed mutants, which still carry the 
heatshock transgene, following heatshock (Figure 3-13).  As previously noted during the 
screening procedure, most of these animals develop tail swellings.  However, suppressor 
nz106 appears capable of suppressing this phenotype.  As the regulation of the tail 
swelling involves additional, important cellular pathways downstream of RHO-1, such as 
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MAP Kinase signalling (Partridge, Gravato-Nobre et al. 2010 and R. McMullan, personal 
communication), this suppressor may be interesting for further study.  
3.9.3 - Levamisole Assays of Suppressor Mutants
3.9.3.1 - Four suppressor mutants are wild-type in their 
response to levamisole
It is possible that a mutation that blocks increased acetylcholine release by nRHO-1* also 
makes muscles hypersensitive to acetylcholine, and this would result in animals which 
remained hypersensitive to aldicarb.  To test for this we have so far tested eight of our 
suppressors by exposure to the drug levamisole, which directly stimulates the cholinergic 
receptors on the body wall muscles and is capable of causing paralysis (Nguyen, Alfonso 
et al. 1995). The nRHO-1* transgene itself does not affect the sensitivity of the body wall 
muscles to levamisole (McMullan, Hiley et al. 2006).  
Strain 0mM Aldicarb 0.2mM Aldicarb
N2
Large mixed population, food 
gone
Mixed population, food left, 
slow movement
nRHO-1* Mixed population, food gone
Very few animals, food left, 
very slow movement
QT688 
(nz109)
Small mixed population, food 
left
Most animals dead, very few 
worms, food left
QT804      
(nz110 1*)
Mixed population, food left Very few worms, food left
QT812 
(nz108 1*)
Mixed population, food left Few worms, food left
QT822 
(nz107 1*)
Small population, food left Very few worms, food left
QT823 
(nz105 1*)
Large population, food gone
Mixed population, looks like 
N2, food gone
Table 3-2 Chronic Aldicarb Assay of Mutants
5 L4 animals were grown in the presence of 0.2mM aldicarb for 6 days, and the plates were 
assayed for growth.  Observatons are the result of two separate trials.  
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Four of the eight mutants tested - nz92, nz97, nz105 1*, nz107 1* - had a wild-type 
response to levamisole, indicating no obvious changes in the response of their body wall 
muscles to neurotransmitter (Figure 3-14).  
nz97, nz105 1* and nz107 1* display aldicarb phenotypes intermediate between 
nRHO-1* and wild-type animals, suggesting some level of suppression of the 
neurotransmitter release phenotype of the nRHO-1* transgene.  This suppression is 
unlikely to be occurring post-synaptically, as they have a wild-type response to levamisole; 
instead it is likely that these animals are neuronal suppressors of neurotransmitter 
release.  
nz92 displays no suppression of the aldicarb phenotype of nRHO-1*, and is also wild-
type for levamisole, suggesting that this mutant affects only the locomotion phenotype 
and has no effect on neurotransmitter release.  
Figure 3-13 Heatshock of suppressor mutants causes tail 
swelling
One-day old adult animals were subjected to our standard heatshock protocol, and left to recover 
at 20oC.  Of the animals tested, only one, the unbackcrossed QT685 carrying suppressor nz106 
(b, above) fails to generate a deformed anal region (dar) phenotype.  
nz105 nz106 nz107
nz108 nz109 nz111
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3.9.3.2 - Four suppressor mutants have an abnormal 
response to levamisole
Of the remaining mutants tested in levamisole assays, three - nz101, nz108 1*, nz110 
3* - are resistant to levamisole.  nz101 had a wild-type response to aldicarb (Figure 3-12) 
which, combined with a resistance to levamisole, suggests that neurotransmitter release 
remains high in this mutant, but that the aldicarb effect is masked by a post-synaptic 
reduction in sensitivity to neurotransmitter.  This suggests that the supression of the 
effects of the nRHO-1* trangene may occur post-synaptically.
nz108 1* and nz110 3* are both hypersensitive to aldicarb (Figure 3-11) and (Figure 
3-9).  They are also resistant to levamisole, and together this data suggests that they 
have an even higher level of acetylcholine release than that suggested by the aldicarb 
assay alone.  These mutants also represent potential post-synaptic mutations, although 
Figure 3-14 Suppressors with a wild-type response to levamisole
Animals were exposed to 100μM levamisole and assayed for paralysis over the course of 100 
minutes.  Error bars indicate SEM for nz107 1* (n=3) and nz105 1* (n=3); nz92 and nz97 data 
is the result of a single trial. 
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homeostatic mechanisms may occur in the muscle in response to acetylcholine release, 
as seen in Drosophila (Davis 2006).  
The final mutant tested, nz95, is hypersensitive to levamisole compared to wild-type 
animals (Figure 3-12).  This suggests that the muscles are hypersensitive to acetylcholine. 
This mutant also appeared hypersensitive to aldicarb (Figure 3-12); hypersensitivity to 
both aldicarb and levamisole suggests that this mutant may have a more wild-type level 
of neurotransmitter release than that indicated by either experiment independently.  
3.10 - Identifying the molecular nature of the nRHO-
1* suppressor mutants is complicated by poor mating 
efficiency
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Figure 3-15 Suppressors with a non-wild-type response to 
levamisole 
Animals were exposed to 100μM levamisole and assayed for paralysis over the course of 100 
minutes.  Error bars indicate standard error of the mean for nz108 2* (n=3) and nz110 3* (n=3); 
nz95 and nz101 data is the result of a single trial.  
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To identify the molecular nature of the suppressor mutations introduced by EMS, it is 
necessary to know which gene is mutated.  The earliest methods for this mapping in C. 
elegans involved identifying complementation groups, and crossing with visual markers, 
such as dumpy or roller mutants, whose relative position on each chromosome was well 
known (Hodgkin 1999).
One commonly used technique for positional mapping of mutants uses strains which 
contain a number physiological markers.  However, this approach is limited by the 
availability of easily distinguished markers.  A later technique is to analyse the distribution 
of single nucleotide polymorphisms (SNPs), at positions known to be different between 
the Bristol strain of C. elegans (N2) and the Hawaiian strain (CB4856) (Wicks, Yeh et al. 
2001).  These can be analysed by PCR and sequencing (a laborious process) or in some 
cases (where the SNP changes a restriction enzyme site), by PCR and enzyme digest. 
This protocol has been refined to take advantage of a 96 well plate system, and 48 SNPs 
that are all susceptible to the restriction enzyme DraI (Davis, Hammarlund et al. 2005). 
The idea is to cross a mutant with a Hawaiian animal, pick mutants and wild type animals 
from the cross, and then perform PCR using a prepared primer set for each SNP, digest 
on the plate and then run the whole plate out on an agarose gel to look for the changes 
in digestion.  
This procedure has been published as providing a fast and effective means of identifying 
both the mutant chromosome, and for finer mapping of the interval that contains the 
mutation.
However, all of our mutations are suppressor mutations, and (with the exception of nz94, 
which will be discussed later) none of these mutations has yet been shown to have 
a strong phenotype in the absence of the nRHO-1* transgene.  This necessitated the 
production of a Hawaiian strain of C. elegans carrying the nzIs29 transgene (see Strains.) 
However, strains carrying the nRHO-1* transgene have proven very difficult to cross, 
especially for crosses involving suppressor mutants carrying additional background 
mutations.  While we had some success generating backcrossed lines for analysis using 
aldicarb and levamisole, difficulties backcrossing our suppressor strains reduced our 
access to conventional (Brenner 1974) and snip/SNP mapping techniques (Wicks, Yeh 
et al. 2001).   We therefore made use of a technique which is quickly becoming a new 
standard for mapping mutants – whole genome sequencing (Sarin, Prabhu et al. 2008). 
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3.11 - Whole Genome Sequencing allows identification 
of mutations in backcrossed and unbackcrossed strains
The principle of the technique is to generate millions of short reads (usually between 36 
and 76 base pairs), randomly distributed across the mutant genome.  Computer algorithms 
are then able to align these short reads against the wild-type genome.  The program then 
identifies bases that are different between the wild type and mutant genomes, and these 
sites can then be further investigated (Figure 3-16).
In previous cases, this sequencing has been performed after several rounds of standard 
mapping – either using the Snip/SNP mapping or by mapping to an arm of a chromosome – 
which then allowed the researchers to focus on the data for those fractions of the genome. 
We reasoned, however, that the number of protein-altering mutations in reported in these 
papers was low enough that, across a mutant genome, we might expect approximately 
200 mutations affecting coding sequences.   Of these we might be able to distinguish 
good candidates for further investigation, or be able to attempt rescuing experiments 
using pools of cosmids and fosmids to narrow down the search.
We therefore decided to proceed with the whole genome sequencing without having 
mapped to the mutations to a specific chromosome.  Should the sequencing prove 
inconclusive, we could return to the traditional mapping approaches and use them to 
filter our (already acquired) sequencing data.  
3.11.1 - Choosing strains to send for Whole Genome 
Sequencing
nz97 – A Group 1 suppressor (Table 3-1), nz97 is ‘Not loopy’ at room temperature, so 
suppresses the nRHO-1* effects on behaviour, and is ‘Not Loopy’ following heat shock, 
suppressing the neuronal effects of hsRHO-1*.  It does become sterile after heatshock, 
and does not suppress changes in pumping, showing that this mutation is specifically 
able to suppress the locomotive phenotype of RHO-1* (Table 3-1).  This mutant has 
high levels of neurotransmitter release, (Figure 3-10), suggesting it does not suppress 
this phenotype associated with nRHO-1*.  We sent strain QT788, which contains the 
nz97 suppressor, and is three times backcrossed, with the aim of reducing background 
mutations. 
nz99 – Also a Group 1 suppressor, nz99 similarly suppresses the locomotive phenotype 
of nRHO-1*, but not other neuronal phenotypes (pumping and hypersensitivity to aldicarb 
(Figure 3-12)) or non-neuronal behaviours (sterility) (Table 3-1).  The strain we selected 
for sequencing - QT677 - is completely unbackcrossed.  With this strain, we wanted to 
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attgctaaaatttctgctttgaaaatgcctacattgtgcctctattagtgcctacataactgaactacaatacgttttat
gtgtatgcttttccagattctatgtgaactcttcaaaaatgtctccactcccactagcactagactcggttcatttttct
ccgtttccacgtgtcatgcagaaacgatagagcgcacttactaacttctaatgttatgtggaatgtgtcaggttattcta
ctttcgaaaaaggttggaaattagattgtgaacttataaaatttaataaattaaattatttttcaaatcaaaaaccagct
A
B
C
Worms were washed in M9 and their genomic DNA extracted using a modied Qiagen
Blood and Tissue protocol involving sonifc
The DNA is annealed to the Illumina
FlowCell chip, and amplied using on-chip
PCR to produce a tiny cluster of DNA strands.
The sequence is read using modied, uorescent
nucleotides, to produce short reads of between
36 and 76bp (typical examples shown below).  
Short read aligned to worm genome
A small number of mismatches 
(red dots) are tolerated
The alignment of a number of mismatches
implies the presence of a mutation.
Figure 3-16 Whole Genome Sequencing
DNA was extracted from mutant animals (A) and sent to GeneService for sequencing (B).  The 
result is millions of short reads which can be aligned against the known worm genome to predict 
mutations (C).  
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test the full capacity of the Whole Genome Sequencing approach, to see whether we 
could identify a mutation in an unbackcrossed, unmapped strain.  
nz110 – This suppressor is in Group 2, and fully suppresses the locomotion phenotype 
of nRHO-1* at room temperature (Table 3-1).  It does however become relatively loopy 
after heatshock, so is possibly a weaker suppressor than the other mutants.  It displays 
high levels of neurotransmitter release, suggesting it does not suppress all the neuronal 
phenotypes of nRHO-1* (Figure 3-9).  We sent strain QT834, which was three times 
backcrossed.  
nz90 – We also included in our sequencing run a mutant from an entirely different 
source.  Emma Hiley, a previous PhD student in the lab, identified nz90 as an mutation 
which causes resistance to aldicarb (Hiley 2006).  While investigating strain VC430, 
which contained a mutation in the Rho GEF RHGF-1, she found a second mutation that 
caused resistance to aldicarb.  This mutation was mapped using Snip/SNP mapping 
to a 500kb region on Chromosome V, and the resistance to aldicarb was rescued by 
injecting cosmid T025B5.  Genes TO2b5.1 and TO2b5.2 were injected individually and 
overexpression of either gene was sufficient to rescue the aldicarb phenotype. 
Subsequent sequencing of the coding regions of these genes detected no mutations. 
Some sequencing has also been performed to look at the non-coding regions of these 
genes without detecting any mutations.  This mutant, which had been mapped to an 3Mb 
interval, but for which the molecular nature of the lesion is unknown, provided a good test 
of the whole genome resequencing. 
This mutant was generated by TMP/UV entirely separately from the EMS mutagenised 
nRHO-1* animals.  However, this strain had been backcrossed through wild-type animals 
from our lab.   We therefore felt confident in classifying any mutations common to this 
strain and our nRHO-1* mutant strains as background mutations or sequencing errors.  
3.11.2 - Preparing genomic DNA for sequencing
We prepared the DNA using the Qiagen Blood and Tissue kit, and a modified protocol 
involving sonication (see Methods).  We obtained genomic DNA and quantified it using 
the NanoDrop spectrophotometer (Table 3-3).
3.11.3 - Running the samples 
The samples were dispatched to GeneService, who ran them on multiple lanes of the 
Illumina sequencing system.  These produced reads of 36, 55 or 76 base pairs (see 
Table 3-4).   All of these sequences are ‘paired end data’.  During fragmentation of the 
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genome, DNA fragments of approximately 500 base pairs are produced.  The paired 
end sequencing procedure reads the sequences at both ends of these fragments, 
and associates the data into a single file.  Essentially, this provides additional spatial 
information, such that in the starting genome those two short reads were no more than 
500 base pairs apart.  This additional data can be used to constrain the search algorithms 
during mapping.  
3.12 - Analysing the Whole Genome Sequencing Data
The runs described above generated a large amount of sequencing data for each of the 
mutants.  Geneservice inputted this data in the program MAQ (Mapping and Assembly 
with Quality  (http://maq.sourceforge.net/)).  This program takes the millions of reads 
produced by the sequencing reactions and attempts to find a good match within a known 
sequence, in our case, the C. elegans genome.
These reads are then used to define a consensus, using the quality scores associated 
with each mapped base.  The coverage of the consensus data is essentially random, but 
may be influenced at any given point by the ease with which a particular sequence can 
be amplified by PCR. 
3.12.1 - Analysis of data obtained by Geneservice indicated 
a premature STOP codon in cbp-1 within mutant QT834
Geneservice provided a list of predicted SNPs in the four mutant animals sent for 
sequencing.  To reduce the number of SNPs which may be relevant to the analysis we 
filtered the SNPs by comparing across all files for any mutations occurring at exactly the 
Mutant Sequenced QT317 QT677 QT788 QT834
Suppressor Allele nz90 nz99 nz97 nz110
DNA Concentration 509 ng/ul 205 ng/ul 815 ng/ul 225 ng/ul
Dilution (Final 
Concentration)
2x (250ng/ul) 1x 4x (200ng/ul) 1x
Table 3-3 - DNA extraction from suppressor mutants
Details of DNA extracted from the four mutants sent for sequencing
144
same genomic location, and introducing the same mutation, in more than one strain (see 
Methods).  These can be considered to be background mutations, possibly present in 
our original starting strain, or introduced during backcrossing.  This reduced the number 
of SNPs which are likely to represent the suppressor mutation in the strains by between 
50 and 80% (Table 3-5).  
Of these remaining mutations, we initially focussed on those that introduced changes 
into protein coding regions of the genome.  However, no annotation of the SNPs was 
provided by Geneservice.  To attempt to overlay the details of the remaining SNPs with 
biologically-relevant information, we ran the details of each SNP through the UCSC 
Genome Browser (http://genome.ucsc.ed), and used this to identify which SNPs fell 
within the regions of genes.  For each of these genes identified as a ‘hit’, we used data 
from WormBase (http://www.wormbase.org) to identify those SNPs which overlay an 
exon, and subsequently those which cause a protein coding change (see Methods for 
more details of this procedure).
This analysis was most thoroughly performed for the SNPs obtained from QT834 with 
the aim of testing the process and then applying it to the other mutants if successful. 
Mutant Sequenced QT317 QT677 QT788 QT834
Suppressor Allele nz90 nz99 nz97 nz110
36bp Data
2 runs  
(271mb and  
258mb)
2 runs  
(271mb and 
295mb)
2 runs  
(200mb and 
196mb)
2 runs  
(252mb and 
278mb)
55bp Data 1 (unknown)
76bp Data 1 run (565mb) 1 run (545mb)
2 runs  
(344mb and 
341mb)
1 run (563mb)
Estimated Coverage 18.2 times 24.7 times 17.8 times 17.9 times
Table 3-4 - Details of sequencing reactions
The raw data from the Illumina Flow Cells was processed by Geneservice using their in-house 
algorithms to determine the quality of the sequencing data.  Where spots on the flow cell 
dimmed too quickly or were too close together these were excluded from the analysis.  This 
data was used to run the program MAQ (see text) and from this a prediction of the coverage of 
the genome was obtained for each mutant.  
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The most severe mutation predicted by this analysis was the introduction of a premature 
STOP codon into the gene cbp-1, the C. elegans homologue of CREB Binding Protein.  
To test the efficiency of this analysis, we sequenced the region of cbp-1 into which this 
mutation had been introduced.  However, the sequencing reactions demonstrated that 
nz110 was wild-type for cbp-1 in the sequenced region.  Repeat bioinformatic analysis of 
this region indicated that the initial assignment of this mutation was incorrect.  
Mutant Sequenced QT317 QT677 QT788 QT834
Suppressor Allele nz90 nz99 nz97 nz110
Number times 
backcrossed
10 (through 
WT)
0
3, through 
starting strain
3, through 
starting strain
SNPs in Geneservice 
File
2520 2960 3346 2675
Unique SNPs in 
Geneservice File
375 895 1457 862
SNPs from 
MAQGene analysis
2369 2809 2464 3083
Unique SNPs from 
MAQGene analysis
843 1278 1608 1500
Protein coding 
changes  in 
MAQGene Analysis
16 42 115 44
Table 3-5 - Details of Mutations identified in sequenced DNA
The total number of mutations in each mutant is relatively consistent (from 2369 to 3346, 
depending on analysis) regardless of the number of times these animals have been backcrossed. 
After filtering for SNPs which occur in at least two strains, the number of mutations decreases 
drastically, with between 35 to 85% of the original SNPs being eliminated from the analysis. 
Using MAQGene, which ascribes biologically relevant context to the SNPs, the number of 
protein coding changes per mutant ranges from 16 to 115, within the range we estimated at the 
start of the process.  
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3.13 - Analysis of WGS data using MAQGene
Following this unsuccessful attempt to analyse the processed data obtained from 
Geneservice, we decided perform our own analysis on the raw data.  As well as the 
processed data obtained from running MAQ, Geneservice provided us with the raw data 
from the flowcells.  
To perform this analysis we made use of a program, MAQGene, developed in the Hobert 
lab (Sarin, Prabhu et al. 2008; Bigelow, Doitsidou et al. 2009;Sarin, Bertrand et al. 2010). 
MAQGene allows a user to run the program MAQ without accessing the Linux command 
line.  Within MAQGene, the MAQ-specific commands are entered into a user-friendly 
webpage-format, MAQGene generates all MAQ-specific files, and produces a list of 
SNPs, similar to that obtained from Geneservice.  
Additionally, MAQGene then interrogates these SNPs using its own specific parameters, 
and then maps those that pass these thresholds onto an annotated database of the 
worm genome.  This database can be updated to hold the most up-to-date release of the 
C. elegans genome.
The final output from MAQGene is a list of SNPs and small deletions referred to as indels, 
detailing both their position in the genome, any genes which are affected by the predicted 
changes, and the nature of those changes – for instance, introducing premature STOP 
codons, or creating read-through mutations. 
These files can be filtered to remove any mutations occurring at the same residue and 
giving rise to the same base change in at least two of the four mutants sequenced, 
as these are likely to represent background mutations or consistent sequencing errors. 
This procedure reduced the total number of mutations from a range of 3083 - 2369 to a 
range of 1608 - 843.  
The mutations can then be sorted according to their molecular nature, for instance to 
list just those affecting protein coding regions.  This reduces the number of mutations in 
each strain to between 16 and 115 which affect protein coding sequences. 
3.13.1 - Distribution of mutations along chromosomes 
following backcrossing reveals potential locations of 
suppressor mutants in QT788
As backcrossing occurs, mutations close to the suppressor are likely to be maintained 
in the genome, while those further away and therefore unlinked are more likely to be 
lost.  This is the essence of all mapping, whether those linked mutations produce visible 
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phenotypes such as dumpy or roller mutants, or whether they represent SNPs which 
have to be analysd through PCR and restriction digests.  A recent idea in whole genome 
sequencing is to look for patches of the genome which have a particularly dense collection 
of mutations following backcrossing, as these linked mutations may indicate the locus of 
the suppressor mutation (Zuryn, Le Gras et al. 2010).  A similar idea has recently been 
tested using crosses with the Hawiaan strain of C. elegans to identify regions linked to 
the candidate mutation (Doitsidou, Poole et al. 2010).
We filtered the MAQGene predictions for the cannoical G/C - A/T mutations introduced 
by EMS (Drake and Baltz 1976), and plotted the frequency of mutation every million 
bases along each chromosome for the three suppressor mutants.  
QT677 provides a good control for this process, as this mutant is entirely unbackcrossed, 
and therefore no selection has been applied which could create linkage between the 
background SNPs and the causative suppressor mutation.  When the G/C - A/T mutations 
are analysed, there are clusters of mutations present on each chromosome, as would 
be expected through a random introduction of mutations by EMS (Figure 3-17, A).  After 
filtering these mutations for quality (see Methods for details) the distribution appears to 
cluster on Chromosome III (Figure 3-17, B).  This cluster does not represent any artificial 
selection causing association to the causative mutation, but may instead indicate a 
susceptibility to mutation in this region, or result from selection pressure occuring at the 
population level during screening.  
For QT788 the initial analysis did not reveal a single concentration of SNPs (Figure 3-18, 
A).  However, after filtering for quality, a single peak of SNPs can be seen to clearly 
cluster on Chromosome II (Figure 3-18, B).  Although far from definitive, this provides a 
good target for investigation of the potential suppressor mutation.
In QT834, neither the unfiltered nor the filtered data provide a good target for further 
investigation (Figure 3-19).  In fact, the total number of SNPs which pass the quality filter 
is very low compared to the other two mutants.  There is a slightly denser concentration 
of SNPs on Chromosome IV, as indicated by the red arrow, but it is not possible at this 
stage to determine whether this is significant.  
3.13.2 - QT834 (nz110) contains a mutation in unc-31 (CAPS)
Without strong positional information from mutant QT834, we took a candidate approach 
to analysing our data. From the filtered output from MAQGene, we obtained a list of 44 
missense mutations predicted to be present in the QT834 (nz110) genome  (Appendix 
2).  The remainder of the predicted mutations are either silent, intronic or in intergenic 
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regions, so we focused first on those predicted to be capable of altering protein-coding 
regions.  Interestingly, we found no predicted premature STOP codons in the data 
produced from MAQGene.  Although premature STOP codons are not the only type of 
mutation capable of disrupting gene function, they are an important class of mutation 
and, in previous studies, mutants regularly contain 5-10 premature STOP codons per 
genome (Sarin, Prabhu et al. 2008; Bigelow, Doitsidou et al. 2009; Sarin, Bertrand et al. 
2010). 
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Figure 3-17 Distribution of SNPS in QT677 (nz99)
QT677 is a completely unbackcrossed mutant, and therefore its distribution of SNPs should 
represent the natural introduction of mutations into the genome by EMS.  In the unfiltered data 
(A), there are peaks of C/G to A/T SNPs (coding and non-coding) on each chromosome.  As can 
be seen from the filtered data (B), there is a higher concentration of SNPs on Chromosome III. 
This cannot be attributed to the causative mutation being present on this chromosome as no 
selection has occurred to drive this accumulation; rather it is the stochastic nature of mutations 
to be unevenly distributed at this level of analysis  However, this region on chromosome III 
corresponds to the location of a strong candidate mutation in dat-1 (purple arrow), suggesting 
that there may be some bias, even without backcrossing.    
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Without the detection of a specific class of strong mutant, we next examined the list of 
mutations for genes known to be involved in synapse function.  One candidate suppressor 
mutation is in the gene unc-31, which encodes the C. elegans homologue of CAPS, 
a protein involved in the release of dense core vesicles (Speese, Petrie et al. 2007). 
These contain neuropeptides, as well as some small molecule neurotransmitters such as 
serotonin and dopamine, and are far larger than the small synaptic vesicles which release 
acetylcholine.  We were interested in this potential mutation because neuropeptides act 
as neuromodulators through activation of seven-pass transmembrane receptors, and we 
0
1
2
3
4
5
6
7
8
0
1
2
3
4
5
6
XVIVIIIIII
XVIVIIIIII
Distribution along Chromosomes
N
u
m
b
e
r o
f f
ilt
e
re
d
 S
N
Ps
N
u
m
b
e
r o
f c
a
n
o
n
ic
a
l S
N
Ps
Distribution along Chromosomes
A
B
Figure 3-18 Distribution of SNPS in QT788 (nz97)
The unfiltered distribution of all C/G to A/T SNPs (coding and non-coding) in QT788 does not 
indicate a strong selection for any particular chromosome, as there are spikes in frequency 
along each chromosome (A).  
After filtering for quality (B), a strong peak of SNP concentration emerges on Chromosome II 
(red arrow), suggesting that these SNPs may be linked to a causative and selected mutation in 
this region. 
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thought that this kind of signal might well be involved in the modulation of the extent of 
body bends in C. elegans.
The predicted unc-31 mutation causes a GCA->GTA[Ala->Val] change in the protein. 
We sequenced this region of unc-31 from the QT834 (nz110) mutant, and confirmed 
the predicted change using Sanger sequencing (Figure 3-20).  This mutation falls in the 
Munc-13 homology domain.  Dr Muna Elmi is currently attempting to rescue the unc-31 
mutation using unc-31 wild-type sequences from a fosmid covering that region. 
3.13.3 - QT677 (nz99) contains a premature STOP codon in 
dat-1, a dopamine reuptake transporter
In the absence of positional information for the suppressor mutation in QT677, we took 
a candidate approach to the mutations obtained from analysis using MAQGene.  We 
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Figure 3-19 Distribution of SNPS in QT834 (nz110)
The unfiltered distribution of C/G to A/T SNPs (coding and non-coding) in QT834 does not 
indicate a strong selection for any particular chromosome, as there are spikes in frequency along 
each chromosome (A).  After filtering for quality, the majority of the SNPs on each chromosome 
are lost (B).  Chromosome IV maintains the highest density of SNPs, indicated by the red arrow. 
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produced a list containing 42 protein-coding alterations, including 39 single nucleotide 
polymorphisms and 3 small insertions/deletions causing frameshifts.  Looking first 
for strong alleles, we found a single predicted premature STOP codon, in dat-1, the 
dopamine reuptake transporter, which works to remove dopamine from the synapse after 
release (Jayanthi, Apparsundaram et al. 1998). 
We sequenced the region of dat-1 predicted to contain the STOP codon using sanger 
sequencing, which confirmed the presence of the mutation (Figure 3-21).  This is our 
top candidate for the suppressor mutation, because it occurs in a protein important for 
synaptic signalling and particularly the control of locomotion.  
3.13.4 - Analysis of QT788 indicates that the suppressor 
mutation may localise to one of two regions on Chromosome 
II
With the analysis of the distribution of SNPs in QT788 we saw a clear concentration 
on Chromosome II (Figure 3-18).  This suggests that the mutation localises to this 
chromosome.  Our analysis from MAQGene predicts a total of 115 protein coding 
changes in this mutant, of which 29 localise to Chromosome II.
We examined the distribution of canonical G/C - A/T mutations on this chromosome in 
more detail (Figure 3-22) and saw that these mutations cluster into two peaks on the 
chromosome.  Within those peaks there are only 8 mutations which are able to cause 
protein coding changes.  While this analysis cannot say that one of those mutations is 
the suppressor mutation, these provide good candidates for further investigation.  
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WT     25477  TACTCTTTCGCTTTTTGTGCATCTCATGTCCATGGAAATAGGTGTATGCCTGATCGACAA  25536 
              ||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||| 
QT834  752    TACTCTTTCGCTTTTTGTGCATCTCATGTCCATGGAAATAGGTGTATGCNTGATCGACAA  693 
 
WT     25537  GGACCTGAAGGAGTTGGTACAGTAACTCTGGAGGAGAAGGAAAAGTTCCAGGAAATCAAG  25596 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT834  692    GGACCTGAAGGAGTTGGTACAGTAACTCTGGAGGAGAAGGAAAAGTTCCAGGAAATCAAG  633 
 
WT     25597  GAACGATTGAGAGTACTTCTAGAGAAGCAAATCACGAATTTCCGTTATTGTTTCCCATTT  25656 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT834  632    GAACGATTGAGAGTACTTCTAGAGAAGCAAATCACGAATTTCCGTTATTGTTTCCCATTT  573 
 
WT     25657  GGAAGACCTGAAGGCGCACTTAAAGGGACATTAGGTCTATTGGAAAGAGTTTTGATGAAG  25716 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT834  572    GGAAGACCTGAAGGCGCACTTAAAGGGACATTAGGTCTATTGGAAAGAGTTTTGATGAAG  513 
 
WT     25717  GATGTTGTGTCGCCAGTTCCACCGGAAGAAGTTCGAGCAGTTATTAGAAAATGTTTGGAG  25776 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT834  512    GATGTTGTGTCGCCAGTTCCACCGGAAGAAGTTCGAGCAGTTATTAGAAAATGTTTGGAG  453 
 
WT     25777  GATGCTGCATTGGTTAATTACACAAGGATTTGCAATGAAGCAAAGATTGAACGTTAGTTT  25836 
              ||||||| |||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT834  452    GATGCTGTATTGGTTAATTACACAAGGATTTGCAATGAAGCAAAGATTGAACGTTAGTTT  393 
 
WT     25837  CATTCGAATTGGAGTTGCTATGGGTGCCGACCAATGAGCAGTGCGGGAGGGGGCGTGGCT  25896 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT834  392    CATTCGAATTGGAGTTGCTATGGGTGCCGACCAATGAGCAGTGCGGGAGGGGGCGTGGCT  333 
 
WT     25897  AGATGTTCTGATTGGTCAGTTGCGCGGCAATTTGAAATTGAACTATGTAGTTTCGATTTT  25956 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT834  332    AGATGTTCTGATTGGTCAGTTGCGCGGCAATTTGAAATTGAACTATGTAGTTTCGATTTT  273 
 
WT     25957  GGAAGAAAAGTTTCAAATAAGAGAAATTGAACTTTCCTGTCTAATTCTTTTAAAATACAG  26016 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT834  272    GGAAGAAAAGTTTCAAATAAGAGAAATTGAACTTTCCTGTCTAATTCTTTTAAAATACAG  213 
 
WT     26017  TACTGAAATATGGAAAATTTGTGAAATTAATTAGATTATGTAGACACAAAATGTCTGCCT  26076 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT834  212    TACTGAAATATGGAAAATTTGTGAAATTAATTAGATTATGTAGACACAAAATGTCTGCCT  153 
 
WT     26077  AGTGTACCTACTTCAAAATCATAAGAGAACATTTTTGGTGTCGCGAAACCCAGGAACTGT  26136 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT834  152    AGTGTACCTACTTCAAAATCATAAGAGAACATTTTTGGTGTCGCGAAACCCAGGAACTGT  93 
 
WT     26137  CGGCCGCTTCGAAGCACCCTCTCAGGTGCTTCACTAGTCCTACTCAAAAATGCAGACAGA  26196 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT834  92     CGGCCGCTTCGAAGCACCCTCTCAGGTGCTTCACTAGTCCTACTCAAAAATGCAGACAGA  33 
Figure 3-20 Mutant QT834 (nz110) contains a mutated version 
of unc-31
Sanger sequencing of genomic DNA from QT834 confirmed a mutation in the unc-31 gene giving 
rise to a mutated codon (red lettering) compared to the wild-type sequence (blue lettering).  The 
single nucleotide change is indicated by the red arrow.
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WT     63    AGTAAGTCTGAATCGTAAGAAAACCTATAGCAGATTATTTTAGTTCGGAGGATCTGAAGC  122 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT677  2709  AGTAAGTCTGAATCGTAAGAAAACCTATAGCAGATTATTTTAGTTCGGAGGATCTGAAGC  2768 
 
WT     123   TATCATCACCGGCCTTTCAGATGAATTTCCAATATTGAAAAAGAACAGAGAAGTGTTCGT  182 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT677  2769  TATCATCACCGGCCTTTCAGATGAATTTCCAATATTGAAAAAGAACAGAGAAGTGTTCGT  2828 
 
WT     183   TGGTTGTTTGTTTGCTTTTTACATGGTAATTGGAATTGCTATGTGTACAGAGGTAACCTT  242 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT677  2829  TGGTTGTTTGTTTGCTTTTTACATGGTAATTGGAATTGCTATGTGTACAGAGGTAACCTT  2888 
 
WT     243   TTCACCGAAAACTATCTTCATCAAAAATTTTTGAAGGGTGGAATTCTAATCATGGAATGG  302 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT677  2889  TTCACCGAAAACTATCTTCATCAAAAATTTTTGAAGGGTGGAATTCTAATCATGGAATGG  2948 
 
WT     303   CTCATCATCTATGGAACTACATGGGGCTTATTGATTGCAGTGTTCTGTGAAGCAATGGTC  362 
             |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||| 
QT677  2949  CTCATCATCTATGGAACTACATAGGGCTTATTGATTGCAGTGTTCTGTGAAGCAATGGTC  3008 
 
WT     363   ATTGCATACATCTACGGTAGGTGTGCTCTGAATCTCAAAATTTCCAAAATTTCACAGGTC  422 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT677  3009  ATTGCATACATCTACGGTAGGTGTGCTCTGAATCTCAAAATTTCCAAAATTTCACAGGTC  3068 
 
WT    423   TGCGACAATTTGTTCATGACGTCAAAGAGATGATGGGATTCCGCCCGGGAAATTATTGGA  482 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT677  3069  TGCGACAATTTGTTCATGACGTCAAAGAGATGATGGGATTCCGCCCGGGAAATTATTGGA  3128 
 
WT     483   AGTTTTGCTGGAGCTGTGCCGCACCATTCATTTTATTGGTAAGAGTCTGGTTTTTGGCGC  542 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT677  3129  AGTTTTGCTGGAGCTGTGCCGCACCATTCATTTTATTGGTAAGAGTCTGGTTTTTGGCGC  3188 
 
WT     543   CAACTGCGTTGGCCCAAACTTTTCAAGTGTCGTTTTGAATTTGCACCAGAACTTGACAAA  602 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT677  3189  CAACTGCGTTGGCCCAAACTTTTCAAGTGTCGTTTTGAATTTGCACCAGAACTTGACAAA  3248 
 
WT     603   AAATGGATCACACTTGATTCAAACTTGGCGCTTTTAACAACATTTGCACTCACAAACTTT  662 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT677  3249  AAATGGATCACACTTGATTCAAACTTGGCGCTTTTAACAACATTTGCACTCACAAACTTT  3308 
 
WT     663   TTATTAAAAAATAAATTTTACATCTTTTCCAATAGGAAGGTGTGGCAATTTTCTATATGT  722 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT677  3309  TTATTAAAAAATAAATTTTACATCTTTTCCAATAGGAAGGTGTGGCAATTTTCTATATGT  3368 
 
WT     723   AGCGGAAAAAGTATTTACAACATCATCCAACATGACCAAATTACCAATATTCCAGTCGAT  782 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
QT677  3369  AGCGGAAAAAGTATTTACAACATCATCCAACATGACCAAATTACCAATATTCCAGTCGAT  3428 
 
Figure 3-21 Mutant QT677 (nz99) contains a premature stop 
codon in dat-1
Sanger sequencing of genomic DNA from QT677 confirmed a mutation is introduced into the 
dat-1 gene in QT677.  The mutation introduces a premature STOP codon (red lettering) with the 
single nucleotide change indicated by the red arrow.  
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Figure 3-22 Detailed analysis of chromosome II mutations from 
QT788 (nz97)
Analysis of the distribution of mutations in QT788 highlighted a concentration of mutations on 
Chromosome II.  Here that distribution is shown in more detail.  There are two peaks of mutation 
frequency around 6 and 11mb along the chromosome.  These have been overlayed with details 
of those mutations capable of causing protein-coding changes.  This analysis suggests that 
one of these 8 mutations may be responsible for suppressing the loopy phenotype of nRHO-1*. 
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3.14 - Discussion
3.14.1 - Screening
The overall aim of the screen was to identify novel downstream targets of RHO-1 which 
regulates neurotransmitter release in C. elegans.  We chose the loopy locomotion 
phenotype of our nRHO-1* animals as a marker, as it is distinct from wild-type locomotion 
and can be observed without special equipment (i.e. does not require high power 
microscopy or UV light) or use of drugs, e.g. aldicarb.  We considered screening for 
animals which suppressed the the alidcarb hypersensitivity of nRHO-1*, but decided 
against this primarily to avoid repeating the ric (resistant to aldicarb) screens performed 
by other labs (Miller, Alfonso et al. 1996).  (A summer student tried a pilot screen using 
aldicarb resistance, but obtained a high number of false positive results).  
Screening on locomotion produced a very large number of candidates (835 mutants from 
2000 haploid genomes screened), but many of these suppressor mutants either died, 
were sterile, or did not appear to be suppressed on further examination. 
At a concentration of 50mM, EMS is predicted to mutate G/C bases to A/T bases (the 
most common EMS-induced mutation) at a rate of 7x10-6 per G/C base, and to introduce 
loss-of-function or reduction-of-function mutations into the average-sized gene at a rate 
of 1x10-4 to 5x10-4 per mutagenised gamete (Anderson 1995).  This rate was estimated 
by Sydney Brenner based on his original screen for mutant phenotypes, (Brenner 1974), 
and has been reinforced by a large number of other screens (for review see (Jorgensen 
and Mango 2002)).  Together these studies estimate that to identify a mutation in any given 
average-sized gene (of around 10kb), it would be necessary to screen approximately 
2000 animals.  
Subsequent investigation using whole genome sequencing, analysing unbackcrossed 
mutants, has given us the most direct examination of the effects of EMS mutagenesis in 
C. elegans (Sarin, Bertrand et al. 2010).  These experiments estimate a slightly higher 
mutational frequency of 1x10-5 per G/C base, and a broader specificity for mutations, 
with 66% of detected mutations creating G/C to A/T transitions, although it is not clear 
whether non G/C to A/T mutations were introduced by EMS or whether they represent 
spontaneous mutations; other studies report a relationship closer to the standard G/C to 
A/T bias of EMS (Flibotte, Edgley et al. 2010).  These studies also identified a significant 
bias for mutations to be introduced into gene rich regions on the arms of the C. elegans 
chromosomes (Sarin, Bertrand et al. 2010).  This more detailed examination predicts a 
loss-of-function mutation rate similar to that of Brenner’s original paper (Sarin, Bertrand 
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et al. 2010).  These studies also reveal the presence large number of spontaneous 
mutations in any given laboratory strain, and while many of these are removed by 
backcrossing, the process of crossing itself introduces fresh mutations (Sarin, Bertrand 
et al. 2010).
Based on this data, our screen, of 1930 haploid genomes, is potentially large enough 
to hit every average-sized gene in the genome once.  Our primary round of screening 
identified 116 suppressor mutants, which strongly suggests, given the small size of the 
screen, that there are a large number of RHO-1 suppressor mutations.  
One of our identified mutants, nz94, has a fainter phenotype which allowed us to identify 
it as an allele of unc-80 (see Chapter 4), a gene with 10,000 coding bases, approximately 
five times larger than the ‘average-sized’ gene.  We identified another mutant with this 
fainting phenotype, nz98 (which may have derived from the same original mutated animal) 
but did not obtain any other ‘fainter’ mutants.  As another large gene, unc-79, also gives 
rise to a fainting phenotype, this suggests that our screen is far from saturated, and that 
further screening will identify additional alleles and additional suppressor genes.  To 
conduct an even larger scale screen, we could adapt the dispersal assay, (which will be 
discussed in Section 4.4) to remove the subjective element from our screening.  Briefly, 
animals would be placed in the centre of a large NGM plate, without food, and allowed 
to migrate to food at the edges of the plate.  nRHO-1* worms are severly impaired in 
this behaviour, and no nRHO-1* animals reach the food within 2 hours (Figure 4-7); we 
could therefore select suppressors from those animals which are able to reach food at 
this time point.  
Nonetheless, our primary round of screening identified 116 suppressor mutants.  While 
this justified our decision to screen based on locomotion, it also raised questions of 
whether the control of locomotion is too complex a phenotype to allow isolations of 
suppressors which specifically interact with our nRHO-1* transgene, as opposed to 
having some gross reduction in locomotion activity.  We addressed these concerns in a 
number of ways, discussed in the following sections.
3.14.2 - Suppressor screening identifies animals which move 
in a wild-type fashion
One advantage of the design of a suppressor screen is that we were trying to identify 
animals that look and move in a more wild-type manner than our starting strain.  There 
are indeed many potential mutations to reduce the rate of locomotion which could act 
independently of RHO-1 regulation – for instance, mutations in SNARE complex genes, 
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such as syntaxin (unc-64) will block neurotransmitter release and should suppress 
locomotion phenotypes.  However, these animals are either highly lethargic or the 
mutations are lethal (Saifee, Wei et al. 1998).  Lethargic movement is as distinct from 
wild-type locomotion as loopy behaviour is, so by focussing on animals which move 
with wild-type locomotion we should avoid mutations in the core release machinery, for 
instance.  This is not a perfect solution, as weak hypomorphs of unc-64 , for example, may 
be sufficient to reduce neurotransmitter release without lethality or excessive lethargy. 
We identfied and retained two lethargic mutants - nz94 and nz98 - and the nature of these 
mutations and their relationship to RHO-1 will be explored in Chapter 4.  The remaining 
mutants isolated in the screen had essentially wild-type locomotion, and the quality of 
this locomotion tended to improve where we were able to backcross the mutants.  
3.14.3 - Levamisole analysis demonstrates we have isolated 
a number of mutants with wild-type post-synaptic responses
If high levels of acetylcholine release are responsible for loopy locomotion, we 
predict another class of indirect suppressors are mutations which alter the body wall 
muscle sensitivity to acetylcholine.  We use levamisole, which directly stimulates the 
acetylcholine receptors on the body wall muscles, to test the muscle activity.  From 
the mutants examined so far, four of eight displayed wild-type responses to levamisole 
(Figure 3-14), while one was hypersensitive to levamisole (Figure 3-15), suggesting that 
a post-synaptic change in the response to acetylcholine is unlikely to be responsible 
for suppression in these strains, although these results are from a mixture of partially 
backcrossed and unbackcrossed animals, and so firm conclusions cannot yet be drawn. 
Three other strains demonstrate resistance to levamisole (Figure 3-15), but these 
animals continue to display hypersensitivity to aldicarb, suggesting that both pre- and 
post-synaptic signalling is being disrupted in these mutants.  This analysis demonstrates 
that a simple model of post-synaptic suppression, whereby the muscles are less sensitive 
to acetylcholine, is unlikely, but further experiments are needed to confirm this.
3.14.4 - Screening for locomotion produces mutants with a 
range of aldicarb phenotypes
As previously mentioned, we were concerned that a screen for suppression of the aldicarb 
response to nRHO-1* would mainly identify genes where mutations cause resistance to 
aldicarb, either indirectly or through processes already characterised.  
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We have subsequently assayed the aldicarb sensitivity of a number of our mutants, and 
have seen a wide range of phenotypes, from those which appear to completely suppress 
the aldicarb phenotype of nRHO-1* mutants, those intermediate between nRHO-1* and 
WT, or completely unsuppressed, and even some more sensitive to aldicarb than the 
starting strain in both the acute assays (Figures 3-5, 3-9, 3-10, 3-11 and 3-12).  This 
indicates that the high levels of acetylcholine release do not correlate directly with loopy 
locomotion.  We do not as yet have evidence for a class of loopy, aldicarb-resistant 
animals.  The lack of this class suggests that while high levels of release do not generate 
loopy behaviour, loopy behaviour may either require high levels of release for sufficiently 
exagerated body bends to occur, or may in fact induce high levels of release through 
some feedback mechanism involving the putatitive motor neurons stretch receptors.  
Figure 3-23 RHO-1 independently regulates acetylcholine 
release and loopy locomotion
We identified a large number of mutants which, despite being non-loopy, have high levels of 
acetylcholine release.  This suggests that RHO-1 independently regulates these two phenotypes. 
However, we have yet to identify a loopy animal which is resistant to aldicarb, suggesting that 
these two aspects remain linked.  
RHO-1 
(RhoA)
PIP2 DAG PA
DGK-1 
(DAG Kinase)
UNC-13
(munc13)
Acetylcholine release
Muscle contraction
Loopy locomotion
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While there is an overlap between the group of mutants which are non-loopy and are 
suppressed for the aldicarb hypersensitivity of nRHO-1*, screening on aldicarb sensitivity 
alone would have been likely to miss the range of other mutations capable of suppressing 
loopy locomotion, confirming our choice of loopy locomotion as a phenotype to study in 
our primary screen.  
3.14.5 - Secondary Screening
The presence of a heatshock transgene in our starting strain allowed us to ensure that 
the mutations we had isolated suppressed the activity of RHO-1 from two separate 
transgene.  Transgenes, even those which are integrated into the genome, are prone to 
silencing because of their highly repetitive nature.  The nRHO-1* transgene contains a 
GFP marker, and silencing of the entire transgene would lead to loss of GFP expression; 
we therefore verified using a UV dissecting microscope that our suppressor mutants 
displayed GFP expression.  
However, it is possible that a reduction in the activity of the transgene might leave GFP 
expression relatively unaffected while reducing the activity of RHO-1 to a level below that 
required for loopy locomotion.  Activating the second transgene and increasing RHO-1* 
levels in the nervous system as well as all other tissues by means of heatshock provided 
a good secondary test for true suppressor mutants.  
3.14.5.1 - hsRHO-1* induces a number of phenotypes in 
many of the suppressor mutants
It is possible that both transgenes could be silenced (although this situation would require 
reduction in RHO-1 activity but retention of GFP expression in both instances), in which 
case the animals will always look non-loopy, even after the induction of heatshock. 
However, heatshock-activated RHO-1* generates a number of additional phenotypes, 
including sterility (McMullan and Nurrish, 2011).  This phenotype persists in over half 
of the mutants which we maintained from the screen (Groups 1 and 2, Table 3-1), 
suggesting that the heatshock transgene is functional and they are truly suppressing the 
loopy locomotion generated by RHO-1*.  
A substantial proportion of the mutants we maintained, those in Group 3, are non-loopy 
and non-sterile (although this non-sterility designation still includes animals which have a 
low brood size, and grow more slowly than the starting strain.)  This group of suppressors 
is the most likely to represent loss of activity in both transgenes, or potentially loss of 
activity of the heatshock response itself, such as mutations in hsf-1.
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Group 3 may also contain more general suppressors of RHO-1, able to suppress both 
loopy locomotion (which as a neuronal origin) and sterility (which may not have).  While 
not the phenotype we originally set out to detect, this suppression of the sterility induced 
by heatshock activation of RHO-1* is an interesting observation and these mutants may 
provide a source for further examining this phenotype of RHO-1.  
As described in Section 3-6, a number of mutants which suppress the locomotion 
phenotype fail to suppress the reported hsRHO-1* effects on slowing pharangyl pumping 
and lengthening the defection cycle (McMullan and Nurrish, 2011).  However, there 
is a range of suppression of these phenotypes and mutants classed as Group 2 and 
Group 3 (Table 3-1) may prove an interesting source for separating out pathways which 
act downstream of RHO-1* in different tissues.  We also examined the dar phenotype 
following heatshock and found that the majority of the mutants tested display this 
phenotype (Figure 3-13, and Appendix 1), suggesting tail swelling acts through a different 
pathway to loopy locomotion behaviour.  nz106 suppresses the dar phenotype (Figure 
3-13) and therefore is worth further investigation as it may represent a more general 
RHO-1* suppressor, while nz107, nz108, nz109 and nz111 suppress all heatshock RHO-
1* phenotypes except tail swelling (Table 3-1 and Figure 3-13), and therefore might form 
the basis for an enhancer screen. 
While we see a range of phenotypes across our identified suppressor mutants, from 
suppression of almost all RHO-1* phenotypes except tail swelling to animals which 
suppress only loopy locomotion, we cannot rule out that some of this diversity arises from 
second site mutations not directly connected to the suppression of loopy locomotion. 
Further backcrossing, identification of the causal mutations and rescue experiments will 
be required to confirm these intial observations.   
3.14.6 - Backcrossing mutants was complicated by poor 
mating efficiency
Of the mutants selected, a number originate from the same plate, meaning they could 
be carrying the same mutation.  Plate 1 gave rise to nz92 and nz97, plate 4 to nz94 
and nz98, plate A to nz104, nz105 and nz110, plate D to nz106 and nz111 and plate L 
to nz107, nz108 and nz109 (Table 3-1).  If we assume that all mutants from the same 
plate represent the same mutation (which is a conservative estimate) we are left with 11 
separate mutations.  Even where animals have been obtained from the same plate we 
see some differences in our assays; most likely this represents behavioural variation, or 
additional background mutations. 
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The genome of lab strains, particularly following mutagenesis and even after backcrossing, 
is considerably more ‘dirty’ than previously imagined, calling into question whether we 
can really talk about the effects of single mutations, or whether we have to consider the 
entire genetic background of a mutant (Sarin, Bertrand et al. 2010).  Based on whole 
genome sequencing, backcrossing has been shown to be effective at reducing the 
mutational load (Flibotte, Edgley et al. 2010; Sarin, Bertrand et al. 2010), although it also 
creates the opportunity for the introduction of fresh mutations, presumably introduced 
during meiosis or by spontaneous mutagenesis during DNA replication.  
Given the need to reduce the background load of mutations, we undertook to backcross 
our mutant strains.  To enable us to follow the first cross more easily, we used a 
strain which produces a high incidence of males (him-5) carrying only the nRHO-1* 
transgene and lacking the hsRHO-1* transgene (QT733), and crossed them with our 
suppressor animals.  These are marked with unc-122::gfp which expresses GFP in 
the coelomocytes,.  In the F1 generation, the animals should be loopy (because the 
suppressor is now heterozygous, and none of the suppressors demonstrated an obvious 
dominant phenotype because we saw no suppression in the first generation of the 
screening process (Figure 3-2), and the nzIs1 transgene will be retained on only one 
chromosome.  The nzIs29 transgene remains homozygous during the cross.  
We let these F1 animals self-fertilise, and looked for non-loopy animals in the F2 
generation, where the suppressor is now homozygous, and is able to suppress the 
loopy locomotion of the nzIs29 transgene.  To ensure that these animals had definitely 
undergone one round of backcrossing, we looked for F2 animals that had lost the ttx-
3::gfp marker of the hsRHO-1* transgene but retained the unc-122::gfp marker of the 
nRHO-1*.  In some instances we found backcrossed animals that had acquired the him-5 
mutation.  We used males from these lines to cross into strain QT309, which carries the 
nRHO-1* transgene without the him-5 mutation.  
On reflection, this loss of the hsRHO-1 transgene was unfortunate.  Even after the initial 
screening the heatshock RHO-1* would have been a useful tool to have retained in these 
strains.  It would have been better to either cross only with starting strain (QT631) and 
follow suppression by heatshock, and then reintroduce nRHO-1* as necessary.
Animals carrying nRHO-1* tend to grow more slowly than wild-type animals and mate 
less efficiently, and this effect is compounded when the strains also carry hsRHO-1*.  This 
made the process of backcrossing more difficult than expected.  While we did manage 
to backcross a number of the mutants (e.g. nz110 in QT834 is 3 times backcrossed) the 
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success varied from strain to strain and limited which mutants we were able to analyse 
in more detail.  
One step which might improve the efficiency of analysis of these mutants would be to 
cross them all with wild-type males and look for additional phenotypes in the absence of 
the nRHO-1* transgene.  These animals could be crossed again with nRHO-1* to ensure 
that the additional mutation is linked to the suppressive effect, and then backcrossing 
could be conducted in the absence of the transgene.  Another approach would be to cross 
our strains with a non-integrated nRHO-1* transgene, follow the suppressor mutation in 
animals carrying the extrachromosomal array, and examine animals which have lost the 
array for any additional phenotypes.  As already mentioned, nz94 and nz98 displayed an 
additional phenotype allowing faster identification of the suppressive allele (Chapter 4).  
3.14.7 - Putting suppressor mutations into complementation 
groups 
This difficulty in crossing strains carrying the nRHO-1* transgene has so far prevented 
us from establishing complementation groups to establish whether different mutants 
represent alleles of the same gene, by looking for crosses which continue to suppress the 
loopy phenotype (although there are rare examples of non-allelic non-complementation 
in the nervous system which could complicate this process (Yook, Proux et al., 2001)
Having yet to perform this analysis we do not know how many different genes we have 
isolated in our screen.  This is why the classification and grouping based on locomotion, 
sterility and aldicarb assays are important to try to distinguish between our mutants, 
although different alleles of the same gene may cause different phenotypes.  In addition, 
where mutants derive from the same original plate we consider that these may contain 
the same mutation, until otherwise shown.  Due to these technical difficulties, we chose 
to use the technique of whole genome sequencing (WGS) as a way of identifying 
suppressor mutants.  
3.14.7.1 - Choosing mutants for whole genome 
sequencing
When we sent three mutants for whole genome sequencing, we used several methods 
in the hope of finding distinct suppressor mutants.  We chose mutants which came from 
different original plates, so that they must have been mutations introduced into different 
animals, itself reducing the probability that they are in the same gene or, at the very least, 
by the laws of probability, that they are the same mutation.  
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Next, we chose mutants which had some distinct levels of behaviour in our tests. 
nz97 and nz99 were both Group 1 mutants, whereas nz110 is in Group 2 (not entirely 
suppressing the locomotion phenotype of hsRHO-1*).  
However, it is still possible that these suppressors could all represent mutations in the 
same gene.  During the analysis of the whole genome sequencing data, we were careful 
to only count as background those mutations which are identical both in position and in 
the nature of the predicted mutation (i.e. Chromosome I, base 204567 A-T) in at least 
two strains.  Although not impossible, it is highly unlikely that we have isolated exactly 
the same mutation from two independent strains.  Therefore, even if the mutations are 
allelic, we should still have the capacity to detect them from our analysis.  
3.14.7.2 - Whole Genome Sequencing without positional 
information
We were able to take advantage of this relatively new technique in our attempt to identify 
the nature of three of our suppressor mutants.  As detailed above, these were chosen 
without detailed knowledge of their genetic position or the nature of the mutations. 
Should data from whole genome sequencing prove inconclusive, additional rounds of 
conventional mapping (Snip/SNP mapping and complementation analysis) could be used 
subsequently to filter the data.  In this way, we felt we were able to test the current limits 
of the technology, to ask the question: is it possible to identify the nature of a suppressor 
mutation simply by looking at high-resolution data representing the entire genome?
Papers published using this technique (Sarin, Prabhu et al. 2008; Shen, Sarin et al. 
2008) suggest that although the total number of mutations introduced into a genome by 
EMS mutagenesis is very high, the number of mutations which change a protein-coding 
sequence represent a small proportion of that total.  The number that introduce premature 
stop codons, a common source of strong mutations, is even lower.  We reasoned that 
it might be possible to produce a list of potential mutants, numbering around 50 to 100, 
and then inject pools of fosmids or cosmids covering those regions to look for rescue. 
Therefore we might be able to determine the suppressor mutant phenotypes without any 
conventional mapping.  Mutations occuring in non-coding DNA or in miRNAs can also 
be identified from WGS, but might require more positional information to identify causal 
mutations.  
We included one mutant which was entirely unbackcrossed.  A recent paper investigated 
the effectiveness of backcrossing mutants, and found that while the first few rounds of 
backcrossing are able to remove a percentage of extraneous mutations, subsequent 
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crosses are less successful, because they allow the introduction of new mutations 
(Sarin, Bertrand et al. 2010).  The source of these mutations is not entirely clear, and 
may be due to a low level of mutagenesis from the environment, or from inefficient DNA 
repair mechanisms involved in chromosome segregation and meiosis.  Nonetheless, 
backcrossing does reduce the mutational load of an individual genome, but we wanted to 
test a completely unbackcrossed mutant   We would always have the option of performing 
those backcrosses, identifying a degree of positional information, and returning to the 
whole genome data for that region.  We see this workflow as being very fluid, even to 
the extent that, should a mutation fall in a region of low coverage, it would be possible to 
send further samples of the original genomic DNA, and having these sequenced.  The 
data from the sequencing is in the form of short reads which are additive; more data can 
be obtained at any time.
3.14.7.3 - Geneservice bioinformatics analysis was 
unreliable 
Our initial work centred around the analysis of the data sent to us by Geneservice.  This 
included the raw output from the sequencing machines, the same data but formatted 
and filtered by quality into FASTQ files (the short read format as mentioned above), and 
a final run of this data through the program MAQ.  This final level of analysis was limited 
in its usefulness as we did not have the details of parameters used, and although it 
identified numerous mutations across the genome, we had no biological information on 
the potential changes to protein coding genes which we were hoping to use to filter the 
data.  
We used custom equations in Excel in an attempt to map the mutations back onto the 
genome and assign biologically relevant details to our data.  This was conducted in 
most detail for mutant QT834, but attempts to confirm one predicted mutation in cbp-1 
suggested that the GeneService bioinformatics analysis was unreliable.  
3.14.7.4 - MAQGene provides a user-friendly platform 
for whole genome sequence analysis
As detailed in the results, we set up the program MAQGene, developed by the Hobert 
lab for analysis of whole genome sequencing data (Bigelow, Doitsidou et al. 2009).  This 
program uses the Apache server to link the short read files, the MAQ program itself, and a 
MYSQL database containing the annotations of the C. elegans genome.  It allows a user 
to run MAQ from webpage-style interface, to easily re-run using different parameters, 
and to extract biologically useful information.
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There are errors in the prediction software, however; a predicted coding change in QT788, 
AAT->AAA (asparagnine to lysine in the gene mpz-1) actually occurs in an intron of MPZ-
1.  This highlights the need to use the most up-to-date genome data from WormBase, as 
well as the need to manually confirm and sequence potential candidates.  
3.14.7.5 - Comparision between data generated in this 
thesis and published whole genome sequencing mutants
The most complete analysis published of whole genome sequencing data obtained from 
mutants exposed to EMS is found in data from the Hobert lab (Sarin, Bertrand et al. 
2010), where 14 mutants are analysed.  These range from unbackcrossed strains to 
strains which have been backcrossed 10 times.  They found that backcrossing reduces 
the mutational load, but that even backcrossed mutants have a high number of protein 
coding changes in their genome, ranging from 24 to 96 per genome.  
We compared our data with this published data set (Table 3-6).  The total number of 
mutations, including background and EMS-induced mutations, is on average twice 
as high in our strains as in those publised by the Hobert lab (p<0.001).  The number 
of mutations which can be attributed to EMS mutagenesis is also twice that seen in 
the published data (1307.25 compared with 610.9, p<0.05).  While significantly higher 
than the average, our data do fit within the range of mutations seen in the Hobert data, 
however, where mutants contain from 324 to 3746 mutations per strain.
We consider three potential reasons why our mutational load is higher on average than 
those of the strains in the Hobert lab.  Firstly, different lab strains of wild-type animals 
may contain different numbers of mutations due to genetic drift, estimated at around 40 
unique mutations introduced spontaneously over 200 generations (Denver, Dolan et al. 
2009).  We may be observing a laboratory-specific difference in rates of mutation in our 
data.  This could account for some of the increase in mutation rate across all four strains.
Secondly, our mutagenesis procedure may dffer subtly from that used in the Hobert lab, 
such that the animals are exposed to a higher concentration of EMS (although we also 
see a higher than average mutation rate in QT317 which was generated independently 
of the others by exposure to UV/TMP).  This would account for an increased number of 
mutations that are non-background. i.e. specific to each strain.  Mutations introduced by 
or linked to the integration of the nzIs29 transgene should be eliminated as background 
mutations and not increase the number of EMS induced mutations as they would likely 
occur in more than one strain.  
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Thirdly, as the number of mutants sequenced increases, the number of mutations which 
can be classified as background also increases.  Were we to sequence additional 
mutants isolated from the screen we would be likely to see a reduction in the predicted 
mutagen-induced mutations.  
Despite the increase in the total number of coding changes induced by EMS in our 
strains compared with the Hobert lab data, the average number of protein coding 
changes induced by EMS is consistent with the published data (54 compared with 62, 
p>0.05).  This could be due to a filtering effect of the probability of hitting a protein-coding 
region which means that more than a two-fold increase in total mutations is required to 
significantly increase the number of protein-coding changes, or it could indicate that 
our nRHO-1* animals are less tolerant of protein-coding changes than the genetic 
backgrounds used in the Hobert lab.    
3.14.7.6 - WGS identified only a single premature STOP 
codon in four separate mutants
We anticipated identifying causative mutations through WGS without backcrossing or 
mapping because the predicted number of protein-coding mutations in a single animal is 
low enough to be able to manually sort through and identify candidate mutations, and the 
number of severe mutations (including premature STOP codons) is even lower (Sarin, 
Bertrand et al. 2010).
However, in our mutants, we found only a single premature STOP codon in all three 
nRHO-1* mutants sequenced, and none in strain QT317 (generated by UV/TMP).  We 
wondered whether this could be an indication of the intolerance of nRHO-1* mutants 
for severe mutations.  However, in the data for mutants from the Hobert lab (Sarin, 
Bertrand et al. 2010), 8 out of 14 mutants have either zero or one premature STOP 
codon generated by EMS, so our data is consistent with this range.
3.14.7.7 - MAQ, the underlying program for MAQGene, 
cannot successfully combine reads of varying lengths
One issue we faced when running this data ourselves was that the Geneservice data 
included reads of varying lengths (36, 55 and 76bps).  This raises a problem when 
attempting to use the program MAQ for analysis.  MAQ, and hence MAQGene, which 
uses MAQ as part of its programming, uses a number of variables for assessing whether 
a read is a good match for the genome.  These include the number of mismatches in the 
first 28 bases (usually set to 2), and the total number of mismatches across the length 
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of the read.  However, assuming a constant level of mis-reading within the sequencing 
machinery, the number of bases which misalign to the genome because of sequencing 
errors will be higher in a 76bp fragment than a 36bp fragment.  However, MAQ does not 
take into account the read length; the number of mismatches is fixed at the start of the 
run.
What this means in practice is that if the number of mismatches is set to a low threshold, 
then 76bp reads will be unnecessarily discounted, while the 36bp reads will have an 
appropriate level of thresholding.  However, if the threshold is set higher, to allow more 
76bp reads to be incorporated successfully, error-ridden 36bp reads will now be allowed 
through.  
Without fundamentally changing the code within MAQ, it is not possible to fully optimise 
this approach for different length reads.  In previous studies, the read length for each 
mutant tends to be constant, and there is some debate as to whether long read lengths 
significantly improve the ability to find SNPs.  Given that cyclical workflow discussed 
earlier, it would certainly be helpful if these parameters in MAQ were made more flexible. 
Longer reads give a much higher degree of certainty in positioning, and are especially 
useful for predicting deletions.  In the future, we may wish to add additional sequence 
to our mutants, and at that stage 152bp reads may be viable.  Ideally we would like to 
be able to combine all of our data into one run and have these variables adjust to the 
specific inputs.
In the absence of such a system, we have tended to rely on setting low thresholds, and 
only counting long reads with few errors.  It is interesting to note that the unc-31 mutation 
predicted in QT834(nz110) is not seen if the thresholds are set higher, suggesting that 
erroneous 36bp data is now being allowed to affect the number of mutant/wild-type reads 
at that position.  
With respect to the data obtained from Geneservice, this too includes a mutation in unc-
31, however it is 1 base pair different from that predicted by MAQGene.  We believe 
there is a systematic error in the Geneservice data which means that the SNP predictions 
are misaligned by 1bp.  This could be because they used a different version of the C. 
elegans genome, or because of some error introduced during the analysis.  Taking this 
error into account, the Geneservice data appears to include the unc-31 mutation we see 
from our own analysis.  However, being unannotated, it was not spotted earlier.  
3.14.8 - Screening and analysis provide a platform for 
future work on targets of RHO-1
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During the course of this screen we have identified 20 mutants which suppress the loopy 
locomotion of the nRHO-1* transgene.  While later chapters contain detailed analysis of 
one of these mutants, we have obtained a large amount of data around the remaining 
animals, which will hopefully be of use in future experiments.  That data is collated here, 
along with candidate mutations where these have been identified.  
3.14.8.1 - QT834 (nz110) contains a mutation in unc-31 
(CAPS)
QT834 contains the suppressor mutation nz110, and has been backcrossed three times. 
These animals are highly suppressed for the loopy locomotion of nRHO-1*, and were 
identified as a top candidate by visual inspection (Appendix 1).  We can be confident 
that these are true suppressors of nRHO-1*, rather than being due to malfunction of the 
transgene, because these animals become sterile upon activation of hsRHO-1*, but still 
remain less loopy than unsuppressed hsRHO-1* animals (Table 3-1).  
These animals have high levels of neurotransmitter release, as measured by the aldicarb 
assay, and this level of neurotransmitter release has increased during backcrossing 
(Figure 3-9).  This suggests that in the unbackcrossed strain there is an additional mutation 
which partly suppresses aldicarb hypersensitivity, and may be of interest in its own right 
Allele
Total number of 
mutations
EMS 
Induced
EMS-induced 
proten coding 
changes
QT317 nz90 2369 843 16
QT677 nz99 2809 1278 42
QT788 nz97 2464 1608 115
QT834 nz110 3083 1500 44
Average 2681.25 1307.25 54.25
Sarin et al 2010 1022.4 610.9 62.4
Table 3-6 - Comparrison of WGS data to published data
We compared the data generated by sequencing our four mutant strains to the data published 
in Sarin et al, 2010, which lists the number of mutations identified in 14 EMS mutagenised 
strains.  We see that our total number of mutations is significantly higher than those in the 
published data (p<0.001).  The mutations attributable to EMS mutagenesis (as opposed to 
background mutations) is also higher on average than those in the Sarin data set (p<0.05).  The 
number of protein coding changes induced by EMS is within the range seen in the published 
data (p>0.05).  Significance was assessed using a 2-tailed T-test.   
169
if deemed suitable for future examination.  These animals are partially suppressed 
for their response to levamisole, which suggests that their post-synaptic response to 
acetylcholine is reduced (Figure 3-15).  Combined with their hypersensitivity to aldicarb 
this suggests that the level of neurotransmitter release in these animals is actually greater 
than in the starting strain, as the levamisole phenotype would normally mask the aldicarb 
hypersensitivity.  This also suggests that a simple model of reduction in neurotransmitter 
release sensitivity is insufficient to explain the suppression of locomotion.  
Further investigation using MAQGene failed to identify any strong suppressors (e.g. 
premature STOP codons, altered splice sites) (Appendix 2), while analysis of the 
distribution of SNPs did not give any clear indication of the potential location of the 
suppressor mutant.  We became interested in a mutation in unc-31 as a potential 
candidate, however; and sequenced this mutation to demonstrate it was present in 
QT834.  UNC-31 is required for the release of dense core vesicles and the neuropeptides 
they contain (Speese, Petrie et al. 2007), and it is possible that these neuropeptides may 
perform some modulatory function with respect to locomotion, and one that we detect the 
action of through our levamisole assay.  
A double nRHO-1*;unc-31(e928), the cannonical mutation of unc-31 also has non-loopy 
locomotion (R. McMullan, personal communication), indicating that loss of unc-31 activity 
is able to suppress loopy locomotion.  Interestingly, an unc-31 null mutation is able to 
suppress some of the increased locomotion phenotype of egl-30 (gain-of-function) 
mutants (Charlie, Schade et al, 2006), although the animals still have a tendancy to 
coil (Charlie, Schade et al, 2006).  egl-30 is a known activator of RHO-1 signalling in 
the nervous system.  In addition, the unc-31;egl-30 (gf) mutant still has high levels of 
acetylcholine release (Charlie, Schade et al, 2006), consistent with the results observed 
with the nz110 mutant.   
The predicted unc-31 mutation in nz110 generates only a small change in the coding 
sequence, replacing an alanine residue with valine (Figure 3-21).  However, this residue 
is at a conserved point when compared to CAPS homologues from other species, and 
is part of the MUNC-13 homology domain.  We expect this to be a weak hypomorph of 
unc-31, because the behaviour of the animals is distinct from previous mutations in this 
gene.  The mutant behaviour associated with unc-31 loss-of-function is for the animals 
to be paralysed while in the presence of food, but capable of wild-type locomotion in 
its absence.  Our animals, meanwhile, have a locomotion phenotype indistinguishable 
from wild-type.  This suggests however that we may have isolated a mutation which 
specifically blocks only a part of unc-31 function (Charlie, Schade et al, 2006).  
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Our working model is that unc-31 is the supressor of nRHO-1* in this strain.  Further to 
this work will be attempts to rescue the QT834 mutant with an wild-type copy of unc-31, 
either isolated as genomic DNA from by a fosmid or from a cDNA driven by a cell-specific 
promoter.  In preliminary rescue experiments with an unc-31 containing fosmid, 1 in 3 
lines were rescued for loopy locomotion.   We intend to generate an unc-31 cDNA which 
we can place under cell-specific promoters to determine the site of action of unc-31 with 
respect to RHO-1.
The mutation we have isolated in unc-31 appears relatively mild, and we will therefore 
introduce this mutation in the unc-31 cDNA, and test whether this mutant form of unc-31 
is able to rescue more severe mutations of unc-31.  
Should this hypothesis prove incorrect, it will be necessary to perform some positional 
mapping to reduce the potential number of protein coding suppressor mutants from 
its current level of 44, so that rescue experiments can be performed on the remaining 
candidates.  
3.14.8.2 - QT677 (nz99) contains a mutation in the 
dopamine reuptake transporter dat-1
QT677 contains the nz99 suppressor.  nz99 is placed in Group 1 as one of the strongest 
neuronal suppressors.  QT677 worms become sterile on activation of the hsRHO-1* 
transgene, demonstrating that the transgene is indeed active in this strain, and remains 
non-loopy.  This also shows specificity for suppressing neuronal activity of nRHO-1*.  
These animals also appear hypersensitive to aldicarb, in both the two time point and 
standard aldicarb assay.  This suggests that increased acetylcholine release does not 
necessarily give rise to loopy locomotion.  Understanding the additional requirements for 
loopy locomotion will be an important goal for future research.  
With this mutant we tested the full capacity of whole genome sequencing to establish 
the nature of an unbackcrossed mutation without standard positional information.  In an 
unbiased assessment of the mutations as provided by MAQGene, we detected 1278 
mutations, of which 42 caused changes in protein coding genes.  If fosmids covering 
each of these mutations were injected in pools of 5, it would only require a maximum of 
8 sets of injections to begin to look for rescue in this strain.  
However, we were also able to identify one strong suppressor candidate, a mutation in 
dat-1, the dopamine transporter.  While suppressor mutations do not have to severely 
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alter protein function, STOP codons are a common source of strong mutations.  This, 
coupled with the known roles for dopamine in locomotion, make this a good candidate.  
DAT-1 is a plasma membrane associated transporter, and part of the same family 
as the GABA transporter SNF-11 and the serotonin reuptake transporter MOD-5.  It 
is expressed in 8 dopaminergic neurons in adult hermaphrodites (Flames and Hobert 
2009).  Dopamine acts a neurohormone, regulating global behavioural states, and is 
important for behaviours such as slowing on food sources (Sawin, Ranganathan et al. 
2000; Chase, Pepper et al. 2004) and the frequency of turning behaviour (Hills, Brockie 
et al. 2004).  Transfer of dopamine via DAT-1 requires the movement of two sodium ions 
and one chloride ion, and it has been suggested that in addition to the ionic movement 
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Figure 3-24 Mutations in unc-31 suppress the loopy phenotype 
of nRHO-1*
We identified an unc-31 mutation in strain QT834, and subsequent evidence confirms that loss of 
unc-31 activity reduces the loopy locomotion of nRHO-1*, but retain high levels of acetylcholine 
release.  As unc-31 (CAPS) is responsbile for priming dense core vesicles, we suggest that 
neuropeptide signalling may be invovled in the generation of loopy locomotion.
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associated with transport, DAT-1 can act as a depolarising ion channel in its own right 
(Carvelli, McDonald et al. 2004).  
Loss of dat-1 reduces the reuptake of dopamine, increasing dopamine signalling which 
has the effect of slowing animals down and preventing vigorous motor activity (McDonald, 
Hardie et al. 2007).  This may indirectly reduce the loopy locomotion of nRHO-1* 
animals (Figure 3-25).  Interestingly, dat-1 mutants have defects in swimming behaviour, 
a phenotype we also observe in other suppressors of nRHO-1* loopy behaviour (see 
Chapters 4 and 5) . Alternatively, dat-1 mayb be acting as a ion channel, depolarising the 
presynaptic membrane and increasing neuronal activity (Carvelli, McDonald et al. 2004). 
If this action were regulated by RHO-1*, then increasing RHO-1 activity might lead to 
further increases in neuronal activity, generating loopy behaviour.  
Direct sequencing confirmed the presence of the mutation in dat-1, a critical step before 
rescue experiments are to be conducted (Figure 3-21).  We will now construct double 
mutants between nRHO-1* and cannonical dat-1 mutants, and attempt to rescue the dat-
1 mutation in QT677 by injection of fosmid DNA covering the dat-1 locus, as well as by 
injection of p.dat-1::DAT-1::GFP (a gift of the Blakely lab).  
Additionally, artificially increasing dopamine levels in these mutants may reduce loopy 
locomotion.  Preliminary experiments to treat nRHO-1* animals with dopamine suggest 
that this may be the case (S. Nurrish, personal communication.)  An alternative experiment 
would be to use cocaine treatment to inhibit the activity of the DAT-1 transporter in nRHO-
1* background to see whether this decreases loopy locomotion.  
3.14.8.3 - QT788 has a number of mutations which cluster 
on Chromosome II
QT788 contains suppressor nz97, which fully suppresses loopy locomotion while having 
no suppressive effect on sterility or pharyngeal pumping.  It is hypersensitive to aldicarb 
(Figure 3-5) in our initial analysis, but slightly suppresses the aldicarb sensitivity of nRHO-
1* (Figure 3-10).  It is completely wild-type in its response to levamisole (Figure 3-12).
We had some difficulty running the QT788 data using MAQGene.  For QT788 we 
obtained two runs of 76bp data, along with two runs of 36bp data.  When we loaded this 
into the computer using our standard parameters, the analysis failed to complete.  Only 
by omitting one set of 76bp data could we obtain a completed analysis.  The analysis in 
this thesis omits the QT788_76bp_B dataset; if in future the source of this malfunction 
can be identified then a more complete analysis can be performed.
173
Analysis of the distribution of SNPs was most successful for this mutant, as it identified 
a strong linkage to Chromosome II), and particularly to two regions on this chromosome. 
While evidence that the suppressor mutation is on Chromosome II requires additional 
study, the current evidence suggests that one of only 8 mutations which affect protein 
coding regions may be the suppressor mutation.  As these mutations are relatively close 
together on the chromosome, between two and four sets of fosmid injections could be 
performed to look for rescue of the loopy phenotype as a fast way to determine whether 
any of these are good candidate mutations.  Alternatively, we could perform RNAi of 
nRHO-1* mutants, taking advantage of the SID-1 strains developed by the Chalfie lab 
which enhance RNAi effects in the nervous system (Calixto et al., 2010).
The genes mutated in the high-frequency peaks on Chromosome II are:
• C2H3.4 - filamentous baseplate protein Ligatin
•	 fbf-1 - FEM-3 mRNA binding protein
• T19D12.9 - Permease of Na/PO4 transporter
•	 mec-15 - Fbox - ubiquitin ligase adaptor
• C07E3.4 - Protein tyrosine phosphatase
• M106.2 - Novel nematode protein
•	 egg-3 - alternative splicing factor / protein tyrosine phosphatase
• T06D8.1 - mucin-like cell surface protein
Of most immediate interest are the two protein phosphatases egg-3 and C07E.4, as 
these could conceivably be part of regulated signalling pathways downstream of 
RHO-1.  mec-15 mutants have a neuronal phenotype and are insensitive to gentle 
touch; mec-15 is required for specification of these neurons (Bounoutas, Zheng et al. 
2009).  It is conceivable that loopy locomotion could arrise from improper activation 
of mechanosensory pathways leading to repeated writhdrawl actions, and loss of 
mechanosensation might suppress this.  Ultimately rescue experiments will be required 
to identify the causative suppressor mutation.  
3.15 - Conclusions
3.15.1 - Additional screening of mutants is a powerful way of 
refining a screen
Only by screening for suppression of additional phenotypes generated by our hsRHO-1* 
transgene could we systematically hone our list of candidate suppressors.  This approach 
of using a second transgene under a separate promoter is recommended for future 
screens where appropriate, as it also reduces the probability of suppressors being purely 
due to reduced function of the original transgene.  
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3.15.2 - Aldicarb phenotype of suppressor mutants is not 
linked to their locomotive suppression
As previously discussed, while we chose to screen with reference to locomotion, once 
we had obtained our mutants we wanted to see whether these locomotion-suppressed 
mutants were also suppressed in their aldicarb phenotype.  
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Figure 3-25 A dat-1 mutation appears to suppress the loopy 
phenotype of nRHO-1*
We identified a premature STOP codon in dat-1, the gene encoding the dopamine reuptake 
transporter.  This suggests that high levels of dopamine signalling may be responsible for reducing 
loopy locomotion (Model 1).  The mutant, QT677, is hypersensitive to acetylcholine, suggesting 
that excess dopamine signalling does not reduce the effects of nRHO-1* on acetylcholine release. 
Alternatively, RHO-1 may stimulate DAT-1 to act as a depolarising ion channel (Model 2), and this 
may lead to increased loopy behaviour.  
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As we looked across the range of our 20 mutants, we saw some which were completely 
suppressed for aldicarb phenotype, and others which showed no change in aldicarb 
response. 
This is interesting because our original hypothesis about the locomotion phenotype was 
that it was caused by the excess release of acetylcholine onto the body wall muscles, 
causing hypercontraction and the appearance of a loopy or coiled posture.  
We favour a model where increased acetylcholine release is necessary, but not sufficient, 
for loopy locomotion . Consistent with this we have never observed a class of mutant with 
loopy locomotion which are wild-type in their response to aldicarb.  The unc-31 mutation 
suggests that at least one of the additional requirements is the release of neuropeptides. 
3.15.3 - Whole Genome Sequencing provides a powerful 
tool for mutant analysis
Using whole genome sequencing we have obtained a large amount of data on the nature 
of mutations in our suppressor mutants.  However, simply by looking at the raw data, and 
even with analysis of the distribution of SNPs following backcrossing, it is not possible 
to definitively identify the nature of the suppressor mutants.  Additional experiments are 
required, although these (injection of rescuing constructs) can be performed after only a 
few weeks of sequencing and analysis, rather than at the end of up to a year or more of 
conventional mapping.
Sequencing multiple mutants from a screen is an invaluable way of reducing the list of 
mutations by eliminating those which are common between animals.  Some of these will 
have been introduced through mutation in the lab, others occur as the result of sequencing 
errors from the system.  Those which occur as systematic errors, or sites which are 
commonly prone to mutation, could be stored in a shared database and systematically 
eliminated from, or at least highlighted in, any future analysis.  In all cases, mutations 
unrelated to the suppressor will be identified.  Although we are not interested in these 
mutations ourselves, it would be advantageous to the C. elegans research community to 
create a database to which details of these mutations could be uploaded and searched 
by other groups.  Ideally, this could be linked to the gene descriptions already present on 
Wormbase, but such a facility is not yet available.  
Backcrossing, while not essential for detecting mutations, does provide valuable linkage 
information for reducing the list of causative mutations.  While the mutation in dat-1 in 
QT677 may indeed prove to be the suppressor, it is fortuitous that the mutation introduced 
a STOP codon into this gene.  To successfully use this technique without further positional 
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information will require better prediction of the role of changes in miRNA, as well as the 
ability to predict in silico the effects of changes in promoter sequences and 3’ and 5’ 
UTRs of genes.  
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4 - UNC-80 ACTS DOWNSTREAM OF RHO-1 
IN THE C. ELEGANS NERVOUS SYSTEM
4.1 - Introduction
Our screen for suppressors of the loopy locomotion induced by overexpressing 
constitutively active RHO-1 (G14V) in the cholinergic motor neurons (nRHO-1*) 
identified over 800 mutants with more wild-type locomotion than our starting strain, 
which we classified as ‘less loopy’ or ‘not loopy’.  These mutants were examined for 
the maintenance of suppression over a number of generations, their ability to suppress 
a second, integrated heat-shock activated transgene (hsRHO-1*) and their level of 
suppression of non-neuronal RHO-1 phenotypes.  From this additional analysis we 
refined our original list of mutants to 20 strong suppressors, as detailed in Chapter 3.  
Included in this group of twenty suppressors were two mutants, derived from the same 
plate, which suppressed the loopy locomotion of the starting strain, producing animals 
without the exaggerated body bends associated with nRHO-1*, but which were also 
lethargic in their locomotion when compared to wild-type.  Our original aim for the screen 
was to identify mutants which moved with wild-type locomotion in an attempt to avoid 
isolating mutants in pathways which only indirectly suppressed the nRHO-1* transgene. 
The suppression of the body bend phenotype in these two strains - nz94 and nz98 - was 
strong enough for us to include them in our list of 20 strong suppressors, despite their 
lethargic locomotion.  The initial characterisation of these mutants was conducted in 
collaboration with Dr Rachel McMullan.  
4.2 - nz94 and nz98 suppress phenotypes associated 
with neuronal activation of RHO-1
Both of these mutants show strong suppression of the loopy phenotype from both 
the neuronal and heatshock transgenes of the starting strain.  These mutations do 
not suppress the non-neuronal phenotypes seen on activation of heat-shock RHO-1 
(G14V).  Activation of hsRHO-1* causes the animals to become sterile, to develop the tail 
swelling phenotype associated with hsRHO-1* activation, and animals which have been 
heatshocked die within 2 days of treatment, which is consistent with our observations of 
the QT631 starting strain.
hsRHO-1* activation also causes a reduction in the rate of pharyngeal pumping, as seen 
in the starting strain.  Pumping of the pharynx is neuronally regulated, indicating that there 
is some specificity of suppression of RHO-1* phenotypes with respect to locomotion.  
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These results with two separate transgenes suggest that these mutations are specifically 
suppressing the activity of RHO-1 in the nervous system.
Observing these effects of hsRHO-1* in these mutants also provides evidence that 
suppression of loopy locomotion is not due to a defect in RHO-1* expression, as we 
would expect any such defect to result in a reduction in all RHO-1* phenotypes.  
4.2.1 - nz94 mutants have a fainting locomotion
On closer inspection of the locomotion of these suppressed animals we observed that 
while the animals remained motionless for extended periods of time compared to wild-
type, they were still capable of wild-type body bends.  When left undisturbed, nz94 
animals appear to be highly lethargic or even paralysed.  However, tapping the plate 
or touching individual animals with a platinum wire induces a strong response, with the 
animals briefly moving with wild-type body bends, but stopping abruptly where wild-type 
animals continue moving. 
While backcrossing these mutants we were able to remove the background hsRHO-1* 
transgene in the  mutant strain.  We subsequently obtained a line (which we named 
QT830) which had spontaneously lost the expression of unc-122::GFP, the marker for 
the nRHO-1* transgene.  We believe this line represents the suppressor mutation in the 
absence of both the hsRHO-1* and nRHO-1* transgenes; however, we have not formally 
assayed the loss of the nRHO-1* transgene.  
We took this opportunity to assess the locomotion of the animals in the absence of 
the neuronally-acting transgene, and observed that the animals did indeed move with 
this unusual fainting phenotype.  The video time series in Figure 4-1 demonstrates that 
when the animals are stimulated by a nose tap they move with wild-type body bends, 
but stop moving prematurely compared to wild-type animals (see Movie 4-1 for wild-type 
response to nose tap, and Movie 4-2 for nz94 response).  
This was reminiscent of a phenotype originally identified by Leon Avery, and subsequently 
referred to as ‘fainting’, which is described on Wormbase as:
“Alternating periods of stopping and moving; Motion is interrupted by periods of inactivity 
lasting several seconds.”
So far, this unusual and subtle phenotype has been seen to result from mutations in only 
four genes – loss of function mutations of the large, unclassified yet conserved genes 
unc-79 or unc-80, or the double mutant of novel ion channels nca-1;nca-2 (Humphrey, 
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Hamming et al. 2007).  (The actual period of inactivity of these mutants, if left undisturbed, 
can last much longer than several seconds as seen from the video time series).  
We were therefore interested in whether our suppressors represented mutations in any 
of these genes, or whether we had identified a novel fainter mutation.  
4.2.2 - Suppressor mutant nz94 fails to complement mutations 
in the large, conserved gene unc-80
We made use of the QT830 strain that lacked the nRHO-1* transgene but retained the 
fainting locomotion to perform complementation analysis of the  mutation.  We thought it 
highly unlikely that we had isolated a double mutant of nca-1 and nca-2 from our screen, 
and instead concentrated on comparing the nz94 mutation to the two single mutations 
known to cause fainting locomotion.  
We crossed nz94 with the unc-79 mutant CB1068, which has fainting behaviour and 
contains the reference mutation e1068 (although the molecular nature of this mutation 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5
8.0 8.5 9.0 9.5 10.0 10.5 11.0 3.5
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5
8.0 8.5 9.0 9.5 10.0 10.5 11.0 3.5
A
B
Figure 4-1 nz94 has a fainting locomotion
Touching the nose of a wild-type worm with a platinum wire induces backwards locomotion with 
a number of body bends (A).  Mutant nz94 failed to respond normally to a nose touch (B).  Its 
initial response appeared wild-type, from time 4.0 to 6.0 it produces two body bends, moving 
backwards. However, the animal then pauses for the remainder of the video.  This is reminiscent 
of the ‘fainting’ locomotion common to unc-80, unc-79 and nca-1;nca-2 mutants.  See also Movies 
4-1 and 4-2.
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remains to be determined).  All animals in the F1 generation were wild-type, suggesting 
that  mutations are able to complement  mutations, and that these represent alleles of 
different genes.
We also crossed nz94 with the unc-80 mutant CB1069; this mutation introduces a 
splice site mutation into  and causes fainting locomotion.  We found that nz94 failed 
to complement this mutation in unc-80, with the F1 generation displaying the fainting 
phenotype (data not shown), suggesting that nz94 represented a mutation in this unc-80. 
4.2.3 - nz94 contains a premature STOP codon in the unc-80 
locus
Complementation analysis strongly suggested that nz94 represents a mutation in 
unc-80. Although uncommon, there are examples of nonallelic non-complementation, 
where two mutations in separate proteins generate the same phenotype while both 
mutations are heterozygous as when either mutation is homozygous.  Usually this 
involves proteins which act together in the same complex or the same pathway, for 
instance proteins which regulate the synaptic vesicle cycle (Yook, Proulx et al. 2001).  To 
determine whether nz94 truly is an unc-80 mutation, we set out to sequence the coding 
region of this gene.
We designed a set of primers to cover the exons of unc-80 (see Primer list).  We generated 
fragments of genomic DNA from strain QT830, which carries the nz94 mutation.  We 
initially performed PCR and sequencing using genomic DNA purified from this strain.  A 
number of the sequencing reactions failed to work successfully, so we complemented 
this source of DNA by using the technique of single worm PCR to generate fragments for 
sequencing (see Methods).  
The positions of these reactions relative to the gene structure of  are shown in Figure 4-2. 
When the sequencing data returned bases which failed to match the wild-type genomic 
sequence we re-sequenced these areas, where possible using primers to perform PCR 
on the opposite strand of DNA from that originally sequenced to control for sequencing 
errors.  In all cases except one (highlighted with an arrow, Figure 4-2) these subsequent 
sequencing reactions returned wild-type sequence, suggesting that the original 
mismatches were due to sequencing errors. 
PCR reactions covering Exon 28 of the F25C8.3b isoform of unc-80 returned a sequence 
differing from wild-type, where a wild-type guanine nucleotide had been substituted for a 
mutant adenosine.  When this mutation was plotted onto the wild-type cDNA it generated 
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a premature stop codon in this exon, where a tryptophan residue (TGG) is replaced with 
a STOP codon (TGA).  This exon is present in all predicted splice forms of unc-80.  
All subsequent sequencing reactions covering this region returned a result different from 
wild-type, and were all in agreement with each other.  We therefore identified a mutation 
introducing a premature stop codon into Exon 28 of unc-80.  The base-pair sequence 
from one of these sequencing reactions is shown in Figure 4-3. 
We suggest that this premature stop codon results in either a truncated form of unc-
80 or, through nonsense-mediated decay of the coding mRNA (Hodgkin, Papp et al. 
1989; Conti and Izaurralde 2005), in a complete loss-of-function of this protein, and 
that it is the mutation in this gene which is responsible for the fainting phenotype we 
observe.  Although UNC-80 is a large protein of between 3166 and 3263 amino acids, 
and this mutation is in the 3’ end of the cDNA sequence, other previously identified loss-
of-function mutations cluster in this region.  This suggests that unc-80 is susceptible to 
mutations affecting this part of its coding sequence (Figure 4-4).
Our evidence so far indicates that the  mutation is recessive, which would suggest it does 
not produce a dominantly-interfering truncated protein.  
20,000 22,000 24,000 26,000 28,000 30,000 32,000 34,000 36,000 38,000
Figure 4-2 nz94 contains a premature STOP codon in unc-80
We designed primers to sequence the coding region of the unc-80 gene.  The regions sequenced 
are represented by the green lines.  Wherever we found disagreement between our sequence 
data and the published sequence we repeated the sequencing.  Only at one region, indicated 
by the arrow, did we find a consistent difference between our mutant and the published unc-80 
sequence, confirmed by four PCR reactions.  
Exons are represented by open boxes, introns as thin red lines.  
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The nz98 mutant, which also demonstrates fainting locomotion, was obtained from the 
same original plate as the  mutant described here.  We believe it most likely contains 
the same mutation identified in the  line, but we have yet to sequence this region in  to 
confirm this.  
4.2.4 - The UNC-80 protein is conserved from nematodes to 
mammals
W.T.   36262  AGTCAGTACTTAATTTCTGATAATTGTTCCTCTTTTTTTAAGGAAAGAAAAAAGATCCAC  36321 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
nz94   1      AGTCAGTACTTAATTTCTGATAATTGTTCCTCTTTTTTTAAGGAAAGAAAAAAGATCCAC  60 
 
W.T.   36322  TGCGGTTGCATGGGAAGCTGCTGAAGTAGAGGAACAACAAAAGGAAACGTATCGACGGCC  36381 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
nz94   61     TGCGGTTGCATGGGAAGCTGCTGAAGTAGAGGAACAACAAAAGGAAACGTATCGACGGCC  120 
 
W.T.   36382  ACGTGATACTCTTCTTCAATTGATAGCAGCTTATATAGAAATGGCGTCGGTCCGTCTGAA  36441 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
nz94   121    ACGTGATACTCTTCTTCAATTGATAGCAGCTTATATAGAAATGGCGTCGGTCCGTCTGAA  180 
 
W.T.   36442  AGAACTTACCAAACTAGGTGCAAACCTAGAACACGCCAAGATTCCTGACGTGCTTGACCA  36501 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
nz94   181    AGAACTTACCAAACTAGGTGCAAACCTAGAACACGCCAAGATTCCTGACGTGCTTGACCA  240 
 
W.T.   36502  CAAATGCTATGTGAAACTTGGAGAAGTTGCATTGGCCTTGTTGAAAGTTGCTCCCTATGA  36561 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
nz94   241    CAAATGCTATGTGAAACTTGGAGAAGTTGCATTGGCCTTGTTGAAAGTTGCTCCCTATGA  300 
 
W.T.   36562  TTTATCAACTACAACGTGTCACGGTCTTCAGAAATATTTCCAGATAATACTACCAGTTAC  36621 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
nz94   301    TTTATCAACTACAACGTGTCACGGTCTTCAGAAATATTTCCAGATAATACTACCAGTTAC  360 
 
W.T.   36622  TGATTGGAGTATAGAGTCTAACAGGAGTGCTCTCAATATTATTCTACGACGATTAGACAA  36681 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
nz94   361    TGATTGGAGTATAGAGTCTAACAGGAGTGCTCTCAATATTATTCTACGACGATTAGACAA  420 
 
W.T.   36682  AACACTATCCAAGATTGCCAAACGTCAAAGTTTTCGAAAAAGAGCTATTTGGATAGCACT  36741 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
nz94   421    AACACTATCCAAGATTGCCAAACGTCAAAGTTTTCGAAAAAGAGCTATTTGGATAGCACT  480 
 
W.T.   36742  TTCATCGTGGATTAATGGCATTTGTGATACTCTAAATGCATTTCCGTACATCGCACATCT  36801 
              ||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||| 
nz94   481    TTCATCGTGAATTAATGGCATTTGTGATACTCTAAATGCATTTCCGTACATCGCACATCT  540 
 
W.T.   36802  TCATCCACTTCGAACAATAACACAGCTATGCTTGAGAATGATGGTTGGAGATCCATGTGT  36861 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
nz94   541    TCATCCACTTCGAACAATAACACAGCTATGCTTGAGAATGATGGTTGGAGATCCATGTGT  600 
 
W.T.   36862  TGAAGATAGCGCAGCTTCCACCGCACTTCATCCAACAACTGTTTTACATCCAACTCCACC  36921 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
nz94   601    TGAAGATAGCGCAGCTTCCACCGCACTTCATCCAACAACTGTTTTACATCCAACTCCACC  660 
 
W.T.   36922  GCCTCAAACTTTT  36934 
              ||||||||||||| 
nz94   661    GCCTCAAACTTTT  673 
Figure 4-3 nz94 contains a premature STOP codon in unc-80
We sequenced the unc-80 gene in nz94 and detected a consistent mutation generating a 
premature STOP codon.  As seen here the alignment to the wild-type unc-80 genomic sequence 
(upper sequence) is perfect except for one base (indicated by a red arrow) where the nz94 mutant 
introduces a change from a guanine to an adenosine base.  
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The large  gene, stretching over ten kilobase in cDNA alone, is predicted to produce a 
protein with molecular weight over 300kD.  This very large protein has close homologues 
in other nematode species, such as C. briggsae, with which it shares 87% homology, 
and orthologues have been identified across the animal kingdom with poorer degrees of 
conservation (24% homology to the mouse homologue). 
Interestingly, there are no domains of known function so far identified in the UNC-80 
protein, apart from a predicted Armadillo repeat of relatively low homology (Pierce-
Shimomura, Chen et al. 2008).
While the overall homology between species is relatively low, some regions of the protein 
are very highly conserved.  Sequence analysis of the mouse homologue of UNC-80 
predicts the existence of four potential transmembrane helices, marked in yellow in Figure 
4-5.  These four regions are relatively well conserved between highly disparate species 
(highlights in blue and purple), suggesting that they have some functional significance. 
Whether they are indeed transmembrane helices remains to be determined.  Associated 
with these predicted helices are further regions of high conservation, marked in green 
across the various species listed.  
This pattern of disparate patches of homology interspersed with regions showing no 
conservation is reminiscent of large proteins commonly classified as scaffolds.  These 
often contain multiple protein-protein interaction domains, which are conserved between 
species, and large, flexible linker domains, which tend to be poorly conserved.
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(G1206E)
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(unc-80)
Figure 4-4 Known alleles of unc-80
The published unc-80 alleles are shown here mapped onto the same gene model.  They appear 
to cluster in two main regions, at the 5’ and 3’ end of the gene, which could indicate a particular 
susceptibility to mutation in those regions.  
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4.3 - unc-80 (e1069) mutants are able to suppress the 
loopy locomotion of nRHO-1* mutants
While complementation and sequencing confirmed that mutant nz94 carries a mutation 
in the  gene, there are likely to be many other genomic variations in this strain since it was 
 
Cre-unc-80             YTLHRKPFLLQMCGAIANIIDNSSNDFEINPMRVKAKYWFNLIKKMEEITDEDPLDILGL 2414  
cb-unc-80              YTLHRKPFLLQMCGAIANIIDNSSNDFEINPMRVKAKYWFNLIKKMEEITDEDPLDILGL 2713  
unc-80                 YTLHRKPFLLQMCGAIANIIDNSSNDFEINPMRVKAKYWFNLIKKMEEITDEDPLDILGL 2459  
Cj-unc-80              YTLHRKPFLLQMCGAIANIIDNSSNDFEINPMRVKAKYWFNLIKRMEEITDEDPLDILGL 2429  
mouse-unc-80           YILHRKPFVLQLFASVAPLLEFPDAANTGSSKGVSAQCLFDLLQSLEGETT-DILDILEL 2323  
human                  YILHRKPFVLQLFASVAPLLEFPDAANNGPSKGVSAQCLFDLLQSLEGETT-DILDILEL 2320  
drosophila-unc-80      YLLNRKPFILQMFGSVSAILDTDEDGTYGEAHKVQSSCLFNLLLSLEDPSP-DPLNIAEL 2407  
                       * *:****:**: .::: :::  .      .  *.:.  *:*:  :*  :  * *:*  *  
 
2401-2421 region 
Cre-unc-80             RLEEETLLSGNSPSAVKHEISQWITMAVEMKALINSCEQLVRGPTRAFDLVNSVSERGKS 2534  
cb-unc-80              RLEEETLASGNSPSAVKHEISQWITMAVEMKALINSCEQLVRGPTRAFDLVNSVSERGKS 2833  
unc-80                 RLEEETLQSGNSPAAVKHEISQWITMAVEMKALINSCEQLVRGPTRAFDLVNSVSERGKS 2579  
Cj-unc-80              RLEEETLASGNSPSAVKHEISQWITMAVEVKALINSCDQLARGPQRAFDLVNSVSDRGKS 2549  
mouse-unc-80           KMKRQTSQVETVP-AAREEIAATAALATSLQALLYSVEVLTR-PMTAPQMSRSDQGHKGT 2440  
human                  KLKRQTSQVETVP-AAREEIAATAALATSLQALLYSVEVLTR-PMTAPQMSRCDQGHKGT 2437  
drosophila-unc-80      QIQSPSY----IPLQGKSERDIILQLAVAIRTMVHNCEGLAKSYNGPYRNSPEHKGSSQR 2522  
                       :::  :      *   : *      :*. ::::: . : *.:    .       .       
 
 
2788-2808 region 
 
Cre-unc-80             RGHSATVSTHRIVRESICQSIYLGLKVLMLTFGKLLAPMWPRVARLVKDLLAKKPGAPSA 2948  
cb-unc-80              RGHSATVSTHRIVRESICQSIYLGLKVLMLTFGKLLAPMWPRVARIVKDLLAKKPGAPSA 3247  
unc-80                 RGHSATVSTHRIVRESICQAIYLGLKVLMLTFGKLLAPMWPRVARIVKDLLAKKPGAPTS 2993 
Cj-unc-80              RGHSATVSTHRIVRESICQSIYLGLKVLMLTFGKLLAPMWPRVARLIKDLLAKKPGAPSA 2963  
mouse-unc-80           PGDAGKDLRKEGLAESTSQAAYLALKVILVCFERQLGSQWYWLSLQVKEMALRKVGGLAL 2836  
human                  PGDAGKDLRREGLAESTSQAAYLALKVILVCFERQLGSQWYWLSLQVKEMALRKVGGLAL 2833  
drosophila-unc-80      SRDAKRPAR---ISGSLYQAAFLALRIVCICFESRLSNEWPRIVRVMRDLGRRNEAAPDL 2915  
                         .:        :  *  *: :*.*::: : *   *.  *  :   ::::  :: ..     
 
2834-2854 
 
Cre-unc-80             LAFVDFLLHSNLPIALFILPMIQNKMKQKPGT-EQEAAWQTEILEKLDARSHN-IIPMSI 3006  
cb-unc-80              LAFVDFLLHSNLPIALFILPMIQNKMKQKPGS-EQEAAWQVEILEKLDARSHN-IIPMSI 3305  
unc-80                 MAFVDFLLHSNLPISLFILPMIQNKMKQKPGT-DQEAAWQTEILEKLDAKSHN-IVPPSI 3051  
Cj-unc-80              LAFVNFLLHSNLPIALFMLPMIQNKIKRKPGN-EQETFWQTEILEKLDAKTHT-VIPTSI 3021  
mouse-unc-80           WDFLDFIVRTRIPIFVLLRPFIQCKLLAQPAENHEELSARQHISDQLERRFIPRPLCKSS 2896  
human                  WDFLDFIVRTRIPIFVLLRPFIQCKLLAQPAENHEELSARQHIADQLERRFIPRPLCKSS 2893  
drosophila-unc-80      WSFMEFVVTHRTPLYIVLLPFILHKISQPPIGDHERHMQFIIRERLRGTPPQGGIKSKGA 2975  
                         *::*::  . *: :.: *:*  *:   *   .:.                      .   
Figure 4-5 UNC-80 is conserved between species
While the UNC-80 protein in C. elegans contains no domains of known function, it does share 
homology to a number of other proteins in other species.  The mouse homologue (listed here 
as mouse-unc-80) has been annotated to contain four potential transmembrane domains 
(highlighted in yellow).  These sequences are relatively well conserved between other species, 
as are a number of adjacent sequences labelled in green.  
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generated by EMS mutagenesis. We therefore tested whether other unc-80 mutations 
are able to suppress of the loopy locomotion of nRHO-1* animals.  We crossed males 
of strain QT733, carrying the nRHO-1* transgene, with strain CB1069 which carries a 
splice-site mutation in unc-80 and has a fainting phenotype.   
While being fainter in their locomotion, the body posture assumed by these unc-80 
mutants (Figure 4-6, C, and see Movie 4-5) looks identical to wild-type animals (Figure 
4-6, A, and see Movie 4-3) in distinct contrast to the loopy body posture of nRHO-1* 
animals (Figure 4-6, B, and see Movie 4-4).
We examined the F2 generation following the cross for animals which were expressing 
(the marker for the nRHO-1* transgene) but which did not appear to have loopy 
locomotion.  We picked these animals to fresh plates and allowed them to self-fertilise. 
The offspring of these animals are also non-loopy, and have a fainting phenotype.  The 
animals obtained from this cross were labelled as strain QT841, and all the animals 
were positive for the nRHO-1* GFP marker.  They are homozygous for the nRHO-1* 
transgene, and are consistently non-loopy.  
This demonstrates that this allele of unc-80 can also suppress the loopy phenotype of 
nRHO-1* (Figure 4-6, D and see Movie 4-7).  All further experiments with respect to 
unc-80 were performed using this strain and the e1069 allele, as it likely contains fewer 
background mutations to our  allele, and has been used in a number of prior publications. 
4.4 - unc-80;nRHO-1* double mutants move efficiently 
towards food
unc-80 mutants have also been identified, using a dispersal assay, as suppressing a 
hypomorphic (synaptojanin) allele (Jospin, Watanabe et al. 2007).  We therefore also 
used a dispersal assay to quantitatively measure the extent to which the unc-80 mutation 
suppresses the loopy locomotion phenotype of nRHO-1* mutants.  
When placed in the centre of a 10 cm plate without food, wild-type animals efficiently 
move towards food seeded at the edge of the plate, with 83±1% of animals on the food at 
60 minutes (Figure 4-7, B, Table 4-1).  In contrast, no nRHO-1* mutants are able to reach 
the food during the 60 minutes of the experiment, possibly due to an increased rate of 
reversals or a failure of chemotaxis (Table 4-1).  The unc-80;nRHO-1* double mutants 
are able to suppress this inability to reach food during the dispersal assay as significantly 
more of these animals are on food at 60 minutes (76±6%, p<0.001, Table 4-1).  Of the 
unc-80 single mutants, despite their fainting locomotion, 63±4% of animals are on food at 
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60 minutes, demonstrating that, although fainter, they are capable of efficient chemotaxis 
in this assay.  
Interestingly, the double mutant, unc-80;nRHO-1* animals move more efficiently than the 
single  mutant, with 76±6% of animals on food at 60 minutes, suggesting that there is 
some synergism between these two mutations, although this difference is not significant 
(Table 4-1).  
A B
C D
Figure 4-6 unc-80 mutations suppress the loopy locomotion of 
nRHO-1*
nRHO-1* mutants are highly loopy (B) compared to wild-type animals (A).  A double mutant, unc-
80;nRHO-1* (D), regains the smooth sinusoidal locomotion of a wild-type animal.  The unc-80 
single mutant, while having a fainter phenotype, is also non-loopy (C).  
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4.5 - Rescue of the unc-80 mutation 
Since we have seen suppression of the loopy phenotype of nRHO-1* mutant animals by 
two alleles of unc-80, nz94 which introduces a premature STOP codon, and e1069, a 
splice-site mutation, this represents strong evidence that it is loss of function of the  gene 
itself which suppresses the loopy locomotion phenotype.  To confirm this we wanted to 
rescue the mutation and restore loopy locomotion in these double mutations using a 
wild-type copy of the unc-80 gene.  We also wanted to determine the site of action of 
with respect to the suppression of the nRHO-1* loopy phenotype. 
To this end we generated an unc-80 minigene.  The most complete unc-80 cDNA 
available, yk1260h6, shows good homology to the genomic sequence of  at its 5’ end, 
but is aberrantly spliced at the 3’ end.  We therefore used the 5’ sequence of the cDNA 
fused to the 3’ genomic sequence, which we obtained  by PCR from wild-type DNA.  We 
also introduced a unique NotI restriction site into the 5’ end of the cDNA to allow the 
insertion a GFP or mCherry fluorescent tag (see 2.22 for more details.) 
The unc-80 tagged and untagged minigenes were placed under the control of four 
different promoters to allow us to assess the site of action of  with respect to suppression 
of nRHO-1* (Figure 4-8).  These were the heatshock promoter from vector pPD79.48, 
which drives expression in most cells in the organism, although with a neuronal bias 
(Stringham, Dixon et al. 1992); the synaptobrevin (snb-1) promoter, which expresses in 
all neurons (Nonet, Saifee et al. 1998), and the acr-2 and unc-17 promoters, both of which 
express in neurons that produce acetylcholine, although with a few subtle differences of 
expression: the acr-2 promoter expresses in some interneurons (Jospin, Qi et al. 2009) 
and the unc-17 promoter drives some intestinal expression (Duerr, Han et al. 2008).
4.5.1 - Pan-neuronal expression of unc-80 from the snb-1 
promoter rescues the suppression of loopy locomotion in an 
unc-80;nRHO-1* double mutant
The expression pattern described for unc-80 indicates expression in neurons and vulval 
muscles (Jospin, Watanabe et al. 2007; Yeh, Ng et al. 2008); we therefore thought it 
likely that a neuronally expressed construct would rescue the suppression. 
We generated transgenic animals by injecting unc-80;nRHO-1* double mutants (QT841) 
with SJN471 (p.snb-1::unc-80), at a concentration of 5ng/μl, along with a ttx-3::GFP 
co-injection marker.  We obtained 2 independent lines in which all animals carrying the 
ttx-3::GFP marker are loopy, demonstrating that pan-neuronal expression of the unc-
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Figure 4-7 unc-80 mutations rescue the inability of nRHO-1* to 
chemotax efficiently
The highly loopy phenotype of nRHO-1* mutants severely impairs their locomotion ability.  Mixed 
populations of animals are collected in M9 (A), and placed in the centre of a large 10cm plate 
ringed with food (B).  Animals migrate over time to the food at the edge of the plate, and the radial 
dispersal index indicates the proportion of animals on food, with 1 being all on food and 0 being 
none on food.
Wild-type animals efficiently move to the food, while nRHO-1* mutants are incapable of reaching 
the food during the 60 minute assay.  unc-80;nRHO-1* double mutants are able to move efficiently 
to the food, demonstrating that the unc-80 mutation suppresses the inefficient chemotaxis of 
nRHO-1* animals (p<0.001).  
unc-80 single mutants, being fainter, reach food at a slower rate than wild-type animals.  The 
unc-80;nRHO-1* double mutants reach food faster than unc-80 mutants alone, suggesting some 
co-suppression, although this is not statistically signficant.  
*** = p<0.001, ** = p<0.01.  Statistics calculated using a 2-tailed T-test.  # = none of the animals 
reached food during the recorded interval.  n=8 for all strains.  
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80 minigene from the snb-1 promoter construct is able to rescue the suppression of 
nRHO-1*. 
We injected unc-80;nRHO-1* animals with SJN481 (p.snb-1::GFP::unc-80) along with 
the ttx-3::GFP marker at a concentration of 6ng/μl, and obtained 2 independent lines.  All 
animals carrying the co-injection marker are loopy.  A representative animal is shown in 
Figure 4-9 (and see Movie 4-7). 
unc-80;nRHO-1* animals were also injected with SJN482 (p.snb-1::mCherry::unc-80) 
along with an unc-17::GFP marker,at a concentration of 12ng/μl.  We obtained 3 
independent lines, all of which produce loopy locomotion in animals carrying the co-
injection marker. 
Animals carrying the SJN481 and SJN482 plasmids were frozen for future reference 
(see Strains list).  QT1086, carrying p.snb-1::GFP::unc-80, was selected for further 
analysis, and is referred to through the remainder of this chapter as unc-80;nRHO-1*;p.
snb-1::GFP::unc-80.  Unfortunately animals carrying the untagged SJN471 plasmid were 
not frozen down; these animals could be generated again by re-injecting the plasmid into 
QT841.  
These constructs were not integrated into the genome of the rescued animals, but instead 
carried as extrachromosomal arrays.  Animals not carrying the construct remain as non-
loopy, fainter animals as an internal control for the effects of transformation. 
4.5.2 - Cholinergic expression of unc-80 under the unc-17 
promoter rescues nRHO-1* loopy locomotion in an unc-
80;nRHO-1* double mutant animal
The nRHO-1* transgene is expressed only in cholinergic neurons, under the control of 
the unc-17 promoter.  unc-17, which encodes the worm synaptic vesicle acetylcholine 
transporter (VAChT), is required in cholinergic neurons for the loading of acetylcholine 
(Alfonso, Grundahl et al. 1993) and expresses in cholinergic neurons (Duerr, Han et al. 
2008).
We generated transgenic animals by injecting unc-80;nRHO-1* double mutants (QT841) 
with SJN469, p.unc-17::unc-80, at a concentration of 5ng/μl, along with a ttx-3::GFP 
co-injection marker.  We obtained 3 independent lines in which all animals carrying the 
ttx-3::GFP marker were loopy. 
We also injected unc-80;nRHO-1* animals with either SJN477 (p.unc-17::GFP::UNC-80) 
at a concentration of 15ng/μl, or SJN478 (p.unc-17::mCherry::UNC-80) at a concentration 
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Figure 4-8 UNC-80 rescuing constructs
We generated a range of UNC-80 constructs using part 5’ cDNA (solid blue section) and part 
genomic 3’ DNA (striped section), along with versions tagged with either GFP (green) or mCherry 
(pink).  These were placed under the control of four promoters: unc-17, acr-2, snb-1 and heatshock. 
We observed rescue with UNC-80 constructs driven from the unc-17 and snb-1 promoters, partial 
rescue with the acr-2 promoter, and have yet to observe rescue from the heatshock promoter.  
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of 5.5 ng/μl, along with the ttx-3::GFP or an unc-17::GFP marker respectively.  We 
obtained 2 independent lines for each set of injections.  All animals carrying the co-
injection marker are loopy.  A representative animal expressing p.unc-17::GFP::UNC-80 
is shown in Figure 4-9 (and see Movie 4-8).  
Animals carrying the SJN477 and SJN478 plasmids were frozen for future reference 
(see Strains list).  Unfortunately animals carrying the untagged SJN469 construct lost the 
expression of their extrachromosomal arrays before they could be frozen down; these 
A B
C D
Figure 4-9 Rescue of the unc-80 suppression phenotype by 
neuronal expression of UNC-80
nRHO-1* mutant animals are highly loopy (A), and the unc-80;nRHO-1* double mutant restores 
wild-type body posture (B).  GFP-tagged UNC-80, expressed either pan-neuronally from the 
synaptobrevin promoter (C) or in the cholinergic motor neurons from the unc-17 promoter (D) is 
sufficient to restore loopy locomotion in unc-80;nRHO-1* animals.  
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animals could be generated again if necessary by reinjecting the plasmid into strain 
QT841.  
These results demonstrate that UNC-80, expressed using the unc-17 promoter, is able 
to restore the loopy locomotion phenotype in unc-80;nRHO-1* double mutants, and 
that UNC-80 and RHO-1* act within the cholinergic motorneurons to generate loopy 
phenotype.  
4.5.3 - GFP-tagged UNC-80 protein is visible in neurons in 
rescued unc-80;nRHO-1* double mutant animals
Using the high-power fluorescent microscope (Zeiss widefield, Axioplan 2) we examined 
the animals carrying the rescuing constructs for expression of the tagged unc-80 
transgenes.  Animals expressing UNC-80 from the synaptobrevin promoter do not show 
detectable levels of GFP or mCherry, although they are rescued for the locomotion 
phenotype.  This suggests that very low levels of expression of UNC-80 are able to 
rescue the loopy locomotion phenotype.  
The line QT1082, which expresses GFP-tagged UNC-80 under the unc-17 promoter do 
show GFP expression in neurons (Figure 4-10).  
No mCherry expression has been detected in lines carrying the mCherry-tagged 
constructs.  The p.unc-17::GFP::UNC-80 construct was injected at a concentration three 
times higher than that in the other rescuing injections.  This suggests that the level of 
expression of UNC-80 protein is too low to produce a detectable fluorescent signal in the 
remainder of the rescued lines.  This may also be due to differences in the efficiency of 
transformation between these independently-generated lines.  Future work to integrate 
these transgenes directly into the genome may increase GFP expression, or the rescuing 
plasmids could be reinjected at higher concentration.  
As the loopy locomotion of these animals is rescued, we surmise that only a low level 
of UNC-80 expression is required to rescue this phenotype.  This strain, QT1082, is 
used in further analysis in this chapter, and is referred to as unc-80;nRHO-1*;p.unc-
17::GFP::UNC-80.
4.5.4 - Limited rescue of loopy locomotion in unc-80;nRHO-1* 
mutants has been obtained with UNC-80 expressed under 
the acr-2 promoter
We injected unc-80;nRHO-1* animals with SJN467, p.acr-2::UNC-80, at a concentration 
of 5ng/μl, along with a ttx-3::GFP co-injection marker.  We obtained 4 independent lines, 
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Figure 4-10 One rescued line expresses neuronal GFP
We have assayed all our rescued lines for expression of GFP- and mCherry-tagged UNC-80. 
While we see rescue of the loopy phenotype in all our rescued lines, we see expression of the 
GFP-tagged protein in only one line, QT1082, shown here.  We see expression in the nerve ring 
(grey arrows) and in the nerve cord and commisures (blue arrows).  We also observe some non-
specific GFP expression (green arrow.)  These animals also express the nRHO-1* co-transfection 
marker unc-122::GFP (red arrows).
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only one of which produced any loopy animals, and not all animals carrying the co-
injection marker were loopy.
The acr-2 promoter drives expression in the ventral cord motor neurons VA, DA, VB, DB, 
DA, IL1, RMD, and PVQ (Jospin, Qi et al. 2009), and its expression overlaps considerably 
with that of the unc-17 promoter, and yet so far we have been unable to rescue the 
loopy phenotype using this promoter.  This may be due to subtle differences either in 
the level or specificity of expression between these promoters.  Further injections, at a 
higher concentration, may yield lines which fully rescue the loopy phenotype.  A similar 
difference was observed between p.unc-17 and p.acr-2 in the rescue of pkc-1 mutants 
(D. Sieburth, personal communication.)  
4.5.5 - UNC-80 expressed from a heatshock promoter does 
not rescue the loopy locomotion of unc-80;nRHO-1* mutant 
animals
Next, we wanted to test whether the timing of expression of UNC-80 protein was 
important for its function with respect to the loopy phenotype of nRHO-1*.  To conduct 
this experiment, we created a number of transgenic lines carrying the rescuing construct 
under the control of the heatshock promoter.
unc-80;nRHO-1* animals were injected with the SJN470 (p.hs::UNC-80) construct at a 
concentration of 5ng/μl, along with a  co-injection marker.  One independent line was 
obtained.  When grown at 20oC, none of these lines displayed loopy locomotion.  We 
used our standard heat-shock protocol (staged adults, placed at 33oC for thirty minutes, 
followed by a rest at 20oC for one hour, and then repeated) to activate the heatshock 
response.  However, none of the animals carrying the co-injection marker became loopy, 
and all retained the fainter phenotype, as did our rescued lines.
We next injected animals with SJN479 (p.hs::GFP::UNC-80) at a concentration of 
10ng/μl, double the previous concentration, along with a p.acr-2::mCherry co-injection 
marker.  We obtained 3 independent lines, and performed our heatshock protocol on all 
three.  No animals carrying the co-injection marker became significantly loopy following 
heat-shock.  
We next tried a range of more severe heatshock protocols to attempt to induce rescue.
• 1 hour at 33oC, recovery for 30 minutes at 20oC, repeated once
• 1 hour at 33oC, recovery for 30 minutes at 15oC, repeated once
• 1 hour at 37oC, recovery for 30 minutes at 15oC, repeated once
• Growth for 2 hours at 33oC
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None of these protocols was able to induce loopy locomotion.  
4.5.6 - GFP-tagged UNC-80 is visible in one line following 
heatshock
One possible explanation for the lack of rescue would be if the heatshock protocol is 
unable to induce expression of UNC-80 in these lines. We looked for expression of the 
GFP-tagged form of UNC-80 following these protocols, and some GFP expression is 
seen in neuronal cells.  Only one line (2.6) has so far demonstrated expression of this 
construct (Figure 4-11).  The expression appears to be mainly neuronal, despite the 
activation of the heatshock response throughout the organism. 
While we have been able to establish that UNC-80 is required neuronally for rescue 
of the loopy phenotype, we cannot determine whether UNC-80 is required for correct 
development of the nervous system, has a function in adult neurons, or a combination 
of these possibilities.  
196
Fluorescence
Bright field
Combined
Fluorescence
Bright field
Combined
A
B
Figure 4-11 heatshock-driven GFP-tagged UNC-80 protein 
expresses in the nervous system 
We have assayed all our lines carrying heatshock-driven GFP- and mCherry-tagged UNC-80. 
Only one line, Injection Line 2.6, demonstrated any expression of the tagged protein. As shown 
here, this line expresses GFP-tagged UNC-80 in the ventral nerve cord of larval animals (A) and 
adults (B) following heatshock.  No expression has been observed in non-neuronal tissues.  
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Figure 4-12 Dispersal assay of UNC-80 rescuing constructs 
(with Dr Rachel McMullan)
We tested two lines of animals rescued with unc-80 under the synaptobrevin promoter and tagged 
with either GFP (QT1086) or mCherry (QT1089).  Animals rescued with the GFP-tagged unc-80 
construct were unable to reach food for the duration of the experiment (marked with #), while 
animals rescued with the mCherry-tagged construct are slightly less loopy, with 18% reaching 
food after 1 hour.  
Animals rescued with unc-80 tagged with GFP and expressed from the unc-17 promoter (QT1082) 
are completely rescued for loopy locomotion, with just 1% of animals on food at 1 hour. 
 *** = p<0.001, ** = p<0.01.  Statistics calculated using a 2-tailed T-test.  # = none of the animals 
reached food during the recorded interval.  n=8 for all strains except QT1089 (n=6). 
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unc-80 0.63 ± 0.04, p<0.01 - 0.76 ±0.06, p<0.01 -
unc-80;nRHO-1* 0.76 ±0.06, ns 0.76 ±0.06, ns 0.76 ±0.06, p<0.01 0 ± 0, p<0.01
Lo
c
u
s 
1
with p.snb-
1::mCherry::UNC-80
with p.unc-
17::GFP::UNC-80
- -
- -
0.19 ± 0.26, p<0.01 0.01 ± 0.0, p<0.01
Table 4-1 Dispersal assay statistics
Summary of dispersal assay data  Animals were constructed from a combination of locus 1 and 
locus 2.  Numbers given indicate the radial dispersal index (at the 60 minute time point) +/- S.E.M. 
The statistical significance was calculated using a 2-tailed T-test.  
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4.6 - Quantifying the level of rescue of the loopy 
phenotype of unc-80;nRHO-1* mutants from UNC-80 
transgenes, in collaboration with Dr Rachel McMullan
While we can see by visual inspection that the unc-80;nRHO-1* animals expressing 
UNC-80 protein in the nervous system appear to be completely rescued for the loopy 
locomotion induced by the nRHO-1* transgene, we wanted to test their locomotion using 
the dispersal assay introduced earlier.  
4.6.1 - Pan-neuronal expression of wild-type UNC-80 rescues 
the locomotion phenotype of unc-80;nRHO-1* mutants 
In the dispersal assay, the unc-80;nRHO-1* double mutant is able to efficiently reach 
food after 1 hour (76±6% on food), while nRHO-1* animals are unable to reach food (0% 
on food after 1 hour).  
We tested two independent lines of unc-80;nRHO-1* double mutants which have been 
rescued with UNC-80 expressed pan-neuronally from the synaptobrevin promoter. 
One of these lines, unc-80;nRHO-1*;p.snb-1::GFP::UNC-80, completely rescued 
the locomotion phenotype of the nRHO-1* transgene, with no animals reaching 
the food after 1 hour (Figure 4-12, Table 4-1).  The second independent line tested, 
unc-80;nRHO-1*;p.snb-1::mCherry::UNC-80, demonstrated slightly weaker rescue 
of the suppression, with 18±2% on food after 1 hours; this is still significantly fewer 
animals reaching the food than seen in the non-rescued animals (Figure 4-12, Table 
4-1).  Differences in these two strains may be due to differences in the level of expression 
from the two transgenes.  
4.6.2 - Cholingergic expression of wild-type UNC-80 rescues 
the locomotion phenotype of unc-80;nRHO-1* mutants 
Double mutant unc-80;nRHO-1* animals, rescued with UNC-80 expressed from the 
unc-17 promoter, which drives expression in the cholinergic neurons, are rescued for the 
suppression of the nRHO-1* loopy phenotype, and only 1% of animals reach the food 
after 1 hour of the dispersal assay (Figure 4-12).  
This demonstrates that expression of UNC-80 in the same cells as RHO-1* is sufficient 
to completely rescue the suppression of the nRHO-1* phenotype observed in the unc-80 
mutant background.
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4.6.3 - UNC-80 rescuing transgenes do not induce loopy 
behaviour in unc-80 single mutants
To test whether the UNC-80 transgenes alone are responsible for the loopy behaviour 
seen in these animals, we crossed unc-80;nRHO-1* rescued animals with  mutant 
animals to remove the nRHO-1* transgene from the genetic background while retaining 
the unc-80 mutation.  
unc-80 mutants expressing wild-type UNC-80 from either the synaptobrevin pan-neuronal 
promoter or the  cholinergic promoter are non-loopy, demonstrating that the transgenes 
themselves are not responsible for the loopy locomotion seen in the unc-80;nRHO-1* 
rescued animals, and do not have a dominant effect on locomotion.  
4.6.4 - UNC-80 rescuing constructs do not rescue fainting 
behaviour in unc-80 mutant animals
Interestingly, the  mutant animals expressing exogenous UNC-80 protein from both 
the unc-17 and snb-1 promoters appear to retain the fainting phenotype of the  mutant 
animals (see Movies 4-17 and 4-18), although the p.unc-17 transgene appears to restore 
more wild-type locomotion than the p.snb-1 transgene.  This suggests that the loopy 
behaviour and the fainting phenotype vary in their requirement for UNC-80 protein, and 
that either higher level of UNC-80 expression are required to rescue fainting, or that 
overexpression of UNC-80 causes fainting locomotion.   
4.6.5 - UNC-80 rescuing constructs do not induce loopy 
locomotion in wild-type animals
We crossed the unc-80;p.unc-17::UNC-80 and unc-80;p.snb-1::UNC-80 animals with 
wild-type animals, and looked for lines in which the animals not carrying the transformation 
marker lacked a fainting phenotype.  We obtained lines in which these extrachromosomal 
arrays are present in wild-type animals.  These animals are non-loopy, indicating that the 
arrays themselves are do not drive loopy locomotion in a wild-type background.  By eye, 
these transformed animals appear to have a subtle reduction in locomotion compared 
with untransformed animals, which would indicate that overexpression of UNC-80 is able 
to induce fainting locomotion on a solid surface.  This suggests that mild overexpression 
is able to induce a dominant negative effect.  
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4.7 - unc-80 mutants display defects in swimming 
behaviour
We have had difficulty finding an assay to successfully quantify fainting behaviour on a 
solid surface.  If we examine body bends per minute, a common measure of locomotion 
rates, or use the dispersal assay (Figure 4-7) we see a reduction in the average locomotion 
rate of unc-80 mutants, but this does not give a true picture of fainting locomotion, which 
allows wild-type movement interspersed with long pauses.  We attempted to write a 
custom algorithm to measure pausing behaviour from videos analysed using the Parallel 
Worm Tracker (Ramot, Johnson et al. 2008), but experienced difficulties in this approach 
due to the sensitivity of unc-80 animals to touch stimulation - analysing populations 
of individuals inducing movement in non-moving animals complicates the analysis of 
fainting.  
We therefore looked at an additional phenotype displayed by  mutants to attempt to 
quantify the behavioural effects of these rescuing transgenes.  unc-80 animals are 
noted to have a defect in swimming behaviour (Pierce-Shimomura, Chen et al. 2008). 
unc-80 mutants are reported to thrash at a much slower rate than wild-type animals, 
which vigorously thrash when immersed in liquid.  We decided to use this phenotype as 
a quantitative marker of the level of fainting in our mutant animals. 
4.7.1 - unc-80 mutants thrash less than wild-type when 
immersed in M9
It has long been known that C. elegans can survive long-term immersion in liquid.  Wild-
type animals thrash vigourously in liquid, and this behaviour has been shown to be 
directed, with animals capable of chemotaxing towards food in a liquid environment.  
After immersion in a drop of M9 and being left to acclimatise for 3 minutes, wild-type 
animals thrash at a rate of 98±7 thrashes per minute (Figure 4-13, and Movie 4-9).  In 
contrast, unc-80 mutant animals thrash signifcantly less, at 39±10 times per minute in 
M9 (Figure 4-13 and Movie 4-10) (p<0.001).  
We had previously described the unc-80;nRHO-1* double mutant as having a fainting 
locomotion.  In the dispersal assay, these animals are able to successfully reach food 
after 1 hour, demonstrating that although fainter they are capable of sufficient locomotion 
for chemotaxis.  In liquid, these animals thrash significantly less than wild-type, at a 
rate of 48±16 times per minute (p<0.001, Figure 4-13 and Movie 4-11).  While not a 
statistically significant difference, this is a greater degree of thrashing than seen in 
unc-80 single mutants.  
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Figure 4-13 Mean thrashing assays of unc-80 mutants
The unc-80 mutants fail to thrash at the same rate as wild-type animals in M9.  After being left for 
three minutes recovery, the number of thrashes in 2 minutes is counted, and an average taken 
for each worm.  Wild-type animals thrash at 98 thrashes per minute, while unc-80 animals thrash 
significantly less at 39 thrashes per minute.  This indicates fainting behaviour in these animals. 
unc-80;nRHO-1* mutants also fail to thrash efficiently, at 48 thrashes per minute, demonstrating 
that these animals are also fainter.  
nRHO-1* animal thrash significantly less than wild-type, but this appears to be due to their loopy 
locomotion (18 thrashes per minute).  
Animals rescued with the UNC-80 transgenes are not rescued for swimming efficieny, although it 
is not clear whether this is due to their loopy locomotion phenotype or the retention of the fainting 
phenotype, as they now swim significantly less than unc-80;nRHO-1* double mutants.  Animals 
expressing UNC-80 under the unc-17 promoter swim more efficiently than those expressing UNC-
80 from the synaptobrevin promoter (19 and 7 thrashes per minute respectively).
Error bars represent standard errors of the mean.  Numbers in brackets indicate number of 
animals assayed.
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4.7.2 - UNC-80 expressed from the unc-17 cholinergic 
promoter does not rescue swimming behaviour in an unc-
80;nRHO-1* double mutant
Animals expressing wild-type UNC-80 in the cholinergic neurons under the unc-17 
promoter in an unc-80;nRHO-1* mutant thrash at a rate of 18±7 thrashes per minute 
in M9 after 3 minutes recovery time (Figure 4-13 and Movie 4-12).  This indicates an 
increase in the severity of the swimming phenotype compared to the double mutants.
These animals are highly loopy, and it may be that this uncoordination prevents successful 
thrashing.  This hypothesis is supported by the behaviour of nRHO-1* mutants, which 
thrash at a rate of 18±10 thrashes per minute (Figure 4-13 and Movie 4-13), significantly 
less that wild-type. 
4.7.3 - UNC-80 expressed pan-neuronally suppresses 
thrashing behaviour in an unc-80;nRHO-1* double mutant
unc-80;nRHO-1* mutants expressing UNC-80 wild-type protein from a synaptobrevin 
promoter thrash at a rate of just 7±5 thrashes per minute (Figure 4-13 and Movie 4-14). 
As with the unc-17-driven expression of UNC-80, this not only fails to rescue the fainting 
behaviour, it actually appears to increase the swimming defect, most due to an increase 
in loopy behaviour.  
4.7.4 - Measuring mean thrashes per minute cannot 
distinguish between uncoordinated, loopy behaviour and 
fainting behaviour in liquid
These rescued strains do not demonstrate rescue of the unc-80 fainting phenotype. 
However, the rescue of suppression of loopy behaviour induced by the nRHO-1* 
transgene means that these animals are highly uncoordinated, and this loopy behaviour 
also reduces thrashing in liquid, for reasons likely to be unrelated to the function of 
UNC-80.
The role of unc-80 was further assayed in a second swimming assay.  It has been reported 
that on immersion in liquid, unc-80 mutants become rigid and fail to thrash.  In our mean 
thrashes assay, we allowed time for recovery and unc-80 mutants do then thrash, but 
at a slower rate than wild-type.  We therefore decided to assay the initial response of 
animals to immersion in liquid in an attempt to find a stronger phenotype to distinguish 
unc-80 mutants from wild-type animals.  
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Figure 4-14 unc-80 mutants fail to thrash on immersion in M9
unc-80 mutants (B) fail to thrash after immersion in M9.  Unlike wild-type animals (A), which 
undergo body bends immediately on immersion in M9, unc-80 animals retain a curled posture for 
most of the video.
(Numbers indicate time in seconds).    
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4.7.4.1 - unc-80 mutants fail to thrash on immersion in 
M9
When immersed in M9, wild-type animals begin thrashing almost immediately.  As can 
be seen in Figure 4-14, the animal undergoes several distinct body movements over the 
course of the first few seconds following immersion, and these continue for the duration 
of the video clip from which the still images were taken (Movie 4-15).  In contrast, the 
unc-80 mutant (Figure 4-14,B) remains immobile, with a slightly bent posture, for 10-12 
seconds after immersion, uncurling slightly towards the end of the clip (Movie 4-16).  
This immobility provides a good measure of the fainting phenotype, as seen in Figure 
4-15.  82±13% of wild-type animals demonstrate 2 thrashes within 5 seconds of initial 
immersion, compared to just 21±12% of unc-80 mutant animals.  This is a statistically 
significant decrease in thrashing behaviour (p<0.001).  
We can now assay whether the UNC-80 transgenes are able to rescue this behaviour in 
an unc-80 background. 
4.7.5 - UNC-80 expressed from the unc-17 promoter partially 
rescues the fainting phenotype of unc-80 mutants
unc-80 mutants expressing wild-type UNC-80 protein in their cholinergic neurons from 
the unc-17 promoter thrash 36±15% of the time on immersion in M9 (Figure 4-15).  This is 
less than 50% of the wild-type level, but does demonstrate a slight increase in thrashing 
compared to the unc-80 mutant alone, indicating partial rescue of this swimming defect, 
and suggesting that UNC-80 is required in the cholinergic neurons for wild-type thrashing 
behaviour.
4.7.5.1 - UNC-80 expressed from the synaptobrevin 
promoter does not rescue thrashing behaviour in an 
mutant
As UNC-80 expressed just in the cholinergic neurons was unable to completely rescue 
the thrashing behaviour of  mutants, we tested whether there is a requirement for UNC-
80 in additional neurons for wild-type swimming behaviour.  However, animals expressing 
wild-type UNC-80 protein pan-neuronally from the snb-1 promoter thrash just 10±12% 
of the time on immersion in M9, a decrease when compared to unc-80 mutants alone 
(Figure 4-15), although more repeats are required to assess the significance of this result. 
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4.7.6 - Overexpression of UNC-80 suppresses thrashing 
behaviour in wild-type animals
We hypothesised that the UNC-80 transgenes might be having a dominant negative 
effect on thrashing behaviour and decided to test their effect in a wild-type background. 
When tested in the thrashing assay, UNC-80 expressed from either the unc-17 promoter 
or the synaptobrevin promoter suppressed thrashing in a wild-type animal (Figure 
4-15).  44±21% of wild-type animals expressing UNC-80 in their cholinergic neurons 
were able to thrash on immersion in M9, compared with 82±13% of wild-type animals. 
The reduction in thrashing behaviour was more severe with UNC-80 expressed pan-
neuronally, where just 12% of the transformed animals were able to thrash on initial 
immersion (Figure 4-15), although this is the result of only a single experiment and so 
needs further investigation.  
These results indicate that lack of UNC-80 function, in an unc-80 mutant, or excess 
expression of UNC-80 from an exogenous transgene are both able to interfere with 
normal thrashing and locomotion.  
4.8 - Drug assays of unc-80 mutants
While mutations in the conserved gene unc-80 are able to suppress the loopy locomotion 
phenotype induced by nRHO-1*, we were also interested in whether these mutations 
had a suppressive effect on the excess neurotransmitter release phenotype of nRHO-1* 
mutants.  We use a pharmacological assay where the rate of paralysis in response to 
aldicarb, an acetylcholine esterase inhibitor, is a function of the amount of acetylcholine 
released from the neurons and the sensitivity of the muscles to that neurotransmitter 
(Nurrish, Ségalat et al. 1999).
As previously mentioned, nRHO-1* mutant animals are hypersensitive to aldicarb, 
indicating high levels of neurotransmitter release (McMullan, Hiley et al. 2006).  We 
wanted to test whether  mutants were able to suppress this aldicarb hypersensitivity 
phenotype as well as the loopy locomotion of nRHO-1*.   
4.8.1 - unc-80 mutants display a slight hypersensitivity to 
aldicarb
We first assayed whether the unc-80 single mutants displayed a phenotype when exposed 
to aldicarb.  unc-80 single mutant animals demonstrate a slight hypersensitivity to aldicarb, 
paralysing faster than wild-type on 1mM aldicarb (Figure 4-16).  After 50 minutes, 41±6% 
of  mutant animals are paralysed, compared with 30±2% of wild-type animals.  Although 
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Figure 4-15 unc-80 mutants initial thrashing assays
When wild-type animals are immersed in M9, they thrash vigorously.  unc-80 animals fail to thrash 
on immersion significantly more often than wild-type. 
unc-80 animals rescued with UNC-80 expressed from either the unc-17 promoter or the 
synaptobrevin promoter do not recover thrashing to wild-type levels, although these results do 
not reach significance.  
Wild-type animals expressing UNC-80 either from the unc-17 promoter or the synaptobrevin 
promoter thrash less efficiently than wild-type animals.  
Error bars indicate standard errors of the mean.  Numbers in brackets represent experimental 
repeats.  
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this is not a statistically significant change (p>0.05) (Table 4-2.), it implies that there is a 
trend towards increased acetylcholine signalling at the neuromuscular junction in unc-80 
mutant animals.  
4.8.2 - Mutations in unc-80 do not suppress the aldicarb 
hypersensitivity of nRHO-1* mutants
As previously demonstrated, nRHO-1* mutants are hypersensitive to aldicarb (McMullan, 
Hiley et al. 2006, and see also Figure 1-13).  unc-80;nRHO-1* double mutant animals 
display a strong hypersensitivity to aldicarb compared to unc-80 single mutant animals 
(Figure 4-16).  At 50 minutes on 1mM aldicarb, 80±6% of the double mutant animals are 
paralysed, compared to 41±6% of the unc-80 single mutant animals, a highly significant 
increase in paralysis (p<0.001) (Table 4-2).  This demonstrates that the nRHO-1* 
transgene is able to potentiate the release of neurotransmitter even in an unc-80 mutant 
background (Figure 4-16). 
The double mutant animals paralyse slightly slower than the nRHO-1* single mutants, 
of which 87±5% of animals are paralysed after 50 minutes exposure to 1mM aldicarb, 
demonstrating some slight suppression of the neurotransmitter release phenotype of 
nRHO-1*, although this result is not statistically significant (p>0.05) (Table 4-2).  
This data suggests that there is separation between the loopy behaviour (which can be 
completely suppressed by mutations in unc-80) and the release of acetylcholine (which 
is not strongly suppressed by unc-80 mutations).  This is similar to the situation seen in 
many of the other suppressors isolated from the screen which have non-loopy locomotion 
with high levels of neurotransmitter release (see Chapter 3, particularly Figure 3-5). 
Table 4-2 Statistical analysis of alidicarb data at 50 minute time 
point
Aldicarb data relating to unc-80 and nRHO-1* is summarised here with statistics derived from the 
50 minute time-point data.  Statistics conducted using a 2-tailed unpaired T-Test.  Data relating to 
PMA treatment is given within the body of the text.  
Locus 2
Locus 1
Wild-type 30 ± 2.3, n=52 41 ± 6.0, n=18, p=0.08
unc-80 41 ± 6.0, n=18, p=0.08 -
nRHO-1* 87 ± 2.5, n=37, p<0.0001 79 ± 6.1, n=10, p<0.0001
unc-80;nRHO-1* 79 ± 6.1, n=10, p<0.0001
unc-80;nRHO-1* compared 
with unc-80 p<0.0001
Percentage of animals paralysed at 50 minutes on 1mM aldicarb
Wild-type unc-80
87 ± 2.5, n=37, p<0.0001 - 34, n=1
79 ± 6.1, n=10, p<0.0001 70 ± 7.5, n=2 45, n=1
- - -
unc-80;nRHO-1* compared 
with nRHO-1* p=0.025
96 ± 1.7, n=5, p=0.02 72 ± 13, n=4, p=0.62
nRHO-1* with p.unc-17::GFP::UNC-80 with p.snb-1::GFP::UNC-80
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4.8.2.1 - UNC-80 expressed pan-neuronally rescues the 
decrease in aldicarb hypersensitivity of unc-80;nRHO-1* 
mutant animals
We tested whether our rescuing transgenes, which restore loopy locomotion, were 
able to restore  the slight decrease in aldicarb sensitivity observed in unc-80;nRHO-1* 
double mutants when compared to nRHO-1* animals alone.  When expressed from the 
pan-neuronal p.snb-1 promoter, the aldicarb curve shifts to the left of that seen in unc-
80;nRHO-1* mutant animals (Figure 4-17).  At 50 minutes, 96±2% of the unc-80;nRHO-
1*;p.snb-1::GFP::UNC-80 animals are paralysed compared with 80±6% of the unc-
80;nRHO-1*, which is a stastically significant increase in paralysis (p<0.05) (Table 4-2). 
0% 
20% 
40% 
60% 
80% 
100% 
0 10 20 30 40 50 60 70 80 90 100 
Wild-type
nRHO-1*
unc-80
unc-80;nRHO-1*
Time (minutes)
%
 p
a
ra
ly
sd
 o
n
 1
m
M
 A
ld
ic
a
rb
Figure 4-16 unc-80 mutations only slightly suppress the aldicarb 
phenotype of nRHO-1* animals
Between 25 and 30 animals are placed on plates containing 1mM aldicarb, and assayed for 
paralysis with a nose touch every 10 minutes.  Animals are counted as paralysed if they fail to 
complete the propogation of one wave of body bends following touch.  
We observe a slight increase in the sensitivity of unc-80 single mutants to aldicarb (orange line, 
n=18) compared to wild-type (blue line, n=52).  nRHO-1* animals are hypersensitive to aldicarb 
(red line, n=37), and this hypersensitivity is only slightly decreased in an unc-80;nRHO-1* double 
mutant (green line, n=10).  
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This suggests that unc-80 is required neuronally to enhance the potentiation of 
acetylcholine release by nRHO-1*.  
4.8.2.2 - Cholinergic expression of unc-80 is not able 
to rescue the decrease in aldicarb senitivity seen in an 
unc-80;nRHO-1* mutant 
UNC-80 expressed from the unc-17 promoter, which also drives expression of the nRHO-
1* transgene, has no effect on the aldicarb sensitivity of unc-80;nRHO-1* double mutant 
animals (Figure 4-17).  72±5% of unc-80;nRHO-1*;p.snb-1::GFP::UNC-80 animals are 
paralysed at 50 minutes compared with 80±6% of unc-80;nRHO-1* (p>0.05) (Table 4-2). 
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Figure 4-17 The p.snb-1::GFP::UNC-80 transgene increases 
aldicarb sensitivity in an unc-80;nRHO-1* mutant animal
unc-80;nRHO-1* mutant animals (orange line, n=10) demonstrate a slight decrease in acetylcholine 
release compared with nRHO-1* animals (red line, n=37).  Expressing UNC-80 from the snb-
1 promoter increases acetylcholine release in these mutant animals (green line, n=5), while 
expression from the unc-17 promoter (blue line, n=4) has no effect on neurotransmitter release.  
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Along with the result for the pan-neuronal expression of UNC-80, this suggests that 
UNC-80 is required neuronally, in cells other than those expressing UNC-17, for a portion 
of the acetylcholine release enhanced by expressing nRHO-1*.  These results could also 
be due to differences in the levels of expression between the two transgenes; assaying 
additional transformed lines may help resolve this.
4.8.2.3 - Cholinergic expression of UNC-80 in an unc-80 
mutant animal causes hypersensitivity to aldicarb
Another explanation for the results observed in unc-80;nRHO-1 animals rescued with 
exogenous UNC-80 protein is that the transgene itself, expressed from the synaptobrevin 
promoter, is increasing acetylcholine release independently of the nRHO-1* transgene, 
and the two together have an additive effect.  We tested this by assaying the aldicarb 
sensitivity of unc-80 single mutant animals expressing exogenous UNC-80 from either 
the snb-1 or the unc-17 promoter.  
In a single trial, we saw no change in aldicarb response in animals carrying the 
p.snb-1::GFP::UNC-80 trasgene (Figure 4-18), although this experiment needs to be 
repeated before firm conclusions can be drawn.  From two trials with unc-80 single 
mutants carrying the p.unc-17::GFP::UNC-80 construct we saw an increase in sensitivity 
to aldicarb, although more repeats are required to confirm this result and assess its 
significance (Table 4-2).
Should these results hold, they suggest that overexpression of UNC-80 can cause 
hypersensitivity to aldicarb under some conditions, in this instance when expressed 
in the cholinergic neurons from the snb-1 promoter, or from the unc-17 promoter in 
combination with the nRHO-1* transgene.
The snb-1 promoter expresses in cholinergic neurons and in all other neurons; the 
difference between results with these transgenes may be due to the effects of UNC-80 
in those additional cells, or due to differences in levels of expression between the two 
transgenes.  Assaying additional transformed lines may allow us to distinguish between 
these possibilities.  
4.8.3 - unc-80 mutants response to levamisole
An increase in the sensitivity of animals to aldicarb could be due to an increase in 
the release of acetylcholine from the motor neurons, or result from an increase in the 
sensitivity of the muscles to acetylcholine (see Chapter 3 (McMullan, Hiley et al. 2006).  
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Animals carrying a mutation in unc-80 paralyse faster than wild-type animals on the drug 
levamisole.  Levamisole directly stimulates the post-synaptic acetylcholine receptors on 
the body wall muscles, and induces paralysis at a rate proportional to the sensitivity 
of those receptors.  The unc-80 response curve is shifted to the left of the wild-type 
curve, which suggests that the unc-80 mutation is having an effect on the body wall 
muscles (Figure 4-14).  This effect is not stastically significant, 19±7% of unc-80 mutant 
animals are paralysed at 50 minutes, compared with 9±1% of wild-type animals (Table 
4-3).  However, it is possible that the unc-80 hypersensitivity to aldicarb is due, in part at 
least, to a change in muscle sensitivity.  
4.8.4 - unc-80;nRHO-1* double mutants are resistant to 
levamisole
We tested the unc-80;nRHO-1* double mutants for their response to the agonist 
levamisole.  The response curve is shifted to the right compared with wild-type, nRHO-
1* and unc-80 mutant animals, suggesting that some interaction between the nRHO-1* 
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Figure 4-18 The p.unc-17::GFP::UNC-80 transgene increases 
aldicarb sensitivity in an unc-80 mutant
Expression UNC-80 from the unc-17 promoter in an unc-80 mutant background increases 
sensitivity to aldicarb (blue line, n=2) compared with unc-80 mutant animals alone (orange line, 
n=18) while expression of UNC-80 from the snb-1 promoter has no effect on aldicarb sensitivity 
(green line, n=1).  
212
transgene and the unc-80 mutation is causing a decrease in the sensitivity of the body 
wall muscles to levamisole.  
At 50 minutes, 7±1% of these animals were paralysed on 100μM levamisole, compared 
to 19±7% of unc-80 single mutant animals (p<0.05) and 27±7% of nRHO-1* single 
mutants (which approaches significance, p=0.06), indicating that these double mutants 
are resistant to the effects of levamisole (Table 4-3).  This reduction in sensitivity to 
levamisole, suggests that in these mutants the aldicarb assay underestimates the levels 
of acetylcholine release as the muscles are less sensitive to acetylcholine (Figure 4-16). 
In turn, this suggests a possible homeostatic compensation mechanism, where the 
muscle sensitivity to neurotransmitter is reduced in an attempt to balance the effects of 
excess neurotransmitter release.  
4.8.5 - Expressing UNC-80 in the nervous system rescues the 
levamisole resistance of unc-80;nRHO-1* animals
We tested whether the expression of the UNC-80 transgenes was able to rescue the 
levamisole resistance of the unc-80;nRHO-1* double mutant animals. 
unc-80;nRHO-1* animals expressing UNC-80 from the synaptobrevin promoter are 
hypersensitive to levamisole, with 75% of the animals paralysed at 50 minutes compared 
with 7±1% of the unc-80;nRHO-1* mutant animals (Figure 4-20).  Similarly, animals 
expressing UNC-80 from the unc-17 promoter are also hypersensitive to levamisole, 
with 74% of animals paralysed at 80 minutes (Figure 4-15).  Although these figures are 
the results of only a single trial, they suggest that presynaptic expression of UNC-80 can 
induce changes in the sensitivity of the body wall muscles to acetylcholine.  
Locus 2
Locus 1
Wild-type 9 ± 1.2, n=14 19 ± 6.7, n=9, p=0.11
unc-80 19 ± 6.7, n=9, p=0.11 -
nRHO-1* 27 ± 6.6, n=8, p<0.03 7 ± 1.7, n=5, p=0.06
unc-80;nRHO-1* 7 ± 1.7, n=5, p=0.4
unc-80;nRHO-1* compared 
with unc-80 p=0.06
Percentage of animals paralysed at 50 minutes on 100µM levamisole
Wild-type unc-80
27 ± 6.6, n=8, p<0.03 - -
7 ± 1.7, n=5, p=0.02 52 ± 6.2, n=2 27 ± 0.5, n=2
- - -
unc-80;nRHO-1* compared 
with nRHO-1* p=0.02
74, n=1 75, n=1
nRHO-1* with p.unc-17::GFP::UNC-80 with p.snb-1::GFP::UNC-80
Table 4-3 Statistical analysis of levamisole data at 50 minute 
time point
All levamisole data in this chapter is summarised here with statistics derived from the 50 minute 
time-point data.  Statistics conducted using a 2-tailed unpaired T-Test.  
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4.8.6 - Expressing UNC-80 in the nervous system of unc-80 
mutants causes hypersensitivity to levamisole
To test whether the ability of the UNC-80 transgenes to increase sensitivity to levamisole 
is dependent on the presence of the nRHO-1* transgene, we assayed the levamisole 
sensitivity of animals carrying UNC-80 transgenes in an unc-80 mutant background. 
Animals expressing UNC-80 protein from the synaptobrevin promoter have essentially 
the same levamisole response as unc-80 mutants (with 27±1% paralysed at 50 minutes 
compared to 19±7% of unc-80 mutants, Figure 4-21), suggesting that alone this transgene 
does not affect signalling.  
UNC-80 expressed from the unc-17 promoter causes a hypersensitivity to levamisole in 
unc-80 mutant animals (Figure 4-21), with 52±6% of animals paralysed at 50 minutes, 
(Table 4-3).  This could reflect a difference between rescue in all motor neurons and 
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Figure 4-19 unc-80;nRHO-1* double mutants are resistant to 
levamisole
Between 25 and 30 animals are placed on plates containing 100μM levamisole, which directly 
stimulates contraction of the body wall muscles, and assayed for paralysis with a nose touch 
every 10 minutes.  Animals are counted as paralysed if they fail to complete the propogation of 
one wave of body bends following touch.  
We observe an increase in the sensitivity of unc-80 single mutants to levamisole (orange line, n=9) 
compared to wild-type (blue line, n=14).  nRHO-1* animals are also hypersensitive to levamisole 
in these assays (red line, n=8).  The double mutant unc-80;nRHO-1* is resistant to the effects of 
levamisole (green line, n=5).  
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rescue only in the cholinergic motor neurons, suggesting a potential role for GABA 
release.  
These preliminary results, based on two repeats for each transgene, must be repeated at 
least two more times before drawing any strong conclusions about effects on levamisole 
response.  Taken together however, these results suggest that overexpression of some 
GFP::UNC-80 transgenes increases sensitivity to levamisole, and that addition of the 
nRHO-1* transgene enhances this effect.  
We have seen that loss of unc-80 allows for a reduction in levamisole sensitivity in 
nRHO-1* animals.  These overexpression experiments demonstrate the opposite 
phenotype.  This suggest a possible role for UNC-80 in neurons increasing muscle 
sensitivity to acetylcholine.  Whether this change in sensitivity plays a role in the observed 
loopy behaviour remains to be determined (see discussion at the end of Chapter 5).  
Figure 4-20 Rescue of the unc-80 suppression phenotype by 
neuronal expression of UNC-80
The double mutant unc-80;nRHO-1* is resistant to the effects of levamisole (orange line, n=5).  We 
tested the lines expressing GFP::UNC-80 under the control of either the unc-17 promoter (green 
line, n=1) or the synaptobrevin promoter (blue line, n=1).  These results are based on a single 
repeat, but do suggest that the GFP::UNC-80 constructs can increase sensitivity to levamisole in 
an unc-80;nRHO-1* double mutant.
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4.9 - unc-80 mutants are able to respond to 
phorbol esters
One theory to explain the suppression of loopy behaviour of the nRHO-1* transgene by 
mutants would be if these mutants were generally able to suppress the activity of the 
nervous system.  This would be consistent with their published role, alongside the nca-1 
and nca-2 ion channels, in propagating neuronal activity in certain neurons in C. elegans 
(Yeh, Ng et al. 2008).  Ye et al suggest that NCA-1 and NCA-2, acting as sodium leak 
channels, could bring the neuronal membrane potential closer to its excitation threshold, 
allowing for passive propogation of nerve impulses to the synapse.
This model provides a simple explanation for the fainting phenotype – when the activity of 
the nervous system reaches some given threshold, the animal is able to move normally 
despite the absence of the NCA-1 and NCA-2 channels; below that threshold the animal 
remains motionless.  It is possible that this threshold is higher in a fainter, meaning they 
remain motionless for a greater period of time than wild-type animals, although strong 
stimulation, such as a nose touch, is sufficient to induce movement. 
Figure 4-21 The UNC-80 rescuing transgenes increase 
levamisole sensitivity in an unc-80 mutant
The unc-80 mutants display a slight hypersensitivity to levamisole compared to wild-type animals 
(Figure 4-19).  Addition of GFP::UNC-80, under the control of the synaptobrevin promoter, does 
not alter this response (blue line, n=2).  Expressing GFP::UNC-80 from the unc-17 promoter in 
an unc-80;nRHO-1* mutant causes an increase in the sensitivity to levamisole (green line, n=2)
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Figure 4-22 unc-80 mutants can respond to PMA by increasing 
sensitivity to aldicarb
Animals are pre-incubated with either PMA or a DMSO control for 2 hours.  Between 25 and 30 
animals are placed on plates containing 1mM aldicarb and either PMA or DMSO and assayed 
for paralysis with a nose touch every 10 minutes.  Animals are counted as paralysed if they fail 
to complete the propogation of one wave of body bends following touch.  These experiments are 
conducted off food.
Wild-type animals on PMA (dotted blue line, n=12) paralyse faster than wild-type animals on the 
DMSO control plates (solid blue line, n=12).  We see a similar increase in the response of unc-80 
mutants exposed to PMA (dotted orange line, n=5), which paralyse faster than the unc-80 animals 
on the DMSO control plates (solid orange line, n=5).  
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One way to test whether unc-80 mutants are globally reducing the activity of the 
nervous system is to see their effect on pharmacological agents which stimulate 
neuronal activity.  One compound with which we can achieve this stimulation is the 
phorbal ester PMA, which is an analogue of diacylglycerol (DAG).  DAG is a key second 
messenger in the nervous system and is removed from the presynatpic membrane by 
diacylglycerol kinase (DGK-1) (Nurrish, Segalat et al. 1999) which in turn is inhibited by 
RHO-1 (McMullan, Hiley et al. 2006), and acts to stimulate release of neurotransmitter 
(Lou, Korogod et al. 2008)
By stimulating  mutant animals with PMA we can test two things.  First, if the overall 
activity of the nervous system is lowered by unc-80 mutations, this should result in a 
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resistance to the effects of PMA.  Secondly, as PMA is an analogue of DAG which acts 
downstream of nRHO-1 to promote release of neurotransmitter we can start to define the 
position the  mutation with respect to other parts of the neurotransmitter release pathway.
The assay is a modified form of the aldicarb assay: animals are placed on plates 
containing either PMA or DMSO control, with food, for two hours preincubation.  Worms 
are then picked to plates containing aldicarb and either PMA or DMSO, and assayed for 
paralysis.  
When exposed to a combination of PMA and aldicarb, wild-type animals paralyse faster 
compared with control animals, (100±1% of animals paralysed at 50 minutes, compared 
to 49±8% of animals on control plates) (Figure 4-22).  We observe a similar increase 
in the rate of paralysis in unc-80 mutants exposed to PMA, with 100±0% of animals 
paralysed at 50 minutes exposure to PMA and aldicarb, compared with 61±25% of 
animals paralysed on the DMSO control plates (Figure 4-13).  
This indicates an increase in the activity of the nervous system in unc-80 animals as a 
result of PMA stimulation (Figure 4-22) in line with that seen for wild-type.  This suggests 
that there is no gross reduction in nervous system activity, and that unc-80 acts in a 
pathway upstream of or in parallel to PMA, and hence to diacylglycerol.
4.10 - Mutations in unc-80 suppress the small body size of 
nRHO-1* animals
We noticed that the animals carrying the nRHO-1* transgene looked smaller than wild-
type animals.  Animals were staged by picking L4 animals, and then images were taken 
using the Micromanager add-on to the ImageJ software.  Animals were measured from 
the tip of the head to the tip of the tail (with each animal being measured twice and the 
average taken).  
nRHO-1* animals are significantly smaller than wild-type animals by about 20% (Figure 
4-23).  The reason for this size difference is unclear.    
The double mutant unc-80;nRHO-1* animals, as well as having a more wild-type 
locomotion, also have a partially restored body size – with their head to tail measurements 
being intermediate between wild-type and nRHO-1* (Figure 4-23, and see Figures 4-6 
and 4-9 for representative images taken at the same magnification.)
We have yet to test whether this phenotype is rescued by addition of the  transgenes, 
although by eye the rescued animals appear smaller than animals not carrying the 
unc-80 transgenes.  
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Figure 4-23 unc-80 mutations suppress the small body size of 
nRHO-1* mutants
The length of animals was assayed from images captured using Micromanager and ImageJ.  Two 
recordings were taken for each animal.  nRHO-1* mutants are significantly smaller than wild-type 
animals or unc-80 mutants, and this difference is partially suppressed in the unc-80;nRHO-1* 
double mutants.  A pan-neuronal UNC-80 transgene under the control of the snb-1 promoter 
partially rescues the suppression of small body size in a unc-80;nRHO-1* double mutant animal. 
Error bars indicate standard errors of the mean.  Numbers in brackets indicate number of animals 
observed.  (Significance assessed using a 2-tailed T-test. * = p<0.05, *** = p<0.001)
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4.11 - Defecation assays
unc-80 mutants exhibit fainting locomotion on a solid surface, and have reduced thrashes 
in liquid, although they are capable of both swimming and crawling during short bursts of 
activity.  The propogation of movement is a rhythmic behaviour, and we speculated that 
they might show defects in other regulated behaviours, such as defecation.  
We tested the animals for any potential defects in defecation, which is a tightly controlled 
cycle lasting about 50 seconds in a well-fed adult animal (Avery 1997).  About 50 genes 
are known to play a role either in the length of the defecation cycle or in controlling its 
frequency, and around 20 of these act in the intestine itself (Branicky and Hekimi 2006). 
The Defecation Motor Program (DMP) consists of three stages which occur over the 
course of approximately 5 seconds: a posterior body contraction (pBoc), an anterior 
body contraction (aBoc), and expulsion of the gut contents (Exp).  The expulsion step 
is the only one that requires neuronal function.  It is regulated by GABA acting in an 
excitatory fashion (Beg and Jorgensen 2003).  These steps reoccur with approximately 
45 second of pause in between.  
4.11.1 - unc-80 mutants have a mildly disrupted defecation 
cycle.
In the assays conducted here, in wild-type animals the pBoc occurs every 59±5 seconds, 
while the Exp step occurs every 62±13 seconds, slightly longer intervals than the recorded 
average (Figure 4-24). 
unc-80 mutants display a slight increase in the length and variability of their defecation 
cycle, with pBoc occurring every 65±13 seconds, and Exp every 71±21 seconds (Figure 
4-24).  This suggests that UNC-80 has a small role in the defecation motor program, 
particularly in the step involving the release of GABA.  A future experiment would be to 
test our animals rescued with UNC-80 expressed pan-neuronally to see if they recover 
from this defect.  
4.11.2 - nRHO-1* mutants display a defect in defecation
nRHO-1* mutant animals were also assayed for their defecation cycle.  We observed 
that they displayed fewer Exp steps than wild-type animals, resulting in an increase in 
the average interval between these steps from 62±13 seconds in wild-type to 104±30 
seconds in nRHO-1* mutants (Figure 4-24).  This is a previously unreported phenotype 
for these animals.  Their pBoc cycles also become highly variable, occurring on average 
every 49 seconds, but with a standard error of the mean of 36 seconds.
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4.11.3 - unc-80;nRHO-1* mutants have increased defecation 
cycle length compared to unc-80 mutant animals
There is a significant increase in the length of defecation cycles to 96±11 seconds for the 
pBoc and 103±13 seconds for the Exp steps (Figure 4-24).  The Exp phenotype is very 
similar to that of the nRHO-1* single mutants, suggesting that the  mutation has no effect 
on this nRHO-1* phenotype.  
0
20
40
60
80
120
W
ild
-t
yp
e
u
n
c
-8
0
n
R
H
O
-1
*
u
n
c
-8
0;
n
R
H
O
-1
*
W
ild
-t
yp
e
u
n
c
-8
0
n
R
H
O
-1
*
u
n
c
-8
0;
n
R
H
O
-1
*
pBoc Interval Exp Interval
100
140
*
**
*
***
***
In
te
rv
a
l (
se
c
o
n
d
s)
(14) (18) (4) (6) (14) (18) (4) (6)
Figure 4-24 Defecation assay of unc-80 and nRHO-1* mutants
Animals were observed for periods of 5 minutes, during which each pBoc and Exp was recorded 
using the program EthoTimer.  Average intervals for each step were obtained for each mutant, 
with the overall average being plotted here.  
unc-80 animals display a lengthening of their defecation cycle compared to wild-type animals. 
nRHO-1* mutants display a defect in the frequency of Exp steps compared to wild-type.  
Error bars indicate standard errors of the mean.  Numbers in brackets indicate number of animals 
observed.  (Significance assessed using a 2-tailed T-test.  * = p<0.05  ** = p<0.01  *** = p<0.001)
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4.12 - The F25N mutation in RHO-1 bypasses the suppressive 
effects of loss of UNC-80 with respect to loopy locomotion
Through the screen we were aiming to identify proteins which acted downstream of 
RHO-1* in neurotransmitter release.  We knew from the experiment with dgk-1 mutants 
expressing C3 transferase (McMullan, Hiley et al. 2006)  that there must be additional 
targets of RHO-1, as inhibition of RHO-1 still reduces the level of neurotransmitter release 
in this mutant background (McMullan, Hiley et al. 2006). 
As demonstrated earlier in this chapter unc-80 mutations have very little effect on the 
neurotransmitter release phenotype of nRHO-1*, but completely suppress the loopy 
locomotion phenotype.  We considered that unc-80 acted in parallel with dgk-1 with 
respect to acetylcholine release.  Therefore, to block the ability of nRHO-1* to increase 
acetylcholine release we sought to block both the unc-80 and dgk-1 pathways. 
To test this, we made use of an additional RHO-1 mutant which carries the mutation 
F25N along with G14V.  This mutation was isolated by Alan Hall, and is common in many 
Figure 4-25 unc-80;nRHO-1(F25N)* double mutants are loopy
unc-80 animals were injected with plasmid RJM39 at a concentration of 1ng/μl.  One transformed 
line, Line 6, produced loopy animals.  This line was very unstable, and lost expression of the 
co-injection marker after three or four generations.  These images were taken of F2 generation 
animals carrying the unc-17::GFP co-injection marker.  
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constructs containing the human homologue, RhoA, where it is used to increase the 
stability of transgenic RhoA protein when expressed in bacteria.  
Another effect of this mutation, however, is to significantly reduce the interaction between 
RHO-1 and DGK-1 (McMullan, Hiley et al. 2006).  It has been speculated that the wide-
spread use of this point mutation might have led to additional RHO-1/RhoA pathways 
being overlooked (McMullan and Nurrish 2007).
The RHO-1(G14V F25N) construct, under either the heatshock or unc-17 promoter, 
is able to increase levels of neurotransmitter release, although to a lower level than 
the RHO-1(G14V) construct (McMullan, Hiley et al. 2006).  Constructs carrying the 
F25N point mutation still cause the animals to become highly uncoordinated and loopy, 
demonstrating that the dgk-1-independent pathway is able to drive behavioural changes 
in a similar way to the dgk-1-dependent pathway.
As the dgk-1-dependent pathway is important for increasing levels of neurotransmitter 
release, and the pathway incorporating  is necessary for loopy locomotion, we wanted to 
examine the phenotype of an unc-80;nRHO-1(F25N)* mutant, to see whether both the 
locomotion and the neurotransmitter release pathways activated by RHO-1 would be 
suppressed.
4.12.1 - Neuronal expression of RHO-1(G14V F25N) in an unc-
80 mutant causes loopy locomotion
We injected plasmid RJM39, carrying RHO-1(G14V F25N) under control of the unc-17 
promoter, directly into unc-80 mutants, along with unc-17::GFP as a co-injection marker. 
RJM39, as with all RHO-1 constructs we have used, can cause pathfinding defects and 
even death in animals misexpressing the construct.  
RJM39 constructs tend to create rather unstable extrachromosomal arrays (R. McMullan, 
personal communication.)  We have not been able to maintain stable lines expressing 
this construct.
However, we were able to sustain one or two generations of animals carrying the nRHO-
1(F25N)* construct.  These animals clearly became loopy in comparison to untransformed 
animals (Figure 4-25). 
4.12.2 - The loopy phenotype of unc-80;nRHO-1(F25N)* 
animals is not associated with pathfinding defects
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We had coinjected an unc-17::gfp construct which allowed us to check for pathfinding 
defects, which are a possible cause of uncoordinated locomotion.  In the animals which 
demonstrated a loopy phenotype, we could not see any gross changes in the morphology 
of the nervous system which might explain the changes. 
4.12.3 - Heatshock expression of RHO-1(G14V F25N) in an 
unc-80 mutant causes loopy locomotion
We crossed unc-80 mutants with a previously generated RHO-1(G14V F25N) heatshock-
inducible line (hsRHO-1(F25N)*).  This construct is not integrated, so by looking for 
animals which lack the coinjection marker we can control for the effects of heatshock on 
the unc-80 mutant background.
Figure 4-26 unc-80;hsRHO-1(F25N)* double mutants are loopy
unc-80 animals carrying the hsRHO-1(F25N)* transgene become loopy following heatshock, 
unlike unc-80 mutant animals, which are unaffected by heatshock, or unc-80;hsRHO-1* mutant 
animals.  This image was taken with the UV light switched on, showing the unc-17::GFP marker. 
unc-80 animals not carrying the marker do not become loopy following heatshock.
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The double mutant unc-80;hsRHO-1(F25N)* is non-loopy and appears fainter prior to 
heatshock.  Following heatshock, the animals carrying the RHO-1 array become highly 
loopy within a period of four hours (Figure 4-26).  Animals not carrying the RHO-1 
construct remain non-loopy (Figure 4-26).  This is in marked contrast to unc-80 animals 
upon heatshock activation of RHO-1*, which do not become loopy.   
We grew the worms are at 15oC, to reduce unwanted activity of the heatshock transgene. 
When adult animals which are non-loopy are subjected to heatshock, they develop loopy 
locomotion, demonstrating that this effect occurs in developed animals.
4.12.4 - unc-80 mutants do not suppress the additional 
phenotypes of hsRHO-1(F25N)*
When unc-80;hsRHO-1(F25N)* animals are subjected to heatshock, we see that after 4 
days of growth there are no progeny from the heatshocked animals.  The sterile adults 
develop the dar phenotype associated with hsRHO-1* expression.
This demonstrates that UNC-80 is not required for the non-neuronal functions of RHO-1 
which manifest even with the F25N mutation. 
4.12.5 - unc-80 mutations do not suppress the increase in 
aldicarb sensitivity caused by activation of the hsRHO-
1(F25N)* transgene
Wild-type animals carrying the hsRHO-1(F25N)* transgene become hypersensitive to 
aldicarb following heatshock (Figure 4-27, Table 4-3).  unc-80 mutants carrying this 
transgene also become hypersensitive to aldicarb following heatshock (Figure 4-27, 
Table 4-3)
Activation of the hsRHO-1(F25N)* transgene in an unc-80 mutant background induces 
slightly less hypersensitivity to aldicarb than in a wild-type background, in a situation 
which appears analagous to that seen in Figure 4-16, where unc-80 mutants partially 
suppress the aldicarb sensitivity induced by the nRHO-1* transgene, although this 
difference is not stastically significant (p>0.05)..  
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Locus 2
Locus 1
Wild-type 
(+heatshock)
17 ± 1.3, n=6 93 ± 4.1, n=3, p<0.0001
unc-80 
(+heatshock)
11 ± 1.6, n=5 83 ± 3.9, n=6, p<0.0001
without hsRHO(F25N)* transgene with hsRHO(F25N)* transgene
Percentage of animals paralysed at 50 minutes on 1mM aldicarb
Table 4-3 Statistical analysis of aldicarb data at 50 minute time 
point
Analysis of effect of activation of the hsRHO(F25N)* transgene summarised here with statistics 
derived from the 50 minute time-point data.  Statistics conducted using a 2-tailed unpaired T-Test. 
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Figure 4-27 hsRHO-1(F25N)* increases sensitivity to aldicarb
unc-80 animals carrying the hsRHO-1(F25N)* transgene become hypersensitive to aldicarb 
following heatshock (orange dotted line, n=6) compared to unc-80 animals without the transgene 
(solid orange line, n=5).  Wild-type animals expressing the hsRHO-1(F25N)* transgene also 
become hypersensitive to aldicarb following heatshock (dotted blue line, n=3) compared with 
animals not carrying the transgene (n=5).  
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4.12.6 - Heatshock expression of RHO-1(G14V F25N) in an 
unc-80;nRHO-1* mutant causes loopy locomotion
When RHO-1 is wildtype at residue 25 (nRHO-1*), its ability to generate loopy locomotion 
is impaired by loss of unc-80.  When the F25N mutation is introduced into RHO-1, 
this somehow bypasses the requirement for UNC-80 in developing loopy locomotion 
phenotype.  
Here I consider three potential explanations (see Figure 5-26).  
i)  The F25N mutation reduces signalling to a RHO-1 effector.  Loss of signalling to this 
effector bypasses the requirement for unc-80 in the generation of loopy locomotion.
ii)  The F25N mutation is able to signal to a new effector, one which is not a target of F255 
RHO-1* and this is independently able to generate loopy locomotion in the absence of 
UNC-80 function.
iii)  The F25N mutation reduces signalling to a RHO-1 effector, allowing additional RHO-
1 signalling through the remaining pathways.  This extra signalling is able to generate 
loopy locomotion in the absence of unc-80.  
To partially distinguish between these hypotheses, we generated an animal carrying both 
the nRHO-1*construct (expressed from the unc-17 promoter) and RHO-1*(F25N) under 
the heatshock promoter, in an unc-80 background.  
Prior to heatshock, these animals are non-loopy - the loss of unc-80 suppresses the 
loopy phenotype of nRHO-1*, as previously observed.  These animals are grown at 15oC 
to avoid unwanted activation of the hsRHO-1*(F25N) transgene. 
Upon heatshock, the animals become highly loopy and uncoordinated in the same 
manner as the unc-80;nRHO-1*(F25N) animals. 
This result appears to rule out hypothesis (i).  If the F25N mutation were to reduce 
signalling to an effector of RHO-1*, and this loss of signalling was able to bypass the 
requirement for  in loopy locomotion, then the expression of RHO-1* in the cholinergic 
motor neurons should negate this effect and restore non-loopy locomotion.  
We cannot yet distinguish between the remaining hypotheses (ii) and (iii), as both are 
consistent with the results observed here.  
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4.13 - Discussion
nz94 is a mutant able to suppress the loopy phenotype of nRHO-1*.  This mutant was 
discovered to have an additional fainting locomotion, which helped us identify it as an 
allele of the large, conserved gene unc-80 (Figure 4-4).  We subsequently found that an 
additional unc-80 mutation was also able to suppress this loopy locomotion phenotype 
(Figure 4-5), and successfully rescued this with transgenes expressed either pan-
neuronally or in the cholinergic neurons, where the nRHO-1* transgene is expressed 
(Figure 4-9).  
Two other classes of mutations - in the large, conserved protein unc-79, and in the 
double mutant nca-1;nca-2 - also generate a fainting locomotion.  These proteins are 
thought to form part of a novel neuronal complex.
The relationship between unc-79, nca-1 and nca-2 and the nRHO-1* transgene will be 
assessed in the following chapter, after which I will discuss in detail the results from 
both sets of experiments, as we believe that these proteins are connected by a common 
pathway.  
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5 - THE NCA-1/NCA-2/UNC-79 ION 
CHANNEL COMPLEX IS REQUIRED FOR THE 
LOOPY LOCOMOTION PHENOTYPE OF NRHO-
1* ANIMALS
5.1 - Introduction
Following our discovery that mutations in unc-80 are sufficient to suppress the loopy 
phenotype of nRHO-1* animals, we next explored the potential for other mutations 
associated with unc-80 to interact with our nRHO-1* mutant animals.
unc-80 and unc-79 share a common fainter phenotype (Pierce-Shimomura, Chen et 
al. 2008; Yeh, Ng et al. 2008), where periods of normal locomotion are interrupted by 
extended periods of inactivity.  
Early reports that unc-80 mutants were hypersensitive to the general anaesthetic 
halothane demonstrated that unc-79 mutants were similarly hypersensitive, and that 
the double mutant was only slightly more sensitive than either single mutant (Sedensky 
and Meneely 1987; Morgan, Sedensky et al. 1988).  Hypersensitivity of both mutants 
to halothane is suppressed by mutations in unc-1 (Morgan, Sedensky et al. 1990), a 
stomatin which forms part of gap junctions - direct electrical couplings between muscles 
cells and cells of the nervous system.  This is suggestive of proteins which act in a 
common pathway.  
The UNC-79 and UNC-80 proteins do not share any significant homology to each other. 
unc-79 (Figure 5-1, A) is a large gene, with a predicted 2092 amino acids in its largest 
splice form, and is conserved from nematodes to mammals, although it does not contain 
any domains of known function, aside from a predicted armadillo repeat domain structure 
(Pierce-Shimomura, Chen et al. 2008), which is also predicted for unc-80.  
The fainting phenotype has been reported for only one other class of mutants, the double 
mutant nca-1;nca-2.  A number of mutations have been identified for both of these 
proteins (Figure 5-1, B and C).
The novel ion channel NCA-1 (also called UNC-77), and its homologue, NCA-2, are 
the C. elegans homologues of the 24-transmembrane-spanning mammalian ion channel 
NALCN (Jospin, Watanabe et al. 2007; Yeh, Ng et al. 2008), part of the protein family 
which includes voltage-gated sodium and calcium channels (Yu, Yarov-Yarovoy et al. 
2005; Snutch and Monteil 2007).  
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This ion channel and its C. elegans homologues are unusual in that the S4 transmembrane 
segments lack some of the charge residues (K and R) found at every third position in 
the S4s of the voltage-gated sodium, calcium and potassium channels which make up 
the rest of the family. In addition, its selectivity filter contains a novel EEKE motif, a 
mixture between the EEEE found in the voltage-gated calcium channels and the DEKA 
motif of voltage-gated sodium channels (Lee, Daud et al. 1999).  These changes make 
NALCN permeable to calcium, potassium and sodium ions.  It appears to be a voltage-
independent channel (Lu, Su et al. 2007).  
In C. elegans, UNC-79, NCA-1, NCA-2 and UNC-80 staining is extrasynaptic, and does 
not colocalise with synaptic markers such as synaptobrevin (Yeh, Ng et al. 2008).  Loss 
of UNC-80 or UNC-79 protein leads to a loss of NCA-1 punctate staining in the nerve 
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Figure 5-1 Gene models of unc-79, nca-1 and nca-2
Alongside unc-80 two other sets of mutations are known to generate fainting locomotion.  These 
are mutations in the large conserved protein unc-79 (A), and the double mutant of nca-1 (B) and 
nca-2 (C), which code for the C. elegans orthologues of the mammalian NALCN ion channel. 
Scale bars indicate 1kb.  Deletions are highlighted in red, known point mutations in orange.  The 
molecular nature of an additional unc-79 mutation, e1068, has not yet been determined.  (Data 
obtained from Wormbase).  
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cord (Yeh, Ng et al. 2008).  This suggests that UNC-79 and UNC-80 somehow regulate 
the localisation of NCA-1.  Interestingly, loss of NCA-1 protein also leads to a diffuse 
rather than punctate staining for UNC-80 and UNC-79 (Yeh, Ng et al. 2008), suggesting 
that all these proteins are all dependent on one another for their localisation. 
Loss of UNC-79, UNC-80 or the ion channel proteins themselves generates the same 
phenotypes – fainting behaviour and altered anaesthetic sensitivity.  Having seen that loss 
of UNC-80 is able to suppress the loopy locomotion of nRHO-1* mutants, we therefore 
decided to test whether loss of UNC-79, NCA-1 or NCA-2 were also able to suppress 
this phenotype.  For these experiments we made use of the following alleles - unc-79 
(e1068), nca-1 (gk9) and nca-2 (gk5).  While the e1068 mutation is the cannonical allele 
for unc-79, its molecular nature is undetermined.  The gk9 and gk5 alleles are both large 
deletions in the nca-1 and nca-2 genes (Figure 5-1).  
5.2 - Fainter mutant animals display a swimming defect
While fainting locomotion on a solid surface is difficult to quantify, we found that studying 
the behaviour of unc-80 mutants in liquid was much easier to quantify (Chapter 4).  We 
used two distinct assays for analysing unc-80 mutants.  In the first, the ‘Mean thrashes 
per minute’ assay, we allowed worms to recover for three minutes after immersion in M9, 
then counted the number of thrashes over a two minute period.  unc-80 fainter mutants 
thrash less than wild-type animals in this assay (Figure 4-13).  
The second test involves placing an animal in a drop of M9, and recording whether it 
completes two body bends in the first 5 seconds following immersion.  unc-80 animals 
display a defect in this initial thrashing assay (Figure 4-15).  
We therefore decided to test whether these results are replicated with the other mutants 
under investigation in this chapter.  
5.2.1 - unc-79 mutants exhibit a swimming defect on initial 
immersion and  following recovery in M9 
On a solid surface, unc-79 mutants move with a fainting locomotion (Sedensky and 
Meneely 1987).  In line with our experiments conducted on unc-80 mutants and previously 
published data on the swimming efficiency of these animals (Pierce-Shimomura, Chen 
et al. 2008), we assayed the response of unc-79 mutants to immersion in M9.  When 
initially placed in liquid, just 10±2% of unc-79 animals thrash in the first 5 seconds of 
immersion, compared with 82±6% of wild-type animals (Figure 5-2, A).  
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When assayed over two minutes, having been allowed to recover for 3 minutes, unc-79 
animals thrash significantly less than wild-type animal (Figure 5-2, B).  
These assays indicate that while initally inert following immersion in M9, by three minutes 
unc-79 mutants have begun to thrash, although this rate of thrashing is below that seen 
in wild-type animals.  
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Figure 5-2 Swimming assays of unc-79 mutants
We assayed the behaviour of unc-79 animals in liquid using two distinct assays.  A)  Initial 
thrashing assay.  Animals were placed in a drop of M9, and assayed for thrashing behaviour for 
5 seconds after immersion.  unc-79 animals thrash significantly less often than wild-type animals 
in this assay.  Each repeat consists of measuring the response of at least 15 animals.  B)  Mean 
thrashes per minute.  Animals were allowed to recover for 3 minutes following immersion in M9, 
and then the total number of thrashes counted for two minutes.  unc-79 exhibit fewer thrashes per 
minute than wild-type animals.
Error bars indicate standard errors of the mean.  Numbers in brackets indicate number of animals 
observed.  (Significance assessed using a 2-tailed T-test. *** = p<0.001)
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5.2.2 - nca-1 mutants are wild-type in their swimming 
behaviour
In the majority of assays reported so far (Jospin, Watanabe et al. 2007; Pierce-Shimomura, 
Chen et al. 2008; Yeh, Ng et al. 2008), nca-1 appears to act redundantly with nca-2 and 
thus nca-1 single mutants appear to be wild-type in their behaviour.  In our swimming 
assay, there was no significant difference in the rate of thrashing of nca-1 mutant animals 
compared with wild-type animals (Figure 5-3).
5.2.3 - nca-1;nca-2 double mutants exhibit swimming 
defects
nca-1 and nca-2 mutants are highly homologous (Figure 5-6), and the loss of both 
genes is required for the establishment of the fainting phenotype.  We generated double 
0 
20 
40 
60 
80 
100 
120 
W
ild
-t
yp
e
n
c
a
-1
(25) (12)
n.s.
A
ve
ra
g
e
 t
h
ra
sh
e
s 
p
e
r m
in
u
te
Figure 5-3 Swimming assays of nca-1 single mutants
Animals were assayed for total thrashes after 3 minutes of recovery in M9.  nca-1 single mutant 
animals exhibit no significant difference in their number of thrashes compared to wild-type animals.
Error bars indicate standard errors of the mean.  Numbers in brackets indicate number of animals 
observed.  (Significance assessed using a 2-tailed T-test. n.s. = not significant)
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mutant animals through crossing nca-1 (VC12) animals with nca-2 (VC9).  Each strain 
naturally produces a low incidence of male animals, which we used for these crosses. 
The resulting strain, QT961, has a fainting phenotype on solid surfaces (Movie 5-1).
When initially immersed in liquid, the nca-1;nca-2 double mutants fail to thrash (Figure 
5-4, A), while their mean thrashing rate after three minutes recovery is significantly 
reduced compared to wild-type animals (Figure 5-4, B). 
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Figure 5-4 Swimming assays of nca-1;nca-2 mutants
We assayed the behaviour of nca-1;nca-2 mutants in liquid using two assays.  A)  Animals were 
placed in a drop of M9, and assayed for thrashing behaviour for 5 seconds after immersion.  nca-
1;nca-2 double mutant animals thrash significantly less often than wild-type animals in this assay. 
B)  Animals were assayed for total thrashes after 3 minutes of recovery in M9.  nca-1;nca-2 
animals have significantly fewer thrashes per minute than wild-type animals.
Error bars indicate standard errors of the mean.  Numbers in brackets indicate number of repeats 
(A) and number of animals observed (B).  (Significance assessed using a 2-tailed T-test. *** = 
p<0.001)
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5.3 - Loss of UNC-79 function is sufficient to suppress the 
loopy locomotion phenotype of nRHO-1* animals
To test whether a loss-of-function mutant of unc-79 might be able to suppress the 
loopy locomotion phenotype of nRHO-1* mutants in the same way as loss-of-function 
mutations in unc-80, we constructed a double mutant between CB1068, carrying e1068, 
the canonical unc-79 mutation, and QT733, a line carrying nzIs29, the integrated nRHO-
1* transgene with unc-122::GFP marker.   The molecular nature of the e1068 mutation 
is unknown.  
In the F2 generation we found non-loopy animals carrying the nRHO-1* transgene 
marker of unc-122::GFP (Figure 5-5, C).  These animals also display the unc-79 fainting 
locomotion, indicating that while the unc-79 mutation suppresses loopy locomotion, the 
nRHO-1* transgene has no apparent effect on the fainting behaviour.  
This demonstrates that UNC-79 is required for the propagation of the loopy locomotion 
phenotype associated with over-expression of gain-of-function RHO-1 expressed in the 
cholinergic neurons of C. elegans. 
5.4 - Loss of NCA-1 function is sufficient to suppress the 
loopy phenotype of nRHO-1* animals
In the literature, nca-1 and nca-2 single mutants are reported to be essentially wild-type 
(Yeh, Ng et al. 2008).  It requires the double mutant nca-1;nca-2 for animals to display 
the fainting locomotion associated with unc-79 and unc-80 mutants.  
NCA-1 and NCA-2 are highly homologues (58%, alignment using Clustal online tools, 
Figure 5-6) and the loss of one appears to be compensated for by the presence of 
the other with respect to locomotion and general anaesthetic sensitivity phenotypes 
(Humphrey, Hamming et al. 2007).  There are some reports of a very subtle fainter 
phenotype in the single mutants, observed through detailed analysis of locomotion using 
computer vision processing (Pierce-Shimomura, Chen et al. 2008), but generally these 
mutants are considered to be wild-type.
We crossed strain VC12, which carries a deletion in nca-1, with strain QT733, which 
carries the nRHO-1* transgene.  In the F2 generation we found animals which were 
non-loopy but carried the nRHO-1* unc-122::gfp marker, demonstrating that the single 
mutation in nca-1 is sufficient to suppress the loopy phenotype of nRHO-1* (Figure 
5-5, D). These animals do not throw any loopy animals, demonstrating that these are 
homozygous for the both the nca-1 mutation and the nRHO-1* transgene.  The double 
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Figure 5-5 Mutations in unc-79, nca-1 and nca-2 suppress the 
loopy phenotype of  the nRHO-1* transgene
nRHO-1* mutants are highly loopy (B), compared with wild-type (A).  Double mutants unc-
79;nRHO-1* (C), nca-1;nRHO-1* (D) and nca-2;nRHO-1* (E) are all non-loopy, demonstrating 
that loss-of-functon of unc-79, nca-1 or nca-2 is able to suppress the loopy phenotype associated 
with nRHO-1*.  
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mutant animals do not exhibit fainting locomotion on a solid surface.  This is the first 
report of a strong phenotype associated with a loss-of-function mutation of this gene. 
5.5 - Loss of NCA-2 function is sufficient to suppress the 
loopy phenotype of nRHO-1* animals
Following our discovery that the nca-1 single mutant is capable of suppressing nRHO-
1* loopy locomotion, we crossed nca-2 VC9 animals with strain QT733 (nRHO-1*).  In 
the F2 generation, as with the nca-1 cross, we found animals which were non-loopy and 
carried the unc-122::gfp marker of the nRHO-1* integrated transgene, demonstrating 
that the single mutation in nca-2 is also sufficient to suppress the loopy phenotype of 
nRHO-1* (Figure 5-5, E).  These animals do not throw any loopy animals, demonstrating 
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                ***************:********:***:***.**::::  .::    : .:*       
nca-2           ----------STFAFPQSQEVLTKGVVLTEAS--PEEDSLQGDKGSGKKKAQRG-----N 1701
nca-1           SSGHSSISHEETVAQRLRFENIRGDSVDTEETESSEEETPPPIRKKAAVKNRRGSIPDVL 1735
                          .*.*     * :  . * ** :  .**::    : ..  * :**      
nca-2           SITEIVAEAQ----------KKSVK------------RATDKISERRGTLR--QMQMGTY 1737
nca-1           SRTGLFQEAARKFMVGSSSEKKQVKSRSPETVQLLPKRANSEIRKGSGQPKNFHLQLNVY 1795
                * * :. **           **.**            **..:* :  *  :  ::*:..*
nca-2           DELEEVEEDEDTDGEIRRSSFEYS------------------GVDMIQMSHEKQLEDVKT 1779
nca-1           DLPDVEERGEDSPFSPKNLSDDFNGEHSPLVITPSLPVPPTHGSPRPLMPCETTKDIEKW 1855
                *  :  *..**:  . :. * ::.                  *     *. *.  :  * 
nca-2           WWTLCD 1785
nca-1           WNSLVD 1861
                * :* *
nca-2           --------MTSTTAKLLGLSACRAAALSTTMLTRRKSSIDGTKTERNRRRGESIGGAFTD 52
nca-1           MSERKKSLITTINNQRKYSQVAKAAVLSSAMLARKNSSSRGAPGSAAGFGARESIAAISD 60
                        :*: . :    ...:**.**::**:*::**  *:  .     ...  .*::*
nca-2           MINIEPTSIINKSTELLHERFLRDMVRVACLLSMISLCLHTPETIKMWPPLNYIILANDV 112
nca-1           MLSSQHKKPVRSS--YVESDRVEWALKIACTISMITVCIHTPRTIELFQPLNYIILAADF 118
                *:. : .. :..*   :..  :.  :::** :***::*:***.**::: ******** *.
nca-2           IVTLIFIGEAAVTINQNGLFDNQNSYLRDRWYQFEFFLLINHILSCVIHIYELCSIWFPA 172
nca-1           ISVSIFMLDSVLRIHYEGIFRCDSSYLSNRWSQFSVFISIIHLLSFLLHCYQLIDNFFPF 178
                * . **: ::.: *: :*:*  :.*** :** **..*: * *:** ::* *:* . :** 
nca-2           LNFVYYPWLGALRSARPFIFLRFIRSIVRFKLPKNRIKLIIKRSSQQIQNVTIFFMFFVF 232
nca-1           LHLNYRAWYGAIRSIRPFIIIRLIPLVVKFKLPKNRIEQLLKRSSQQVKNVTLFFVFFMT 238
                *:: * .* **:** ****::*:*  :*:********: ::******::***:**:**: 
nca-2           SYAIMGVQLFGRLNYHCVVNGTDPNNVTIADLAIPDTMCSQKGAGGYECPGNMVCMRLQL 292
nca-1           LYAIFGIQLFGRMDYHCVQPKTDPNNVTIMDLAIPDTMCAPEGIGGYECPAPMVCMQLNL 298
                 ***:*:*****::****   ******** *********: :* ******. ****:*:*
nca-2           KPQEEGFYGQFSDFASSLFTVYLAASQEGWVYVLYDCLDSLPSFLAFFYFVTLIFFLAWL 352
nca-1           NAKGEGFYGMFNDFGASVFTVYLAASEEGWVYVLYDCMDSLPSYLAFLYFCTLIFFLAWL 358
                :.: ***** *.**.:*:********:**********:*****:***:** *********
nca-2           VKNVFIAVITETFAEIRVQFSEMWQTREATTDHVYTQKLEKDEDGWKLVEVDKYNRAHSN 412
nca-1           VKNVFIAVITETFAEIRVQFSEMWQKKEVTLDEGFRKKLEKTDDGWRLIRLDGEVEPEGP 418
                *************************.:*.* *. : :**** :***:*:.:*   .... 
nca-2           NSLFLHTIVTSTAFQTVMQLLILANAIFHATFVFYHDESDQIRKIWYYYVEVGFTILFNT 472
nca-1           K-QKLQWMLRSMYFQCFVIIFVVINAIGNAMFVYRHDETDKPRKYNFYLFEVGFTILFNV 477
                :   *: :: *  ** .: :::: *** :* **: ***:*: **  :* .*********.
nca-2           EVIIKIYAFGWKAYIARGQHKFDCILCVGSSLNAIWVLYETNIFTYFQVFRIARLIKASP 532
nca-1           ECIIKILCYGFRNFIRRGIFKFELILCLGSSLNCVKFFYERNYFTYFQTFRLLRLIKASP 537
                * **** .:*:: :* ** .**: ***:*****.: .:** * *****.**: *******
nca-2           MLEDFVYKIFGPGKKLGGLVIFTGILLIVTSAISLQLFCYVPKLNKFTNFAVAFMSMFQI 592
nca-1           ILEDFVWKIFSPGKKLGGLVIFTIAFICCYSAISLQLFYSVPNLHHFRTFPQAFMSMFQI 597
                :*****:***.************  ::   ********  **:*::* .*. ********
nca-2           ITQEGWTDVVIEILRACNEQAVPFVAIYFVAYHLLVTLFVLSLFVAVILDNLEMDEELKK 652
nca-1           ITQEGWTDFVVEVLRATDDNLVPLVALYFVAYHLFVTLIVLSLFVAVILDNLEMDEELKK 657
                ********.*:*:*** ::: **:**:*******:***:*********************
nca-2           VKQLKAREQDT-IKTTLPMRLRIFNRFPTAPTMVTMKKVSSEFPLPKIRDSFTRQFADEF 711
nca-1           VKQLRAREATTSMRSTLPWRLRVFEKFPTRPQMAAMRKADSDFPMPKVRGSFTHQFAVDH 717
                ****:***  * :::*** ***:*::*** * *.:*:*..*:**:**:*.***:*** :.
nca-2           VETSDDTIQEIGFKVRSMLSGRGPSKETRITTTIRHVGQLSNKTILTSMLTESNRNRALF 771
nca-1           SLETTDVIESDFEFPKRIMKSAGKRKISKSGLTFRQIGSTSLRCSLNNLLEMSDRTRQSL 777
                   : *.*:.     : ::.. *  * ::   *:*::*. * :  *..:*  *:*.*  :
nca-2           SESNQHLASLTRSNTSSKHGKSGALSTNSRSRTRGLASLKGKHMVEGFKENGDL-RPEDT 830
nca-1           SNSLSFLPHFTRS-SGSLYPRKDALPKSRSMTGKFLQTAVRNKQFNMYSENGDLSRPSDS 836
                *:* ..*. :*** :.* : :..**...     : * :   :: .: :.***** **.*:
nca-2           AR-KVEKHGEIDFKALQMKRAHAEITRNRIEEEMRENHPMFDRPLFLVGRESSLRRMCQL 889
nca-1           APKKNAKQGEIDIRALQQKRQLAEITRNRIEEDMRENHPFFDRPLFLVGRASQLREFCKK 896
                *  *  *:****::*** **  **********:******:********** *.**.:*: 
nca-2           IAHSRHSYDQNDGQHR--KHSNKYKQFHDFLAIMTYMDWTMVLVTTLSCCSMLWESPWPT 947
nca-1           MVHSKYDS-QDDGTNGGAKTKKRFKEIRALIGIMPYIDWAMATVTIVSCISMLFESPWPT 955
                :.**::.  *:** :   * .:::*::: ::.**.*:**:*. ** :** ***:******
nca-2           TGENLIFNNFYLQIAEYIFVLVMSFELIVKCIANGLFFTPKALVTDVGDILTIFIYITSL 1007
nca-1           TGENLVMNNGYLQISDYFFVLSMTFELCVKIIANGLFFTPKAVVRDVGGVMNLFIYFTSV 1015
                *****::** ****::*:*** *:*** ** ***********:* ***.::.:***:**:
nca-2           MFLIWMPNHIEINSWAQLLMVCRAMRPLRVYALIPHIRRVVVELCRGFREILLVTILLVV 1067
nca-1           IFLAWMPKHVEINSLAQFLMICRAMRPLRIYTLVPHIRRVVLEFFRGFKEILLVTILMIV 1075
                :** ***:*:**** **:**:********:*:*:*******:*: ***:********::*
nca-2           LMFIFASFGVQLVGGKLASCNDPMITSRENCTGLYDVKLFVTRMEVYGKNDNLMHPSIIV 1127
nca-1           VMFIFASFGVQIVGGKLAACNDPTVSSRENCTGVFWQKLFVTRLEVYGKDTEAMHPKIMV 1135
                :**********:******:**** ::*******::  ******:*****: : ***.*:*
nca-2           PRVWTNPRNFNFDHIGNAMLALFETLSYKGWNVVRDVLYLRHGAWAVLFIHIYVFIGCMI 1187
nca-1           PRVWTNPRNFNFDHVGNAMLALFETLSFKGWNVIRDILWSRHGPWAVVFIHIYVFIGCMI 1195
                **************:************:*****:**:*: ***.***:************
nca-2           GLTLFVGVVVANYTENRGTALLTVDQRRWHDLKARLKMAQPLHVPPKPPESAKLRCYLYD 1247
nca-1           GLTLFVGVVIANYTQNRGTALLTVDQRRWHDLKARLKMAQPLHVPPKPSESARLRTKLYD 1255
                *********:****:*********************************.***:**  ***
nca-2           LTTSRWFKQLFAVLVVVNSFTLVIPWNVSEEQDRKTFLLCLTVISAICNILFTLECLLKM 1307
nca-1           LTMSRWFNQAFALLVVLNSFTLVIPWNVEEEEQRATYVFTVTALAAFMNMLFVIEIILKV 1315
                ** ****:* **:***:***********.**::* *::: :*.::*: *:**.:* :**:
nca-2           IAFTLSGFWQSRRNRIDFIITILGINWIVFHFLFQLPAYFAGG--ITEWKRLTYTYGYLV 1365
nca-1           IAYTFSGFWQSRRNRVDLLITVFGVIWIFLHFFVALPSSKIDVDVQVELKKFTYTFGYLV 1375
                **:*:**********:*::**::*: **.:**:. **:   .    .* *::***:****
nca-2           VILRFFTIAGRKSTLKMLMLTVVMSMVRSSFIIAAMFLLVLFYANAGVVLFGMVKYGQAV 1425
nca-1           VILRFFTIASRNSTLKMLMLTVIMSMFRSFFIITALFLLVLFYAYTGVILFPMVKYGMAV 1435
                *********.*:**********:***.** ***:*:******** :**:** ***** **
nca-2           GKHVNFRNGREALVVLFRSVTGEDWNDIMHDCMRAPPFCNWHPGLSYWQTDCGNYVGAIV 1485
nca-1           SKHVNFRTASEALVVLFRCLTGEDWNDIMHDCMRSAPFCYWNEGMNYWETDCGNFYGAII 1495
                .******.. ********.:**************:.*** *: *:.**:*****: ***:
nca-2           YFCSFYLIITYIVLNLLVAIIMENFSLFYSSEEDALLSYADIRNFQLVWNMVDIEQKRSI 1545
nca-1           YFCSFYLIITYIVRNLLVAVIMENFSLFYSSEEDALLSYADIRNFQYVWNMVDQEQKRTI 1555
                ************* *****:************************** ****** ****:*
nca-2           PVRRVKFLLRLLKGRLEVNDESDGLLFKHMCHEMERLHNGDDVSFHDVLNMLSYRSVDIR 1605
nca-1           PVERVKFLLRLLKGRLEVDPEKDRILFKHMCYEMERLHNGEEVSFHDVLYMLSYRSVDIR 1615
                **.***************: *.* :******:********::******* **********
nca-2           KSLQLEELLQREELEYIIEEEVAKHTIRAWLENCLKNIKAKQNNTLGKMSSIG------- 1658
nca-1           KSLQLEELLQREELEFIIEEEVAKQTIRTWLEGCLRKMRNPSQKDAEGVLPFGGGHPVIH 1675
                ***************:********:***:***.**::::  .::    : .:*       
nca-2           ----------STFAFPQSQEVLTKGVVLTEAS--PEEDSLQGDKGSGKKKAQRG-----N 1701
nca-1           SSGHSSISHEETVAQRLRFENIRGDSVDTEETESSEEETPPPIRKKAAVKNRRGSIPDVL 1735
                          .*.*     * :  . * ** :  .**::    : ..  * :**      
nca-2           SITEIVAEAQ----------KKSVK------------RATDKISERRGTLR--QMQMGTY 1737
nca-1           SRTGLFQEAARKFMVGSSSEKKQVKSRSPETVQLLPKRANSEIRKGSGQPKNFHLQLNVY 1795
                * * :. **           **.**            **..:* :  *  :  ::*:..*
nca-2           DELEEVEEDEDTDGEIRRSSFEYS------------------GVDMIQMSHEKQLEDVKT 1779
nca-1           DLPDVEERGEDSPFSPKNLSDDFNGEHSPLVITPSLPVPPTHGSPRPLMPCETTKDIEKW 1855
                *  :  *..**:  . :. * ::.                  *     *. *.  :  * 
nca-2           WWTLCD 1785
nca-1           WNSLVD 1861
                * :* *
igure 5-6 lignment between NCA-1 and NCA-2
The worm homologues of NALCN, NCA-1 and NCA-2, are highly similar, as shown here with an 
alignment between the two longest predicted translations of each gene (NCA-2 top sequence, 
NCA-1 bottom sequence).  
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that these are homozygous for the both the nca-2 mutation and the nRHO-1* transgene. 
The double mutant animals do not demonstrate fainting locomotion on a solid surface. 
This is the first demonstration of a strong independent phenotype for the nca-2 single 
mutation.  
This result, coupled with that in Section 5.4 suggests that nca-1 and nca-2 have 
independent roles within C. elegans nervous system.  To our knowledge this is the first 
experiment to demonstrate non-redundancy of these genes, and may give some insight 
into why C. elegans has retained two highly similar copies of this protein (Figure 5-6) 
which is present as a single copy in Drosophila, mouse and human genomes.  
We would need to perform rescue experiments for unc-79, nca-1 and nca-2 to confirm 
that these are genuinely the mutations which are able to suppress the loopy phenotype 
of nRHO-1*.  However, the probability of all three mutants tested containing a second-
site mutation capable of suppressing the loopy locomotion of nRHO-1* is very low, 
suggesting that the loss of nca-1, nca-2 or unc-79 function is likely to be the reason for 
restoration of normal locomotion in the presence of the nRHO-1* transgene.  
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Figure 5-7 Aldicarb Assays - unc-79 mutants
unc-79 single mutants (n=12) are hypersensitive to aldicarb compared with wild-type animals. 
The double mutant unc-79;nRHO-1* animals (n=7) paralyse faster than unc-79 single mutants, 
and slower than nRHO-1* mutants.  Error bars indicate the S.E.M.
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5.6 - Neurotransmitter release assays of NCA complex 
mutants
NCA-1, NCA-2, UNC-79 and UNC-80 are considered to form part of a novel ion channel 
complex (Jospin, Watanabe et al. 2007; Yeh, Ng et al. 2008, Lu, Su et al. 2009), hereon 
referred to as the NCA complex, although its subunit composition is unknown at present. 
We had previously seen that mutations in unc-80, while sufficient to suppress the loopy 
locomotion of nRHO-1* animals is insufficient to suppress the hypersensitivity to aldicarb 
generated by nRHO-1* (Figure 4-16).  We wanted to test what effect, if any, the other 
components of the NCA complex have on neurotransmitter release, and its regulation by 
nRHO-1*.
5.6.1 - Aldicarb responses of unc-79 mutants
5.6.1.1 - unc-79 mutants are hypersensitive to aldicarb
unc-79 single mutants are hypersensitive to aldicarb compared to wild-type (Figure 
5-7), with 55±7% of animals paralysed at 50 minutes, compared with 30±2% of wild-
type animals.  This suggests that, despite their reduction in locomotion rate due to 
the fainting phenotype, that these animals have increased levels of neurotransmitter 
release.  It remains a possibility that a second site mutation alters aldicarb sensitivity in 
these mutants, and therefore testing additional unc-79 alleles, and performing rescue 
experiments would enable us to determine whether unc-79 is the mutation responsible 
for this increase in aldicarb sensitivity.  .  
Locus 2
Locus 1
Wild-type 30 ± 2.3, n=52 55 ± 6.6, n=12, p=0.0016
unc-79 55 ± 6.6, n=12, p=0.0016 -
nca-1 36 ± 5.0, n=9, p=0.35 -
nca-2 77 ± 4.9, n=5, p=0.0001 -
nRHO-1* 87 ± 2.5, n=37, p<0.0001 57 ± 9.8, n=7, p=0.02
nca-1 (gf) 77 ± 4.7, n=9, p<0.0001 -
Wild-type unc-79
Percentage of animals paralysed at 50 minutes on 1mM aldicarb
36 ± 5.0, n=9, p=0.35 77 ± 4.9, n=5, p=0.0001 87 ± 2.5, n=37, p<0.0001
- - 57 ± 9.8, n=7, p=0.8
- 41 ± 10.2, n=6, p=0.7 55 ± 5.0, n=7, p=0.02
41 ± 10.2, n=6, p=0.01 - 53 ± 3.2, n=4, p=0.01
55 ± 5.0, n=7, p=0.0002 53 ± 3.2, n=4, p=0.04 -
nca-1(gf) compared with nca-
1 p<0.0001 -
 nca-1(gf) compared with 
nRHO-1* p=0.06
nRHO-1*nca-1 nca-2
Table 5-1 Statistical analysis of aldicarb data at 50 minute time 
point
All aldicarb data in this chapter is summarised here with statistics derived from the 50 minute 
time-point data.  Statistics conducted using a 2-tailed unpaired T-Test.  Data relating to PMA 
treatment is given within the body of the text.    
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5.6.1.2 - unc-79;nRHO-1* double mutants are 
hypersensitive to aldicarb
The double mutant unc-79;nRHO-1* mutants paralyse faster than wild-type on 1mM 
aldicarb (Figure 5-7).  These animals paralyse at a slightly faster rate than unc-79 single 
mutants in the second half of the assay, indicating that the nRHO-1* transgene is able 
to increase neurotransmitter release in this mutant background.  However, their rate of 
paralysis is less than that of the nRHO-1* single mutant.  This suggests that the lack of 
unc-79 limits the extent to which nRHO-1* can increase neurotransmitter release.  
5.6.2 - Aldicarb responses of nca-1 mutants
5.6.2.1 - nca-1 single mutants are wild-type in their 
response to aldicarb
Animals carrying a deletion in nca-1 (gk9) have a wild-type response to aldicarb (Figure 
5-8), with 36±6% of animals paralysed at 50 minutes compared to 30±2% of wild-type 
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Figure 5-8 Aldicarb Assays - nca-1 mutants
nca-1 single mutants have a wild-type response to aldicarb (n=9).  The nca-1;nRHO-1* double 
mutant animals paralyse faster than nca-1 mutant animals on 1mM aldicarb (n=7).  However, their 
rate of paralysis is less than that of nRHO-1* animals.
Error bars indicate the standard error of the mean.  
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animals.  This follows the rest of the literature which reports that the nca-1 single mutant 
appears wild-type under all conditions so far tested.
5.6.2.2 - nca-1;nRHO-1* double mutants are 
hypersensitive to aldicarb
The double mutant nca-1;nRHO-1* animals are non-loopy, as the nca-1 mutation alone 
is able to suppress the loopy phenotype of nRHO-1*.  These double mutants paralyse 
faster than wild-type or nca-1 single mutants (Figure 5-8) on 1mM aldicarb, a highly 
significant increase (Table 5-1).  This indicates that the nRHO-1* transgene is still active 
and able to increase neurotransmitter release in this mutant, although the level of release 
is less than that seen in an nRHO-1* single mutant, implying that some suppression of 
the nRHO-1* activity occurs in an nca-1 single mutant background.  
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Figure 5-9 Aldicarb Assays - nca-2 mutants
nca-1 single mutants have a wild-type response to aldicarb (n=9).  The nca-1;nRHO-1* double 
mutant animals paralyse faster than nca-1 mutant animals on 1mM aldicarb (n=7).  However, their 
rate of paralysis is less than that of nRHO-1* animals.
Error bars indicate the standard error of the mean.  
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5.6.3 - Aldicarb responses of nca-2 mutant animals
5.6.3.1 - nca-2 mutants are hypersensitive to aldicarb
Unlike nca-1 (gk9) mutants, which appear wild-type for their response to 
acetylcholinesterase  inhibitor treatment, nca-2 (gk5) single mutants paralyse much faster 
than wild-type animals on 1mM aldicarb (Figure 5-9).  77±5% of nca-2 single mutant 
animals paralyse at 50 minutes compared with 30±2% of wild-type animals (Table 5-1).  
Along with the ability of the nca-2 single mutant to suppress the loopy phenotype of 
nRHO-1* animals, this result implies that the nca-1 and nca-2 proteins are not entirely 
redundant and have distinct functions within the nervous system of the worm.  However, 
this result is also consistent with a second site mutation increasing sensitivity to aldicarb, 
and testing additional nca-2 mutants, and performing rescue experiments, would help 
determine whether nca-2 is the causative mutation.  
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Figure 5-10 Aldicarb Assays - nca-1;nca-2 mutants
The double mutant of nca-1;nca-2 displays a fainter phenotype reminiscent of that seen in unc-79 
and unc-80 mutants.  The response of these animals to aldicarb appears wild-type (n=6).  The 
aldicarb hypersensitivity observed in the nca-2 single mutants is not seen in the double mutant 
animals.
Error bars indicate the standard error of the mean.  
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5.6.3.2 - nca-2;nRHO-1* mutants are hypersensitive to 
aldicarb
The non-loopy nca-2;nRHO-1* double mutants paralyse faster than wild-type animals 
on aldicarb but paralyse at a slower rate than nca-2 single mutant animals (Figure 5-9). 
With nca-2 mutants being hypersensitive it is not possible to determine whether the 
hypersensitivity of the double mutant (compared to wild-type) reflects activity of the 
nRHO-1* transgene, or is due to the effects of the nca-2 mutation alone.  
The rate of paralysis of the double mutant is less than that of the nRHO-1* single mutant, 
which suggests there is an interaction between nRHO-1* and nca-2 with respect to 
neurotransmitter release such that nca-2 suppress some of the effects of the nRHO-1* 
transgene, but further experiments are required to understand this relationship.
5.6.4 - nca-1;nca-2 double mutants are wild-type for their 
response to aldicarb
The nca-1;nca-2 double mutant exhibits a fainter phenotype similar to that seen in 
the unc-79 and unc-80 single mutants (Figure 5-10).  When tested in their response 
to aldicarb, they appear wild-type, with 41±10% of animals paralysed at 50 minutes, 
compared with 30±2% of wild-type animals at the same time point.
The hypersensitivity seen in nca-2 single mutant animals is not present in the double 
mutant.  Potentially this hypersensitivity might reflect a change in the activity of NCA-1, 
compensating for the loss of NCA-2.  When both NCA-1 and NCA-2 proteins are absent, 
the effect is lost.  This result is also consistent with loss of a second-site mutation in the 
nca-2 mutant which has been lost during the cross.  
5.7 - Levamisole response of NCA complex mutants
The changes in aldicarb response observed in the NCA complex mutants could result 
either from increased acetylcholine release (a presynaptic event) or from increased 
sensitivity of the body wall muscles (a post-synaptic event).  To distinguish between the 
two, we use levamisole, a cholinergic agonist, to directly stimulate the body wall muscles 
and subsequently assay the post-synaptic response.  
5.7.1 - unc-79 mutants are hypersensitive to levamisole
When exposed to 100μM levamisole, unc-79 animals paralyse faster than wild-type 
animals (Figure 5-11).  25±9% of unc-79 mutant animals are paralysed at 50 minutes, 
compared with 9±1% of wild-type animals (Table 5-2), although this result is not statistically 
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significant, most likely due to the relatively large variations in the response levamisole 
between repeats.  More repeats might achieve significance, but the trend suggests that 
the body wall muscles of unc-79 animals are hypersensitive to acetylcholine.  
unc-79 mutants are also hypersensitive to aldicarb, which enhances the signalling effect 
of endogenously-released acetylcholine.  Together these two experiments suggest 
that the absolute level of acetylcholine release in unc-79 animals may be closer to that 
of wild-type animals than suggested by the aldicarb assay; if the body wall muscles 
become hypersensitive to compensate for decreased signalling, this will give rise to 
hypersensitivity to both levamisole and acetylcholine.  
5.7.2 - unc-79;nRHO-1* double mutants are resistant to 
levamisole
The non-loopy, fainter, unc-79;nRHO-1* mutants, which are hypersensitive to aldicarb, 
are resistant to levamisole, compared to the unc-79 and nRHO-1* single mutants with 
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Figure 5-11 Levamisole assay - unc-79 mutant animals
We observe an increase in the sensitivity of unc-79 single mutants to levamisole (orange line, 
n=6) compared to wild-type (blue line, n=14).  nRHO-1* animals also appear hypersensitive to 
levamisole in these assays (red line, n=8).  The double mutant unc-79;nRHO-1* is resistant to the 
effects of levamisole (green line, n=3).  
Error bars indicate the standard error of the mean.  
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Figure 5-12 Levamisole assay - nca-1 mutant animals
nca-1 single mutant animals, which have wild-type locomotion, display no change in levamisole 
response compared to wild-type animals (n=5).
Error bars indicate the standard error of the mean.  
Locus 2
Locus 1
Wild-type 9 ± 1.2, n=14 25 ± 8.3, n=6, p=0.6 27 ± 6.6, n=8, p=0.03
unc-79 25 ± 8.3, n=6, p=0.6 - 4 ± 1.1, n=3, p=0.3
nca-1 16 ± 6.3, n=5, p=0.2
nca-2 - - 7 ± 1.7, n=5, p=0.02
nca-1 (gf) 17 ± 5.3, n=4, p=0.2
nRHO-1* 27 ± 6.6, n=8, p=0.03 4 ± 1.1, n=3, p=0.01 -
Percentage of animals paralysed at 50 minutes on 100µM levamisole
Wild-type unc-79 nRHO-1*
- -
-
7 ± 1.7, n=5
23 ± 13.2, n=5, p=0.6 -
nca-1(gf) compared 
with nca-1 p=0.9 -
- -
nca-1 nca-2
Table 5-2 Statistical analysis of levamisole data at 50 minute 
time point
All levamisole data in this chapter is summarised here with statistics derived from the 50 minute 
time-point data.  Statistics conducted using a 2-tailed unpaired T-Test.  
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the response curve shifted to the right (Figure 5-11).  At 50 minutes, just 4±1% of the 
double mutants are paralysed, a stastically significant decrease compared with the unc-
79 single mutant animals (Table 5-2).  
Thus two mutants, unc-79 and nRHO-1*, which alone give hypersensitivity to levamisole, 
when combined produce resistance to levamisole.  This suggests that some combined 
effect of the nRHO-1* transgene in an unc-79 mutant background is able to decrease the 
muscle sensitivity to acetycholine.   
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Figure 5-13 Levamisole assay - nca-2 mutant animals
nca-2 single mutant animals which have wild-type locomotion, have a wild-type response to 
levamisole (n=8).  nca-2;nRHO-1* double mutants are slightly resistant to levamisole when 
compared with wild-type animals (n=7).  (n=5 for wild-type animals.  These experiments were 
conducted with a separate batch of 100μM levamisole on which the wild-type animals paralysed 
slower than normal.  Therefore comparrisons are made to the controls obtained only from this ste 
of experiments)  Error bars indicate S.E.M. 
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5.7.3 - Levamisole responses of nca-1 and nca-1;nca-2 
mutants
5.7.3.1 - nca-1 mutant animals have a wild-type 
response to levamisole
We tested the levamisole phenotype of nca-1 mutant animals.  These animals have wild-
type locomotion, and wild-type response to aldicarb (Figure 5-12), with no difference 
observed at 50 minutes compared with wild-type animals (Table 5-1).  We also observe 
that these animals show no discernible levamisole phenotype.  16±6% of nca-1 animals 
are paralysed at 50 minutes, compared with 9±1% of wild-type animals, which is not a 
statistically significant difference (Table 5-2).  
5.7.3.2 - nca-2 mutant animals have a wild-type 
response to levamisole
We tested the levamisole phenotype of nca-2 (gk5) mutant animals.  These animals 
have wild-type locomotion, but appear hypersensitive to aldicarb (Figure 5-12) when 
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Figure 5-14 Levamisole assay - nca-1;nca-2 mutant animals
nca-1;nca-2 double mutant animals, which have fainting locomotion, are hypersensitive to 
levamisole with respect to wild-type animals.  Error bars indicate the standard error of the mean. 
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compared with wild-type animals (Table 5-1).  However, these animals are wild-type in 
their response to levamisole (Figure 5-13).  16±6% of nca-1 animals are paralysed at 50 
minutes, compared with 9±1% of wild-type animals, which is not a statistically significant 
difference (Table 5-2).  
5.7.3.3 - nca-1;nca-2 double mutants display slight 
hypersensitivity to levamisole
We have already seen that unc-79 and unc-80 animals, which display fainting locomotion, 
are hypersensitive to the agonist levamisole.  We tested the levamisole response of nca-
1;nca-2 double mutant animals, which also have a fainting locomotion, and see that 
these animals display a hypersensitivity to levamisole, with the response curve shifted 
to the left (n=5) (Figure 5-14).  The difference at 50 minutes is not statisically significant, 
however (Table 5-2).
5.8 - Treatment with phorbol esters stimulates 
neurotransmitter release in NCA complex mutants
One theory to explain the suppression of loopy behaviour of the nRHO-1* transgene by 
loss-of-function NCA complex mutants would be if these mutants had a defect where 
the nervous system could not be stimulated by nRHO-1*.  This also offers a simple 
explanation of the fainting phenotype.  I would suggest that the fainter mutants could 
have a non-specific neuronal defect where their neurons are unable to maintain high 
levels of activity, causing them to pause for long intervals unless stimulated, for instance 
by a harsh nose touch.  
One way to test whether these mutations are globally reducing the activity of the nervous 
system is to look in conditions where the nervous system is stimulated, such as stimulation 
with the DAG analogue PMA  If the overall activity of the nervous system is lower in unc-
79, nca-1, nca-2 or nca-1;nca-2 mutants should result in a resistance to the effects of 
PMA as assayed by aldicarb.  Secondly, we can start to define the position the NCA 
complex genes in the neurotransmitter release pathway with respect to DAG signalling.
5.8.1 - unc-79 mutants respond to phorbol esters by 
increasing acetylcholine release
Wild-type animals respond to PMA by becoming hypersensitive to aldicarb, with the 
response curve shifting to the right in the presence of the drug (Figure 5-15).  Without 
PMA, 67±7% of animals are paralysed at 50 minutes; when exposed to PMA, 99±1% of 
animals are paralysed at this time point (Table 5-3).
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unc-79 animals display a similar response to PMA as wild-type; 98±2% of animals 
paralysed at 50 minutes, compared with 64±12% of animals without PMA (Table 5-3), 
and this change is borderline significant (p=0.07).  This data indicates that UNC-79 acts 
upstream of or in parallel to the pathway activated by PMA.
5.8.2 - nca-1 mutants respond to phorbol esters by increasing 
acetylcholine release
nca-1 mutants are able to respond to PMA and increase their sensitivity to aldicarb, as 
demonstrated by a shift to the left of the response curve (Figure 5-17).  After two hours 
pretreatment with PMA or DMSO, the animals were placed on plates containing PMA or 
DMSO along with 1mM aldicarb.  On the DMSO-treated plates, 45±4% of nca-1 animals 
are paralysed at 50 minutes, whereas when treated with PMA 88±6% of animals were 
paralysed at the same time point, a stastisically significant change (Table 5-3).  .  
This indicates that, as with the unc-79 result, NCA-1 acts either upstream of or in parallel 
to the pathway activated by PMA.   
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Figure 5-15 PMA assays - unc-79 mutant animals
unc-79 mutants were assayed for paralysis on a combination of either aldicarb and PMA (a 
diacylglycerol analogue which stimulates neurotransmitter release) or on control aldicarb and 
DMSO plates.  unc-79 mutants exposed to PMA (dotted orange line, n=4) become hypersensitive 
to aldicarb compared to unc-79 mutants on control plates (solid orange line, n=4).  This shift of the 
curve to the left is also seen in wild-type animals exposed to PMA (blue lines, n=7). 
Error bars indicate the standard error of the mean.  
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Wild-type 67 ± 7.1, n=9 99 ± 0.9, n=9, p=0.002
unc-79 64 ± 12.0, n=4 98 ± 1.6, n=4, p=0.07
nca-1 45 ± 4.4, n=5 88 ± 6.1, n=5, p=0.008
nca-2 62 ± 10.1, n=3 77 ± 13, n=3, p=0.5
nca-1;nca-2 17, n=1 96, n=1
With DMSO control With PMA
Percentage of animals paralysed at 50 minutes on 1mM aldicarb
Table 5-3 Statistical analysis of aldicarb and PMA data at 50 
minute time point
Treatment with aldicarb and PMA is summarised here with statistics derived from the 50 minute 
time-point data.  Statistics conducted using a 2-tailed paired T-Test.  
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Figure 5-16 PMA assays - nca-1 mutant animals
nca-1 mutants were assayed for paralysis on a combination of either aldicarb and PMA or on 
control aldicarb and DMSO plates.  nca-1 mutants exposed to PMA (dotted orange line, n=5) 
become hypersensitive to aldicarb compared to nca-1 mutants on control plates (solid orange 
line, n=5).  
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5.8.3 - nca-2 mutants partially block the increase in 
acetylcholine release stimuated by treatment with phorbol 
esters
nca-2 mutants are able to respond to PMA and increase their sensitivity to aldicarb (Figure 
5-17).  After two hours pretreatment with PMA or DMSO, the animals were placed on 
plates containing PMA or DMSO along with 1mM aldicarb.  On the DMSO-treated plates, 
62±10% of nca-2 animals are paralysed at 50 minutes, whereas when treated with PMA 
77±13% of animals were paralysed at the same time point (Table 5-3), although this 
change is not statisically significant.  This suggests that the nca-2 mutation is having 
a suppressive effect on the action of PMA, although the response curve is still partially 
shifted to the left in the presence of the drug.  
Given that nca-2 single mutants are hypersensitive to aldicarb, and only partially 
responsive to PMA (in contrast to other NCA complex mutants) it will be essential to 
confirm that a second site mutation is not modulating ACh release in these animals.  
Figure 5-17 PMA assays - nca-2 mutant animals
nca-2 mutants were assayed for paralysis on a combination of either aldicarb and PMA or on 
control aldicarb and DMSO plates.  nca-1 mutants exposed to PMA (dotted orange line, n=3) 
become hypersensitive to aldicarb compared to nca-1 mutants on control plates (solid orange 
line, n=3).  
Error bars indicate the standard error of the mean.  
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5.8.4 - nca-1;nca-2 double mutants are sensitive to the 
effects of PMA
We tested the response of nca-1;nca-2 fainter mutants to PMA, a DAG analogue, by 
assaying their response to aldicarb in the presence of either PMA or a DMSO-control.  
Animals on the control plates paralyse at the same rate as wild-type animals on the control 
plates, demonstrating no underlying change in the response to aldicarb.  When treated 
with PMA, nca-1;nca-2 mutant animals become hypersensitive to aldicarb, paralysing at 
a faster rate (Figure 5-18).  Without PMA, 17% of animals are paralysed at 50 minutes, 
whereas 92% of animals treated with PMA are paralysed at the same time point.  
This result is obtained from only a single repeat, and so needs further trials for 
corroboration.  However, the trend identified from this experiment indicates that loss of 
nca-1 and nca-2 in the same animals has no effect on the response to PMA.  
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Figure 5-18 PMA assays - nca-1;nca-2 mutant animals
nca-1;nca-2 mutants were assayed for paralysis on a combination of either aldicarb and PMA or 
on control aldicarb and DMSO plates.  nca-1;nca-2 mutants exposed to PMA (dotted orange line, 
n=1) become hypersensitive to aldicarb compared to nca-1;nca-2 mutants on control plates (solid 
orange line, n=1).  
Error bars indicate the standard error of the mean.  
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5.9 - nca-1(gf) mutants phenocopy nRHO-1* mutant 
animals
5.9.1 - nca-1(gf) mutants are highly loopy
The gene originally isolated as unc-77 (Brenner 1974) for its loopy phenotype (Figure 
5-19, B) has subsequently been identified as an allele of nca-1 (Yeh, Ng et al. 2008).  This 
mutant carries the mutation e625 (Figure 5-1), which introduces a mutation A717V in the 
sixth predicted transmembrane domain of the second repeat of the protein.  This residue 
is conserved between species, as is a mutation in the sixth transmembrane domain of 
the first repeat (hp102, R403Q, Figure 5-1).  Both of these represent dominant mutations 
in the protein, and the loopy locomotion phenotype can be suppressed by mutations in 
unc-79 or unc-80, possibly due to los of NCA-1 localisation (Yeh, Ng et al. 2008).  
A
B
C
Figure 5-19 nca-1(gf) mutant animals are highly loopy
Animals carrying a gain-of-function mutation in the nca-1 gene (B) become highly loopy when 
compared with wild-type animals (A).  This loopy locomotion is reminiscent of that seen in nRHO-
1* mutant animals (C).  
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The loopy phenotype of these animals is highly similar to that seen in the nRHO-1* 
mutants (Figure 5-19, B and Movie 5-2).  We therefore speculated that these animals 
may also have high levels of neurotransmitter release. 
5.9.2 - nca-1(gf) mutants are hypersensitive to aldicarb
We tested the response of mutants carrying the e625 dominant mutation in nca-1 for their 
response to 1mM aldicarb.  Unlike animals which have a deletion in nca-1, which are 
wild-type in their response to aldicarb, nca-1(gf) mutants are hypersensitive to aldicarb, 
with 77±5% of animals paralysed at 50 minutes, compared with 30±2% of wild-type 
animals (Figure 5-20, Table 5-1).
5.9.3 - nca-1 mutants are wild-type in their response to 
levamisole
Mutants with a deletion in nca-1 display a wild-type response to levamisole (Figure 
5-21).  Animals carrying the nca-1(gf) mutation are also wild-type for their response to 
levamisole (Figure 5-20, Table 5-2).  Along with their hypersensitivity to aldicarb, this 
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Figure 5-20 nca-1(gf) mutant animals are hypersensitive to 
aldicarb
Animals carrying a gain-of-function mutation in the nca-1 gene are hypersensitive to the 
acetylcholinesterase inhibitor aldicarb, as demonstrated by a shift in their response curve to the 
left compared with wild-type and nca-1 (loss-of-function) mutants (n=9). 
Error bars indicate the standard error of the mean.
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indicates that these animals have excess levels of acetylcholine release compared to 
wild-type and that the nca-1(gf) mutation acts presynaptically.  
It would be useful to express nca-1(gf) cDNA from cell-specific promoters, such as the 
unc-17 promoter, to determine the site of action of nca-1 with respect to increasing 
aldicarb sensitivity.  
5.9.4 - nca-1(gf) mutants have a defect in their swimming 
behaviour
The highly loopy nca-1(gf) animals display a defect in their ability to thrash in liquid.  We 
previously used this assay, where animals are suspended in a drop of M9 solution, allowed 
to recover for three minutes, and the number of thrashes recorded for the following two 
minutes, to assay fainting behaviour (Chapter 4, and Figure 5-2,3 & 4), but also observed 
a defect in the swimming behaviour of highly loopy nRHO-1* mutant animals, resulting in 
fewer thrashes per minute than wild-type animals (Figure 5-22).  nca-1 mutant animals 
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Figure 5-21 nca-1(gf) mutants have a wild-type response to 
levamisole
nca-1(gf) mutants are wild-type in their response to levamisole.  
Error bars indicate the standard error of the mean.
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also show a drop in their rate of thrashing in liquid compared with wild-type animals 
(Figure 5-22), to 31±2 thrashes per minute, compared with 97±3 for wild-type.  While this 
drop appears similar to that seen in nRHO-1* mutant animals, nca-1(gf) mutant thrash 
rate remains significantly higher than that seen in nRHO-1* mutant animals.     
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Figure 5-22 nca-1(gf) mutants demonstrate a defect in swimming
When placed in M9 and allowed to recover for 3 minutes, nca-1(gf) mutants thrash significantly 
less often than either nca-1 single mutant animals or wild-type animals.  Their loopy locomotion 
is likely to be the cause of this defect.  However, their mean number of thrashes per minute is 
significantly different from that exhibited by the nRHO-1* mutants.   
Error bars indicate standard errors of the mean.  Numbers in brackets indicate number of animals 
observed.  (Significance assessed using a 2-tailed T-test. *** = p<0.001)
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5.9.5 - nca-1(gf) mutants have a defect in the Exp step of 
the defecation cycle
We had previously observed a defect in the Exp step associated with nRHO-1* mutant 
animals, and therefore we tested the gain-of-function nca-1 mutants to see whether they 
displayed a similar defecation defect.  
nca-1(gf) mutants are wild-type in the pBoc step of the defecation cycle (Figure 5-23), 
although there is an increase in the variability of this step compared with wild-type 
animals.  The expulsion step of the defecation cycle is significantly longer than in wild-type 
animals (Figure 5-23).  There is an even more significant increase in average expulsion 
interval in nRHO-1* mutant (Figure 5-23) compared with wild-type animals, but there 
is no significant difference between nRHO-1* animals and nca-1(gf) mutant animals. 
Together these data suggest that the defecation cycle is operating normally within these 
two mutant animals (as demonstrated by wild-type pBoc intervals), but that not every 
pBoc is followed by an Exp step.  The Exp step requires the release of GABA acting as 
an excitatory neurotransmitter (Beg and Jorgensen 2003), and our result suggests a 
possible defect in GABA release in gain-of-function mutations in both NCA-1 and RHO-1.
5.10 - Strain QT958 contains a spontaneous suppressor of 
nca-1(gf)
When conducting these experiments with the gain-of-function allele of nca-1, we thawed 
out animals from strain DR1089, which had been frozen and stored at -80oC for a number 
of years since being obtained from the CGC.  On thawing, the animals which survived 
the freezing process were non-loopy, and their progeny were also non-loopy.  We also 
observed that these animals appeared to have a fainting locomotion phenotype.
The description of strain DR1089 described them as being highly uncoordinated, and 
did not contain any reference to this fainter phenotype.  Knowing that unc-80 and unc-79 
mutations can suppress the loopy aspect of nca-1(gf) mutants, we speculated that they 
had spontaneously acquired a suppressor mutation.
We crossed the strain carrying nz112 with him-5 animals, and in the F2 generation 
obtained animals with two distinct phenotypes.  One set of animals bred true for the 
loopy phenotype associated with the gain-of-function nca-1 mutation.  The other set of 
animals, however, bred true for a fainter phenotype.  We named the unknown suppressor 
as nz112.
We crossed this strain with unc-80 and unc-79 mutants to see whether this mutation was 
complementary with either of them.  However, in the F1 generation following crosses 
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with both unc-79 and unc-80 some fainter mutants were obtained.  This result suggests 
that this mutation is able to complement both of these genes.  This experiment needs 
to be repeated, but this mutant remains of interest for the future.  We would also like to 
cross these animals with nRHO-1* to see test whether nz112 is able to suppress the 
loopy behaviour of those animals.  
5.11 - Gadolinium treatment failed to induce fainting 
behaviour in C. elegans
It has been reported that the ion gadolinium (Gd3+) is a specific inhibitor of the NALCN ion 
channel (Lu, Su et al. 2007) in tissue culture experiments.  It has also been successfully 
used to block the effects of NCA-1, which causes an increase in cell death when 
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Figure 5-23 nca-1(gf) mutants display a defect in defecation
nca-1(gf) mutants display a significant increase in the length of the explulsion step of defecation 
compared with wild-type animals.  They are not defective in the cycle as a whole, as demonstrated 
by the regular pBoc interval.
nRHO-1* animals also display an increase in the expulsion interval but no change in the pBoc 
interval.  This suggests that in both mutants they are failng to initiate Exp following every pBoc.  
Error bars indicate standard errors of the mean.  Numbers in brackets indicate number of animals 
observed.  (Significance assessed using a 2-tailed T-test. * = p<0.05 *** = p<0.001)
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transfected into HEK293 cells (Yeh, Ng et al. 2008).  We therefore speculated that it 
might act as a specific inhibitor of the NCA-1 and NCA-2 ion channels in live C. elegans, 
and potentially induce a fainting phenotype.
We added gadolinium from a 100mM stock diluted in dH2O to our NGM plates, giving 
final concentrations of 10mM, 1mM, 100μM, 10μM and 0μM (control).  L4 animals were 
picked the day before the assay, and 30 were placed on these plates, with food, and left 
on for either 6 hours or 24 hours.  No effect on locomotion was observed in the treated 
animals compared to control animals.  
We performed the same experiment with age-matched nRHO-1* animals, to see 
whether gadolinium treatment was able to suppress the loopy locomotion phenotype of 
these animals.  After 6 hours and 24 hours of treatment, no change was observed in the 
locomotion of these animals compared to controls.
It is possible that highly charged gadolinium ions react with the materials of the NGM 
plates and becoming unavailable to treat the worms.  We therefore tested the response 
of wild-type animals to concentrations of 10mM, 1mM, 100μM, 10μM and 0μM (control) 
dissolved in 1% agarose plates.  However, after exposure up to 24 hours, no difference 
was observed with control.  We also tested nca-1 and nca-2 single mutant animals under 
these conditions, speculating that with a background reduction in channel activity we 
may see an effect of gadolinium exposure, but no effects were seen after 24 hours of 
growth.
As an additional measure, we washed mixed populations of wild-type animals into 
gadolinium solutions at concentrations of 10mM, 1mM, 100μM and 10μM and 0μM 
(control).  At time points of 2, 6 and 24 hours, 200μl of solution containing a mixed 
population of animals was transferred to NGM plates for examination.  No effect on 
locomotion was observed compared with control-treated animals. 
5.12 - Cloning NCA-1 introduces cDNA rearrangements
We wanted to produce an nca-1 rescuing construct which would allow us to restore 
NCA-1 function in an an nca-1 mutant, to test whether this was sufficient for recovery of 
loopy locomotion in nca-1;nRHO-1* mutant animals, and determine the site of action of 
NCA-1 with respect to fainting locomotion in the nca-1;nca-2 double mutant animals.  We 
also designed primers to allow us to introduce the two known gain-of-function mutations 
into our rescuing construct by site-directed mutagenesis, to analyse the effects of these 
mutations when expressed under cell-specific promoters.  
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We obtained the full-length predicted cDNA of nca-1, contained in plasmid YK1346e10 
produced by Yuji Kohara.  However, upon sequencing this plasmid, we detected a number 
of variations compared to the wild-type predicted cDNA.  Including two gaps of 22 and 
138 base pairs respectively, and several point mutations.  We decided to attempt to use 
this cDNA sequence, despite the differences to wild-type, cloned this cDNA into the heat-
shock expression vector.  However, upon sequencing, this plasmid, APP7, contained a 
number of rearrangements of the nca-1 sequence.
Subsequent attempts to clone the nca-1 cDNA were also unsuccessful.  We hypothesise 
that the cDNA contains sequences toxic to bacteria which creates a selection pressure 
in culture to remove or mutate these sequences.  Similar problems have been reported 
with the NALCN cDNA sequence (D. Ren, personal communication.), and we have so far 
been unable to produce a stable plasmid containing the NALCN mouse cDNA sequence 
(the original vector was a gift from D. Ren.)  
We therefore made an NCA-1 minigene which contains some introns that are not spliced 
in bacteria, and thus we hypothesise that this construct fails to produce the toxic element 
of the NCA-1 protein during replication in E. coli.  Preliminary experiments suggest we 
can rescue nca-1 mutants with this minigene (M. Elmi, personal communication).    
5.13 - Discussion of Chapters 4 and 5
5.14 - A fainter mutation suppresses the loopy phenotype 
of nRHO-1* mutant animals
During our screen for suppressors of the loopy behaviour of animals expressing 
constitutively-active RHO-1 from the unc-17 promoter (nRHO-1*), we identified two 
mutants, nz94 and nz98, isolated from the same original plate, which were non-loopy. 
These animals continued to be non-loopy upon activation of a second constitutively-
active RHO-1 transgene driven by the heatshock promoter (hsRHO-1*), indicating that 
these are genuine suppressors of the activity of RHO-1*.
We observed that these two mutants had an additional phenotype - as well as being 
non-loopy they appeared lethargic, and upon further investigation were reclassified as 
fainters, because they were capable of wild-type locomotion upon stimulation but tended 
to remain motionless unless disturbed.  
This phenotype has so far been ascribed to only three classes of mutants - unc-80 and 
unc-79 single mutants, and the double mutant nca-1;nca-2.  We found that nz94 failed 
to complement a known mutation in unc-80, and sequenced the unc-80 gene in nz94. 
Sequencing revealed a premature STOP codon towards the five prime end of the gene 
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(Figure 3-4).  While we have yet to assay this position in nz98, we believe it is likely to 
contain the same mutation due to its originating from the same plate in the screen.
Mutations in unc-80 cluster in two locations, one towards the 5’ end of the gene where 
we found nz94, and another at the 3’ end (Figure 4.4).  This clustering may be revealing 
regions that are important for function.  As a further experiment, we would like to 
demonstrate that nz94 represents a true null mutation by assaying for the cDNA of unc-
80, or by examining the protein levels by western blot.
5.15 - unc-80 and unc-79 mutations suppress the loopy 
locomotion of nRHO-1*
For further assays we decided to use an allele of unc-80, e1069, which had been 
previously characterised and backcrossed, as this was likely to contain fewer background 
mutations.  This allele is also able to suppress the loopy locomotion of nRHO-1* animals 
(Figure 4-6). 
We also tested an allele of unc-79, e1068, which shares a fainter phenotype with 
unc-80, and demonstrated that loss of activity of UNC-79 is also able to suppress the 
loopy locomotion of nRHO-1* (Figure 5-5).
We were able to successfully demonstrate rescue of the suppression of loopy locomotion 
in unc-80;nRHO-1* double mutants by using a number of UNC-80 minigenes (Figure 
4-8).  Pan-neuronal expression, under the synaptobrevin promoter, was able to restore 
loopy locomotion (Figure 4-9), demonstrating that UNC-80 is required neuronally for 
RHO-1 to generate loopy locomotion.  We were also able to rescue the suppression by 
expressing UNC-80 in the cholinergic motor neurons, using the unc-17 promoter (Figure 
4-9).  This same promoter is used to drive the expression of the nRHO-1* transgene, 
indicating that unc-80 is required presynaptically in the same cells as RHO-1* for the 
generation of loopy locomotion.  
We tested the efficiency of rescue using a dispersal assay, and found that expression 
from both of these promoters was sufficient to restore chemotaxis in nRHO-1* mutant 
animals (Figure 4-12).
We have been unable to obtain rescue using heatshock expression of UNC-80, so 
cannot rule out a developmental role for UNC-80 in the nervous system.  We have seen 
little expression of the GFP or mCherry tagged forms of the UNC-80 minigene following 
heatshock in animals carrying these constructs (Figure 4-11).  It may be that these 
large transgenes do not express well from the heatshock promoter, and that insufficient 
protein is being expressed to rescue the phenotype.  Additional experiments, perhaps 
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utilising other conditional expression systems (see Chapter 7) may allow us to answer 
the question of whether UNC-80 is required for the development of loopy locomotion. 
We may also be able to answer this question by examining heat-shock driven rescue of 
other components of the NCA complex, such as NCA-1, which is smaller than UNC-80 
and may express at higher efficiency from the heatshock promoter.  
We have also been unable to rescue the loopy locomotion phenotype by expressing 
unc-80 from the acr-2 promoter; this promoter has a largely overlapping expression 
pattern to unc-17, and so additional experiments, injecting our rescuing constructs at 
higher concentration, may reveal that this lack of rescue is due to inefficient expression. 
Alternatively, lack of rescue may result from subtle differences in the expression pattern 
of these two promoters which may in turn shed light on the cell-specificity of UNC-80.  
A large body of literature points to a relationship between unc-80 and unc-79, another 
large, unclassified gene (Sedensky and Meneely 1987; Morgan, Sedensky et al. 1988; 
Morgan, Sedensky et al. 1990; Humphrey, Hamming et al. 2007; Pierce-Shimomura, 
Chen et al. 2008; Yeh, Ng et al. 2008).  They appear to function in the same pathway with 
respect to anaesthetic sensitivity, locomotion and localisation of the NCA-1 and NCA-2 
ion channels.  
The work in this thesis demonstrates that unc-79 mutants are also able to suppress the 
loopy phenotype of nRHO-1* mutant animals (Figure 5-5).  However, to be confident 
of this result we would like to test additional alleles of unc-79, and to generate UNC-79 
rescuing constructs.  These would also enable us to determine the site of action of unc-
79 with respect to the suppression of nRHO-1* loopy locomotion, but we have reason to 
believe that UNC-79 is working in the same cells as UNC-80.  Rescue experiments will 
also be important for testing whether the unc-79 mutation is genuinely able to increase 
sensitivity to aldicarb (Figure 5-7).  
UNC-79 and UNC-80 are two large proteins which do not share any common domains, 
apart from a predicted armadillo repeat domain (Pierce-Shimomura, Chen et al. 2008), 
nor do they share homology to any other proteins so far classified.  They are however 
conserved between species, indicating that they may play some important biological 
function (Humphrey, Hamming et al. 2007).  Both are expressed in neurons in C. elegans 
(Jospin, Watanabe et al. 2007; Yeh, Ng et al. 2008) and their homologues are expressed 
in the nervous systems of Drosophila and mice (Humphrey, Hamming et al. 2007).  Loss 
of function of the Drosophila homologue of unc-79, dunc79, causes a hesitant walking 
phenotype reminiscent of the fainting locomotion observed in unc-79 mutants in C. 
elegans (Humphrey, Hamming et al. 2007).  This represents quite striking conservation of 
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function between two distantly related species.  This hesitant walking phenotype is also 
observed in mutants of the single Drosophila homologue of NALCN, known variously 
as narrow abdomen or α1U (for unusual α1 subunit).  Loss-of-function of this gene also 
disrupts the circadian rhythms of flies, reducing their activity in anticipation of daylight 
(Lear, Lin et al. 2005; Zhang, Chung et al. 2010).  It is tempting to see disruption of 
circadian rhythms as further evidence of a role for NALCN and its associated factors in 
the regulation of rhythmical behaviours. 
Complete loss of function of the mouse homologue of UNC-79, mUNC79 (also known 
as Leightweight (Lwt)) is lethal, with the mice dying 24 hours after birth due to interupted 
respiratory rhythms (Speca, Chihara et al. 2010).  Loss of NALCN in mice is also lethal 
with the animals dying from similarly interupted respiration (Lu, Su et al. 2007).  This 
suggests a potential role for NALCN and munc79 in regulating respiration, which is also 
a rhythmical behaviour.  
Early work on unc-80 and unc-79 mutants focused on their role in the response to general 
anaesthetics.  unc-80 and unc-79 were shown to be hypersensitive to the halothane 
class of general anaesthetics (Sedensky and Meneely 1987; Morgan, Sedensky et al. 
1988), which bucked the trend at the time of mutants affecting anaesthetic sensitivity 
affecting all classes equally.  This was a very exciting development, because it indicated 
that the target of these drugs might be specific neuronal proteins, as opposed to some 
general lipid-membrane disrupting mechanism proposed by contemporary theories.  The 
Drosophila homologue of unc-79, dunc79, has also been shown to be hypersensitive 
to halothane (Humphrey, Hamming et al. 2007), indicating a conservation of function 
between species.  Lwt/+ heterozygotes are hypersensitive to the intoxicating effects of 
ethanol (Speca, Chihara et al. 2010), an effect also seen in unc-79 and unc-80 mutant 
animals as measured by an increase in swimming activity (Speca, Chihara et al. 2010).
Early work on unc-79 and unc-80 mutants isolated a number suppressors of 
hypersensitivity to halothane, including unc-9 (Sedensky and Meneely 1987; Boswell, 
Morgan et al. 1990) and unc-1 (Morgan, Sedensky et al. 1990; Rajaram, Sedensky et 
al. 1998).  unc-1 and unc-9 mutants possess a ‘kinker’ mutation (‘The animal moves or 
rests with uncharacteristic muscle spasms causing loss of smooth sinusoidal motion 
or body posture. Movement is often characterized by severe bending motions, more 
sharply angled and/or much deeper than stereotypical sinusoidal body bends of the 
control animals’ Wormbase via Fernandes, J and Yook, K); other kinker mutations unc-
7 and unc-24 also suppress the hypersensitivity of unc-79 and unc-80 to halothane. 
unc-7 and unc-9 encode stomatins, which form part of the gap junctions.  Gap junctions 
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regulate the flow of ions in the nervous system, while unc-1 and unc-24 encode innexins, 
which associate with ion channels and lipid rafts.  This places unc-79 and unc-80 into 
pathways which regulate neuronal activity and behaviour, as well as a connection to 
mutations which cause kinking and coiling behaviour.  unc-8 mutations also suppress 
the hypersensitivity of unc-80 and unc-79 mutants, and unc-8 is potentially part of a 
mechanosensory complex involved in proprioception (Tavernarakis, Shreffler et al., 
1997).  
The double mutant unc-79;unc-80 is only slightly more sensitive to anesthetic than 
either of the single mutants, and these experiments suggested that unc-79 and unc-80 
act in the same pathway, and placed unc-79 genetically upstream of unc-80.  In our 
experiments we see that both unc-80 and unc-79 suppress the action of nRHO-1* in 
loopy locomotion placing them downstream of RHO-1 (Figures 4-6 and 5-5).  It would 
be instructive to see whether mutations in any of unc-1, unc-7, unc-9 or unc-24 interact 
with our nRHO-1* transgene, or whether triple mutants (such as nRHO-1*;unc-80;unc-1) 
would have restored loopy locomotion due to suppression of the effects of the loss of 
unc-80 function.  Preliminary data from the lab suggests that unc-1 interacts with dgk-1, 
a known target of RHO-1 signalling (S. Nurrish, personal communication.)  
Other targets of general anasethetic have subsequently been identified.  goa-1 mutants 
are resistant to the effects of anaesthetic (van Swinderen, Metz et al., 2001), while egl-
30(lf) mutants are hypersensitive (Hawasli, Saifee et al., 2004).  These proteins also 
regulate the activity of RHO-1 and the levels of neurotransmitter release.  Syntaxin 
(unc-64) mutants have a range of anaesthetic phenotypes depending on the specific 
mutations, suggesting a role for the core release machinery in anaesthetic response 
(van Swinderen, Saifee et al., 1999).  The mechanism of general anaesthesia is still 
not well understood, and the identification of a genetic interaction between rho-1 and 
unc-79 and unc-80 may provide a fresh perspective for investigating this medically 
important phenomena.  It would also be useful to test the sensitivity of nRHO-1* animals 
to halothane.  It is also interesting to note that screens for response to anaesthetic in 
worms use observations of locomotion - body bends, dispersal assays - and this may 
explain some of the overlap between locomotion mutants and anaesthetic response.  
5.16 - nca-1 and nca-2 single mutants suppress the loopy 
locomotion of nRHO-1* animals
While the effects of unc-79 and unc-80 on anaesthetic sensitivity were being investigated, 
a further class of fainter mutants was identified.  Loss of function of both nca-1 and nca-
2 produces a fainting locomotion identical to that of unc-80 and unc-79.  These genes 
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encode the two C. elegans orthologues of the mammalian protein NALCN (for Sodium 
(Na+) Leak Channel, Non-selective).  NALCN was first identified as a novel four repeat 
ion channel (Lee, Cribbs et al. 1999), initially classed as a leak channel (Lu, Su et al. 
2007), but since shown to be regulated by neuropeptide signalling and Src family kinases 
(Gilon and Rorsman 2009; Lu, Su et al. 2009; Swayne, Mezghrani et al. 2009; Wang and 
Ren 2009).  It is voltage-independent, at least in the voltage ranges tested so far (Lu, Su 
et al. 2007).  Its putative ion selectivity filter contains a novel EEKE motif, a combination 
of the EEEE motif of calcium channels and DEKA found in sodium channels, which 
makes it permeable to calcium, sodium and potassium ions.  
We tested whether mutations in the two C. elegans orthologues were able to suppress 
the loopy locomotion of nRHO-1*.  Surprisingly, given that the single mutants do not 
display a fainting locomotion phenotype, both single mutants were able to suppress the 
loopy locomotion of nRHO-1* animals (Figure 5-5).  This the first evidence that nca-
1 and nca-2 are not completely redundant.  It suggests that NCA-1 and NCA-2 have 
overlapping but distinct activities which cannot be entirely compensated for through the 
activity of the homologous protein.   
5.17 - NALCN-MUNC-80-MUNC79 form a complex in 
neurons
A number of pieces of evidence suggest that the action of UNC-80 and UNC-79 is 
mediated, at least in part, through binding to NCA-1 or NCA-2.  First, loss of nca-1 and 
nca-2 phenocopies the effects of unc-80 and unc-79 mutations with respect to the fainter 
phenotype and hypersensitivity to halothane (Sedensky and Meneely 1987; Morgan, 
Sedensky et al. 1988).  Secondly, loss-of-function mutations in any of the genes leads to 
a mislocalisation of the remaining proteins in C. elegans suggesting that they play a role 
in localisation or trafficking of each other in a reciprocal fashion (Humphrey, Hamming 
et al. 2007; Jospin, Watanabe et al. 2007; Yeh, Ng et al. 2008).  Third, by analogy to the 
mammalian systems, where MUNC80 has been shown to bind to NALCN in a MUNC79 
dependent fashion (Lu, Su et al. 2009; Wang and Ren 2009) we anticipate that the C. 
elegans proteins will form a complex, although this has yet to be confirmed by biochemical 
analysis.  We therefore think the major mechanism by which loss of unc-80 suppresses 
the loopy phenotype of nRHO-1* mutants is through mislocalisation or misregulation 
of the NCA-1 and NCA-2 ion channels (Figure 5-24).  For simplicity I will refer to this 
putative UNC-80/UNC-79/NCA-1/NCA-2 complex as the NCA complex.  
nca-1, nca-2 and unc-80 play a role in synaptic transmission as seen from 
electrophysiological recordings from body wall muscles in an nca-1;nca-2 mutant animal 
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(Jospin, Watanabe et al. 2007, Yeh, Ng et al. 2008).  The frequency of spontaneous 
release is either wild-type (Jospin, Watanabe et al. 2007) or decreased (Yeh, Ng et 
al. 2008), while the amplitude of evoked release was decreased (Yeh, Ng et al. 2008). 
Interestingly, the recordings of miniature postsynaptic currents in some mutants exhibit 
near wild-type release, while others show virtually no activity (Jospin, Watanabe et 
al. 2007; Yeh, Ng et al. 2008).  This raises the possibility that we are observing the 
physiological effects, or causes, of fainting locomotion; animals being assayed may 
be fixed in one of two states - normal locomotion, or fainting locomotion - which may 
correspond to the two states of wild-type release, or lack of release.  
RHO-1 
(RhoA)
PIP2 DAG PA
DGK-1 
(DAG Kinase)
UNC-79
(munc79)
UNC-80
(munc80)
NCA-1/
NCA-2
(NALCN)
UNC-13
(munc13)
Acetylcholine release
Muscle contraction
Loopy locomotion
Figure 5-24 The NCA complex is downstream of RHO-1
Loss of the activity of any component of the putatitve NCA complex - the NCA-1 and NCA-2 ion 
channels, or the potential scaffolding proteins UNC-79 and UNC-80 - is sufficient to suppress 
the loopy locomotion phenotype of nRHO-1* mutant animals.  The loss of any of these proteins 
has only a partial suppressive effect on the aldicarb release phenotype of nRHO-1* mutants 
which, along with experiments with the DAG analogue PMA, suggest that the NCA complex acts 
in parallel (or downstream) of the action of RHO-1 to increase DAG levels in the presynaptic 
membrane.  
Necessary but not 
sufficient?
Interaction based 
on suppression of 
loopy locomotion
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Recordings from HSN (neurons involved in egg-laying) using cameleon, a genetically 
encoded Ca2+ sensor, demonstrated a failure to transmit signals to the synapse from the 
soma in some individuals, while others were capable of normal transmission (Yeh, Ng et 
al. 2008).  This is consistent with the proposed mammalian role for NALCN of enhancing 
neuronal activity (Lu, Su et al. 2007; Lu, Su et al. 2009; Swayne, Mezghrani et al. 2009). 
More recently, the NALCN channel has been demonstrated to be sensitive to variations 
in the extracellular calcium levels (Lu, Zhang et al. 2010).  Reduction in extracellular 
calcium concentrations activate the NALCN-UNC-80 complex in a G-protein dependent 
manner, leading to an increase in neuronal excitibility (Lu, Zhang et al. 2010).   
A number of studies have indicated the wider physiological role of NALCN (and by 
extension the homologues of UNC-80 and UNC-79) in human health.  NALCN plays 
a role in the release of insulin from the Islets of Langerhans in the pancreas of mice 
(Swayne, Mezghrani et al. 2009; Swayne, Mezghrani et al. 2010) where it is activated by 
muscarinic receptors and G-protein signalling.  The sensitivity of NCA complex mutants 
to anaesthetics (Humphrey, Hamming et al. 2007) and ethanol (Speca, Chihara et al. 
2010) is significant as these are two major factors influencing human health and medical 
treatment.  The lightweight mutant animals also demonstrate an increased preference 
for ethanol, as well as increased sensitivity.  Complete loss of function of NALCN (Lu, 
Su et al. 2007) or the unc-79 homologue (Speca, Chihara et al. 2010) in mice is lethal, 
and mice are thought to die from interrupted respitory rhythms, indicating an essential 
function for these genes.  
Conflicting reports have emerged about a role for NALCN in schizophrenia (Souza, Rosa 
et al. 2010; Wang, Liu et al. 2010), while a role for the Drosophila homologue in regulating 
circadian rhythms (Humphrey, Hamming et al. 2007; Zhang, Chung et al. 2010) has led 
to some suggestions of links to manic depression.  
5.17.1 - Rescue experiments hint at dominant negative 
effects of overexpressing UNC-80 protein in neurons
As described above, we generated a set of constructs for expressing wild-type UNC-80 
protein.  We obtained rescue of the loopy phenotype of unc-80;nRHO-1* animals using 
these, but it appeared as if the animals had retained a fainting locomotion.  To test this, 
we crossed out the nRHO-1* transgene and observed by eye that unc-80 mutant animals 
carrying these constructs retained a fainting locomotion.  We saw the same effect in wild-
type animals, suggesting that expressing UNC-80 from either the snb-1 or the unc-17 
promoters had a dominant-negative effect on UNC-80 activity.  We also saw that these 
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constructs failed to rescue swimming behaviour in unc-80 mutants (Figure 4-13 & 4-15), 
and induced a reduction in swimming behaviour in wild-type animals (Figure 4-15).   
Loss of UNC-80 protein appears to alter the localisation of NCA-1 (Jospin, Watanabe et 
al. 2007; Yeh, Ng et al. 2008) and we suggest UNC-80 (and potentially UNC-79) may act 
in a scaffolding role.  Scaffolds have been observed to cause defects when both absent 
or overexpressed.  When absent, components in a pathway are not brought together 
at the correct location in a cell, while ovexpressing scaffolds can lead to the titration of 
components away from each other, causing a dominant negative effect.  
We suggest that overexpression of UNC-80 produces such a dominant negative effect 
due to titration of components of the NCA complex, and that this causes a similar 
locomotive phenotype to loss of function of the NCA complex.  We may in the future 
be able to use this dominant negative effect as an assay - we could create constructs 
expressing fragments of the UNC-80 protein with the aim of disrupting normal NCA 
complex function, and then biochemically and bioinformatically anaylse those fragments 
with the aim of determining more about the structure and function of UNC-80.  
The size and conservation of UNC-79 and UNC-80 suggest that they may have multiple 
conserved protein/protein interactions, and it would be interesting to test whether other 
components of our neurotransmitter release pathway, including RHO-1, EGL-30, UNC-
73 and DGK-1 are able to bind to these proteins.  
5.18 - NCA complex mutants response to aldicarb and 
levamisole
5.18.1 - The fainter mutants tend towards hypersensitivity to 
aldicarb
We tested the response of nca-1, nca-2, nca-1;nca-2, unc-79 and unc-80 mutants to 
the acetylcholine esterase inhibitor aldicarb, and the acetylcholine agonist levamisole. 
These experiments were intended to pharmacologically probe the activity of the nervous 
system of the mutants and the response of their body wall muscles to acetylcholine as a 
way to uncover the effects of the mutations on neurotransmission.
unc-79 mutants are more sensitive to aldicarb than wild-type animals (Figure 5-7), 
and more sensitive than unc-80 mutants, which also display a slight hypersensitivity to 
aldicarb (Figure 4-16).  However, nca-1;nca-2 double mutants are essentially wild-type 
for aldicarb sensitivity (Figure 5-10).  
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The nca-2 single mutant, while being wild-type in locomotion, displays a strong 
hypersensitivity to aldicarb (Figure 5-9).  The loss-of-function mutant of its paralogue, 
nca-1, displays no aldicarb phenotype (Figure 5-10), while a gain-of-function mutation 
in nca-1 leads to aldicarb hypersensitivity (Figure 5-19).  This may not indicate a direct 
role for the NCA-1 channel in acetylcholine release; the gain-of-function allele may 
be a neomorphic mutation which makes the channel more permable to sodium ions, 
constitutively depolarising the neurons, or to calcium, initating membrane fusion , causing 
an increase in the release of neurotransmitter.  
Whether these results reflect real differences in the activity of UNC-79, UNC-80, NCA-1 
and NCA-2, or is simply a result of differences in the strength or penetration of the two 
mutations, or additional background mutations, is not clear.  Therefore it would be useful 
to test additional alelles of these genes to see whether this trend continues, or is related 
in some way to the specific mutations tested here.  There is a second deletion mutant 
of nca-1, tm1851, a 1213bp deletion, and two of nca-2, tm377 (which deletes 355bp 
of genomic sequence) and tm1305, a 794 base pair deletion which overlaps with the 
gk5 deletion studied here (Figure 5-1), while a number of additional unc-79 and unc-80 
mutants are also known and could be obtained for testing (Figures 5-1 and 4.4).  Testing 
these additional mutants might give further insight into the aldicarb effects seen in the 
nca-2 mutant tested.
However, it remains a possibility that the NCA complex does play a role in acetylcholine 
release.  The increase in aldicarb sensitivity in a nca-2 mutant may be due to a 
compensatory increase in the activity of the NCA-1 channel.  The differences in the 
aldicarb sensitivities of unc-79 and unc-80 mutants may be due to changes in the 
localisation or activity of the NCA-1 and NCA-2 ion channels, which are mislocalised in 
these mutant backgrounds (Yeh, Ng et al. 2008).  
To confirm a role for these proteins in acetylcholine release we would like to examine 
the aldicarb sensitivity of rescued animals.  In the experiments conducted so far with the 
UNC-80 rescuing transgenes, we see an increase in aldicarb sensitivity in an unc-80 
mutant expressing UNC-80 from an unc-17 promoter, and no change when UNC-80 is 
expressed from the synaptobrevin promoter.  These experiments need to be repeated, 
and additional rescued lines tested, but if the results with the unc-17 promoter remain 
consistent, this increase in aldicarb sensitivity could be attributed to changes in the 
activity or localisation of the NCA-1 and NCA-2 ion channels.  
5.18.2 - nRHO-1* is able to increase sensitivity to aldicarb in 
NCA complex mutants 
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We tested whether the increase in acetylcholine release was affected by mutations in the 
NCA complex genes.  unc-80 mutants only partially suppress the aldicarb hypersensitivity 
of nRHO-1* animals (Figure 4-22),  while unc-79;nRHO-1* (Figure 5-15), nca-1;nRHO-1 
(Figure 5-16) and nca-2;nRHO-1* (Figure 5-17) mutants have an aldicarb sensitivity 
intermediate between nRHO-1* and wild-type.  Again, this suggests that there is a 
small some role for the NCA complex in neurotransmitter release, but also indicates 
that reduction in release is unlikely to be the main mechanism for suppressing the loopy 
locomotion of nRHO-1* mutants.  Other mutants isolated in our screen also had little or 
no effect on acetylcholine release and yet had wild-type locomotion (Chapter 3, Figure 
3-5).
Preliminary experiments with the UNC-80 transgenes indicate that expressing UNC-
80 pan-neuronally in an unc-80;nRHO-1* mutant is able to rescue the suppression of 
acetylcholine release seen in these animals (Figure 4-17), although expression from the 
unc-17 promoter has no effect in these double mutant animals (Figure 4-17).  This may 
indicate a requirement in cells other than the cholinergic neurons for UNC-80 with respect 
to the aldicarb sensitivty generated by nRHO-1*, unlike loopy locomotion, which can 
be successfully rescued with cholinergic expression of UNC-80.  This experiments are 
preliminary, and the data from additional transformed lines will help us address whether 
differences in rescue are due to physiological effects of expression in different cell types, 
or simply due to differences in the level of expression between the two transgenes, 
although all transgenes are expressed at a sufficient level to rescue loopy locomotion.  
5.18.3 - Fainter mutants tend towards hypersensitivity to 
levamisole
The response of animals to aldicarb is a product of the amount of acetylcholine released, 
and the sensitivity of the muscles to stimulation by acetylcholine.  We therefore tested the 
animals for their response to levamisole, which directly stimulates the body wall muscles. 
We see that mutants displaying fainter locomotion (unc-79, unc-80 and nca-1;nca-2) 
are hypersensitive to levamisole (Figures 5-14, 4-19 and 5-16).  This might suggest that 
there is an overall reduction in acetylcholine release in these mutants, coupled with an 
increase in the sensitivity of the muscles as part of a homeostatic response.  This is 
consistent with the electrophysiological data obtained from nca-1;nca-2 double mutant 
animals, and has been observed at the Drosophila neuromuscular junction.  
nca-1 single mutants are wild-type in their response to levamisole (Figure 5-16), and 
nca-2 mutants remain to be tested.  It would be enlightening to determine the levamisole 
response of nca-2 mutants to determine whether the cause of the hypersensitivity to 
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aldicarb is a muscle sensitivity alteration, although we cannot rule out a second site 
mutation in nca-2 and rescue experiments would be required to confirm this hypothesis. 
We tested whether this change in levamisole response is rescued in a unc-80 mutant 
expressing our UNC-80 rescuing constructs.  As with the aldicarb phenotype, we see 
differences between constructs expressing pan-neuronally, which have no effect on 
levamisole sensitivity, and constructs expressing in the cholinergic neurons, which 
increase sensitivity to levamisole (Figure 4-21).  
5.18.4 - unc-79;nRHO-1* and unc-80;nRHO-1* double mutants 
are resistant to levamisole
While animals displaying fainting locomotion are hypersensitive to levamisole, introducing 
the nRHO-1* array into these animals causes a reduction in sensivity to levamisole. 
While nRHO-1* and unc-80 single mutant animals are hypersensitive to levamisole, the 
unc-80;nRHO-1* double mutant is resistant to levamisole even compared with wild-type 
animals (Figures 4-19)  We see a similar striking change in levamisole sensitivity in an 
unc-79;nRHO-1* double mutant.  unc-79 mutants are hypersensitive to levamisole, but 
the unc-79;nRHO-1* double mutant is resistant (Figure 5-11).  
We suggest that loss of the NCA complex function, as regulated by unc-79 and unc-80, 
may allow for a greater degree of homeostasis to occur at the neuromuscular junction 
than in wild-type animals.  Homeostasis is a mechanism for maintaining activity in 
biological systems at a predefined set point, such that increases in activity at one point 
in a system are resisted by decreases at another point (for review of this phenomena 
in the Drosophila nervous system, see Davis 2006).  We speculate that the loss of the 
NCA complex may facilitate homeostatic effects in the  the C. elegans nervous system, 
such that in the presence of high levels of acetylcholine release, mediated by the 
nRHO-1* transgene, the body wall muscles are able to reduce their response to 
acetylcholine more than in a wild-type background.  We would like to test this hypothesis 
by generating an nca-1;nca-2;nRHO-1* triple mutant, entirely lacking in NCA complex 
activity, which we predict would have a reduced sensitivity to levamisole compared with 
nRHO-1*, nca-1 or nca-2 single mutants.  
We also tested whether loss of UNC-80 function is responsible for this reduction in 
sensitivity to levamisole by assaying the levamisole sensitivity of unc-80;nRHO-1* mutant 
animals rescued with the UNC-80 transgenes.  Although we have only conducted this 
experiment once, these animals appear hypersensitive to levamisole compared with the 
unc-80;nRHO-1* and the nRHO-1* mutant animal (Figure 4-20).   
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The nca-1(gf) mutant animals demonstrate a wild-type levamisole response, however, 
suggesting that activation of this complex alone is insufficient to affect the activity of the 
body wall muscles.  
If loss of activity of the NCA complex somehow enhances homeostatic regulation, we 
would predict that loss of the complex would enhance release of neurotransmitter in 
mutants which have reduced levels of release. unc-26 (synaptojanin) mutants have 
reduced levels of spontaneous release; this level of release is increased in combination 
with loss of unc-80 or nca-1;nca-2 (Jospin, Watanabe et al. 2007).
5.18.5 - NCA complex mutants respond normally to phorbol 
ester treatment
One concern is whether mutations in the NCA complex specifically block increased 
neuronal activity due to nRHO-1*, or if they are able to block any increase in neuronal 
activity.  We tested whether NCA complex mutants are able to suppress the effects of 
PMA, a phorbol ester and DAG analogue.  We reasoned that if these mutants were 
reducing the overall activity of the nervous system we would see a reduction in their 
aldicarb sensitivity in response to PMA.  We see that with all three fainter mutants 
unc-80, unc-79 and nca-1;nca-2, and in the single mutant nca-1, stimulation with PMA 
increases the sensitivity to aldicarb in line with the responses seen in wild-type animals. 
This indicates that mutations in the NCA complex genes do not prevent all increases in 
motor neuron activity.  
It also suggests that this complex acts in a pathway either upstream of in parallel to that 
regulated by PMA, and endogenously by DAG.  This is consistent with our results which 
indicate that mutations in the NCA complex have only a partial suppressive effect on the 
neurotransmitter release phenotype of nRHO-1*, while completely suppressing the loopy 
phenotype, although they may act in parallel for acetylcholine release with DGK-1 (see 
later).  
Interestingly, in an nca-2 mutant, PMA does not stimulate acetylcholine release to wild-
type levels.  We have previously seen high levels of acetylcholine release in the nca-
2 single mutant compared with both the nca-1 single mutant and nca-1;nca-2 double 
mutant, and this experiment with PMA also produces a result which is against the pattern 
seen with other NCA complex mutants.  This is most likely due to a second site mutation 
in this strain, and either further backcrossing or the use of an additional mutant may shed 
light on this matter.  
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5.19 - UNC-80 and nRHO-1* play a role in body size
There may be additional points of interaction between the nRHO-1* activity and the 
NCA complex.  We observe a stastically significant decrease in the size of age-matched 
nRHO-1* animals compared with wild-type controls, (Figure 4-23) which is partially 
suppressed in an unc-80;nRHO-1* double mutant animal (Figure 4-23).  The source of 
this change is unknown; possible reasons may include an overall reduction in growth 
rate, changes in metabolic rates due to increased activity, or reductions in energy intake 
due to defects in chemotaxis or feeding.  
We also observe that both nRHO-1* and nca-1(gf) mutants are highly loopy. (Figure 
5-19).  This suggests that overactivation of the NCA complex is sufficient to drive loopy 
locomotion behaviour.  Interestingly, these nca-1(gf) mutants also become hypersensitive 
to aldicarb, indicating an increase in acetylcholine release (Figure 5-20)..  Since loss of 
activity of the NCA complex only partially suppresses the excess neurotransmitter release 
generated by the nRHO-1* transgene, we surmise that this increase in acetylcholine 
release may be due to the NCA-1 channel becoming highly permeable to either sodium 
or calcium ions, and inducing neurotransmitter release through depolarisation of the 
nervous system.  This effect may therefore be a neomorphic mutation.  
In addition, nca-1(gf) mutants display a defect in the Exp step of defecation, similar to 
that seen in nRHO-1* mutants (Figure 5-23).  This step is regulated by the release of the 
neurotransmitter GABA, and  this observed defect suggests that this may be regulated 
by the NCA complex and RHO-1.
Taken together, these additional phenotypes suggest that the NCA complex and RHO-1 
may combine to regulate a number of processes in C. elegans. 
5.20 - Loopy locomotion and fainting may be part of 
different pathways
We observed that while the loopy phenotype of nRHO-1* is suppressed in an unc-80 
background, these double mutants retain the fainting locomotion exhibited by unc-80 
mutant animals.  unc-80 mutants have a number of locomotive defects, including a 
fainting locomotion on solid surfaces and a reduction in swimming behaviour in a liquid 
medium.  If an integrated model of C. elegans locomotion is correct (Berri, Boyle et al. 
2009), then these represent different aspects of the same phenotype .  
When we reintroduce a rescuing transgene into unc-80;nRHO-1* mutant animals, we 
completely rescue the loopy behaviour (Figures 4-9 and 4-12).  However, animals 
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expressing even a pan-neuronal UNC-80 transgene appear to retain the fainting 
locomotion (see Movie 4-7) on a solid surface.  This suggests that there is a difference in 
the requirement for UNC-80 in mediating loopy locomotion and and preventing fainting. 
There may be a non-neuronal component to fainting behaviour not rescued by this 
transgene, or the level of expression from this transgene may be insufficient to rescue 
fainting.  
We also examined the swimming phenotype of unc-80 animals carrying these rescuing 
transgenes (Figures 4-13 and 4-15).  This demonstrates that animals carrying the UNC-
80 transgenes, under either a pan-neuronal or unc-17 promoter, retain some of the 
swimming defect of unc-80 mutants, even in the absence of the nRHO-1* transgene. 
Interestingly, the p.unc-17-driven transgene appears to restore more wild-type behaviour 
than the p.snb-1-driven transgene (see Movies 4-16 and 4-17).  
One possibility is that the p.snb-1 transgene is having some dominant negative effect 
on behaviour; to test this we crossed these transgenes into a wild-type background, 
and saw that they were able to induce some defects in swimming in wild-type animals 
(Figures 4-13 and 4-15).  If UNC-80 is acting as a scaffold, we may be observing dominant 
negative effects of overexpression.  Further experiments with varying levels of transgene 
expression, and by examining rescue in unc-79 and nca-1;nca-2 mutant animals will 
shed further light on this differential requirement of the NCA complex in fainting and 
loopy behaviour.  
5.21 - The NCA complex may be regulated by PIP2
unc-79, unc-80 and nca-1;nca-2 mutants increase the frequency of spontaneous release 
in hypomorphic unc-26 mutants (Jospin, Watanabe et al. 2007).  They also partially 
rescue the locomotion defect in animals carrying a hypomorphic allele of unc-26 (Jospin, 
Watanabe et al. 2007), and increase the number of synaptic vesicles present in presynaptic 
terminals (Jospin, Watanabe et al. 2007).  UNC-26 is a PIP2 phosphatase, and the unc-26 
hypomorphic mutants have an increase in PIP2 levels.  This can be mimicked
by overexpressing PPK-1, which encodes a PI4P5 kinase, which generates PIP2.  unc-
80 mutants are also able to suppress the locomotion defects of PPK-1 (overexpression) 
animals (Jospin, Watanabe et al. 2007), suggesting a link between unc-80 and PIP2 
levels.  unc-80 mutants fail to rescue null alleles of unc-26, suggesting that they cannot 
bypass the endocytosis defect in these more severly affected mutants.  
PPK-1 encodes a PI4P5 kinase, which generates PIP2, while synaptojanin encodes 
a lipid phosphatase which removes PIP2 from the presynaptic membrane.  PIP2 is an 
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Figure 5-25 The NCA complex may be regulated by PIP2
unc-80 mutants are able to suppress the behavioural effects of either loss of function unc-26 or 
PPK-1-overexpressing animals.  This suggests that the NCA complex may be regulated either 
directly or indirectly by PIP2.  RhoA is able to bind to an activate PI4P5K, and we suggest a 
model in which excess RHO-1 activity stimulates production of PIP2, driving the activity of the 
NCA complex and generating loopy locomotion.  
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activator of ion channel activity, the lipid from which DAG and IP3 are generated, and an 
important marker of membrane domains in the presynaptic membrane (Niggli 2005).  It 
has been proposed that excess PIP2 may misregulate the localisation or activity of the 
NCA-1 and NCA-2 ion channels (Jospin, Watanabe et al. 2007).  
RhoA is known to enhance the activity of PI4P5K, and subsequently the production of PIP2, 
through activation of Rho kinase (Oude Weernink, Schulte et al. 2000; Santarius, Lee et 
al. 2006) and through direct binding to PI4P5K (Ren, Bokoch et al. 1996).  Unpublished 
data from our laboratory has demonstrated binding of RHO-1 to PPK-1 in COS cells (Dr 
Muna Elmi, personal communication).  We propose that this activated RHO-1 stimulates 
activity of PPK-1, leading to an excess production of PIP2 (Figure 5-25).  We hypothesise 
that excess PIP2 either directly activates the NCA complex, or causes a change in the 
trafficking of the complex; with either mechanism leading to the changes in neuronal 
activity which produce loopy locomotion.  
5.22 - The F25N mutation in RHO-1* bypasses the 
requirement for unc-80 in loopy behaviour
During experiments to understand the relative importance of pathways mediated by 
dgk-1 and those mediated by unc-80, we transformed unc-80 mutant animals with a 
mutant version of RHO-1 which contains the F25N mutation.  When expressed from 
either the unc-17 neuronal promoter, or from the heatshock promoter, expression of this 
version of RHO-1 generated loopy locomotion in unc-80 mutant animals.  
RHO-1 increases neuortransmitter release through inhibition of DGK-1 and via a DGK-
1 independent pathway, and we therefore tested whether the NCA complex represents 
this DGK-1 independent pathway.  We tested whether a heat-shock driven version of 
RHO-1(F25N)* (a mutation which blocks binding to DGK-1) was able to induce loopy 
locomotion in the presence of the nRHO-1* transgene.  Following heatshock, the unc-80 
animals carrying both transgenes became highly loopy.  This suggests that it is not the 
lack of binding to a specific effector, such as DGK-1, which is responsbile for the ability 
of this mutation to bypass the requirement for UNC-80 (Figure 5-26).  
This result demonstrates that NCA complex mutants do not have a general neuronal 
defect which makes loopy locomotion impossible, and b) either there is a third pathway 
independent of both DGK-1 and the NCA complex which can generate loopy locomotion 
and increase acetylcholine release, or that the F25N mutation increases signalling 
through the exisiting pathways such that it can bypass the loss of NCA complex function. 
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It will be informative to perform similar experiments in an unc-79 mutant background; 
following our previous work we would predict that the unc-79, would also fail to suppress 
loopy locomotion generated by the RHO-1(F25N)*, as we believe that unc-80 and unc-
79 work through a common pathway.  
5.23 - More quantitative methods for assaying the effects 
of loss-of-function of the NCA complex are required
While the fainting locomotion of unc-79, unc-80 and nca-1;nca-2 mutants is well 
described, it still remains somewhat mysterious.  We can identify a number of different 
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Figure 5-26 The F25N mutation bypasses the requirement for 
UNC-80 in loopy locomotion
RHO-1(F25N)* is able to drive loopy locomotion in a unc-80 mutant background.  We proposed 
three models for this action.  1)  Loss of binding to an effector bypasses the requirement 
for UNC-80.  2)  The F25N mutation induces binding to a novel effector which independently 
generates loopy locomotion.  3)  The loss of binding to an effector allows excess signalling 
through existing pathways.  Model 1 has been discounted as the F25N mutation bypasses 
the requirement for UNC-80 even in the presence of the F25 form of RHO-1.  We cannot yet 
distinguish between the other two models.  
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phenotypes in these mutant animals which may be related.  First, fainting locomotion, 
where animals remain at rest for long periods of time (Figure 4-1).  Secondly, a reduction 
in locomotion as measured in the dispersal assay (Figure 4-7), which may be related to 
reduced rates of locomtion, or a defect in chemotaxis.  Third, defects in two assays of 
swimming behaviour - mean thrashes after recovery, and initial thrashing (Figures 4-13, 
4-14, 4-15, 5-2, 5-3 and 5-4).  
We were interested in whether our rescuing constructs for UNC-80 were able to restore 
wild-type swimming behaviours, and found that animals rescued either in the entire 
nervous system or in the cholinergic neurons still displayed a swimming defect (Figures 
4-13 and 4-15), suggesting that either that UNC-80 is required in cells other than neurons 
for the reduction of fainting behaviour, or that the absolute levels of UNC-80 expression 
are important.  We assayed whether these constructs were able to cause swimming 
defects in wild-type animals, and found a reduction in swimming behaviour (Figure 
4-15).  This strongly suggests a dominant-negative effect of these constructs, which is 
consistent with a scaffolding or trafficking role for UNC-80. 
We would like to expand these experiments by overexpressing UNC-79 rescuing 
constructs in a wild-type background to look for defects in swimming behaviour.  
5.24 - Conclusions and future work
We have demonstrated that loss-of-function mutations in the genes unc-79, unc-80, nca-
1 and nca-2 can suppress the loopy locomotion behaviour associated with nRHO-1*, 
while having only a small effect on the increase in neurotransmitter release generated in 
nRHO-1* mutant animals.
The protein products of these genes are thought to form a novel, regulated ion channel 
complex, which is located at perisynaptic regions in the neurons of C. elegans, and 
plays a role in the propogation of neuronal signalling in certain neurons.  We also have 
evidence that loss of function of unc-80 suppresses a reduction in the size of nRHO-1* 
animals, suggesting multiple points of interaction between these genes.  
Evidence from the literature suggest that this NCA complex may act downstream of PIP2, 
and we propose that regulation of PPK-1, a PI4P5K by RHO-1 may cause misregulation 
or mislocalisation of this complex, leading to a generation of loopy locomotion.  
Our results indicate that a novel, conserved ion channel complex, involved in many 
biologically interesting processes, such as the response to ethanol and general 
anaesthetics, and responsible for similar phenotypes in distantly related organisms 
incuding flies and worms, is regulated by the action of RHO-1. 
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Evidence strongly suggests a link between the NCA complex and the overproduction of 
PIP2 (Jospin, Watanabe et al. 2007), and this is part of our working hypothesis for the 
link between RHO-1 activity and changes in the NCA complex.  Our model suggests that 
PPK-1 functions downstream of RHO-1 in the nervous system.  To further investigate 
this link, we are currently conducting experiments to reduce the activity of PPK-1 in adult 
neurons using RNAi.  Several methods allow cell-targetted RNAi in C. elegans, and 
we are expressing complimentary sequences of PPK-1 cDNA, one from a cell-specific 
promoter and the second from a heat-shock to generate double-stranded RNA in adult 
animals.  Preliminary experiments suggest that reducing PPK-1 activity in nRHO-1* 
animals by RNAi is able to suppress the loopy locomotion phenotype of nRHO-1* (M. 
Elmi, personal communication.)  
We would also predict that if PPK-1 is regulated by RHO-1, PIP2 levels would increase 
in the nRHO-1* animals.  We could test this using PIP2 reporters to measure the levels of 
PIP2 in nRHO-1* animals and following heat-shock activation of RHO-1. 
The screen which identified unc-80 as a suppressor of RHO-1* was conducted based 
on the loopy locomotion phenotype.  While mutations in unc-80 and the rest of the NCA 
complex strongly suppress loopy locomotion, they only partially suppress the aldicarb 
hypersensitivity of nRHO-1* mutant animals, and we have seen this with separation 
between locomotion and acetylcholine release in other mutants isolated from our 
screen (Chapter 3).  This strongly suggests that our original hypothesis that high levels 
of acetylcholine release are responsible for loopy behaviour is oversimplistic, and that 
we are in fact looking for a second factor which promotes loopy behaviour.  We were 
interested in whether there was a general reduction in neuronal activity in NCA complex 
mutants, but our experiments with PMA (summarised in 5.18.5) suggest that this is not 
the case, at least at a gross level of activity.  This lack of a straightforward explanation, 
coupled with the successful rescue of the loopy phenotype with exogenous UNC-80 
leads to the question: ‘What mechanism requires the NCA-1 and NCA-2 ion channels to 
allow the nRHO-1* transgene to stimulate loopy locomotion?’  I would like to propose a 
number of hypotheses which can be subjected to further investigation.  
Given the isolation of mutations in unc-31, which has an established role in the exocytosis 
of dense core vesicles (see Section 3.14.8.1), there may be a role for neuropeptide 
release in the production of loopy locomotion.  This neuropeptide release would provide 
a second factor to modulate the muscle response to high levels of acetylcholine release, 
perhaps acting in a homeostatic fashion.  This explanation would go some way to explain 
the mechanism by which presynaptic changes affect levamisole response in the nRHO-
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1*;unc-80 and nRHO-1*;unc-79 double mutant animals (5.18.3 and 5.18.4).  To test 
this hypothesis we could attempt to assay neuropeptide release in the various mutant 
backgrounds using tagged neuropeptides (Sieburth, Madison et al 2007).  Physiologically, 
the release of these peptides could also be part of a mechanism to regulate turning 
behaviour as a component of locomotion, for instance in the regulation of chemotaxis. 
The NALCN ion channel is regulated by the neuropeptide Substance P (Lu, Su et al. 
2009), and it may be that a neuropeptide, whose release requires UNC-31 activity, is 
involved in the regulation or activity of the NCA complex in C. elegans (Figure 5-27). 
A second hypothesis involves the relationship between the NCA complex and unc-8, 
a proposed mechanosensory channel.  It could be that the NCA complex represents 
part of the proprioceptive stretch receptor complex long hypothesised to regulate body 
posture.  Overactivation of this complex by RHO-1, possibly by increasing levels of PIP2, 
might directly lead to changes in locomotion; again, in a physiological situation, this 
could be part of the regulation of search behaviours.  The NCA complex could also be 
a regulator of stretch response, for instance through the release of neuropeptides as 
described above.  Loss of this stretch receptor could lead to a failure to propogate waves 
successfully, leading to what we observe as a fainting phenotype.  
A further possibility involves the role that the NCA complex appears to play in regulating 
rhythmical behaviours.  A recent publication suggests that an NCA-1 homologue acts as 
a central pattern generator (CPG) controlling breathing in a snail (Lu and Feng 2011). 
Again, misregulation of this CPG could lead to an increase in the rate of wave production; 
loss could lead to fainting behaviour.  
5.24.1 - Future work
A large network of regulated G-protein signalling pathways have been shown to control 
acetylcholine release in C. elegans (Perez-Mansilla and Nurrish 2009), and EGL-30 
(Gαq), GOA-1 (Gαo/i) and GPA-12 (Gα12) are known to converge on RHO-1 (Figure 
5-27).  We will generate double mutants between these G-proteins and the NCA 
complex mutants to test whether loss of activity of the NCA complex is able to suppress 
the hyperactive locomotion and increased neurotransmitter release phenotypes of 
egl-30 (gf) and goa-1.  Subsequently we can use mutations in other members of this 
signalling complex, such as EGL-8 (PLCb) and UNC-73 to epistatically place the NCA 
complex into our existing pathways.  This would be the first example of this G-protein 
signalling network regulating the function of an ion channel in C. elegans neurons. 
G-proteins regulate ion channel function in mammalian neurons and, if this finding is 
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upheld, it would bring the C. elegans nervous system even closer as a model organism 
to the the mammalian system (Perez-Mansilla and Nurrish 2009).
Based on our work with the nz110 suppressor which may due to a mutation in unc-31 
(see Section 3.14.8.1), we will examine the potential for a role of the NCA complex in the 
release of neuropeptides.  We would also like to look at the localisation of the NCA complex 
in nRHO-1* mutant animals using our GFP- and mCherry-tagged rescuing transgenes 
of UNC-80.  We would like to confirm that the loss of the ion channel components of the 
complex is the source of both fainting locomotion and the suppression of nRHO-1* loopy 
behaviour by assaying the effects of an NCA-1 rescuing transgene which has recently 
been generated in the lab.
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Figure 5-27 The NCA complex and neuropeptide release are 
required for loopy locomotion induced by nRHO-1* 
Loss of any components of the NCA complex in C. elegans suppresses the loopy locomotion 
phenotype induced by nRHO-1*.  Mutations in the NCA complex also suppress mutations 
associated with excess PIP2 levels, putting the NCA complex downstream of PPK-1, which may 
be regulated by RHO-1*.  Mutations in unc-31 (CAPS) are also able to suppress loopy locomotion 
(Chapter 3), suggesting a role for neuropeptide release in loopy locomotion, possibly through 
regulation of the NCA complex, homologous to the action of substance P on the mammalian 
homologue NALCN.   Mutations in dat-1 also appear to suppress loopy behaviour (Chapter 3). 
These mutations have only a small effect on acetylcholine release, suggesting that they act in 
parallel pathways.  However, our model suggests that high levels of acetylcholine release are 
necessary but not sufficient for loopy locomotion. 
Green arrows and protein names relate to interactions which drive loopy behaviour.  
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6 - SYNTAXIN MAY BE REGULATED BY A 
NOVEL APKC PHOSPHORYLATION
6.1 - Introduction
The release of neurotransmitter in C. elegans is tightly regulated, and part of a complex 
network of interlinked G-proteins signalling pathways (Perez-Mansilla and Nurrish 2009), 
many of which converge on nRHO-1* (Chapters 3-5).  
The pathways examined so far extend from the reception of neuromodulatory signals, 
through changes in DAG levels at the presynaptic membrane, to changes in priming of 
synaptic vesicles.  Further regulation occurs at the level of exocytosis. 
For example, fusion is mediated, at least in part, by the SNARE complex, (see section 
14.2 for a detailed introduction.)  Syntaxin (UNC-64), an important member of the SNARE 
complex, interacts with mUNC-13 (UNC-13), one of the key diacylglycerol (DAG) binding 
proteins whose localisation is regulated by the activity of RHO-1 in the worm nervous 
system.  
A key regulator of syntaxin is the protein Tomosyn (Tom-1) (Section 1.4.3).  Tomosyn 
binding is able to dissociate the binding of munc18 from syntaxin (Fujita, Shirataki et 
al. 1998), disrupting a key step in vesicle priming, and tomosyn acts as an inhibitor 
of invoked, calcium-dependent neurotransmitter release in vitro (Fujita, Shirataki et al. 
1998; Baba, Sakisaka et al. 2005).  In C. elegans, the single tomosyn homologue, tom-1, 
has been identified as an endogenous inhibitor of neurotransmission (Dybbs, Ngai et al. 
2005).  tom-1 mutants have a higher evoked release as measured electrophysiologically 
in C. elegans; this appears to be as  a result of increased numbers of primed vesicles 
rather than overall structural changes to the nervous system (Gracheva, Burdina et al. 
2006).  Loss of tom-1 is able to overcome some of the defects in neurotransmission 
observed in an unc-13 mutant animal (Gracheva, Burdina et al. 2006; McEwen, Madison 
et al. 2006).  Tomosyn also plays a role in the release of neuropeptides in C. elegans 
(Gracheva, Burdina et al. 2007; Gracheva, Burdina et al. 2007).  
Tomosyn is structurally related to the Drosophila protein lethal giant larvae (LGL) with 
which it shares a similar WD40 repeat domain (Fujita, Shirataki et al. 1998), and the 
yeast homologues of both proteins bind the yeast homologue of syntaxin and function in 
regulated exocytosis in budding yeast (Lehman, Rossi et al. 1999) (Figure 6-1).  
LGL is a tumor suppressor, and competes with the polarity protein PAR-3 to form a 
complex with the small GTPase CDC-42, Par-6 and an atypical protein kinase C 
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(Yamanaka, Horikoshi et al. 2003).  The Fujita lab at the MRC LMCB has maintained 
an interest in tomosyn, and they hypothesized that a similar complex might exist for 
the regulation of neurotransmitter release.  Tomosyn is capable of binding to Par-6 and 
Syntaxin, Par-6 is capable of recruiting atypical protein kinase C, and this turn could act 
to regulate neurotransmitter release by phosphorylating syntaxin (Figure 6-1).  
The Fujita lab identified 4 potential aPKC phosphorylation sites in syntaxin, all of which 
are conserved in the worm homologue, UNC-64 (Figure 6–2).  The potential for an 
CDC-42
LGL
PAR-6
aPKC
Tomosyn
Syntaxin (Habc)Syntaxin 
(SNARE helix)
Potential 
phosphorylation
PAR-6
aPKC
Figure 6-1 Similarities between the Par complex and the 
Syntaxin/tomosyn complex
Tomosyn, a syntaxin binding partner (dark purple), resembles LGL (purple), one of the constituents 
of the polarity complex.  Both contain a WD40 domain (purple octagon), which allows interaction 
with PAR-6 (green).  This observation led to the hypothesis that there might be a vesicle fusion 
complex, involving tomosyn, PAR-6 and an atypical PKC (blue) (B) which is able to regulate the 
function of syntaxin by phosphorylation.
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atypical protein kinase C to phosphorylate each of these in sites mammalian syntaxin 
was tested in vitro through site-directed mutagenesis of each site.  Only one, the most 3’ 
of the four potential threonine residues (T252), was actively phosphorylated by aPKC in 
vitro (Y. Fujita, personal communication.)  No reports currently exist for in vivo evidence 
of a phosphorylation at this residue, which is conserved in syntaxin homologues involved 
in regulated exocytosis (Littleton, Chapman et al., 1998).  The equivilent site in the 
Drosophila protein Syntaxin 1 (T254) was found to be mutated to isoleucine in a screen 
for temperature-sensitive paralysis mutants, and the T254I mutation was thought to 
reduce regulated exocytosis (Littleton, Chapman et al., 1998).  
Syntaxin homologues implicated in constitutive exocytosis have either isoleucine or 
leucine at this position, and do not interact with synaptobrevin (Littleton, Chapman et 
al., 1998), and this site is considered as part of a neuron-specific interaction domain 
involved in fusion (Littleton, Chapman et al., 1998).  A more recent investigation of this 
mutant suggests that in fact a mutation to isoleucine at this residue increases rates of 
both regulated and constitutive exocytosis (Lagow, Bao et al., 2007), and that T254 acts 
to slow the rate of exocytosis, while I254 increases opportunities for interaction within the 
SNARE complex, and therefore increase rate of exocytosis.  
Whether an as-yet undetected phosphorylation event is occuring at this threonine residue 
remains to be determined.  The Fujita lab speculated that there may be a functional 
effect of this phosphorylation of syntaxin, and wanted to pursue this investigation in a 
MTKDRLSALKAAQSEDEQDDDMHMDTGNAQYMEEFFEQVEEIR
GSVDIIANNVEEVKKKHSAILSNPVNDQKTKEELDELMAVIKR
AANKVRGKLKLIENAIDHDEQGAGNADLRIRKTQHSTLSRRFV
EVMTDYNKTQTDYRERCKGRIQRQLDIAGKQVGDEDLEEMIES
GNPGVFTQGIITDTQQAKQTLADIEARHNDIMKLESSIRELHD
MFMDMAMLVESQGEMVDRIEYNVEHAKEFVDRAVADTKKAVQY
QSKARRKKIIILIVVTILIGFVSLWLIQYIPGI 
Figure 6-2 aPKC sites in UNC-64
UNC-64 is the C. elegans homologue of syntaxin, which forms part of the SNARE complex and 
is a positive regulator of neurotransmitter release.  The amino acid sequence is shown here. 
Syntaxin contains four potential sites of phosphorylation by atypical protein kinase C (highlighted) 
but only that marked in red is an in vitro target.
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whole organism.  We therefore began a collaboration to investigate the T252 residue of 
syntaxin as a potential in vivo aPKC site.  
6.2 - Rescuing syntaxin mutants
To test the potential impact of this phosphorylation site, we decided to replace the C. 
elegans wild-type syntaxin (UNC-64) with mutated forms carrying specific mutations to 
the threonine phosphorylation site.  
Three plasmids were generated in the lab for these experiments.  Plasmid KP#505 
contains the wild-type genomic coding sequence of unc-64, covering all three predicted 
splice variants (Saifee, Wei et al. 1998).  This construct also contains 5kb of the unc-64 
promoter region, and 450bp of 3’  UTR sequence. 
This plasmid was modified by site directed mutagenesis to produce two mutant versions 
of syntaxin, also controlled by the endogenous promoter.  
Plasmid SJN367 was generated from KP#505 and contains the mutation T252A, which 
modifies the threonine residue 252, which is the predicted aPKC phosphorylation site, to 
an alanine residue, which cannot be phosphorylated.
Plasmid SJN368 was also generated from KP#505 by site-directed mutagenesis, and 
modifes the predicted T252 phosphorylation site to a glutamate residue (Figure 6-3). 
Both glutamate and threonine are polar and hydrophilic amino acids, but glutamate 
carries a charge, unlike threonine, and this is intended to mimic the effects of the addition 
H2N COOH
CH3
O-
O
P
O
O-
H2N COOH
O-O
Phospho-threonine Glutamate
Figure 6-3 Comparision of the structure of phospho-threonine 
and glutamate
To mimic constitutive phosphorylation at threonine 252 in UNC-64, we substituted the threonine 
residue for a glutamate residue.  The negatively-charged carboxyl group mimics the negative 
charge added to the theronine residue upon phosphorylation.  To generate a mutant incapable 
of being phosphorylatd at this residue, we also substituted the threonine residue for an alanine 
residue (not shown.)  
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of a phosphate group at this position in the protein, generating an artificial, constitutively-
phosphorylated residue (Figure 6-3).   . 
Together, these plasmids allow us to test whether we can rescue loss of syntaxin 
function, and subsequently whether lack of ability to phosphorylate this site, or effective 
constitutive phosphorylation at this site has an effect in C. elegans.  
6.2.1 - NM979 is a heterozygous balanced syntaxin deletion 
mutant
Complete loss of syntaxin function is lethal, either embryonically or at the L1 larval stage, 
or causes growth arrest at L1 (Saifee, Wei et al. 1998).  To conduct these experiments, 
we used a heterozygous balanced deletion mutant of syntaxin, NM979 (unc-64(js115)/
bli-5(e518) III), into which we injected the rescuing plasmids along with ttx-3::GFP or 
unc-122::GFP as a co-injection markers  
To look for rescue we look for lines where all adult animals express the GFP co-injection 
markers and no longer display the blister phenotype, and where the GFP-negative 
animals are L1 lethal.  
6.2.2 - Loss of endogenous syntaxin in NM979 can be rescued 
by expression of wild-type syntaxin from a transfected 
plasmid
The plasmid carrying wild-type syntaxin under its own promoter, KP#505, had previously 
been injected into NM979 mutant animals (S. Nurrish, personal communication), and a 
total of 3 stable lines obtained, named QT415, QT416 and QT417.  These also contain 
an unc-122::GFP co-injection marker, which expresses GFP in the coelomocytes along 
the body of the transformed worms, and plasmid KP#282, which expresses CFP-tagged 
VAMP, under the control of the acr-2 promoter, as a marker for the structure of the 
nervous system in these animals.  
These three lines produced GFP-positive animals which were successfully able to reach 
maturity. By eye, the locomotion of these animals appears like that of wild-type animals. 
This demonstrates that plasmid KP#505, which expresses wild-type syntaxin from its 
endogenous promoter, can successfully rescue the loss of endogenous syntaxin function 
in NM979 mutant animals.
6.2.3 - The syntaxin mutant T252A is able to rescue the 
lethality of syntaxin-null mutant animals
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The non-phosphorylatable form of syntaxin, T252A (Plasmid SJN367) was injected into 
the strain NM979 at a concentration of 25 ng/μl, along with an unc-122::gfp plasmid as 
a co-injection marker.  
We obtained one independent line in which all the GFP-positive animals which were able 
to survive to adulthood, which we named QT930.  By eye, these animals appear to be 
wildtype in their locomotion (see Movie 6-2).  
6.2.4 - Phosphomimetic syntaxin (T252E) is able to rescue 
the lethality of syntaxin-null animals, but the rescued animals 
are highly lethargic
We injected the phosphomimetic form of syntaxin, T252E (Plasmid SJN368) into the 
NM979 animals at a concentration of 25 ng/μl, along with a ttx-3::gfp co-injection marker. 
We obtained three independent lines - QT827, QT838 and QT839 -  in which all GFP-
positive animals survive to adulthood.  These animals appear to grow normally, but are 
strongly lethargic, almost to the point of paralysis (Movie 6-3).  
The fact of their survival and normal growth suggests that this mutation allows at least 
some level of normal syntaxin function, sufficient to rescue the null mutation in this strains.
As this phenotype could result from insufficient syntaxin function caused by poor 
expression of this construct, rather than as a direct result of mimicking phosphorylation 
at T252, we reinjected at a higher concentration.  This time we obtained a further two 
independent lines, and these animals are also strongly lethargic.
Upon nose touch, the animals respond with subtle body movements, showing some level 
of sensitivity and some limited movement, but these animals are essentially paralysed 
under normal conditions.  
6.3 - Drug assays of rescued animals
All three syntaxin constructs – wild-type, T252A and T252E - are able to rescue loss of 
syntaxin in the NM979 mutant.  The wild-type and T252A constructs appear to rescue 
back to wild-type behaviour, at least at the level of gross morphology, while the T252E 
construct produces viable animals which are paralysed, or at least highly lethargic.  A 
possible explanation for this paralysis is that the phosphorylation site T252 is required for 
inhibiting neurotransmitter release.  Therefore we wanted to see whether animals which 
contained the version of syntaxin not able to be phosphorylated at this residue might 
have higher levels of neurotransmitter release.
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6.3.1 - Syntaxin mutants rescued with wild-type syntaxin are 
slightly hypersensitive to the acetylcholinesterase inhibitor 
aldicarb
To establish a baseline for our neurotransmitter release experiments, we tested the 
aldicarb response of the syntaxin mutants rescued with wild-type syntaxin.  The three 
independent lines, QT415, QT416 and QT417 paralyse faster on 1 mM aldicarb than 
wild-type, with 49%, 53% and 67% of animals paralysed at 50 minutes, compared with 
30% for wild-type animals (Figure 6-4).  
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Figure 6-4 Aldicarb assays of syntaxin mutants rescued with 
wild-type syntaxin
The syntaxin mutant, NM979, when rescued with wild-type syntaxin expressed from the syntaxin 
promoter, becomes slightly hypersensitive to the acetylcholine esterase inhbitor aldicarb.  Three 
independent lines, QT415 (orange curve, n=4), QT416 (green curve, n=5) and QT417 (light blue 
curve, n=6), carrying the rescuing construct, paralysed faster on 1mM aldicarb than wild-type 
animals (blue curve.)  
Hypersensitivity to aldicarb indicates increased release of the neurotransmitter acetylcholine. 
This suggests that the wild-type syntaxin cDNA not only rescues the syntaxin deletion, but 
actually promotes neurotransmitter release compared to animals expressing endogenous levels 
of syntaxin.  
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6.3.2 - Syntaxin mutants rescued with mutant syntaxin T252A 
are wild-type in their response to aldicarb
While we speculated that the animals containing a form of syntaxin unable to be 
phosphorylated at the in vitro aPKC site might have lower levels of neurotransmitter 
release, these animals are wild-type in their response to aldicarb, indicating that their 
levels of acetylcholine release are normal (36% paralysed at 50 minutes compared to 
30% for wild-type animals, Figure 6-5). 
Compared with syntaxin mutant animals rescued with a wild-type syntaxin construct, 
these animals are slightly resistant to aldicarb (Figure 6-5), potentially indicating that this 
construct is less efficiently able to rescue neurotransmitter release.  More investigation 
is required to determine whether this is a significant difference.  
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Figure 6-5 Aldicarb assay of syntaxin mutants rescued with 
mutant syntaxin
We obtained one independent line of syntaxin mutant animals (NM979) rescued with a plasmid 
containing a mutant version of syntaxin, SJN367.  This plasmid contains a mutation altering an 
in vitro aPKC phosophorylation residue, threonine, to an alanine residue that is unable to be 
phosphorylated.  The aldicarb profile of these mutants, QT930 (purple curve, n=4) appears the 
same as wild-type animals.  
When exposed to 1mM aldicarb, these animals paralyse at the same rate as wild-type animals, 
suggesting that this mutated residue is not important in the regulation of release of acetylcholine 
under basal conditions.  
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6.3.3 - Syntaxin mutant animals rescued with phosphomimetic 
syntaxin T252E are resistant to aldicarb
The animals rescued with syntaxin are so lethargic that an accurate aldicarb assay is 
difficult to perform.  If we use our standard criteria for paralysis, essentially all the animals 
would be counted as paralysed at the start of the experiment.  
To enable the experiment to be performed, we used a different criteria for paralysis for 
these animals.  They respond to a harsh nose touch with very small body movements, 
and  this simple response diminishes during an alidcarb assay.  Therefore we counted as 
paralysed those animals which failed to respond to nose touch in any way.  
Using this criteria, the animals appear resistant to aldicarb, compared to wild-type animals 
assayed in the normal manner (where we count as paralysed any animals unable to 
propogate a full wave of body bends from head to tail.)  The animals produced from the 
second set of injections are more resistant to aldicarb than those produced in the first 
set, but it is difficult to draw strong conclusions given the problems with performing this 
assay.  
Interestingly during these experiments, we see that some of the animals which are 
counted as not paralysed towards the end of the experiment move faster and respond 
more strongly to nose touch than they did at the beginning of the experiment.  This 
suggests that aldicarb is enhancing the exisiting, very low level of neurotransmitter 
release to allow greater responses from the body wall muscles.  
6.3.4 - Automated tracking of syntaxin mutants
To further assay the effects of these two mutant versions of syntaxin on the whole animal 
we decided to make use of the computer vision package Parallel Worm Tracker (Ramot, 
Johnson et al. 2008).  This program analyses videos taken of multiple worms as they 
move across an agar plate, and provides information on their average speeds.  This can 
be used to produce an automated drug assay, such as looking for rate of paralysis on 
aldicarb, or to compare the rate of locomotion between strains.  
6.3.5 - Syntaxin mutants rescued with phosphomimetic 
syntaxin are highly lethargic, but capable of some movement
One question we continue to return to is whether the T252E mutant form of syntaxin is 
causing the animals to become lethargic because it is a hypomorphic form of syntaxin 
due to a misfolding of the protein, or whether the change at this site mimics a regulated 
response causing the animals to become highly lethargic.  
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We measured the speed of the syntaxin mutant animals rescued with T252E on food 
using the Parallel Worm Tracking software, and found that they move at an average 
speed of 0.005 mm/sec.  This is 15 times slower than wild-type animals, which move at 
an average speed of 0.076 mm/sec on food.
We recorded a video of these animals at a very low framerate over a 10 hour period. 
Interestingly, when played back at 100 times normal speed the animals appear to move 
like wild-type animals.  This suggests that the syntaxin protein is capable of driving 
neurotransmitter release, but at a very low rate compared to wild-type.  
6.3.6 - Syntaxin mutants rescued with phosophomimetic 
syntaxin move faster when exposed to PMA
If this mutant version of syntaxin is simply misfolded, it might allow a low level of 
neurotransmitter release, but prevent increases in release in response to normal 
regulators.  We wanted to test whether these were still able to respond to PMA, a phorbol 
ester and diacylglycerol (DAG) analogue, a key second messenger in neurotransmitter 
release.
Again we made use of the parallel worm tracker to record the speeds of animals moving 
on PMA compared to their rate on food.  
Wild-type animals show a fast response to PMA, with an increase in their average speed 
to 0.11 mm/sec after 10 minutes exposure to the drug (Figure 6-7).  
The animals rescued with the T252E form of syntaxin also show a response to PMA, 
increasing their average speed to 0.009 mm/sec as measured by the worm tracker. 
Although this speed is still well below that seen in wild-type animals, the relative increase 
in average speed is around 80%, similar to the 70% increase in speed seen in wild-type 
animals for the same period of exposure (Figure 6-7).  This suggests that the T252E 
mutation acts in pathway parallel to that activated by PMA signalling.  
6.3.7 - Animals rescued with the T252A form of syntaxin 
respond normally by slowing in their response to serotonin
While we are unable to establish whether the phosphomimetic mutation is causing the 
animals to move slowly because of some function of that phosphorylation site as opposed 
to misfolding of the protein, another approach is to find situations in which the mutant 
which is unable to be phosphorylated is unable to slow down.  If phosphorylation at T252 
is able to cause slowing of movement, we hypothesised that the alanine mutation might 
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prevent this slowing from occuring.  We therefore sought conditions under which the 
animals would naturally reduce their rate of locomotion.  
One condition in which we know that C. elegans reduces its rate of locomotion is in the 
presence of food, which is signaled by increases in the levels of serotonin.  Animals 
exposed to serotonin have fewer body bends and a slower rate of locomotion than 
animals on control plates (Horvitz, Chalfie et al. 1982; Segalat, Elkes et al. 1995).  
We tested whether we could observe this response in wild-type animals using the parallel 
worm tracker.  Figure 6-8 shows a histogram representing the speeds of wild-type animals 
on food.  When animals are exposed to serotonin for 15 minutes, this distribution shifts to 
the left, showing that the animals are slowing in response to serotonin.
Figure 6-7 - Exposure to serotonin causes a reduction in 
locomotion in animals rescued with a mutant form of syntaxin
Wild-type animals exposed to the phorbol ester PMA (a DAG analogue) respond by increasing 
their rates of locomotion.  15 minutes exposure to PMA shifts the distribution of speeds in wild-
type animals to the right (B) compared with that of animals moving on food in the absence of PMA 
(A), with an average increase in speed from 0.076mm/sec to 0.1104 mm/sec.  QT931 animals, 
rescued with a phosphomimetic form of syntaxin, are also able to increase their average speed 
on food, from 0.005 mm/sec to 0.009mm/sec, indicating that these animals are able to respond 
to PMA.  (The distribution of speeds in these animals is not shown.)  Data obtained from two 
independent experiments, each taken from videos of 30 animals.  
Condition Wild-type Phosphomimeitc Syntaxin 
(QT931)
-PMA 0.076 mm/sec 0.005 mm/sec
+PMA 0.1104 mm/sec 0.009 mm/sec
WT (-PMA) WT (+PMA)
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The distribution of speeds in the T252A animals is highly similar to that seen in wild-type 
animals, confirming that this point mutation rescues the loss of wild-type syntaxin and 
generates animals capable of wild-type movement under basal conditions.  However, 
should phosphorylation of this site be necessary for slowing, we might expect that these 
animals would be unable to respond to the presence of serotonin.  However, when the 
animals are exposed to serotonin for 15 minutes, the distribution of speeds shifts to the 
left in the same way as observed for wild-type animals.  This demonstrates that the lack 
of a phosphorylation site at T252 does not affect the ability of the animals to slow in 
response to serotonin.    
6.4 - Testing Phosphomimentic syntaxin constructs for 
dominant negative activity
6.4.1 - Wild-type animals carrying phosphomimetic syntaxin 
have normal locomotion
A question which remains in response to these experiments is whether the phosphomimetic 
syntaxin represents a low-functioning, possibly misfolded form of syntaxin, which 
produces viable but highly lethargic offspring as a result of low activity, or if this mutation 
mimics and endogenous pathway that reduces neurotransmitter release via inhibition of 
syntaxin.
It is possible that a misfolded protein will have dominant negative effects, such as 
sequestering factors away from wild-type versions of the protein, or binding to and 
interfering with the normal function of the wild-type protein.
Therefore we injected wild-type animals with the phosphomimetic syntaxin construct 
SJN368 at a concentration of 25 ng/μl.  We obtained 2 independent lines, and both of 
these lines had normal locomotion; none displayed the severe lethargy of the syntaxin 
mutants rescued with this construct.  From this we conclude that the construct is does 
not act in dominant negative fashion.
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Figure 6-8 - Exposure to serotonin causes a reduction in 
locomotion in animals rescued with a mutant form of syntaxin
Syntaxin mutant animals rescued with mutant syntaxin which is unable to be phosphorylated 
by aPKC appear to have wild-type locomotion.  We tested the response of these animals to 
exposure to serotonin.  A) Distribution of speeds of wild-type animals on food.  Around 15% of 
animals do not move during the recording, and a fraction of the animals are moving at speeds 
over 0.1 mm/sec.  B) Distribution of speeds in animals carrying the version of syntaxin unable to 
be phosphorylated by aPKC is very similar to that of wild-type animals.  C)  15 minutes exposure 
to serotonin, over 40% of the animals have stopped moving completely, and virtually no animals 
are travelling faster than 0.05 mm/sec.  D) The response of QT930 animals to 5-HT mimics that 
of wild-type animals, with nearly 40% of the animals immobile during the video recording, and 
only a small fraction travelling faster than 0.05 mm/sec.  Data obtained from two independent 
experiments, each taken from videos of 30 animals.
6.8 - Looking for a kinase which may phosphorylate 
syntaxin in vivo
Our hypothesis for the lethargy seen in the animals carrying a phosphomimetic 
form of syntaxin is that this mutant syntaxin strongly mimics the effects of an in vivo 
phosphorylation event at residue T252.  If this hypothesis is correct, then we would 
predict the existence of a kinase associated with this phosphorylation event which, 
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,when active, should cause slowing of the animal.  P We do not expect that the in vivo 
effects of phosphorylation would be as strongly evident in reduced locomotion as our 
mutation which mimics permanent phosphorylation; nonetheless we expect animals with 
an activated kinase would travel slower than wild-type animals, at least under some 
conditions.
As the research from the Fujita lab was into the effects of an atypical protein kinase C 
phosphorylation, we decided to investigate the effects of activating a homologous protein 
in the worm.  
6.5 - PKC-3 is an C. elegans atypical protein kinase C
The original hypothesis from the Fujita lab in vitro experiment was that an atypical protein 
kinase C might be recruited by tomosyn to allow phosphorylation of syntaxin (Figure 6-). 
The model drew on comparisons to the polarity establishing complexes.  The kinase in 
C. elegans most homologous to that found in the mammalian complex is PKC-3, which 
associates with and is correctly localized by the PDZ domain of PAR-3 (Tabuse, Izumi et 
al. 1998).  We set out to make a constitutively active form of PKC-3, a candidate for the 
kinase which phosphorylates syntaxin at residue T252.  
6.5.1 - Constitutively active PKC-3 causes pathfinding 
defects
We obtained three pkc-3 cDNAs from Yuji Kohara - YK1447b7, YK284f7, YK526h11 – 
and grew these according to standard methods.  These plasmids were miniprepped, 
and used as templates for amplifying the full-length cDNA of PKC-3 by PCR.  We used 
primers to introduce unique NcoI and SacI sites for further subcloning, and a NotI site at 
the 5’ end for the introduction of protein tags, such as GFP.  
PCR of PKC-3 from YK526h11 produced a band of the predicted size (1800bp) for full-
length pkc-3 cDNA, which produced two bands of approximately 1200bp and 700bp 
when diagnostically digested with NheI, as predicted (for more details, see Methods).  
The pkc-3 cDNA fragment was subcloned into plasmid pSC#205, containing the acr-2 
promoter, which drives expression primarily in the cholinergic neurons of C. elegans, 
together with a few additional neurons in the nerve ring (Nurrish, Segalat et al. 1999).  We 
then generated a constiutitvely active version of PKC-3 by mutating the pseudosubstrate 
domain, a region of the protein which reduces the kinase activity (Pears, Kour et al. 1990). 
This activating mutation, where an alanine residue is replaced by a glutamate residue, 
has been successfully demonstrated in classical, novel and atypical protein kinases 
(Decock, Gillespie-Brown et al. 1994).  We generated PKC-3 constructs containing the 
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mutation A116E by site-directed mutagenesis, and this construct was named APP3, and 
will be referred to as PKC-3* to denote the activating mutation.  
PKC-3* was injected into wildtype at a concentration of 25ng/μl, along with QT#238, 
which expresses GFP from the unc-17 promoter, and a ttx-3::GFP co-injection marker.  2 
independent lines were obtained, and offspring from these lines appeared uncoordinated.
When examined using our high-power GFP microscope, we could observe classic 
pathfinding defects in these animals as observed by changes in the unc-17-driven 
GFP pattern.  The commisures, the connections between the dorsal and ventral nerve 
cord, which normally travel across the body of the animal perpendicular to the anterior-
posterior axis, were now migrating along the AP axis.  These pathfinding defects are 
likely to be the cause of the uncoordinated locomotion we observed.  However, this is a 
good indication that the PKC-3* construct is active when injected into the worms.  
6.5.2 - PKC-3* does not affect neurotransmitter release or 
the gross behaviour of transformed animals 
To try to avoid these pathfinding defects we reinjected our PKC-3* construct into wild-
type animals at a concentration of 10 ng/μl.  These animals did not appear to have the 
pathfinding defects seen at the higher concentration. 
The locomotion of these transformed animals appears wild-type.  There was no gross 
slowing of the animals, so we decided to test whether there were any changes in 
neurotransmitter release as a result of the presence of this activated protein.  
We tested these animals using the aldicarb assay (Figure 6-9), but saw that they appeared 
the same as wild-type with respect to aldicarb treatment, indicating that this construct 
had no effect on the release of acetylcholine.  
6.6 - CDC-42 is a small GTPase implicated in the activity 
of PKC-3 in cell polarity establishment
As the PKC-3* construct was able to cause pathfinding defects, and did not phenocopy 
the phosphomimetic syntaxin strains for extreme lethargy, we decided to try to activate 
endogenous PKC-3.  We therefore looked to CDC-42, a Rho GTPase associated with 
the activity of the Par complex, of which PKC-3 is a constituent.  CDC-42 and the PAR-
3/PAR-6/PKC-3 complex have been shown to function together (Welchman, Mathies et 
al. 2007), so we reasoned that activating CDC-42 might activate PKC-3, and potentially 
phenocopy the phosphomimetic syntaxin mutants, if PKC-3 is the endogenous kinase 
which phosphorylates syntaxin.  
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6.6.1 - Making constitutively active and dominant negative 
cdc-42 constructs
Two mutants of cdc-42 are available, but neither were suitable for these experiments. 
ok825 is a deletion which only affects part of the 3’UTR of cdc-42, while gk388 is deletion 
which is lethal.  We already had available two CDC-42 plasmids: Heat-shock driven 
cdc-42 (SJN376) and p.acr-2 driven cdc-42 (SJN381).  We ordered primers to generate 
constitutively-active (G12V) and dominant negative (T17N) versions of CDC-42 (see 
Methods).  
Using the Quikchange protocol we successfully introduced the constitutively active and 
dominant negative mutations into the plasmid driven by the acr-2 promoter (plasmids 
APP004 and APP005), and generated a heatshock-driven constitutively active CDC-42 
(APP006, hsCDC-42*).  
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Figure 6-9 - Aldicarb Assay of animals carrying a PKC-3 (gf) 
construct
Animals overexpressing gain-of-function PKC-3 from the unc-17 promoter do not display any 
changes in their response to aldicarb (organge line, n=4).  
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6.6.2 - Lines carrying constitutively active, heatshock driven 
CDC-42 appear wildtype
We injected hsCDC-42* into wild-type animals and obtained 2 independent lines.  Prior 
to heatshock, the animals appeared wild-type.  We then subjected these transformed 
animals to our standard heatshock protocol (see Methods) but no gross behavioural 
changes were observed in adults.  
We therefore performed heat-shock on a mixed population of animals, where we should 
activate the heat-shock transgene in developing larvae, but we did not see any visible 
response to activation compared to wild-type control animals.  This is surprising given 
CDC-42 has a well-defined role in development, and suggests that our constitutively-
active construct is not active within the transformed animals.  However, without tagging 
the construct with a fluorescent marker such as GFP, we do not know at this stage 
whether CDC-42 is being expressed.  
6.7 - Discussion
We developed a range of mutant syntaxin constructs, based on research conducted by 
the Fujita lab which indicated that a specific threonine residue in syntaxin was capable 
of phosphorylation by an atypical protein kinase C in vitro.  To mimic this mutation we 
generated a phosphomimetic version of the worm orthologue of syntaxin, UNC-64, and 
also a version which was unable to be phosphorylated.
Upon injection into unc-64 mutant animals, which are homozygous lethal, we found that 
both of these constructs, and the wild-type form of unc-64, were able to rescue the lack 
of syntaxin function in these mutants.
Interestingly, we noted that the animals rescued with the phosphomimetic form are highly 
lethargic, and appear almost paralysed. These animals are capable of movement, as 
seen in videos taken over long (10 hour) time periods, but this movement is at least an 
order of magnitude slower than that seen in wild-type animals.  They are also resistant to 
aldicarb, an acetylcholinesterase inhibitor (although using a modified protocol to account 
for their initial low level of movement), which suggests that they have lower levels of 
neurotransmitter release, and this may be responsible for their impaired locomotion. 
One issue not addressed as this stage is the level of expression of the three constructs. 
To compare more precisely the phenotypes across the rescued lines, we could perform 
quantification of expression of mRNA, using qPCR, or of UNC-64 using a western blot. 
Alternatively, these experiments could be conducted using the MosSCI single copy 
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insertion method of transformation, which is predicted to give rise to more wild-type 
expression levels (Frokjaer-Jensen, Davis et al., 2008).
This led us to speculate that an in vitro phosphorylation of syntaxin at this residue, T252, 
might be involved in a regulated slowing response.  We therefore set out to test whether 
activating the C. elegans atypical protein kinase C - PKC-3 - or its upstream activator 
CDC-42, more commonly associated with the polarity complex involved in development, 
might be able to phenocopy the lethargy seen in the rescued animals.  However, 
we have so far failed to see an adult phenotype for the activation of PKC-3.  We are 
reasonably confident that the PKC-3* construct, driven by the acr-2 promoter, is working, 
because we see pathfinding defects in animals carrying this construct.  However, these 
pathfinding defects make assaying behavioural changes in adults difficult, because 
we do not know how much of any observed behaviour to ascribe to the developmental 
defect. When reinjected at lower concentration, we saw no developmental changes with 
the PKC-3* transgene, but no gross changes in behaviour were observed either.  As 
syntaxin/UNC-64 is a key regulator of neurotransmitter release, we tested whether these 
animals expressing activated PKC-3 in their cholinergic neurons had any changes in 
their response to aldicarb, but the transformed animals remained wild-type.
It is possible that the PKC-3* construct is capable of causing adult behavioural changes, 
but that by being expressed throughout development from the acr-2 promoter animals are 
able to compensate for increased PKC-3 activity into adulthood.  It would be interesting 
to see if PKC-3 under the control of a heat-shock promoter, or PKC-3 expressed using 
tetracycline-response would produce a change in the adult organism, as these methods 
bypass the potential for compensation during development.  
While we were unsuccessful in seeing an adult phenotype for activated, exogenous PKC-
3, we attempted to activate endogenous PKC-3 using CDC-42* constructs.  However, 
these constructs did not show any phenotype either in the adult or during developmental 
stages.  We have no evidence to confirm this transgene successfully expressed the 
CDC-42 protein.  
Without further evidence, we cannot be sure whether the mutant UNC-64 protein 
containing the phosphomimetic mutation is demonstrating the effects of constitutive 
phosphorylation at residue 252, or whether this version of UNC-64 is simply a misfolded 
protein, only weakly able to rescue for total loss of syntaxin function in an unc-64 mutant. 
Alternatively, this mutation could be interefering with the reported function of the T252 
site in the interaction with synaptobrevin, or in the ‘zippering’ of SNARE proteins during 
fusion (Littleton, Chapman et al., 1998; Lagow, Bao et al., 2007).
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To help address this, we examined a second mutated form of syntaxin in which the 
potential aPKC site is mutated to alanine, preventing phosphorylation.  A number of 
observations about these rescued animals rescued shed additional light on the 
phosphomimetic mutant phenotype.
The animals rescued with T252A UNC-64 appear wild-type for their locomotion.  This 
indicates that the threonine residue is not essential for the functioning of the protein, 
i.e. that its loss does not cause constitutive paralysis.  The conversion of threonine to 
alanine is distinctly non-conservative, and yet generates a version of UNC-64 capable 
of substituting for wild-type.  Whether the addition of a glutamic acid residue destabilizes 
the protein is something that will require further study; for now, we can say that is not the 
loss of the threonine residue which generates the paralysed phenotype.
Phosphorylation at T252 is not required for syntaxin function.  T252A UNC-64 does not 
cause any gross effects developmental or behavioural effects on rescued animals.  If the 
phosphomimetic mutation is genuinely mimicked regulated phosphorylation then it might 
be predicted that the inability to phosphorylate at this site might cause animals to move 
too quickly.  However, in the experiments looking at locomotion and aldicarb release, the 
animals rescued T252A UNC-64 are indistinguishable from wild-type animals.  This does 
not mean that the phosphorylation event is not occurring, but it does suggest that it is 
rather transient, or that only a small percentage of the UNC-64 is phosphorylated under 
normal conditions.  
Although the alanine mutant is able to move at normal speeds under standard conditions 
we hypothesized that there might be a lack of slowing under other conditions, consistent 
with reports of the T254I mutation in Drosophila increasing exocytosis (Lagow, Bao et al., 
2007).  We investigated whether the animals were able to slow down when exposed to 
serotonin, a key signal for the dwelling response, and saw that the animals have the same 
profile of response to the neurotransmitter as wild-type animals.  There may be other 
circumstances in which C. elegans will reduce its speed only with wild-type syntaxin, but 
these remain to be investigated.  
Should phosphorylation at site T252 prove to be capable of regulating locomotion, it is likely 
to only be actively phosphorylated at specific times, as loss of the phosphorylation site 
has had no discernable effect in our investigations so far.  This has led us to look for other 
situations where C. elegans speed changes at distinct times, and a phenotype which has 
recently been gaining attention is that described as ‘lethargus’ (Raizen, Zimmerman et 
al. 2008).  This phenotype occurs during molting, when the C. elegans larval stages shed 
their outer cuticle.  Here the animals enter what is referred to as a ‘sleep-like state’.  This 
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reduction in locomotion is not simply due to lack of the cuticle, but is a state that can be 
regulated; if the animals are disturbed by touching with a platinum wire they move, and 
if left undisturbed will compensate for the disturbance by ‘resting’ longer at the following 
lethargus stage.
Interestingly, this phenotype is regulated by EGL-4, which is a cyclic GMP-dependent 
protein kinase.  A gain-of-function egl-4 mutant has prolonged periods of rest during 
molting compared to a wild-type animal (Raizen, Zimmerman et al. 2008).  It would be 
interesting to test whether our animals rescued with a mutant version of syntaxin are 
either unable to enter lethargus, or have a reduced response to the EGL-4 gain-of-
function protein, which would suggest that T252 is a phosphorylation site for EGL-4.  
More investigation is needed into the phenotype arising from these mutations.  Our model 
so far suggests that there is no, or a low level of, phosphorylation of syntaxin at the T252 
residue under most conditions, but that under certain types of stimuli, phosphorylation 
occurs, and causes the animals to decrease their rate of locomotion (Figure 6-10).  
A number of kinases are capable of phosphorylating syntaxin.  Casein kinase II (CKII), 
phosphorylates serine-14 on syntaxin 1A/B (Hirling and Scheller 1996) , and this 
phosphorylation affects the distribution of syntaxin along axons, positively regulating 
neurotransmitter release (Folletti, Lin et al, 2000).  Lack of CKII activity, and subsequent 
reductions in syntaxin-1 phosphorylation have recently been implicated as a source 
of reduced neurotransmitter release in the brains of patients with schizophrenia 
(Castillo, Ghose et al. 2010).  In addition, in non-neuronal systems, protein kinase C 
phosphorylates syntaxin-4, which increases granule secretion from platelets (Chung, 
UNC-64
(Syntaxin)
UNC-64
(Syntaxin)
P
Promotes slowing
Normal locomotion
Kinase
Phosphatase
Figure 6-10 - Model of syntaxin regulation
We propose that phosphorylation of syntaxin at site T252 promotes slowing of locomotive 
behaviour.  The absence of an observable effect of loss of this phosphorylation site leads us to 
suggest that, under standard laboratory conditions, this site is either not phosphorylated, or that 
any phosphorylation is removed by a regulatory phosphatase which we have yet to identify.  
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Polgar et al. 2000).  In each of these instances, phosphorylation of syntaxin is a positive 
regulator of neurotransmitter release.  Should the phosphorylation site at T252 prove to 
be a true endogenous site of regulation of syntaxin activity it may also represent the first 
example of inhibitory phosphorylation of syntaxin.  
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7 - TAMOXIFEN REGULATION OF PROTEIN 
ACTIVITY IN C. ELEGANS
7.1 - Introduction
One of the key tools in modern molecular biology is the ability to selectively activate 
or deactivate proteins in specific cells at specific times.  This can be used to introduce 
exogenous proteins for study, or to allow an organism to pass through development and 
then activate a protein of interest in the adult organism, such that it does not disrupt 
normal growth.   While C. elegans research uses a number of important tools to regulate 
temporal expression, such as heatshock activation, or spatial regulation, such as cell-
specific promoters, it lacks tools for combined temporal-spatial control.  
7.1.1 - Methods of cell-specific expression
The ability to use cell-specific promoters that express proteins in a desired subset of 
cells (Figure 7-1), such as the cholinergic neurons, is a key tool for investigating the site 
of action of novel proteins, or for overexpressing proteins in specific cell-types (Mello 
and Fire 1995).  For example, two main options are available for cholinergic expression; 
either the unc-17 promoter, (Alfonso, Grundahl et al. 1993), used in this thesis for 
overexpressing activated RHO-1 (Chapter 3) and cell-specific rescue of unc-80 mutants 
(Chapter 4), or the acr-2 promoter, used here for driving expression of unc-80 (Chapter 
4) or activated PKC-3 (Chapter 6).   The endogenous unc-17 promoter drives expression 
of the vesicular acetylcholine transporter (Alfonso, Grundahl et al. 1993), which loads 
acetylcholine into synaptic vesicles, while the acr-2 promoter is a nicotinic acetylcholine 
receptor subunit (Squire, Tornoe et al. 1995, Jospin, Qi et al. 2009).  Only cells which 
express transcription factors capable of activating transcription from the specific promoter 
will express the protein of interest (Figure 7-1).
One disadvantage of these promoters is that they are limited to the endogenous 
expression pattern and timing of the promoter used.  The particular transcription factors 
and associated DNA binding proteins that regulate endogenous expression from the unc-
17 promoter will drive expression of any exogenous DNA in the same way. We do not 
as yet have the technology or the knowledge to build our own cell-specific promoters to 
avoid these issues.  We can use promoter fragments to achieve expression in a subset 
of cells (Teng, Girard et al. 2004; Appleford, Gravato-Nobre et al. 2008), which provide 
some measure of addtional specificity.  
304
Another approach is to fragment the protein of interest into two halves, each of which 
is expressed from separate, overlapping promoters.  This has been demonstrated with 
GFP (Zhang, Ma et al. 2004; Feinberg, Vanhoven et al. 2008) and with a caspase (Chelur 
and Chalfie 2007), but this approach is limited the requirement for a protein which can 
successfully be reassembled.  
Interestingly, we have seen occasions in which the unc-17 promoter successfully 
drives rescuing constructs when the acr-2 promoter does not appear to (Chapter 4), 
which is consistent with results seen by other labs with rescue of pkc-1 mutants (D. 
Sieburth, personal communication) .  This may be due in part to differences in the level of 
expression, or timing of expression, from these two promoters, which should theoretically 
have largely overlapping expression patterns. 
Another issue with the lack of control given by using cell-specific promoters is that when 
proteins are expressed throughout the lifetime of the organism there is the possibility for 
adaptation to occur.   When we express RHO-1 from the unc-17 promoter, which is active 
p.unc-17 Gene of Interest p.unc-17 Gene of Interest
No expression of protein of interest
Protein of interest
produced
Cell-specific Promoters
Cell expressing appropriate 
transcription factors
Cell not expressing appropriate 
transcription factors
A
B
Lack of temporal control - protein is expressed throughout development
Embryo Larval Stages Adult
Transcription 
factors
Transcription 
factors absent
Figure 7-1 Tissue-Specific Expression in C. elegans
Tissue-specific promoters, such as the unc-17 promoter shown here, drive expression only in 
subset of cells which express the appropriate transcription factors (A).  The timing of expression is 
determined by the endogenous factors acting on the promoter; in the case of the unc-17 promoter, 
it is expressed throughout development (B), leading to the possibility of adaptation to whichever 
exogenous protein is being expressed.  
305
during embroygenesis and into adulthood, there is potential for the animal to compensate 
for the extra levels of expression of the protein, potentially masking interesting effects. 
7.1.1 - Methods of temporal control of expression
It is possible to obtain temporal control of protein expression in C. elegans, using the 
heat-shock promoter (Lis and Wu 1993).  The heat-shock factor (HSF-1) is constitutively 
synthesized, but is inactive until changes in temperature cause it to induce transcription 
from its specific promoter (Figure 7-2).  
This technique has been widely used and to great effect.  Our lab has made repeated 
use of the heat-shock promoter to drive RHO-1 (G14V) expression (McMullan, Hiley et 
al. 2006).  Expression of RHO-1 (G14V) during development has the capacity to cause 
a variety of developmental defects, such as miswiring of the nervous system, as well as 
the potential for compensation as mentioned above.  
To bypass these effects, we restrain expression of excess RHO-1 until the animal has 
a fully developed nervous system, and express it by exposing the animals to a series of 
temperature changes (see Methods for details).  Animals overexpressing RHO-1* from 
the heatshock promoter develop a loopy locomotion highly similar to that seen in animals 
expressing RHO-1* from the unc-17 promoter (McMullan, Hiley et al. 2006), along with 
additional phenotypes which we attribute either to expression in additional cells, or to a 
lack of compensation during development.  
Similarly, when using the RHO-1-specific inhibitor C3 transferase (C3T) (Aktories and 
Hall 1989), we use heat-shock expression to limit C3T expression to the adult organism. 
C3T expressed early in development leads to the death of the animals expressing it, 
meaning we are unable to assay adult phenotype.  While heatshock activation of C3T 
eventually leads to the death of the animals, there is sufficient time (approximately one 
day) during which assays can be performed to examine adult phenotypes (McMullan, 
Hiley et al. 2006).  
Problems remain with the use of heat-shock to drive expression, however.  This method 
lacks cell specificity; all cells will tend to express the protein under heat-shock control, 
so it is not possible to examine the effects of expression in a specific tissue type.  One 
possible counter to this is the use of a number of heatshock promoters, which have 
slightly different patterns of expression (Stringham, Dixon et al. 1992; Ding and Candido 
2000), 
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Another problem with the heat-shock promoter is that it tends to be leaky, i.e. without 
deliberately inducing expression from the promoter, background changes in temperature 
can to lead to unwanted expression.  For instance, animals carrying the heatshock C3T 
constructs tend to have reduced levels of neurotransmitter release when grown at room 
temperature compared with wild-type animals, indicating low background levels of C3T 
activity (McMullan, Hiley et al. 2006), while the heatshock RHO-1* transgene has been 
shown to have some activity at 20oC (Diogon, Wissler et al. 2007).
The heatshock activation of protein production, while not offering perfect temporal control, 
still has the potential to reduce compensation to exogenous protein during development, 
but at the cost of cell-specificity.  A combinatorial approach has been developed which 
helps overcome some of these problems.  
Gene of Interest p.heatshock Gene of Interest
No protein of interest produced
p.heatshock
HSP-1 (inactive)
Embryo Larval Stages Adult
Cell without heatshock Cell following heatshock
A
B
HSP-1 
(active)
Protein of 
interest produced
Lack of cell-specificity - protein is expressed across the organism following heatshock
Heatshock activatedNo Heatshock
Figure 7-2 Temporal control of protein exprssion in C. elegans
The heatshock promoter can be used to temporally control expression of a protein in C. elegans 
by altering the external temperature to activate the endogenous heatshock response.  Following 
this temperature change, HSP-1 binds to the heatshock promoter, driving expression (A).  This 
allows control on the timing of expression, but the heat-shock promoter lacks cell-specificity (B). 
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7.1 - Combined methods for cell-specific and temporal 
control of expression - Heat-shock expression in a heat-
shock mutant
Animals lacking the heat-shock protein HSF-1 are unable to induce expression from a 
heat-shock promoter.  One method showing promise is to express the heat-shock protein 
under a cell specific promoter in an hsf-1 mutant (Bacaj and Shaham 2007).   
Gene of Interest
Protein of interest
produced
p.heatshock
HSP-1 (inactive)
Embryo Larval Stages Adult
A
B
Cell-specific temporal control in a hsp-1 mutant 
Heatshock activatedNo Heatshock
p.unc-17 HSP-1
Gene of Interest
HSP-1 (active)
p.unc-17 HSP-1
Gene of Interestp.heatshock
p.unc-17 HSP-1
Gene of Interestp.heatshock
p.unc-17 HSP-1
Cell does not produce HSP-1 Cell does not respond to heatshock
Cell expressing appropriate 
transcription factors
(without heatshock)
Cell expressing appropriate 
transcription factors
(following heatshock)
Cell not expressing appropriate 
transcription factors
(without heatshock)
Cell not expressing appropriate 
transcription factors
(following heatshock)
p.heatshock
Figure 7-3 Combinatorial promoters produce tissue-specific 
temporal control of protein expression in C. elegans
The heatshock promoter can be combined with a tissue-specific promoter to allow cell-specific, 
temporal control of expression. The tissue-specific promoter is used to drive the expression of 
HSP-1 in a hsp-1 mutant, and only those cells expressing HSP-1 are able to respond to heatshock 
(A).  This allows expression in specific cells at a specific developmental stage (B), although this 
requires the use of a mutant background.
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C. elegans has only one heat-shock factor protein, and these mutant animals are 
deficient in their heat-shock response. A driver plasmid, carrying the HSF-1 construct 
under control of a cell-specific promoter, is injected into hsf-1 mutant animals. This driver 
plasmid is now able to rescue the heat-shock response in a tissue-specific manner, 
determined by the promoter used (Figure 7-3).
A second construct, termed the responder, is co-transfected with the rescuing HSF-1 
plasmid.  This construct carries the protein of interest under the control of the heat-shock 
promoter.  On heat-shock activation, the protein of interest is expressed only in those 
cells which are rescued for heat-shock activity, giving cell-specific, temporal control 
(Figure 7-3).
While this method offers cell-specificity and temporal regulation, it does have its 
disadvantages.  Temporal control is activated by changes in temperature, but the use of 
the hsf-1 mutant background means cells lacking the HSF-1 protein are unable to intiate 
their endogenous heatshock response, raising the possibility of cellular damage during 
treatment.  hsf-1 mutants also display a number of mutant phenotypes when grown at 
25oC (Bacaj and Shaham 2007), although they appear wild-type at 20oC.  
This method also relies on both a cell-specific promoter and a heatshock promoter, and 
so is potentially subject to the problems inherent in both these methods, such as limited 
promoter choice and low-level heatshock activation without treatment.  
7.1.1 - Recombination as a method of regulation
An alternative use of heatshock to activate protein production involves the use of the FLP 
recombinase, which removes elements contained between specific FRT sites in DNA.  A 
plasmid containing the gene of interest, containing an inactivating fragment flanked by 
FRT sites, expressed under a cell-specific promoter, is transfected into animals carrying 
a plasmid containing the FLP recombinase (which can be expressed under a heatshock 
promoter).  On activation of heatshock, the FLP recombinase removes the inactivating 
fragment, and transcription of the gene of interest proceeds (Davis, Morton et al. 2008) 
(Figure 7-4).  The cells affected continue to stably produce the protein of interest.  
A similar system has been generated using the Cre recombinase, which is capable of 
removing DNA coded between loxP sites.  In this instance two sets of promoters with 
overlapping cell-types were used to drive the recombinase and the construct of interest, in 
this case containing flp-21.  The flp-21 construct contains a terminator sequence between 
two loxp sites.  The promoters overlap in only a single cell, meaning that activation of 
this gene occurs in one specific neuron where both the recombinase and the target 
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plasmid are present (Macosko, Pokala et al. 2009).  Switching one of the promoters for 
a heatshock promoter would make this system temporally regulated as well.  
7.1.1 - Alternative methods for temporal regulation of 
cellular activities
Another potential mechanism is the use of the drug tetracycline and the tetracycline-
responsive element (Gossen and Bujard 1992; Gossen, Freundlieb et al. 1995).  This 
element is found in bacteria that are able to mount a response to the antibiotic tetracycline, 
which can configured to drive activation or inhibition of transcription of a target protein. 
We are currently investigating this system for use in C. elegans.   
Temporal control of cell activity, meanwhile, can be achieved by using light-activated 
channels, which allow cell-specific activation based on the production of channelrhodopsin 
(Nagel, Brauner et al. 2005), or light-activated inhibiton of cells with light-activated 
FLP p.heatshock
No protein of interest produced
p.heatshock
HSP-1 (inactive)
Embryo Larval Stages Adult
A
B
HSP-1 
(active)
Heatshock activatedNo Heatshock
FLP 
p.unc-17p.unc-17
Recombination removes
terminator sequence
Terminator sequence in plasmid
Protein of interest 
produced
Cell expressing appropriate 
transcription factors
(without heatshock)
Cell expressing appropriate 
transcription factors
(following heatshock)
Cell-specific temporal control in a wild-type background; protein of interest stably expresses
Figure 7-3 Recombinanation can be used to control protein 
expression in C. elegans
A construct containing a terminator sequence is placed under the control of a tissue-specific 
promoter, but no protein expression occurs until the FLP recombinase is expressed following 
heatshock (A).  This allows for tissue-specific, temporal control, and persistent protein production 
following heatshock.  
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chloride channels .  This method is only currently applicable to specific light-activated 
proteins, however.
A method has also been developed based on the pathway of nonsense-mediated decay 
(NMD).  Genes with long 3’ untranscribed regions containing many introns are normally 
degraded by NMD pathway, but a number of temperature-sensitive mutants exist which 
prevent this degradation.  Transgenes can be engineered under a cell-specific promoter 
such that their mRNAs are degraded when the animals are maintained at the non-
permissive temperature, and successfully translated at the permissive temperature.  This 
offers a mechanism of temporal regulation coupled to cell-specificity, but this requires a 
mutant background, and has a relatively high background activation of the exogenous 
genes.  
7.1.1 - Current mechanisms of cell-specific, temporal control 
act at the level of transcription
While these mechanisms are promising, they suffer from a number of additional problems. 
First, they usually require the presence of two constructs in each strain to be used; these 
need to be on separate arrays requiring two separate integration events, increasing the 
workload, although in time these strains would become available to other researchers. 
The two integrated constructs would each have their own levels of control and regulation, 
adding additional complexity into the system.  
Secondly, while all these methods require the incorporation of a at least 1 trangene, 
some require additional genomic mutations, while it would be advantageous to conduct 
these experiments in a background as close to wild-type as possible.  
A third point is that these mechanisms control the expression of a protein at the level of 
transcription.  For large proteins, the time it takes to produce and traffic the protein to 
its site of action can be extensive, and this means that the experiments are not able to 
examine acute activation of a protein.  
7.1 - Tamoxifen regulation
Taking these factors into consideration, we thought that it would be useful to implement 
a further technique, widely used in mammalian systems, into C. elegans biology.  This 
is regulation of protein function by the small molecule tamoxifen, which we believe will 
provide a complimentary system to those mentioned above.  
The modified mammalian estrogen receptor (ER) is fused directly to the protein of interest, 
such as the Cre recombinase mentioned above (Metzger, Clifford et al. 1995).  In this 
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Cre-fusion case, the presence of tamoxifen regulates recombination and activation of 
expression of a protein of interest.  Again, this relies on a transcriptional level event, 
and takes time to manifest the activity of the protein of interest.  We would rather use an 
approach where the estrogen receptor is fused directly to the protein of interest, as has 
been demonstrated with a large number of proteins, including myc (Littlewood, Hancock 
et al. 1995) and raf (Lloyd, Obermuller et al. 1997).
The presence of the modified estrogen receptor element causes the inactivation of the 
protein to which it is attached (Figure 7-5).  While the exact mechanism of inactivation is 
still unclear, it is thought that the estrogen receptor is bound by a variety of inactivating 
polypeptides, with the heat-shock protein Hsp90 being the canonical factor in mammalian 
systems.  C. elegans has a number of homologues of Hsp90, including DAF-21 (Birnby, 
Link et al. 2000).  Addition of tamoxifen releases the inhibiting effect of these complexes, 
and allows the protein of interest to become functional.  The only way to discover whether 
this system works in C. elegans is to test it experimentally.  
The modified protein construct can be expressed under a cell specific promoter, and 
transcription and translation progress as dictated by that promoter and any additional 
elements such as 3’UTR sequences or introns, giving spatial control of expression.  The 
protein is hopefully post-translationally modified and trafficked to its normal location, in 
an inactive state.  Only on addition of tamoxifen does the protein become active; but 
this activation occurs without the need for further transcription or translation, so the lag 
between dosing with the drug and activation of the activity of the protein is much shorter 
than treatment either with heat-shock or with tetracycline.  This allows a way to test the 
response of the cells of interest to an acute increase in protein activity.
There are disadvantages to this method, however.  While this approach requires only a 
single plasmid to be transfected into the target animal, decreasing the complexity of the 
system, this does mean that each protein must be individually modified to accommodate 
the estrogen receptor.  The protein construct is therefore chimeric, and it is not a certainty 
that the protein will be active, and this may mean that some proteins are unsuitable 
targets for this approach.  
This technique has been successfully used in a wide variety of mammalian systems, 
both tissue-culture based and in vivo, and has proven highly successful, for instance in 
the generation of knock-out mice using tamoxifen-regulated Cre recombinase (Brocard, 
Warot et al. 1997).  We wanted to see whether we could use this system in C. elegans 
to provide a complementary approach to cell-specific, temporal regulation to those 
discussed previously.  
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We decided that regulating C3T by adding the estrogen receptor would be both a good 
test case for the use of tamoxifen regulated activation of a protein, and a very useful tool 
for our experiments.  C3T is a highly toxic protein, and we regularly find that animals 
transfected with constructs expressing it either die or have pathfinding defects.  Given 
the deleterious nature of the transgene, animals from lines which carry the construct and 
which have a silenced copy of the transgene have a selective advantage.  Therefore, 
these lines often completely lose the transgene expression (S. Nurrish, personal 
communication).  We reasoned that a line carrying an essentially inactive form of the 
transgene would be much more stable.
We did consider using expression of GFP fused to the estrogen receptor as our test 
case.  However, following conversations with another lab using the tamoxifen-regulated 
system, we felt this would be a poor choice because GFP can be resistant to inactivation 
by the estrogen receptor fusion (Alison Lloyd, personal communication.)  
7.1 - Results
7.1.1 -  Producing a C3T  construct tagged with the 
mammalian estrogen receptor
We obtained a plasmid containing the modified estrogen receptor as a gift from the 
Lloyd lab, and were able to combine it with the cDNA for C3T, the RHO-1 specific toxin. 
We had previously generated a GFP-tagged C3T which is active, demonstrating that 
N-terminal fusion to the transferase is tolerated.  
For ease of reference the modified estrogen receptor-C3T construct will now be referred 
to as ER:C3T , signifying a tamoxifen-responsive element fused to C3T.  The construct is 
under the control of the acr-2 promoter, and so will express only in cholinergic neurons, 
where we have already established a role for RHO-1 (McMullan, Hiley et al. 2006).   The 
fusion protein should be inactive until the addition of tamoxifen, allowing for normal 
development of the nervous system.
7.1.1 - Transgenic lines containing C3:TMX appear wild-type
The ER:C3T  construct was injected into N2 adults at a concentration of 10ng/ul, along 
with plasmid KP#307 (p.acr-2::GFP) as a co-injection marker.  It was relatively easy 
to obtain a transgenic line carrying this construct, which suggested to us that the C3T 
protein was indeed in an inactive state, as untagged C3T is highly toxic.  From a typical 
set of 20 injections, 6 of the injected animals produced transgenic progeny.  Three of the 
lines gave some transgenic progeny which were malformed, looking dumpy, suggesting 
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Figure 7-5 Control of protein expression using tamoxifen
The gene of interest is coupled to the modified estrogen receptor (green shape), and expressed 
from a tissue specific promoter in an inactive state due to the binding of chaperones (light 
blue circles).  Upon addition of tamoxifen (red cirlcles), the estrogen receptor undergoes a 
conformational cange, the chaperone proteins are released and the protein is activated (B).
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that some C3T activity might be present without the addition of tamoxifen.  These lines 
were not frozen.  
The remaining three lines of animals carrying this construct, as marked by the presence 
of the acr-2::GFP co-injection marker, appear wild-type, and were named QT947, QT948 
and QT949.  This marker also allowed us to examine the nervous system wiring for 
pathfinding defects common with C3T expression, and these animals did not display any 
defects (data not shown.)  
The locomotion of these transformed animals does not appear to be affected by the 
presence of the RHO-1 inhibitor, in contrast to animals expressing untagged C3, which 
are lethargic almost to the point of being paralysed (McMullan, Hiley et al. 2006).   
7.1.1 - Addition of tamoxifen to wild-type animals has no 
discernable effect on locomotion or response to aldicarb
One of the potential issues of using tamoxifen to activate proteins tagged with the 
estrogen receptor is the need to separate the effects of the activated protein from any 
effects of the drug itself.  As part of this testing process, tamoxifen was administered to 
wild-type animals for us to observe its effects on locomotion and behaviour.
In mammalian tissues, tamoxifen itself is modified to more active compounds, such as 
5-OH-Tamoxifen (5-OH-T) which has a far greater affinity for the estrogen receptor.  As 
C. elegans may lack the ability to convert the prodrug to its more active form, these 
experiments make use of 5-OH-Tamoxifen.  This has a recommended dilution of 20mg/
ml, with 100nM being the recommended final concentration for use in tissue culture 
experiments. 
Based on the use of other pharmacological compounds in C. elegans (Rand 1995) and 
our own protocols for administering compounds such as aldicarb, we diluted the drug in 
99% EtOH to 10mg/ml, and prepared NGM plates containing 1μM 5-OH-T, 100 times the 
tissue culture concentration. 
1 day old adult animals were placed onto these plates, and after 5 minutes showed 
uncoordinated locomotion, where the animals appeared to be dragging their tails rather 
than moving smoothly.  After 1 hour, the animals were highly lethargic, but animals 
removed at this time point recovered normal locomotion after 2 hours of recovery in the 
absence of the drug.  After 2 hours exposure to tamoxifen, animals were completely 
paralysed.  
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Having seen these effects on animals exposed to tamoxifen, we next wanted to try a 
range of concentrations of the drug, to find a safe exposure limit that would not cause 
paralysis.  We again made NGM plates, this time containing 2nM, 10nM, 20nM, 50nM, 
100nM, 200nM, 500nM, and 1μM tamoxifen.  We also prepared plates containing an 
equivalent amount of ethanol as a control.
10 young adult animals were picked to each plate, and examined for paralysis or 
uncoordinated locomotion at intervals of 10 minutes, 30 minutes, 1 hour and 2 hours.  No 
difference to the control plates was observed at any concentration used over the course 
of the experiment, in contrast to the results seen previously.  
Animals left on these plates overnight exhibited no ill effects to exposure to the drug, 
so we prepared a further range of dilutions to test exposure to greater concentrations 
of 5-OH-T.  This new set of NGM plates contained 1μM, 2μM, 5μM, 10μM and 20μM 
concentrations of the drug.   After 1 hour of observation, there were no visible changes in 
locomotion, except at the 20μM concentration range, where animals exposed to 5-OH-T 
appeared to have  slightly shallower body bends.  However, after 4 hours, these animals 
looked wild-type, whereas the animals exposed to 2uM appeared slightly loopy, and 1 of 
the 10 adult animals on the 5uM plate was paralysed.  
7.1.1 - Tamoxifen does not enhance paralysis in combination 
with the acetylcholinesterase inhibitor, aldicarb
The first experiment, which showed dramatic behavioural changes in response to 
tamoxifen, appears to be an outlier based on these further experiments.  It is possible 
that the plates used were contaminated with aldicarb from a parallel experiment, so we 
prepared plates containing both aldicarb and tamoxifen in an attempt to recreate this 
potential scenario.  
Over the course of a two hour experiment, animals were exposed to either 1μM tamoxifen 
with 100mM aldicarb, 1μM tamoxifen alone, 100mM aldicarb alone or an alcohol-only 
control, to control for the ethanol in which tamoxifen is suspended.  During the course 
of two hours of observation, there was no visible difference in the paralysis of animals 
exposed to aldicarb and tamoxifen compared to exposure to aldicarb alone.  While the 
animals paralysed in both situations, this paralysis was not at the fast rate observed in 
the first experiment, leaving the cause of that paralysis unexplained.  
In every case except one we have observed no effect on wild-type adult from exposure 
to tamoxifen.  In that single instance, we saw that animals became paralysed within 1hr 
after being placed on tamoxifen plates.  Having been unable to replicate that result, even 
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at very high concentrations of tamoxifen, we are unable to say whether this represents a 
true response to tamoxifen which was uncovered due to an additional, unknown factor, 
or whether this response was due entirely to some other unknown factor.
7.1.1 - Addition of tamoxifen to ER:C3T  animals via NGM 
plates did not cause paralysis
Having tested the response of wild-type animals to tamoxifen, we attempted to activate 
the C3T in the ER:C3T  lines.  We first adminstered tamoxifen via uptake from our 
NGM plates, as described in the testing of wild-type animals.  We used a range of 
concentrations to attempt to activate the C3T construct: 7μM, 12.5 μM, 21.5μM and 
70μM, along with control plates containing an equivalent amounts of ethanol solvent.  No 
effect on locomotion was observed when animals carrying the ER:C3T  transgene were 
placed on these plates for a period of up to 6 hours.
Tamoxifen is light-sensitive, so we wondered whether exposure to light might be 
inactivating the compound in the plates.  We therefore used a further concentration 
range: 2.5μM, 10μM and 100μM, and a 20μl EtOH plate as control, and kept these 
plates in a light-proof box to avoid photoinactivation.  However, after a period of two 
days grown in the presence of tamoxifen in the dark, none of the animals from the three 
independent lines showed any response indicating C3T activation.
It is possible that the drug is inactivated by the salts found in the NGM plate, and therefore 
we made use of a number of different solvents, including olive oil, to try to prevent this 
inactivation. We also used a fresh stock of tamoxifen, at 20mg/ml, obtained as a gift from 
the Lloyd lab, who were successfully using it in their mammalian experiments, in case 
our own stock had been photoinactivated.
We dissolved the olive oil/tamoxifen mix into the worm mixture, at 0.1μg/ml, 0.2μg/ml, 
5μg/ml and 1μg/ml.  10 N2 and 10 ER:C3T  L4 animals animals were placed on these 
plates, and left to grow for 4 days.  After this time, none of the animals were paralysed. 
However, the animals carrying the ER:C3T  were not starved, whereas the N2 plates 
were starved.  This suggests that the ER:C3T  animals were slower growing, which may 
be as a very subtle result of carrying the ER:C3T  plasmid.
7.1.1 - Direct exposure to tamoxifen did not cause paralysis 
in ER:C3T  animals
A number of drug compounds, such as phorbol esters, aldicarb and levamisole are 
able to penetrate the cutilcle of the worm by absorption from the NGM plate, but we 
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wondered whether this mechanism was ineffective for 5-OH-T.  Therefore we soaked the 
ER:C3T  expressing worms in a solution of tamoxifen, to expose them directly to a high 
concentration.  Animals expressing ER:C3T  were placed in drops of olive oil containing 
20mg/ml tamoxifen for up to 2 hours, but did not become paralysed during exposure, or 
when observed for several days afterwards.  
7.1.1 - Injection of Tamoxifen into ER:C3T  animals shows 
some limited effects on behaviour
It is possible that the cuticle is a physical barrier to the entry of the drug.  Therefore, we 
tried to inject the drug into the worms, using tamoxifen dissolved in olive oil.   These 
injections were either into the gonad (to try to induce C3T activation in the developing 
embryos), intestine or ceolemic space.  Of 17 injected animals, 6 were dead one day 
after injection, and a further 3 were dead three days post-injection.  In many of these 
animals, bubbles of oil were visible.  It is not clear whether the retention of oil was 
responsible for killing these animals, as some of those which survived also contained 
oil bubbles, or whether the tamoxifen was activating the C3T plasmid with toxic effects. 
Perhaps more precision targeting of the ceolemic space would give a greater likelihood 
of activation in the injected animal.
Of the remaining 8 animals, 5 produced offspring which were uncoordinated, and tended 
to drag their tails when moving.  This subtle behavioural change is different to severe 
paralysis associated with expression of C3, so it is unclear whether it results from some 
level of C3T activation or from some other effect of the injection procedure.  Further 
injections of tamoxifen failed to produce any uncoordinated offspring.  On examining 
animals from these further rounds of injections with tamoxifen, it was discovered that 
even some animals not injected appeared to have uncoordinated locomotion, suggesting 
some background C3T activation.  
The net result of these experiments is an inability to see a response to tamoxifen, either 
in a wild-type background or in animals carrying a construct expressing C3T fused to the 
estrogen receptor.  
7.1 - Conclusions
There are a number of potential reasons why this method was unsuccessful.  These 
could be due to problems with the construct, with the fusion protein or the application of 
tamoxifen itself.  I will address these three briefly in turn.
7.1.1 - The ER:C3T  construct may not express efficiently
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We do not have evidence that the construct expressing ER:C3T  is indeed being 
expressed in the transfected animals.  There are a number of reasons why it might not 
be expressing well.  
First, the modified estrogen receptor contains a sequence with a mammalian codon 
bias.  It is possible that this is an impediment to high expression, and that synthesising 
an estrogen receptor with a C. elegans codon bias might improve the efficiency of this 
method.  
Secondly, including an additional green fluorescent protein (GFP) tag into the construct 
would provide a serviceable way of checking expression.  While the presence of the 
estrogen receptor might not prevent GFP fluorescence, making it a poor target for 
observing regulation, the GFP might still act as a good indicator of expression.  
Future experiments would be to quantify the level of expression of C3T  from the construct; 
we could make use of a C3T -specific antibody, or an ER antibody.  Given more time we 
would have liked to have used this method to whether C3T  is present in our transformed 
lines. 
7.1.1 - The ER:C3T  fusion protein may not be activated by 
tamoxifen in C. elegans
If the tagged C3T protein is being expressed, it may be that the C3T is permanently 
inactivated by the addition of the estrogen receptor, and not able to be activated by the 
addition of tamoxifen.  
We have previously tagged the C3T with GFP without affecting activity, but there may be 
additional conformational changes induced by the estrogen receptor which completely 
inactivate the protein.  
The mechanism of activation by addition of tamoxifen is somewhat unclear, but is thought 
to be due to chaperones, such as those involved in the heat-shock response, accumulating 
around the estrogen receptor and physically masking the effects of whatever protein is 
attached to the receptor.  It may be the case that in C. elegans these chaperones bind in 
a way that is not tractable to tamoxifen addition.
7.1.1 - Tamoxifen delivery to C. elegans may be inefficient
The addition of tamoxifen by a number of methods failed to elicit a response in the 
ER:C3T  strain.  A simple explanation is that the drug fails to be absorbed by the animals. 
A wide range of drugs are able to penetrate the C. elegans cuticle, but perhaps tamoxifen 
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is unable to.  One way to test this would be to conduct the same experiments using strains 
which are hypersensitive to drugs due to mutations in their cuticle integrity, such as bus-8 
(Partridge, Tearle et al. 2008).  It could also be that we are accidentally inactivating the 
drug through our handling, perhaps by exposure to light or bacteria.  It may even be the 
case that C. elegans is able to metabolise tamoxifen to an inactive form, which would 
make it an unsuitable compound for use in worm biology.  
7.1.1 - Final thoughts
We believe a temporally and spatially controlled C3T would allow us to investigate the 
acute effects of loss of RHO-1 function in more detail than previous techniques allow. 
While tamoxifen regulation has not proven successful at this stage, its usefulness in 
mammalian systems indicates that it would be a valuable addition to the tools available 
C. elegans researchers, and one worth pursuing with the modifications suggested above. 
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Appendix 2 - Non-silent mutations
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Appendix 2 - Non-silent mutations
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